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 is needed to identify the causal variants.    
TRACT  
aims of this study were to analyse known and potential biomarkers of common 
netically complex human disorders and to identify genetic and environm
in n associated with plasma biomarker concentrations. Two groups of prote
kers were analysed. First, plasma complement factor H (CFH) was selected 
 potential biomarker for age-related macular degeneration (AMD), 
mon variants in the CFH gene show strong association with this disorder. 
since 
condly, two isoforms of amyl id-β (Aβ40 and Aβ42) were selected as biomarkers o
for Alzheimer disease (AD) since Aβ deposits are major constituents of the amyloid 
ques characteristic of this disorder. 
Physiological and anthropometric measurements and samples of human 
 and genomic DNA were collected from a population sample of 1,021 
iduals from the Croatian island of Vis. Quantitative determination of plasma 
Aβ40 and Aβ42 concentrations was performed using enzyme-linked 
osorbent assays. Heritabilities and significant covariate effects were 
ed for each trait in the Croatian data set. Genome-wide linkage and 
ciation analyses were conducted for the biomarker traits.  
A novel finding was the genome-wide significant association between 
a CFH and several polymorphisms close to and within the CFH gene. The 
st association was with an intronic SNP within CFH, which explained 28% of 
e total trait variance (P < 10 ). The association was also replicated in a Dutch -50
sample set. A SNP haplotype was identified which accounted for a higher proportion 
 the phenotypic variance. Conditional haplotype analysis showed that the effect of 
s haplotype on plasma CFH concentration was independent of the CFH Y402H 
nt, and significantly stronger than a deletion of the adjacent CFHR3/CFHR1 
 which was already known to affect AMD susceptibility. Genetic analysis of 
D cases and 201 controls was consistent with the CFH Y402H variant being 
trongest AMD susceptibility locus. Variation in plasma CFH concentration was 
o explain up to 1.8% of the variation in susceptibility to AMD with an odds 
 2.1 (95% C.I. 1.3-3.4, P = 0.003). SNPs that were strongly associated with 
a CFH concentration also influenced AMD susceptibility (P < 0.05) 
ly of the CFH Y402H polymorphism. Functional analysis of genomic 
regions associated with plasma CFH     
 i
ii
s were observed between plasma Aβ40 concentration and 




several novel candidate loci, spanning regions of approximately 0.2 Mb, on 
chromosomes 9 and X. Similarly, novel associations with plasma Aβ42 were found 
in several regions, each spanning 0.2-0.4 Mb, on chromosomes 2, 5, 9, 15 and 20. 
The proportion of the phenotypic variance in plasma Aβ42 explained by these 
putative associations ranged between 1.8 and 2.8%. However, none of the 
associated SNPs was significant after correction for multiple testing, therefore 
replication is required. 
Finally, attempts were made to identify and quantitate new protein 
biomarkers of disease in human plasma using mass spectrometry. Development 
and optimisation of techniques was init
plasma proteins and improve signal:noise ratio. This allowed the assessment of 
downstream proteomic approaches including MALDI-TOF mass spectrometry (MS), 
capillary electrophoresis (CE) and ion exchange chromatography (IEC), each with 
the potential for large-scale quantitation of plasma proteins. Although the analysis of 
single protein analytes, using CE and IEC proved promising, the results highlighted 
the difficulty associated with MALDI-TOF and protein ionisation techniques in 
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1.1 Mapping genes for common, complex human diseases 
 
The recent completion of the human genome sequence and rapid improvements in 
genotyping technologies can allow the genome-wide analysis of genetic variation 
influencing complex disorders (Mayeux, 2005).  Some of these variants may have a 
direct effect on disease, and some may influence quantitative traits which are risk 
factors for disease.  Success has been achieved in mapping genes for Mendelian 
diseases (Thomas & Kejariwal, 2004).  However, unravelling the complex nature of 
common diseases has proven more challenging.  The main differences between 
Mendelian and complex disorders and some of the techniques employed to study 
them are summarised below. 
 
Mendelian and complex disorders 
 
In Mendelian disorders, disease is typically caused by one of several genes, each 
with many rare alleles (Wright et al., 1999).  These are usually highly penetrant 
deleterious alleles with high allelic heterogeneity and low disease prevalence which 
segregate in families.  In the case of more genetically complex disorders, a 
combination of intermediate phenotypes, each under genetic control, affects 
predisposition to disease.  Common, complex diseases characterised by late age of 
onset are a manifestation of many genetic variants and loci with incomplete 
penetrance which interact with one another (epistasis) and with the environment.  It 
is often preferable to study the intermediate disease endpoints rather than categorical 
diseases as the number of susceptibility loci may be so high and the disease state can 
be a complex and insensitive indicator of underlying pathogenic processes (Wright et 
al., 1999)  
 A number of factors have resulted in shifts in the selection pressure acting on 
the biological processes that underlie major classes of common disease (Di Rienzo, 
2006).  Crucial factors include the dispersal of modern humans out of Africa, and a 
shift away from a hunting and gathering life-style in addition to the more recent 
transitions associated with industrialisation and globalisation.  These have resulted in 
major changes in environmental factors which are believed to influence the evolution 
of susceptibility variants for common diseases (Di Rienzo, 2006). 
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Linkage and LD mapping strategies 
 
Linkage and association mapping are the two main genome-wide approaches for 
mapping genes that underlie common diseases and their associated quantitative traits 
(QTs).   
 Genome-wide linkage analysis is the traditional method of identifying disease 
genes and has proven successful for mapping genes that underlie monogenic disease. 
The principle is based on the segregation of genetic markers flanking the disease 
gene with the disease in families (Blangero, 2004).  Genome-wide linkage analysis 
has also been used in mapping quantitative trait loci (QTL) with the aim of finding 
chromosomal regions with evidence of QTL-specific heritability and inferring the 
existence of a QTL.  However, limited success has been achieved for most complex 
traits using linkage and the few genes discovered in this way only explain a small 
proportion of the overall trait heritability (Altmuller et al., 2001).  This lack of power 
can be due to the relatively low heritability of complex traits and the inability of the 
standard set of microsatellite markers (5-10cM apart) to extract complete information 
about inheritance (Hirschhorn & Daly, 2005).  The complex architecture of common 
diseases (described in the next section) and the presence of common genetic variants 
of small to modest effect also make linkage studies less powerful.   
 Genome-wide association studies have become possible since the advent of 
high density single nucleotide polymorphism (SNP) genotyping platforms.  A SNP is 
a single nucleotide substitution with a minor allele frequency of 0.01 or greater.  In 
quantitative trait association analyses, the effect of a marker genotype on the 
distribution of the QT is directly assessed using a linear regression model (Blangero, 
2004).  Success in this type of study will depend on the magnitude of linkage 
disequilibrium (LD) between the genetic marker and the causal variant in the 
population.  Linkage disequilibrium is defined as the non-random association of 
alleles at two or more loci, not necessarily on the same chromosome (Cannon, 1963). 
The LD relationship is highly dependent on the allele frequencies of the marker and 
of the functional variant, a feature that cannot be predicted (Blangero, 2004).  Larger 
sample sizes can compensate for the negative effect of low LD and mismatch in QTL 
allele frequencies (Figure 1.1).   
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Figure 1.1 Comparison of linkage and association strategies in mapping QTL.
Number of individuals required to achieve 80% power to detect a QTL. The Model is 
based on the assumption that the QTL explains 15% of the trait variance and the 
prevalence of the disease is 25%. The association approach is highly dependent on the 
strength of LD between genetic marker and QTL and is shown to be
 
more powerful than 
the linkage approach for both pedigrees (when LD > 0.20) and affected sib-pairs (when 
LD > 0.40). The association approach is successful if detecting up to five quantitative trait 
nucleotides (QTN) with equal relative effects, when a moderately
 
large sample size is 
used. However, linkage is more powerful in many circumstances when such as high 
penetrance null alleles even in the presence of rather high LD. Figure adapted from 
Blangero, 2004.  
Figure 1.2 Modelled distribution of phenotypic effect sizes and the number of 
underlying disease susceptibility variants. 
A model for the exponential or L-shaped distribution of the allelic effect sizes associated 
with complex disease susceptibility variants.  It suggests that the underlying genetic 
variation, which affects complex traits, is based on a small number of variants with large 
effects and a large number of variants with small effects.  Figure adapted from Wang et 
al., 2005.  
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 When comparing two contrasting linkage designs (sib-pairs and large 
pedigrees) the extended pedigree design is up to four times more efficient than the 
sib-pair design as has been shown in family-based linkage studies of thrombosis 
(Blangero et al., 2003).  Assuming there is a single variant accounting for 15% of the 
trait’s variance, the association approach using unrelated individuals is more 
powerful than the affected sib-pair design for all LD correlations greater than 0.20 
(Blangero, 2004). However, for LD correlations smaller than 0.20 the affected sib-
pair design would have more power in detecting a single underlying polymorphism. 
For LD correlations smaller than 0.4 the extended pedigree approach would be more 
efficient in detecting a single variant and similarly for LD correlations smaller than 
0.75, this approach would have enough power to detect five variants associated with 
the trait. Therefore, linkage is more powerful in many circumstances such as the 
presence of highly penetrant null alleles even with high LD correlations.  Although 
association studies are prone to population stratification, they represent an unbiased 
approach that can be attempted even in the absence of evidence regarding the 
function or location of the causal genes (Blangero, 2004). 
1.1.1 Genetic architecture of complex traits 
 
An important route for complex disease mapping is through the study of normal 
physiological variation of quantitative trait risk factors (Falchi et al., 2004).  
Intermediate phenotypes, which are assumed to be functionally related to a broader 
phenotype such as disease, may have stronger genetic determinants than the 
downstream phenotype they mediate, contributing to the added power of QT analysis 
over binary traits (Falchi et al., 2004).   
Quantitative genetics theory assumes an explicit genetic model to describe 
the genetic architecture of a complex trait.  A comprehensive understanding of the 
genetic architecture of any complex trait requires knowledge of several factors;  the 
numbers and identities of the genes which lead to the trait phenotype; their effect 
sizes and allele frequencies; the mutation rates at these loci; all two-way and higher 
order epistatic interaction effects; the presence of pleiotropic effects on other traits, 
especially reproductive fitness; finally, the molecular mechanisms causing the 
differences in trait phenotype (MacKay, 2001). 
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Two main models have been proposed to account for the allelic architecture 
of common diseases (Wang et al., 2005).  First, the common disease/common variant 
hypothesis (CDCV) suggests that susceptibility to common diseases is a result of the 
joint action of several common variants, so that unrelated affected individuals share a 
significant proportion of disease alleles in common (Reich & Lander, 2001).  The 
alternative is the classical disease heterogeneity model, which suggests that disease 
susceptibility is mainly due to distinct genetic variants of low minor frequency (MAF 
< 0.01) that are present in different affected individuals (Smith & Lusis, 2002). 
The distribution of genetic effect sizes conferred by individual variants also 
has an effect on the allelic architecture of complex traits.  Studies of Drosophila 
melanogaster and animal models have indicated that the distribution of phenotypic 
effect sizes of genetic variants is consistent with the existence of a small number of 
genetic loci with large effects and numerous loci with small effects (Figure 1.2).  
1.1.2 Lessons from association/linkage mapping of QTL 
 
The lack of success of linkage analyses can either be due to the small size of the 
study population (i.e. size of the pedigrees) or the lack of power in linkage to detect 
variants of modest effect size as reflected by a low QTL-specific heritability (Dawn 
& Barrett, 2005).  The power in genome-wide analyses has been shown to be directly 
related to the QTL heritability in the case of association but to the square of the QTL 
heritability in the case of linkage (Sham et al., 2000).  Therefore, it is expected that 
with decreasing QTL heritability, association will become progressively more 
powerful than linkage.  Using simulations, Sham and colleagues (2000) have 
estimated that approximately 20,000 sib-pairs would be required to detect a QTL of 
10% effect size (i.e. explaining 10% of the QT variance) using linkage with 80% 
power.  The number of sib-pairs decreases to approximately 1,000 for detection of 
statistically significant associations, assuming that the degree of linkage 
disequilibrium between the causal QTL and the marker is strong (R2 > 0.50). 
 For linkage, the level of significance required is set at a LOD score of 3 for 
monogenic traits, which is equivalent to a fixed-sample one-tailed significance level 
of 0.0001 (Morton, 1955).  The LOD score is defined as the common logarithm of 
the likelihood ratio (1,000) that is necessary to convert the odds from 50:1 against 
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linkage to 20:1 in favour of linkage (Ott, 1991).  For complex traits, slightly higher 
LOD score thresholds are required (Lander & Kruglyak, 1995).  Interpretation of 
significance levels in genome-wide association studies aims to keep the false positive 
rate resulting from small sample sizes and population stratification within acceptable 
bounds and leads to the view that very low P-values are needed for strong evidence 
of association (Wellcome Trust Case Control Consortium (WTCCC), 2007). For a 
given significance threshold, the probability of a true association depends on the 
prior odds and the power (Wacholder et al., 2004).  Interpreting the strength of 
evidence in an association study depends on the likely number of true associations 
and the power to detect them, which in turn depends on effect sizes and sample size 
(WTCCC, 2007). 
 Hidden population structure is a cause of false-positive findings due to 
confounding when different ancestries carry higher disease risk and are, as a result, 
over-represented in cases or between subgroups in the population (WTCCC, 2007). 
For example, a genome-wide study of seven common diseases has shown that the 
British population is heterogeneous, identifying thirteen genomic regions showing 
strong geographical variation in allele frequencies (WTCCC, 2007).   
 The statistical power to detect causal variants increases with increasing allele 
frequency and penetrance, as reflected by the proportion of the phenotypic variance 
explained by the variant (Hirschorn & Daly, 2005).  Mapping by association requires 
low genetic and environmental heterogeneity (Kruglyak, 1997).  Although linkage 
approaches are less affected by allelic heterogeneity, they lack power to detect 
variants with small effect (Risch & Merikangas, 1996; Camp, 1997).  The most 
efficient method may be to search for linkage and association jointly (Terwilliger & 
Weiss, 1998).  If allelic association is present, it can increase the power of a linkage 
test, if it is not present, linkage remains a viable approach for low-resolution 
mapping (Wright et al., 1999).      
1.1.3 Mendelian randomisation 
 
A setback in genetic epidemiological analyses is the lack of consistency between 
observational studies and randomised controlled trials. This arises when potentially 
causal factors are associated with a disease-related trait but this is not confirmed 
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when tested in randomised controlled trials. The most likely explanation is the 
presence of a confounding factor (Hill, 1965). By definition, a confounding variable 
is associated with both the probable cause and the outcome. The principle of 
Mendelian randomisation is to make use of genetic markers that alter the level of a 
modifiable environmental exposure that is associated with disease risk. Genetic 
variants of this sort should be associated with disease risk if the association is causal 
but not if it is due to confounding (Davey et al., 2005). Therefore, genetic 
polymorphisms influencing a disease risk factor can be used to study the causal 
relationship between an intermediate and disease risk. The use of genetic markers in 
this way has several advantages (Davey et al., 2005).  Firstly, genetic variants are not 
generally affected by behavioural and physiological factors.  Furthermore, such 
variants will not be associated with other variants, except as a result of linkage 
disequilibrium (LD).  Secondly, genetic variants are not influenced by reverse 
causality i.e. they never occur as a result of the phenotype they control.  For example 
intermediate phenotypes such as plasma cholesterol, CRP and fibrinogen can be 
associated with coronary artery disease but it is not clear whether this is due to a 
causal effect.  Genetic markers can be advantageous over biological markers which 
may be influenced by disease status (reverse causality).  Thirdly, genetic markers are 
less prone to measurement error and within-individual variability compared with 
intermediate phenotypes.   
 The major limitation of Mendelian randomisation is the difficulty in 
establishing a reliable association between genetic markers and either disease-related 
intermediate phenotypes or disease itself (Davey & Ebrahim, 2003).  This can be 
difficult because of population stratification, small sample size and lack of suitable 
polymorphisms for studying modifiable exposures of interest. 
1.1.4 Choice of population 
 
Association analyses are dependent on the extent of LD between the marker and 
QTL of interest.  The number of generations since the common ancestor or the 
number of meioses during this time are the main causes of the decay in linkage 
disequilibrium, and are related to the number of recombination events and the 
effective population size.  Recombination equilibrates linked alleles, whereas small 
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population size results in the generation of new allelic disequilibria by genetic drift.  
Genetic drift is defined as the random sampling of mutations from generation to 
generation resulting in chance changes in allele frequencies (Hartl & Clark, 1997).    
 Different types of population have been successfully used in mapping genes 
influencing human diseases.  Recent founder populations such as Finland, Iceland, 
Sardinia and Japan have been useful in finding rare Mendelian genes (Laan & Paabo, 
1997).  In these populations allelic heterogeneity may have diminished due to genetic 
drift before population expansion.  However, due to the small allelic effect sizes, 
they have not proven as useful in mapping complex disease genes (Wright et al., 
1999).  Small populations that have remained stable in size such as the Scandinavian 
Saami may prove to be more successful in LD mapping due to the presence of large 
extents of LD caused by genetic drift as shown by experimental data on the X-
chromosome (Laan & Paabo, 1997).   
 Isolated inbred populations such as those found in Switzerland (Ellis & 
Starmer, 1978), Sardinia (Workman et al., 1975) and North America (Bear, 1988) 
also have potential in LD mapping.  Inbreeding has been shown, in a simulation 
study, to increase the power to detect susceptibility alleles in complex disorders 
(Genin & Clerget-Darpoux, 1996).  Furthermore, genome-wide linkage mapping has 
successfully mapped loci influencing plasma triglyceride concentration in a single 
1,623-member pedigree from the Hutterite population (LOD > 3, P < 0.05) despite 
lack of success in other populations (Newman et al., 2003).  This is due to reduced 
effective population size, resulting in reduced genetic heterogeneity and more 
extended regions of LD as a result of recent founding effects or genetic drift.     
 Genetically simplified isolated populations provide optimal conditions for LD 
mapping (Wright et al., 1999).  Isolation, due to geographical or cultural factors, 
results in a more uniform distribution of environmental risks as well as reduced 
genetic heterogeneity.  Furthermore, increased inbreeding in these populations can 
influence both disease prevalence and its underlying quantitative traits. 
1.1.4.1 Gene mapping in isolated populations 
 
A powerful approach to mapping genes influencing complex traits is to study 
isolated founder populations.  Genetic heterogeneity is likely to be reduced, 
 9
depending on the original composition of the particular isolate and the number of 
founders.  Environmental variation is also likely to be reduced because of uniform 
social behaviour, for example absence of cigarette smoking in the Hutterite 
population for religious reasons (Newman et al., 2003).  In isolates, extended 
genealogical data can often be readily obtained facilitating the identification of 
identity-by-descent relationships in mapping.  A population may be referred to as an 
“isolate” if it has not had a large degree of admixture with surrounding populations 
for a given number of generations due to either geographic or socio-political barriers 
(Escamilla, 2001).  If an isolate does not admix with its neighbours there is a chance 
that particular founder mutations may be present in a large number of members of 
the current generation.  This may be the result of normal growth of the population, 
selection or random genetic drift.   
In a simulation study of 1,053 related individuals in 4-5 generation pedigrees 
from a Dutch isolate, large fluctuations were observed in allele frequencies when the 
initial allele frequencies were lower than or equal to 1%; and smaller fluctuations 
when the initial frequencies were larger than 1% (Pardo et al., 2005).  Comparing 
empirical data from the Dutch and Icelandic isolates and the CEPH outbred 
population, Pardo and colleagues showed that although large fluctuations in allele 
frequencies might occur in recent isolates due to drift and founder effects, common 
genetic variants with a frequency higher than 1% are expected to be present in both 
young genetic isolates and outbred populations.   
Successes in mapping susceptibility loci for complex disorders have been 
achieved in some European isolate populations.  In the Icelandic population, 
common susceptibility variants have been mapped for prostate cancer (Gudmundsson 
et al., 2008; Gudmundsson et al., 2007), abdominal aortic aneurysm and intracranial 
aneurysm (Helgadottir et al., 2008), glaucoma (Thorleifsson et al., 2007), periodic 
limb movements in sleep (Stefansson et al., 2007), atrial fibrillation (Gudbjartsson et 
al., 2007), breast cancer (Stacey et al., 2007; Stacey et al., 2006), myocardial 
infarction (Helgadottir et al., 2007) using genome-wide association.  QTL for 
migraine (Bjornsson et al., 2003), osteoarthritis (Stefansson et al., 2003), Parkinson 
disease (Hicks et al., 2002), stroke (Gretarsdottir et al., 2002) and essential tremor 
(Gulcher et al., 1997) were mapped using genome-wide linkage.  All the above 
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studies have involved large numbers of related individuals and the results have been 
replicated in Icelandic, U.S. or other European populations.  Furthermore, the effect 
sizes observed range between odds ratios of 1.1 to 4.9 (moderate to large effect size).  
However, the success in mapping common variants for common traits in this 
population could be purely due to the large number of samples available and well-
designed studies.  It has been proposed that the Icelandic population is not a 
homogeneous genetic isolate, but instead was founded by a large mix of populations 
of Norse and Gaelic origin (Arnason et al., 2000).  Therefore, it is important that 
investigators provide evidence that their samples are from truly isolated populations 
(Heutink & Oostra, 2002).       
A common susceptibility locus for asthma-related traits has been mapped to 
chromosome 7p using linkage followed by fine-scale association mapping in a series 
of Finnish patients and controls from Kainuu (Laitinen et al., 2004).  The assumption 
was made that founder effects in this population might aid the identification of 
common variants influencing such common traits   Laitinen and colleagues identified 
a G-protein-coupled receptor for asthma susceptibility which lies within a 133-kb 
genetic segment containing an asthma-predisposition haplotype.  The findings of the 
study were simultaneously replicated in two other populations with histories of a 
founder effect, Quebec (Canada) and North Karelia (Finland).   
 Fine-mapping by association of a previously-identified region of linkage on 
chromosome 1q21-1q23 (Pajukanta et al., 1998) in 60 extended Finnish families with 
familial combined hyperlipidemia from a relatively isolated population, identified the 
susceptibility locus Upstream Transcription Factor 1 (USF1), which is observed in 
about 20% of individuals with premature coronary heart disease (Pajukanta et al., 
2004).  The effect size of the associated variant was found to be significantly larger 
in males with higher plasma triglyceride concentration.  However, the findings of 
this study were not replicated in another population and it was not clear whether 
using an isolated population facilitated the identification of the associated locus.   
A study consisting of 44 families (775 individuals) from the isolated 
Sardinian village of Talana, identified a 15 cM (~15 Mb) region on chromosome 
2q21-22, involved in determining total plasma cholesterol and low-density 
lipoprotein cholesterol, using genome-wide variance-component linkage analysis 
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(Falchi et al., 2004).  The magnitude of effect ranged from LOD score of 3.9 (LDL 
cholesterol) to 4.3 (total cholesterol).  The findings of the study were simultaneously 
replicated in an isolated population from the same region of Sardinia, the village of 
Perdasdefogu.  The results of the study by Falchi and colleagues replicated the 
findings of the genome-wide linkage scan, conducted in another isolated population 
(Hutterite).  This study involved 485 individuals in a 1,623-member pedigree 
enriched for cardiovascular disease, in which a locus with a multipoint LOD score of 
3.40 was identified for TG in a nearby linked region (Newman et al. 2003). 
Although isolated populations can benefit gene localisation, findings made in 
isolated populations might not be valid in the general population, especially in very 
old isolated populations where new mutations may arise or old mutations remain 
while becoming extinct in other populations.  Younger isolates may not suffer from 
this drawback, since they are still genetically similar to the general population 
because of their recent separation (Heutink & Oostra, 2002). 
1.1.5 The Croatia project 
 
The principal aim of the Croatia Project is to evaluate the use of isolate populations 
for the identification of genes which affect quantitative traits underlying the 
predisposition to common diseases.  This is based on the assumption that the choice 
of study population and use of quantitative traits rather than categorical diseases are 
both critical factors in mapping susceptibility genes influencing complex diseases 
(Wright et al., 1999).  Croatia has 15 islands in the Adriatic Sea with populations 
greater than 1,000 (Figure 1.3).  The villages on the islands have unique histories 
and have preserved their isolation from other villages and the outside world through 
many centuries.  The history, demography and genetic structure of these villages 
have been investigated for more than fifty years mainly by the Institute for 
Anthropological Research in Zagreb (Rudan et al., 1987). 
 In 2002, ten village settlements were carefully selected by Dr. I. Rudan and 
colleagues to present a wide range of differing ethnic histories, past admixture and 
bottleneck events and known founding times, in order to examine the unique 



























         Figure 1.3 Map of the Dalmatian islands of Croatia in the Adriatic Sea. 
 
       Geographic location of the island of Vis, from which samples used in this study were 
        obtained. Other islands of the Eastern Adriatic, Northern and Middle Dalmatia, and 
        mainland Croatia are also shown. Figure adapted from Vitart et al., 2006.             
 
A preliminary field survey of 10 Croatian isolates was then carried out in 100 
individuals from each isolate to clarify their suitability for the genetic analysis of 
complex traits (Vitart et al., 2006).  A high level of differentiation and structure is 
observed between most of the island communities, which was likely to be the result 
of strong isolation and endogamy (Vitart et al., 2006).  Furthermore, the extent of LD 
compared with the urban UK population correlated significantly with the extent of 
differentiation and was also very high in most of the populations.  The extent of LD 
was assessed using eight linked markers on Xq13-21, a region of low recombination 
(0.25 cM/Mb) which has been has been used to explore population-specific 
differences in LD.  Markers in that chromosomal region consistently displayed 
increased pair-wise association in populations with a history compatible with a 
reduced effective population size (Kaessmann et al., 2002; Vitart et al., 2005).    
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To analyse a diverse range of quantitative traits, blood samples were obtained 
from 1,042 adult volunteers from the villages of Komiza (N = 584) and Vis (N = 
458) in 2003, both located on the island of Vis (Figure 1.3).  Clinical histories and 
questionnaires were administered and anthropometric and physiological measures 
were obtained for a range of more than fifty QTs, including blood pressure, lung 
function, clotting factors, lipids and other clinical biochemistry measures on fasting 
blood.  The availability of plasma samples provided a rich resource for the analysis 
of biochemical quantitative traits with potential roles in disease susceptibility.  
Successful studies have been conducted involving the analysis of differentiation and 
structure in the isolated islands of Dalmatia (Vitart et al., 2006), analysis of 
personality and psychological traits (Ivkovic et al., 2007) and the identification of 
SLC2A9 as a novel urate transporter using a genome-wide association approach 
(Vitart et al., 2008).      
1.2 Proteomics and the human plasma 
 
Human blood plasma is generally the most informative proteome from a medical 
viewpoint since it is the primary clinical specimen and represents one of the largest 
and most clinically accessible collections of proteins in bodily fluids.  An estimated 
ten thousand different proteins typically exist in the human plasma, twenty-two of 
which constitute about 99% of the total protein content of plasma while the 
remaining fraction are low abundance proteins and peptides (Adkins et al., 2002) 
(Figure 1.4).  Almost all body cells communicate with the plasma either directly or 
through tissues/biological fluids, and many of these cells release at least a part of 
their contents into the plasma upon damage or death (Fujii et al., 2005).  However, 
characterisation of the human plasma proteome may pose one of the greatest 
challenges.  Plasma contains low abundance proteins, mainly products of tissue 
leakage at pg/ml levels, in the presence of several relatively dominant, high 
abundance proteins such as serum albumin at 35-50 mg/ml (Figure 1.4).   
Human serum albumin is a single molecule with a molecular weight (MW) of 65 
kDa which is the most abundant plasma protein and accounts for approximately 50% 
of the plasma proteome.  It has an important role in the osmo-regularity of the 
plasma, as well as in transport of many different substances and peptides due to its 
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specific binding abilities (Campbell & Smith, 1999).  Other major components of the 
highly abundant fraction of plasma proteins include the immunoglobulins (IgG, A, 
and M, 10-14 kDa, 12-18%), transferrin (75kDa, 2-3%), fibrinogen (2-6%) and α1-
antitrypsin (44 kDa, 2-5%) (Tirumalai et al., 2003).  Figure 1.4 summarises the 






Figure 1.4 Pie chart representing the relative contribution of proteins within plasma.          
 
Twenty-two proteins constitute ~99% of the protein content of plasma, nevertheless 
there are estimated to be around 10,000 low abundance proteins in plasma (Adkins et 
al., 2002).  Diagram adopted from Tirumalai et al., 2003. 
 
 
 Human plasma contains a complex array of proteolytically derived peptides 
(plasma peptidome) that may provide correlates for biological events occurring in the 
organism (Villanueva et al., 2004).  Most of these peptides are thought to be 
fragments of larger proteins that have been partially degraded by endogenous 
proteolytic enzymes, but their precise identities remain undetermined (Villanueva et 
al., 2004). 
1.2.1 Analysis of plasma proteins 
 
The low abundance fraction of the plasma may contain an unexplored archive of 
useful biomarkers for disease detection.  The concentrations of such biomarkers may 
serve as reliable intermediate phenotypes which are functionally related.  However, 
the identification and analysis of these low abundance proteins and peptides is 
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hampered by the presence of the more abundant proteins in plasma.  To date 
numerous methods for detection and quantitation of peptides and proteins have been 
employed as summarised in Table 1.1.   
 
Technique Details
Photometric               
(absorption)
Commonly used for quantitative assays, simple and rapid.  May be 
affected by colour or turbidity
Photometric 
(fluorescence)
More sentitive than absorption but more limited choice of fluorescent 
substrates
Radiometric Highly sensitive.  Problems associated with radioactivity e.g. health hazard and quenching
HPLC Separation performed rapidly and with high sensitivity.  Has not been assessed for quantitation.    
Electrochemical Inexpensive and convenient.  Unaffected by colour or turbidity.  Not practical for large number of samples.
Electrophoresis Simple and standard procedure.  Semi-quantitative.  Limited types of proteins can be assayed, but not a high throughput method.
Immunological Specific and sensitive for detection and quantitation.  High throughput but time-consuming.
 




1.2.1.1 Enzyme-linked immunosorbent assay 
 
Enzyme-linked immunosorbent assay (ELISA) is an immunological detection 
technique, which offers a highly specific and sensitive assay for detection and 
quantitation of a wide range of antigens (Engvall & Perlman, 1971; van Weemen & 
Schuurs, 1971).  ‘Sandwich’ ELISA is the most commonly used form of the assay.  
In this type of assay, the analyte to be measured is bound between two antibodies: 
the capture antibody and the detection antibody.  The capture antibody is 
immobilised onto a specially coated surface (e.g. a microtitration plate) and non-
specific sites are then blocked.  A solution containing the protein or peptide of 
interest is added and unbound protein is removed by washing and bound antigen is 
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quantified using a secondary enzyme-linked antibody.  Upon addition of substrate, 
the enzyme produces a coloured product that can be detected photometrically.  An 
important consideration when designing a sandwich ELISA is that the capture and 
detection antibodies must recognise two non-overlapping epitopes.  When the 
antigen binds to the capture antibody, the epitope recognised by the detection 
antibody must not be obscured or altered. 
 The limiting factor in design and use of immunological assays is the 
availability of antibodies to detect a specific protein.  This also implies that ELISAs 
can only be applied to proteins already identified, and to which antibodies have been 
raised.  Therefore identification of novel proteins is not possible.  Moreover, 
immunological assays would not allow for large-scale quantitation of many plasma 
proteins as these types of assay are often optimised for detection of one or only a few 
antigens. 
 
1.2.1.2 Mass spectrometry 
 
The ability to screen and discover multiple biomarkers simultaneously in clinical 
proteomics has been advanced by the recent success of mass spectrometry (MS).  MS 
consists of two key processes, the generation of gas phase ions of the molecule of 
interest by ionisation, a process that occurs at the source area of the mass 
spectrometer, and the analysis of the mass-to-charge ratio (m/z) of these ions using a 
mass analyser.  During the past two decades, MS has become established as the 
primary method for protein identification from complex mixtures of biological 
origin, through the analysis of mass to charge ratio of ions.   
The main protein ionisation techniques employed in MS proteomic analysis 
are matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) and 
electro-spray ionisation (ESI).  In MALDI-TOF MS the analyte is dispersed in a 
solid matrix and spotted onto a so called MALDI target plate (platinum or gold) and 
ionised through application of a laser beam which is primarily absorbed by the 
matrix causing desorption and ionisation of the analyte (Karas & Hillenkamp, 1988).  
The matrix consists of crystallized molecules, of which the three most commonly 
used are 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid), α-cyano-4-
hydroxycinnamic acid (alpha-cyano or alpha-matrix) and 2,5-dihydroxybenzoic acid 
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(DHB) depending on the type and size of the analyte molecules.  Matrix compounds 
have the following characteristics: firstly, they are of a fairly low molecular weight 
(to allow facile vaporisation), but are large enough (with a low enough vapour 
pressure) not to evaporate during sample preparation; secondly, they are acidic, 
therefore act as a proton source to encourage ionization of the analyte; and thirdly, 
they have a strong optical absorption in the UV range and rapidly and efficiently 
absorb the laser irradiation.  The ionisation process creates a vaporous mixture of 
charged particles which is accelerated down a so called flight tube through 
application of an electric field (Figure 1.5).  The time-of-flight (TOF) of the ionised 
particles depends on their mass-to-charge ratio (m/z) and the conversion of the flight 
times to corresponding m/z is achieved via a quadratic transformation in which the 
time of flight of the ion varies with the square root of its mass-to-charge ratio (van 
der Werff et al., 2008). 
 SELDI-TOF MS is a similar technique to MALDI-TOF MS, but the analyte 
is spotted on a target plate which has been coated to preferentially bind a sub-class of 
proteins and the unbound molecules are washed off (Hutchens & Yip, 1993).  
Examples of SELDI-TOF MS application include the analysis of the amyloid-β (Aβ) 
species in the cerebral cortex using Aβ-specific antibodies (Terai et al., 2001) and 
identification of biomarkers in synovial fluid for rheumatoid arthritis (Uchida et al., 
2002). During ESI, the liquid sample flows through a thin needle and, by application 
of high voltage, the small droplets are charged and a very fine spray is generated 
(Fenn et al., 1989).  During the passage from the needle to the MS instrument the 
solvent is evaporated and the density of the charges within the droplets rises, which 
















Figure 1.6 The Principle of electrospray ionisation.  
The analyte solution flow passes through the electrospray needle
 
across which there is a 
high potential difference. This forces the spraying of charged droplets from the needle 
with a surface charge of the same polarity to the charge on the needle. The droplets are 
repelled from the needle and as the droplets traverse the space between the needle tip 
and the cone, solvent evaporation occurs.  The droplet then shrinks until it reaches the 
point that the surface tension can no longer sustain the charge,
 
at which point the droplet 
is fragmented into small molecules.  These charged analyte molecules (they are not 
strictly ions) can be singly or multiply charged.  Diagram illustrated by Dr. P Gates 


















Figure 1.5 The Principle of MALDI-TOF Mass Spectrometry 
Bombardment of sample molecules with a laser light brings about sample ionisation.  
The laser energy is transformed into excitation energy by the matrix compound with 
which the sample has been mixed.  The analyte and matrix ions are then released and 
the time taken for them to be detected, which is directly proportional to their size, is 
converted to a mass-to-charge ratio (m/z).
Measurement
Matrix-embedded analyte











Since the m/z value is in many cases not unique for a protein or a peptide, it 
is often not sufficient for an unambiguous protein identification (Frohlich & Arnold, 
2006).  Therefore, tandem mass spectrometry (MS/MS) techniques have been 
employed which consist of firstly identifying the m/z of the precursor ion and 
secondly, isolating the precursor ion from all other peptide ions in the instrument and 
dissociating them into fragments, the masses of which are determined in the second 
MS step (McLafferty, 1981).  The most common fragmentation techniques for 
peptide ions is the collision induced dissociation (CID), where peptide ions collide 
with inert gas atoms or molecules such as He, Ar, N2 (Hayes & Gross, 1990).  The 
MS/MS spectra obtained are correlated with theoretical spectra calculated from 
sequence databases as described before.   
Identification of proteins in samples which have been subject to mass 
spectrometry is carried out using a probability-based scoring algorithm, Mascot, that 
uses information from either molecular weights of digested proteins or tandem mass 
spectrometry (MS/MS) data against protein databases such as the national centre for 
biotechnology information (NCBI) or SwissProt (Perkins et al., 1999).      
A summary of the potential advantages and disadvantages of different mass 
spectrometry or MS-linked techniques with regard to large-scale quantitation of 
proteins in complex mixtures is shown in Table 1.2. 
Two main approaches have been suggested for in vitro analysis of proteins by mass 
spectrometry (Chait, 2006).  One involves the use of intact proteins which have not 
been subject to cleavage and would therefore be a true representation of the state of 
the complex mixture in vivo.  These methods are generally referred to as ‘top-down’ 
approaches.  On the other hand many mass spectrometry techniques depend on 
labelling of the products of protein digestion.  These methods have proven successful 
in relative quantitation of proteins in complex mixtures and are generally classified 














Have been successful in 
identification of proteins in
simple mixtures.
Use in relative/absolute 
quantitation in complex
mixtures is not established 
> 950 Protein identification in  
complex mixtures can only be
carried out with certainty
when coupled with MS/MS.
ESI > 100 Allows identification of 
proteins of up to 100 kDa
in conjunction with LC-MS.
Use in quantitation of 








CE > 2-10 High sensitivity achieved 
when coupled with other
instruments e.g. FT-ICR.
Relative quantitation of 





Low volume of starting
material required (~10 nl of
plasma).








> 100 Relative quantitation of 
proteins in complex 




al., 2005; Ziese, 2006)
when coupled with MS/MS.
Involves extensive upstream
sample treatment i.e. gel 
separation and
immunodepletion.
A major limitation is the
expensive cost of reagents.
Table 1.2 Summary of the techniques used in identification and characterisation of 
proteins in complex mixtures.
A summary of approaches involved in mass spectrometry or MS-linked techniques used 
in the identification and/or quantitation of proteins in complex
 
mixtures.  Major 
advantages and disadvantages of each technique have also been summarised. 
21
1.2.1.2.1 Top-down’ approach 
 
ESI has been the standard ionisation method for liquid chromatography (LC)-MS and 
LC- MS/MS (Figure 1.5), although separated protein fractions can also be deposited 
onto a MALDI target for analysis.  In LC-ESI, the elute is directly pumped, at low 
flow rates (~ several nl/min) through a small diameter electrospray emitter needle 
thereby spraying the protein solution into the mass spectrometer (Righetti et al., 
2005).  ESI is especially useful in the analysis of macromolecules as it overcomes the 
propensity of these molecules to fragment when ionised (Baldwin, 2004).  This 
method of ionisation can be employed by mass spectrometry techniques such as 
Fourier transform ion cyclotron resonance (FT-ICR) in the ‘top-down’ analysis of 
proteins (Adkins et al., 2005).  FT-ICR MS is a high resolution technique with high 
accuracy in determining protein masses, with sub-femto mol sensitivity (Hipple et 
al., 1949).  The technique is based on trapping ions in a fixed magnetic field and 
applying an excitation pulse which results in higher energy movement of ions, whose 
frequency is proportional to the mass-to-charge ratio.          
MALDI-TOF MS has enabled the analysis of a large number of proteins and 
peptides (Hillenkamp et al., 1991).  In contrast to ELISA, MALDI-TOF MS allows 
detection of the analyte directly by an intrinsic property – its molecular weight 
(Figure 1.5).  An MS protein profile can be used to detect multiple biomarkers 
simultaneously, by the use of sophisticated pattern determination and class prediction 
algorithms.  However, there have been concerns about the reproducibility and 
coverage of MALDI/SELDI-TOF MS.  MALDI-TOF profiling of plasma proteins 
and peptides has been carried out after sample pre-treatment with magnetic beads 
(Villanueva et al., 2004; Villanueva et al., 2006).  These studies showed that plasma 
from brain tumour patients could be distinguished from controls with 96% certainty 
based on a pattern of 274 peptide masses.  A study of plasma samples from patients 
with ovarian cancer, compared with normal controls, observed protein profiles 
(1,000-12,000 kDa) using MALDI-TOF MS which significantly differed between 
cases and controls (Callesen et al., 2005).  On the other hand, a study of differential 
protein patterns between plasma samples collected from 82 pancreatic cancer 
patients and 40 controls showed low specificity associated with detection of only the 
highly abundant plasma proteins (Koomen et al., 2005).   
 22
Protein fractionation prior to MS is a technique that can be used to solve the 
problem of sample complexity.  Capillary electrophoresis coupled with FT-ICR 
followed by MS is an example of such techniques.  In capillary electrophoresis (CE), 
a large voltage (usually around 30 kV) is applied across a narrow bore silica capillary 
(75 mm internal diameter) and separation is based on differences in solute velocity in 
an electric field.  The solute velocity is a function of an ion’s electrophoretic mobility 
and applied voltage.  The bulk flow of molecules through the system, when a current 
is applied, is by electro-osmotic flow (EOF).  The magnitude of EOF is strongly 
dependent on pH; at high pH, EOF is greater than at low pH. CE-MS/MS analysis 
requires only nanolitres of sample and each analysis can be completed in less than 60 
minutes.  Capillary electrophoretic techniques have been employed in protein 
quantitation of complex bodily mixtures including urine (Weissinger et al., 2004) 
and plasma (Gay-Bellile et al., 2003; Zinellu et al., 2005).  However, to date, studies 
have only succeeded in quantitative assessment of highly abundant proteins such as 
creatinine, albumin and globulins in plasma, and fragments of albumin in urine. 
Furthermore, all quantitation procedures have involved comparison of disease cases 
and controls and no assessment of normal variation has been carried out. 
 
1.2.1.2.2 Bottom-up’ approach 
 
Conventional methods of protein characterisation such as the TOF instruments, 
MALDI and SELDI, or ionisation techniques, often fail with low abundance proteins 
due to the sequestering effect of the high abundance proteins in complex mixtures.  
Quantitative analysis of plasma proteins is also limited to differential protein profiles 
compared between disease cases and healthy controls (Villanueva et al., 2004; 
Villanueva et al., 2006; Callesen et al., 2005) which has also been shown to suffer 
from lack of sensitivity (Koomen et al., 2005).  Analysis is also limited to those 
proteins that fit the optimal size or concentration range for the MS methods (Koomen 
et al., 2005).  To overcome some of the above limitations, a number of advances 
involving the stable isotope labelling technology for relative quantitative profiling 
via mass spectrometry have been established.   
The relative quantitation approach by labelling is based on the abundance 
ratios of the individual proteins in two or more biological stages or samples (Frohlich 
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& Arnold, 2006).  A common strategy is to firstly label the samples with chemically 
identical reagents (i.e. stable non-radioactive isotopes) differing in their isotopic 
composition and hence in their molecular weight (so called heavy and light reagents), 
and secondly to pool samples after labelling and thirdly, to perform LC-MS/MS 
experiments.   
Isotope coded affinity tags (ICAT) are the most widely used of these 
techniques (Gygi et al., 1999), in which two samples (i.e. control versus 
experimental) are covalently labelled with chemically identical affinity tags (e.g. 
biotin) that differ only in isotopic composition.  The samples are combined, 
enzymatically digested and the labelled peptides are selectively enriched by affinity 
chromatography based on the tags (e.g. biotin avidin).  ICAT-labelled peptide 
fragments differ in mass by a known amount and can be separated and quantified by 
mass spectrometry.  A major drawback of this technique is that only cysteine 
residues can be labelled, resulting in loss of many important proteins, especially 
those with post-translational modifications.  ICAT has been successfully applied to 
the comparison of the relative quantities of proteins between two samples from 
cultured liver cells (Yan et al., 2004), animal tissues (Harris et al., 2003) and human 
plasma (Wu et al., 2003).   A similar approach, referred to as stable isotope labelling 
by amino acids in cell culture, SILAC, involves labelling proteins by growing cells in 
media containing isotopically labelled amino acids including 2H-leucine, 13C-lysine, 
13C-tyrosine, 13C-arginine and 13C/15N-arginine rather than using a covalently-linked 
tag (Ong et al., 2002).  An advantage of SILAC is that the stable isotopic tags are 
incorporated into the early stages of sample preparation and thus reduce variation 
between samples.  A disadvantage is that this method is not practical for analysing 
biological samples that cannot be grown in culture, such as bodily fluids.   
A variation of the ICAT technology, which has been reliably used for relative 
quantitation of proteins in multiple samples involves the use of isobaric tags for 
relative and absolute quantitation (iTRAQ™) (Ross et al., 2004).  The iTRAQ 
reagents consist of a reporter group, a balance group and a peptide reactive group.  
The peptide reactive group specifically reacts with primary amine groups of peptides.  
The reporter group is a tag with a mass of 114, 115, 116 and 117 Da depending on 
differential isotopic combinations in each individual reagent.  The balance group 
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ranges in mass between 28 to 31 Da to ensure that combined mass of the reporter and 
the balance groups remain constant (145 Da).  Peptide labels with different isotopes 
are isobaric and are chromatographically indistinguishable which are important for 
accurate quantitation.  During collision induced dissociation, the reporter group ions 
fragment from the backbone peptides displaying distinct masses of 114 to 117 Da.  
The intensity of these fragments is used for quantitation of the individual 
representative peptides.  The most important advantage of iTRAQ is that it allows 
labelling of up to four samples within a single experiment.  This technology has been 
successfully applied to the quantitation of proteins in yeast (Ross et al., 2004) and 
also to the relative quantitation of proteins in tissue samples of diseased individuals 
compared with the normal controls (DeSouza et al., 2005). 
 Another method for separation and characterisation of protein molecules is 
ion exchange chromatography (IEC).  IEC is based on the interaction between 
charged solute molecules and an oppositely charged resin covalently linked to a 
chromatography matrix (Bonnerjera et al., 1986).  Following the reversible binding 
of the desired solute molecules to the matrix based on their net ionic charge, and 
release of the unbound substances, the bound fraction is eluted by changing the 
elution conditions to ones that are unfavourable for ionic bonding of the solute 
molecules.  This is achieved by increasing the ionic strength of the eluting buffer or 
by changing its pH.  IEC coupled with LC-MS/MS is a label-free method for relative 
quantitation of proteins and requires comparison of identical proteolytic peptides to 
accurately determine relative ratios of the proteins which depend on the accuracy of 
mass measurement and chromatographic reproducibility (Frohlich & Arnold, 2006).  
IEC LC-MS/MS has been successfully used to determine relative quantities of 
proteins in human plasma by the use of internal controls of known concentration 
(Chelius & Bondarenko, 2002). 
 
1.3 Alzheimer disease 
 
Alzheimer disease (OMIM # 104300) is the most common cause of dementia in 
Western societies.  United Nation population projections estimate that the number of 
people older than 80 years will approach 370 million by the year 2050.  Currently it 
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is estimated that 50% of people over the age of 85 are afflicted with Alzheimer 
disease.  If these statistics hold true, in 50 years, more than 100 million people 
worldwide will suffer from dementia.   
The onset of Alzheimer disease (AD) is gradual with the appearance of 
clinical symptoms occurring in most sufferers between 60-70 years of age.  AD is 
characterised by progressive loss of cognitive function.  The pathological hallmarks 
of the disease include formation of extracellular senile (neuritic) plaques containing 
β-amyloid (Aβ) and intracellular tau-rich neurofibrillary tangles (NFT), associated 
with widespread neuronal degeneration (Glenner & Wong, 1984; Masters et al., 
1985; Spires & Hyman, 2004).  Morphological changes preceding cell death change 
the connectivity of neurons and consequently disrupt the signalling in neuronal 
circuits.  Neurons involved in higher-order functions such as learning, memory, 
consciousness, perception and self-awareness are particularly vulnerable in AD 
(Spires & Hyman, 2004).  The assembly of Aβ into protofibrils, fibrils, or other toxic 
moieties has long been implicated as a key pathologic trigger of AD, leading to the 
amyloid hypothesis of Alzheimer disease (Hardy & Selkoe, 2002) (Figure 1.7). The 
cloning of the gene encoding a large single transmembrane protein, Amyloid 
Precursor Protein (APP) and discovery of mutations in familial Alzheimer disease 
(FAD) patients led to the hypothesis that Aβ accumulation is the primary event in 
AD pathogenesis (Hardy & Selkoe, 2002).  Earlier recognition that trisomy 21 
(Down’s syndrome) invariably led to the neuropathology of AD by the 4th or 5th 
decade of life further reinforced the hypothesis since APP is localised to 
chromosome 21 (Glenner & Wong, 1984).  APP is a type 1 transmembrane and cell 
surface receptor protein expressed in all cell types but mainly in the brain which is 
believed to be involved in synapse formation and transmission (Priller et al., 2006).  
Since amyloid plaques are a defining feature of AD neuropathology, and Aβ can be 
detected in cerebro-spinal fluid (CSF) and plasma, Aβ measures in biological fluids 






Figure 1.7 The sequence of pathogenic events leading to Alzheimer disease as 
proposed in the amyloid cascade hypothesis.




may directly injure the synapses and 
neurites
 
of brain neurons, in addition to activating microglia
 
and astrocytes.  This 
phenomenon has been implicated as the key patho-physiological hallmark of AD.  
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 Aβ is a normal product of APP metabolism throughout life.  In addition to 
causing FAD, mutations in the APP gene can also cause hereditary cerebral 
hemorrhage with amyloidosis (Dutch type), which have been shown to result in Aβ 
deposition largely in blood vessels and outside the brain parenchyma (van 
Broeckhoven et al., 1990).  Aβ is proteolytically derived from APP as a result of 
sequential cleavages by β- and γ-secretases (Vetrivel & Thinakaran, 2006) (Figure 
1.8).  β-Secretase has been identified as a type I membrane aspartyl protease.  γ-
Secretase is believed to be a multi-protein complex composed of presenilins I and II, 
nicastrins, Anterior Pharynx defective 1 Homolog (C. elegans) (APH1), and 
Presenilin Enhancer 2 homolog (C. elegans) (PSEN), with presenilin believed to be 
the functional catalytic subunit.  The C-termini of secreted N-terminal Aβ peptides 
are generated by three major intra-membranous cleavages, including one referred to 
as γ-cleavage, which cleaves at residues 40 or 42 for Aβ40 and Aβ42, respectively 
(Figure 1.8).  This produces the C-termini of Aβ species that end at amino acids 40 
(Aβ40) or 42 (Aβ42) with molecular masses of 4.3 kDa and 4.5 kDa, respectively.  A 
second type of cleavage, ε-cleavage, occurs between Aβ residues 49 and 50 and 
produces the N-terminus of most of the APP intracellular domain (AICD).  A third 
major cleavage site, ζ-cleavage, has also been identified at Aβ46, between the known 
γ- and ε-cleavage sites (Zhao et al., 2004).  Aβ46 has recently been identified as an 
intermediate precursor of Aβ which is tightly associated with presenilin in intact 
cells (Zhao et al., 2005).  Zhao and colleagues showed that another intermediate 
product, Aβ49, is generated by ε-cleavage, which is further processed by ζ- and γ-
cleavage to generate Aβ46 and ultimately the secreted Aβ40 and Aβ42.   
Amyloid fibrils are filamentous structures with width of ~ 10 nm and a length 
of 0.1-10 μm.  A defining feature, originally revealed by X-ray fibre diffraction 
analysis is the presence of cross-β structures (Chaney et al., 1998).  Ribbon-like β-
sheets are formed by β-strands running nearly perpendicular to the long axis of the 
fibril and hydrogen bonds that run nearly parallel to the long axis (Ross & Poirier, 




Figure 1.8 Proteolytic processing of APP. 
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Covalent modification of proteins such as oxidative modifications associated 
with ageing may also facilitate aggregation, as in sporadic forms of 
neurodegenerative diseases (Ross & Poirier, 2004).  Ageing may also decrease the 
ability of the cell to clear misfolded proteins (Ross & Poirier, 2004).  
1.3.1 Genetics of Alzheimer disease 
 
The initiation of aggregation can be due to protein-coding mutations, which result in 
the autosomal dominant FAD, which is believed to account for ~1% of all AD cases 
(St George-Hyslop et al., 1987; Finckh et al., 2005).  The age at onset in these 
families is typically in the 40's and 50’s, although sometimes as early as the 20’s.  
Pathogenic FAD mutations usually cluster at, or very near, the sites within APP that 
are normally cleaved by α-, β- and γ-secretases.  These mutations promote the 
generation of Aβ by favouring proteolytic processing of APP by β- or γ-secretase.  
Other single gene mutations have also been identified in PSEN1 (chromosome 14) 
and PSEN2 (chromosome 1), the genes encoding presenilin 1 and 2, respectively 
(Rubinsztein, 1997; Walker et al., 2005).  Furthermore, APP mutations internal to the 
Aβ sequence heighten the self-aggregation of Aβ into amyloid fibrils (Hardy & 
Selkoe, 2002) (Figure 1.8).   
Alzheimer disease provides an excellent paradigm for the genetic basis of a 
complex disorder, with contributions from both common modifier genes and rare 
variants of large effect.  Heritability of AD has been estimated to be around 67% and 
22% in monozygotic and dizygotic twins, respectively (Gatz et al., 1997), suggesting 
that genetic variation plays a significant role in the disease process.  However, the 
major insights into disease mechanisms to date have come from mutations in genes 
that are so rare that they make essentially no contribution to the heritability of the 
disease as a whole (Chinnery, 2006).  Case-control studies have high sensitivity for 
detecting risk alleles influencing multifactorial disorders; however, almost none of 
the association findings in late onset AD (LOAD) have turned out to be reproducible 
and therefore most fall into the category of false-positive results (Schellenberg et al., 
2004; Prince et al., 2001; Finckh, 2003).   
To date only one gene, APOE, has been reliably associated with LOAD in 
multiple studies.  The APOE gene, described later in more detail, has three common 
 30
alleles APOE*E2, APOE*E3 and APOE*E4, and serves as one of the best examples 
of the common disease-common variant hypothesis (Reich & Lander, 2001).  The 
APOE*E4 allele has been associated with an increased risk of AD in many studies, 
by promoting an earlier age at onset in a dosage-dependant manor (Saunders et al., 
1993; Corder et al., 1993).  For example, a person of European descent who is 
homozygous for the APOE*E4 allele has a lifetime risk of AD that is two times as 
great as that for a heterozygous individual and four times as great as that for someone 
of European descent who does not have an E4 allele (Bird, 2005).  Although the 
association between the E4 allele and AD has been replicated in many studies, the 
protective effect of the less common E2 allele is still disputed and requires further 
investigation (Corder et al., 1994; Smith et al., 1994).  The estimated contribution of 
APOE*E4 to the total variation in age at onset of AD has been estimated to be 7-9% 
(Daw et al., 2000).  Daw and colleagues suggest that several other loci may play a 
significantly larger role than APOE in susceptibility to LOAD (Daw et al., 2000).   
The analysis of intermediate or quantitative traits such as plasma or CSF Aβ 
is a major advantage in that it provides greater power for detecting genetic influences 
on AD compared with binary case/control studies (Brookes & Prince, 2005).  
 
1.3.2 Biochemistry and genetics of amyloid-β 
 
Secreted, soluble Aβ40 and Aβ42 are products of normal cell metabolism which are 
found in various bodily fluids, including plasma and CSF.  In AD brains, Aβ42 has 
been found to be deposited first and constitutes the predominant form in senile 
plaques (Hardy & Selkoe, 2002).  Aβ40 is deposited later in the disease and is more 
prominent in vascular amyloid deposits.  Although cerebral deposition of Aβ42 is 
unlikely to directly result from increased plasma Aβ42, elevated plasma levels 
probably do reflect a generalised alteration in Aβ in both neural and non-neural cells 
(Mayeux et al., 1999).  It has been proposed that elevated plasma levels of the 
released Aβ42 may be detected several years prior to the onset of symptoms (Figure 
1.9) (Mayeux et al., 2003) and Aβ42 concentrations are believed to gradually 
decrease in CSF and plasma because of preferential sequestration as insoluble 
deposits in brain (Figure 1.10) (van Oijen et al., 2006). 
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Figure 1.9 Risk of Alzheimer disease by quartiles of plasma Aβ42 concentration.
The graph shows the cumulative proportion of individuals developing Alzheimer disease 
(AD) over a ten year period of follow-up by the plasma Aβ42 concentrations at the 
baseline (mean age=83.2 years). These results show that individuals with increased 
plasma Aβ42 concentrations are at an increased risk of developing AD. Filled circles, 
Aβ42>84.15 pg/ml; triangles, 60.2<Aβ42<84.15 pg/ml; asterisks, 36.97<Aβ42<60.2 pg/ml; 
open circles, Aβ42<36.97. Figure adapted from Mayeux
 
et al., 2003. 
Figure 1.10 Hazard ratios for dementia by concentrations of Aβ40 and Aβ42.
Diagram showing the significant effect of high plasma concentrations of Aβ40 combined 
with low concentrations of Aβ42 on increased risk of dementia. These results show that 
individuals with concentrations in the highest tertile
 
of Aβ40 combined with concentrations 
in the lowest tertile
 
of Aβ42 compared with individuals with concentrations in the lowest 
tertiles
 
of both Aβ40 and Aβ42 (R), are at 10 times increased risk of developing AD. *P
 
< 




The genetic component responsible for the variability of plasma Aβ has been 
estimated previously from the additive (narrow-sense) heritability of plasma Aβ40 
and Aβ42 (Ertekin-Taner et al., 2001).  This study was based on analysis of 15 
extended LOAD families (N = 396) ascertained via AD patients or first-degree 
relatives with high plasma Aβ levels.  Narrow-sense heritability was found to be 
73% for Aβ42 and 54% for Aβ40 (both highly significant) using a variance 
component methodology.   
Ertekin-Taner and colleagues have since analysed two genes, Catenin 
Cadherin-associated protein alpha 3 (CTNNA3) and Plasminogen Activator 
Urokinase (PLAU)) on chromosome 10q, previously shown to be linked to AD using 
extended LOAD pedigrees (Ertekin-Taner et al., 2000).  CTNNA3 encodes α-T 
catenin, which is expressed at high levels in human and mouse brain and interacts 
with β-catenin.  This makes CTNNA3 a strong functional candidate because β-
catenin interacts with presenilin 1 (Zhang et al., 1998), in which mutations have been 
shown to increase Aβ42 concentration in plasma and cause early-onset FAD (St 
George-Hyslop et al., 1987).   
PLAU, a gene encoding urokinase-type plasminogen activator which converts 
plasminogen to plasmin, has also been shown to be associated with risk of LOAD in 
10 extended families (N = 554) ascertained via the presence of a proband with high 
plasma Aβ concentration (Ertekin-Taner et al., 2005).  This association has been 
replicated in six independent case/control LOAD cohorts (Neach > 200) (Ertekin-
Taner et al., 2005).  Others have reported the absence of association between variants 
in PLAU and risk of LOAD in three independent cohorts, consisting of 200-800 
individuals (Myers et al., 2004).  The PLAU protein is a serine protease which is 
involved in degradation of the extracellular matrix.  Aβ aggregates might induce 
PLAU expression, thereby increasing plasmin which degrades both aggregated and 
non-aggregated forms of Aβ (Ertekin-Taner et al., 2003).   
Furthermore, plasma Aβ40 and Aβ42 have also been shown to increase in 
PLAU knockout (KO) mice by 11 months of age, suggesting that this effect may 
become more pronounced with ageing (Ertekin-Taner et al., 2005).     
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The above studies have reinforced the need to identify genetic variants 
influencing both susceptibility to LOAD and circulating Aβ concentrations.  A 
thorough analysis of QTL associated with changes in plasma Aβ concentrations 
could lead to the discovery of new biochemical pathways involved in the 
pathogenesis of Alzheimer disease. 
 
1.3.3 Rodent models of Alzheimer disease 
 
Several rodent models of AD have been developed which display the amyloid plaque 
pathology (as a result of APP over-expression), the neurofibrillary tangle (NFT) 
pathology (as a result of microtubule-associated protein tau tangle formation) or 
both.   
 Table 1.3 summarises the models developed to date and their advantages and 
disadvantages in relation to the neuropathology of plaque or NFT phenotypes.  Other 
phenotypes such as memory deficits and age of onset of pathology have also been 
assessed in these models (Spires & Hyman, 2005).   
 The amyloid plaque models have aimed at over-expressing human APP or 
fragments of it that contain missense variants which have been detected in the 
familial forms of the disease in humans.  Although all such models have resulted in 
plaque formation as early as three month, some, like the PDAPP mice (Games et al., 
1995), do not display global neuronal loss (Irizarry et al., 1997).  The Tg2576 (Hsiao 
et al., 1996), APP23 (Sturchler-Pierrat et al., 1997), TgCRND8 (Dudal et al., 2004) 
and APPSwe TgC3-3 (Borchelt et al., 1997) mice all develop the amyloid plaque 
neuropathology, with neural loss of up to 14% (in the case of APP23) and memory 
loss (not reported for APPSwe TgC3-3) between 3 and 18 months (Table 1.3).   
 Mutations in the human APP gene cause only a small fraction of the already 
rare number of FAD cases, therefore, FAD-associated presenilin variants have been 
used to generate animal models carrying both APP and PSEN missense variants.  For 
example, the PSAPP mice (cross between Tg2576 and PSEN1 M146L) (Holcomb et 
al., 1998) show elevated concentrations of Aβ42 in the brain and an accelerated rate 


































































































































































































































































































































































































































































































































































The Tg478/1116/11587 transgenic rat model (carrying two APP variants and 
PSEN1 M146V) (Spires & Hyman, 2005) shows amyloid deposition similar to that 
seen in Tg2576 mice (Table 1.3).  The advantage of using rat models of AD is that 
several types of experiment such as behavioural testing of cognitive function and 
electrophysiological recordings can be carried out more easily than in mice.   
 Several mouse models of the NFT phenotype have also been developed.  In 
healthy adult brain, MAPT is located in axons but in AD and other taupathies (such 
as Parkinson’s disease), it is hyperphosphorylated and is found in cell bodies and 
dendrites as well as axons (Brion et al., 1985).  The two TNF mouse models, ALZ7 
(Gotz et al., 1995) and ALZ17 (Probst et al., 2000), show hyperphosphorylation of 
MAPT but do not develop NFT (Table 1.3).  These two models show that 
overexpression of the normal human MAPT is insufficient to induce NFT formation 
but the localisation of MAPT in neurons does resemble the pre-tangle state in AD.  
The best model developed to date, is the 3xTg-AD mouse (Oddo et al., 2003) which 
harbours the APP (Swedish), PSEN1 (M146V) and MAPT (P301L), which develops 
Aβ plaques around 3 months of age and tangles after the amyloid pathology.  The 
regional and temporal development of pathology closely mimics the development of 
pathology in AD, making this a good disease model.   
 The development of animal models of AD has led to promising targets for 
therapeutics.  Successful findings include the targeting of the PSEN1 action by 
nonsteroidal anti-inflammatory drugs (NSAIDs) which modulate γ-secretase 
cleavage in 11-month old Tg2576 mice leading to reduced plaque formation (Yan et 
al., 2003).  Metal ions have been implicated as Aβ-interacting molecules leading to 
reduced risk of AD (Gnjec et al., 2002), and treatment of Tg2576 mice with the 
antibiotic clioquinol that chelates zinc and copper ions has resulted in decreased Aβ 
brain deposition (Lee et al., 2002).  Finally, immunotherapy with Aβ antibodies in 
3xTg mice has resulted in plaque clearance and a reduction in NFT formation (Oddo 
et al., 2004).  However, the clinical trial involving human AD patients was 
unsuccessful due to 6% of the participants developing meningoencephalitis 
(Orgogozo et al., 2003). 
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1.4 Biochemistry and genetics of APOE 
 
Apolipoprotein E (OMIM # 107741) is a member of the apolipoprotein multi-gene 
family, which also includes APOA1, APOA2, APOA4, APOC1, APOC2 and APOC3.  
The APOE gene is located on chromosome 19q13.2 and is closely linked to the 
APOC1/C2 gene complex.  It consists of four exons and three introns spanning 3,597 
nucleotides and encodes a 299 amino acid polypeptide (Eichner et al., 2002).  The 
APOE protein is synthesised primarily in the liver but other organs and tissues, 
including brain, spleen, kidneys, gonads, adrenals and macrophages, also produce it.  
APOE plays a central role in plasma lipoprotein metabolism and in lipid transport 
within tissues (Mahley, 1988).   
Three major APOE isoforms are found in humans, E2, E3 and E4 identified 
by isoelectric focusing (Utermann et al., 1979).  These isoforms differ in amino acid 
sequences at two sites, residue 112 and residue 158.  E2, E3 and E4 isoforms contain 
cys112/cys158, cys112/arg158, and arg112/arg158, respectively (Weisgraber et al., 1981; 
Rall et al., 1982).   
The products of the three common APOE alleles differ in their affinity for 
binding low-density lipoprotein (LDL) receptors and lipoprotein particles 
(Weisgraber et al., 1981).  The APOE isoforms interact differently with specific 
lipoprotein receptors, altering circulating levels of cholesterol (Dong et al., 1994).  
Studies have associated APOE*E2 carriers with lower levels of plasma total and 
LDL cholesterol, compared with those in APOE*E3 homozygotes (Schneider et al., 
1981; Weisgraber et al., 1982; Utermann et al., 1985; Sing & Davignon, 1985).  
However, these results are open to dispute due to the low frequency of the APOE*E2 
allele in the general population (0.08 in the UK population) (Corbo et al., 1995; 
Lucotte et al., 1997).  Moreover, few studies have large enough sample sizes to 
examine the less prevalent E2/E2 genotype (0.003 in the UK population) (Corbo et 
al., 1995; Lucotte et al., 1997).  The APOE*E4 allele displays an opposite pattern 
with higher associated concentrations of total and LDL cholesterol (Utermann et al., 
1985; Sing & Davignon, 1985; Davignon et al., 1988) and has been shown to be 
associated with increased risk of cardiovascular disease (Scuteri et al., 2005; Kang et 
al., 2005).   
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Studies of non-human primates have revealed that they carry the APOE*E4 
allele (Hanlon & Rubinsztein, 1995).  This suggests that E4 is the ancestral allele and 
that after the human and chimpanzee lineages split, E3 and E2 arose by mutation 
events and later spread among humans.  Selection may also have contributed to the 
present distribution of the APOE alleles since the three alleles differ in their 
functional properties (Hanlon & Rubinsztein, 1995).  The E3 allele has been shown 
to be the most frequent in all human populations (0.78 in the UK population).  
Furthermore, the frequency of the E3 allele is negatively correlated with that of E4.  
The highest frequencies of the E3 allele are found in populations with a long 
established agricultural economy (Mediterranean, 0.85-0.89; or East Asian 0.82-
0.87) compared with African populations (Pygmies, 0.54).  The frequency of the E4 
allele remains higher in populations with lower plasma cholesterol levels (e.g. 
Pygmies, 0.41) than those observed in Western countries (Mediterranean, 0.07) in 
which an economy of foraging still exists, or the food supply has been scarce (Corbo 
et al., 1999). 
 
1.4.1 APOE and dementia 
 
Gene dosage of the APOE*E4 allele has been shown to be a major risk factor for 
familial and sporadic Alzheimer disease (Saunders et al., 1993; Corder et al., 1993).  
The first reported association between APOE*E4 and late-onset AD (LOAD) showed 
a reduction of 17 years in age of onset associated with every copy of the E4 allele 
(Corder et al., 1993).  However, this may have been overestimated due to the small 
sample size used (N < 100) leading to the “Beavis effect” (Beavis, 1994).  The 
Beavis effect was first demonstrated using large-scale simulation experiments, which 
examined 10 or 40 associations where each associated genetic marker explained a 
proportion of the phenotypic variance ranging from 0.75 to 9.5% with sample sizes 
ranging from 100 to 1,000.  The experiment showed that the average estimates of 
phenotypic variances associated with correctly identified markers were greatly over-
estimated if only 100 progeny were evaluated, slightly over-estimated if 500 progeny 
were evaluated and fairly close to the actual magnitude if 1,000 progeny were 
evaluated.    
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A study consisting of 115 unrelated LOAD cases and 243 healthy age-
matched controls showed that APOE*E4 was associated with increased risk of 
LOAD with odds ratios of 19.3 (two copies) and 4.4 (one copy) in an age-dependent 
manor (Corder et al., 1994).  Similar findings have been obtained by several well-
powered studies (N > 400) (Lucotte et al., 1994; Myers et al., 1996; Bickeboller et 
al., 1997).        
APOE is produced in abundance in the brain and is induced to reach high 
concentrations in response to peripheral nerve injury (Mahley & Rall, 2000).  It also 
appears to play a key role in repair by redistributing lipids to regenerating exons and 
to Schwann cells during remyelination (Mahley, 1988).  A key to understanding the 
role of APOE in neurological diseases is believed to reside in determining how 
APOE modulates neural repair and protection (Mahley & Rall, 2000).  It has been 
hypothesised that the APOE isoforms differentially affect amyloid plaque formation 
by direct protein-protein interaction, Aβ peptide metabolism, or both.  Lipid-free 
APOE*E4 has been shown to form a stable complex with Aβ peptide in vitro 
(Strittmatter et al., 1993).  In contrast, lipidated APOE*E3 has been found to bind 
Aβ peptide with a 20-fold higher affinity than lipidated E4 (Figure 1.11) (Stratman 
et al., 2005).  The increased binding of lipidated E3 and E2 to Aβ species could 
enhance their clearance, preventing the accumulation of the neurotoxic Aβ species 
(Mahley & Huang, 1999). 
 
 
1.5 Age-related macular degeneration 
 
Age-related macular degeneration (AMD) (OMIM # 603075) is the most common 
cause of irreversible visual loss in the elderly population of developed countries, with 
approximately 25 million people affected worldwide (Evans & Wormald, 1996).  
AMD is characterised by degeneration of the macula.  An intermediate stage of the 
disease, called age-related maculopathy (ARM), affects about 12 million individuals 
worldwide while the late-onset, advanced forms of the disease including dry AMD 
(geographic atrophy) and wet (neovascular) form of AMD or affects about 8 million 
people worldwide (Vingerling et al., 1995).    
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Figure 1.11 The hypothetical isoform-specific effects of APOE on neuronal 
repair, remodelling and protection.




















 The wall of the human eyeball consists of three layers of tissue: the outer 
supporting layer (forming the tough outer layer or sclera and the transparent cornea), 
the vascular middle layer (containing choroidal blood vessels) and the inner layer 
consisting of neural retina and the retinal pigment epithelium (RPE) (Figure 1.12).  
The RPE cells support the photoreceptors (rods and cones) by engulfing and 
phagocytosis of up to 10% of the photoreceptor outer segment each day, maintenance 
of the Bruch’s membrane (a specialised extracellular structure in the basement 
membrane of RPE), absorption of scattered light and transport of ions and fluids 
from the choriocapillaries (Lotery & Trump, 2007).  The retina is a ten-layered tissue 
consisting of three layers of neurones including 1- the light-sensitive photoreceptor 
rods and cones, 2- horizontal, bipolar and amacrine cells, and 3- the ganglion cells.  
AMD affects the macular region of the eye defined as the central area of the retina 
(central 10%, 5 mm diameter) containing the fovea, the only region of the retina 
where the density of photoreceptors is sufficient to permit high acuity vision.   
Early AMD is associated with moderate vision loss associated with 
extracellular deposits between the RPE and the Bruch’s membrane (BrM), which can 
either be focal (drusen) or diffuse (basal deposits).  Drusen are the hallmark of the 
disease and form between the basement membrane of the RPE and BrM.  Drusen 
have been shown to contain a complex mix of proteins, lipids and lipoproteins 
including complement factors (C1q, C3a and C5a) (Nozaki et al., 2006), complement 
regulators (complement factor H, C-reactive protein and clusterin) (Hageman et al., 
1999; Johnson et al., 2001), immunoglobulins (Johnson et al., 2001), amyloid-β, 
apolipoproteins and cholesterol esters (Mullins et al., 2000). 
Age-related macular degeneration can be referred to as either “dry” (85% of 
cases) (geographic atrophy) or “wet” (neovascular or exudative) (15% of cases).  The 
dry form is characterised by areas of hypopigmentation or depigmentation or 
apparent absence of the RPE, in which the choroidal vessels are more visible than in 
surrounding areas (Lotery & Trump, 2007).  Wet AMD is characterised by the 
presence of choroidal neovascularisation (CNV) resulting in sub-retinal 







Figure 1.12 The structure of the human eye. 
A.
 
Schematic cross section of the human eye indicating its main structures.  The 
macula is a cone-rich area located in the centre of the retina. B.
 
Horizontal section of a 
human eye stained with haematoxylin and eosin (left) and a schematic diagram (right) 
showing the variety and the organisation of the retinal neurons.
 
The outer nuclear layer 
(ONL) comprises the nuclei of rod and cone photoreceptor cells, where the 
phototransduction
 
takes place.  The inner nuclear layer (INL) contains the nuclei
 
of 
Muller, horizontal, bipolar and amacrine
 
cels.  The ganglion cell (GC) layer is the most 
apical layer of the retina.  The retina is in close proximity to
 
the retinal pigment 
epithelium.  Images taken from http://images.medicinenet.com/images/illustrations
 
(A), 
Vlachantoni, 2006 (B, left) and http://webvision.med.utah.edu/imageswv/scheme.jpg
 
(B, 























 AMD is a progressive disease with genetic influences as well as other strong 
risk factors including increasing age (Klein et al., 1992, 1997; Friedman et al., 2004), 
cigarette smoking (two- to four-fold increase in risk) (Christen et al., 1996; Seddon 
et al., 1996), diet (positive association between total fat intake and ARM) (Seddon et 
al., 1994, 2003a); Mares-Perlman et al., 1995) and BMI (high BMI associated with 
both dry and wet AMD) (Seddon et al., 2003b).  A direct molecular link between 
oxidative damage to the macular RPE and AMD has been established by finding 
protein modifications in drusen and BrM that can be generated from the oxidation of 
lipids and carbohydrates (Hollyfield et al., 2003).  Such modifications are likely to 
be found in drusen and BrM due to the photo-oxidative environment in the retina and 
the lipid-rich photoreceptor outer segments, which provide an excellent source of 
reactive oxygen species and oxidation products.  It has also been suggested that 
immune-mediated complement activation triggered by unknown signals from the 
RPE, are causally involved in the process of drusen formation which leads to AMD 
(Hollyfield et al., 2003). 
 
1.5.1 Genetics of AMD 
 
Familial aggregation studies (comparing AMD prevalence in relatives of cases to 
AMD prevalence in relatives of controls) and twin studies have provided strong 
evidence of an underlying genetic component to AMD.   
 In familial aggregation studies, the prevalence of AMD in first-degree 
relatives of 119 AMD cases was found to be significantly higher than in relatives of 
72 sex- and age-matched controls (23.7% vs. 11.6%) (Seddon et al., 1997).  Similar 
results have been found by others using siblings and offspring of AMD cases 
compared with age- and sex-matched controls, showing that siblings of individuals 
with AMD have a three to six-fold increase in disease risk (Klaver et al., 1998b; 
Klein et al., 2001).    
Twin studies have provided more direct evidence of AMD heritability by 
comparing disease concordance rates in monozygotic (MZ) versus dizygotic (DZ) 
twins.  A study of 840 US elderly male twins (210 MZ and 181 DZ twin pairs) and 
58 singletons, of whom 268 twin pairs showed signs of maculopathy (106 with 
advanced disease), found heritabilities of 0.67 for intermediate disease and 0.71 for 
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advanced disease (including geographic atrophy and exudative AMD) (Seddon et al., 
2005).  Similarly, a study of 506 pairs of female twins (226 MZ and 280 DZ pairs) 
with ARM  (defined as the presence of soft drusen, > 63 μm in diameter, no late 
AMD) found the concordance for ARM to be 0.37 (in MZ twins) and 0.19 (in DZ 
twins) and the heritability of ARM was estimated to be 0.45 (Hammond et al., 2002). 
Population-based studies of incidence and prevalence of AMD have shown 
that white individuals of European ancestry in US have a higher age-adjusted risk of 
developing AMD compared with individuals from other ethnic groups (Friedman et 
al., 2004).  A lower prevalence of AMD has also been reported in populations from 
Japan and China compared with Europe (Oshima et al., 2001; Li et al., 2006b).  It is 
not clear if these population-specific differences are due to genetic or environmental 
factors, or both; however, differences in disease prevalence between different ethnic 
groups emphasise the importance in design of genetic studies (Pritchard et al., 1999). 
Nearly every chromosome in the human genome has been implicated by one 
or more genome-wide linkage studies for AMD, indicating that multiple genes may 
by involved in the development of AMD.  However, most replicated linkage findings 
with statistical significance (LOD ≥ 3) have been on chromosomes 1q25-31 (Klein et 
al., 1998; Seddon et al., 2003c; Majewski et al., 2003; Iyengar et al., 2004; 
Jakobsdottir et al., 2005; Santangelo et al., 2005) and 10q26 (Majewski et al., 2003; 
Seddon et al., 2003c; Kenealy et al., 2004; Iyengar et al., 2004; Jakobsdottir et al., 
2005). 
1.5.2 AMD and the complement pathway 
 
The earliest links between the innate immune system and AMD susceptibility came 
from proteomic and biochemical analyses of the drusen obtained from eye donors 
(Hageman et al., 2001; Crabb et al., 2002).  Identification of complement 
components C3, C5b-9, and inhibitors of the membrane attack complex in the drusen 
suggested that specific immune-mediated pathways may play a significant role in the 
process of drusen biogenesis (Hageman et al., 2001; Crabb et al., 2002).   
 Complement is a central part of innate immunity, which mediates the immune 
response to infectious agents and links innate and adaptive immunity (Walport, 
2001).  The alternative pathway of the complement cascade recognises, attacks and 
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eliminates microbes or modified host cells, therefore it needs to be targeted to 
foreign surfaces and prevented from being activated on host cells and tissues 
(Walport, 2001).  The pathway is initiated in the fluid phase by the formation of C3 
by the enzyme C3 convertase, which cleaves C3 into C3a and C3b (Figure 1.13).  
The alternative pathway is non-discriminatory and the initial enzymatic components 
such as C3 are deposited on tissue surfaces but do not differentiate between activator 
and non-activator surfaces.   
In order to avoid damage, host cells need to actively and continuously 
downregulate amplification of the complement cascade (Zipfel et al., 2006).  There 
are four regulators of the alternative pathway which are expressed on the surface of 
host cells (CR1, MCP, DAF and CD59).  Two potent regulators are also found in the 
fluid phase, complement factor H (CFH) (150 kDa, plasma concentrations of 110-
615 μg/ml (Esparza-Gordillo et al., 2004)) and factor H-like protein 1 (FHL-1).  The 
full-length human CFH is a multidomain, multifunctional glycoprotein (Ripoche et 
al., 1988) which binds C3b, accelerates the decay of the alternative pathway C3 
convertase (C3bBb), acts as a cofactor for factor I-mediated proteolytic degradation 
of C3b and competes with factor B for binding to C3b together leading to down-
regulation of the alternative complement pathway (Figure 1.13) (Whaley & Ruddy, 
1976).  FHL-1 is an alternatively spliced product of the CFH gene with a molecular 
mass of 43 kDa (Misasi et al., 1989). 
The identification of the complement factor H (CFH) gene variants 
influencing AMD is one of the best examples of success in genome-wide association 
studies (GWAS) of common, complex disorders.  CFH rs1061170 (Y402H) is a 
common variant that was initially identified in a genome-wide association scan for 
polymorphisms associated with AMD (Klein et al., 2005; Edwards et al., 2005; 
Haines et al., 2005; Hageman et al., 2005).  These studies have shown that the CFH 
Y402H variant increases susceptibility to AMD with odds ratios (ORs) of 2.45 (one 
copy) and 5.57 (two copies) and the population attributable risk for AMD is 





Figure 1.13 Regulation of the Cleavage of C3 by Factor H and Factor I.
The first product of the cleavage of C3 by a C3 convertase
 
is C3b, which has an 
activated internal thioester
 
bond. This bond enables C3b to bind covalently to hydroxyl 
groups on nearby carbohydrates and protein-acceptor groups. If the acceptor molecule is 
on a host cell surface, then protective regulatory mechanisms come into play. This is 
illustrated by the binding of factor H to C3b, which acts as a cofactor to the serine 
esterase factor I. Factor I cleaves the C3 into an inactive product, iC3b, releasing a small 
peptide, C3f. The iC3b can no longer participate in the formation of a C3 convertase
 
enzyme. If C3b binds covalently to a bacterium, then the enzyme precursor factor B binds 
to the C3b. Factor B that is bound to C3b is susceptible to cleavage and activation by the 
enzyme factor D. This leads to the formation of the C3 convertase
 
enzyme C3bBb, which 
is stabilized by the binding of properdin. This enzyme cleaves more C3, leading to the 
deposition of additional C3b on the bacterium. The carbohydrate environment of the 
surface on which the C3b is deposited determines the relative affinity of C3b for factor H 




acid, factor H binds to 
C3b with a higher affinity than does factor B. On microbial surfaces that lack a 
polyanionic
 
coating, factor B binds to C3b with a higher affinity than does
 
factor H, 
leading to amplified cleavage of C3 (Diagram and text adapted from Walport, 2001).
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The association between CFH rs1061170 (Y402H) and AMD has been replicated by 
many studies in different populations (Zareparsi et al., 2005a; Lau et al., 2006; 
Simonelli et al., 2006). 
CFH is located on human chromosome 1q31 within the regulator of the 
complement activation (RCA) gene cluster which contains more than 60 genes of 
which 15 are complement-related genes, including CFHR1, CFHR2, CFHR3, 
CFHR4 and CFHR5, to which CFH is closely related.  CFH is a member of a group 
of structurally and immunologically related plasma proteins which consist of 
individually folding protein domains called short consensus repeats (SCRs) (Zipfel & 
Sherka, 1994).  CFH is capable of complement regulation in both the fluid phase and 
on the surface of cells where it is localised by binding to cell surface polyanions such 
as sialic acid and heparin-like glycosaminoglycans (GAGs) (Fearon et al., 1978).  
The CFH protein also binds cellular receptors such as CD18 (DiScipio et al., 1998), 
heparin (Meri & Pangburn, 1990), the acute phase protein C-reactive protein (CRP), 
although not confirmed by Jarva et al. (1999), and the surface of certain pathogenic 
microorganisms such as S. pyogenes, N. gonorrhoeae and B. afzelii (Lindahl et al., 
2000).  
The CFH rs1061170 (Y402H) polymorphism occurs in the SCR7 domain and 
has been shown to bind heparin, using an SCR7 construct and heparin-affinity 
columns  (Clark et al., 2006), and retinal pigment epithelial cells in vitro (Skerka et 
al., 2007).  This supports the case for a causal link between the polymorphism and a 
disease mechanism involving insufficient complement regulation in the ageing 
choroid.  CFH has also been found to co-localise with C3b in drusen of AMD 
patients (Hageman et al., 2005).  Direct coordination of the binding between GAGs 
and CFH by the Y402H variant has been shown using the crystal structure of the 
region containing the CFH Y402H variant (Prosser et al., 2007).   
The prevalence of CFH rs1061170 (Y402H) shows great variation between 
ethnic groups with a 34% frequency in the Caucasian and Somali populations and 
35% in the African Americans but only 7% frequency in the Japanese and 17% in 
Hispanics (Lotery & Trump, 2007; Hageman et al., 2006).  Considering the 
significant differences in prevalence of AMD in African Americans and Caucasians 
(Klein et al., 1999; Friedman et al., 2004), the similarities in frequency of the CFH 
 47
rs1061170 risk allele in these populations suggest that additional factors are involved 
in the pathogenesis of AMD. 
A more detailed analysis of the CFH locus has also been carried out.  In a 
study analysing 84 SNPs within and around the CFH gene in 544 cases of AMD and 
268 age and sex-matched controls, 20 SNPs were found to be more significantly 
associated with AMD than CFH Y402H (Figure 1.14) (Li et al., 2006).  
Furthermore, multiple polymorphisms formed a set of 5-SNP haplotypes, using a 
stepwise regression analysis of all SNPs.  Non-coding variants of CFH have been 
found in other studies of similar sample size to affect AMD susceptibility (Maller et 
al., 2006; Hageman et al., 2006).   
A common deletion of two CFH-related genes, CFHR3 and CFHR1 which 
significantly protects against AMD (independently of CFH Y402H) has also been 
discovered using 173 cases of AMD and 170 age and sex-matched control (Hughes 
et al., 2006).  The deletion is present on a protective haplotype in 7.8% of AMD 
chromosomes and 20% of chromosomes of control individuals and the proteins 
encoded by these genes are absent in the plasma of homozygotes (Hughes et al., 
2006).  The CFHR3/CFHR1 deletion polymorphisms which span approximately 86 
kb, have been found to be in strong linkage disequilibrium with a protective 
haplotype spanning intron 11 of the CFH gene by Hughes et al. (2006).  The findings 
of these studies have emphasised the presence of multiple susceptibility alleles in the 
region with non-coding CFH variants playing a significant role in determining 
disease risk. 
Following the identification of CFH as a susceptibility locus for AMD, 
candidate gene studies of other components of the complement pathway have been 
conducted in AMD cases and controls.  Variants in the complement component C2 
and complement factor B (CFB) were found to be associated with decreased 
susceptibility to AMD in multiple studies each consisting of approximately 900 
AMD cases and 400 controls (ORs ranging between 0.3 and 0.5) (Gold et al., 2006; 





Figure 1.14 Results of the AMD association analysis of CFH
 
SNPs carried out by 
Li et al., 2006.
P-values are shown for single-SNP associations, when 544 unrelated cases of AMD 





< 1.0E-30) is marked by the red arrow. Twenty 
other SNPs showed stronger associations with AMD than the CFH
 
rs1061170 (Y402H) 
variant. The dotted horizontal line is –log10(P) of the CFH
 
rs1061170 (Y402H) variant 
(P
 
< 1.0E-25) (circled in blue). Significantly associated SNPs fall into one of two LD 
groups (r2within group
 
> 0.80; r2between groups
 
< 0.50). SNPs in one of these groups are 
colored in green; SNPs in the other group are colored in purple;
 
SNPs outside either 
group are in black. Results of this study showed that additional
 
susceptibility alleles at 
the CFH
 
locus may play a role in disease predisposition and CFH
 
rs1061170 (Y402H) 
in unlikely to be the only major determinant of disease susceptibility in this region. The 
five SNPs (CFH
 
rs1048663, rs2274700, rs412852, rs11582939 and rs1280514) 
selected from the stepwise haplotype association analysis are circled in red. 
Haplotypes containing the five SNPs were identified, three of which were shown to act 
independently of CFH
 
rs1061170 (Y402H). Linkage disequilibrium across the CFH
 








Diagram adapted from Li et al., 
2006). 
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Furthermore, variation in the complement C3 gene has recently been shown 
to be strongly associated with increased risk to AMD.  Odds ratio of 2.6 using 603 
cases and 350 controls (Yates et al., 2007), and OR of 3.3 using 1,238 cases and 934 
controls (Maller et al., 2007) were reported for the homozygous allele of the 
common rs2230199 variant, which confers an arginine to glycine substitution at 
residue 80 and may influence binding between C3b/C3d and CFH (Yates et al., 
2007).  These findings have improved our understanding of age-related macular 
degeneration and the involvement of the complement pathway in pathogenesis of this 
complex disease.   
1.5.3 AMD association with chromosome 10q 
 
In addition to the CFH locus (1q31), significant linkage to chromosome 10q26 has 
been observed in individual genome-wide studies (Majewski et al., 2003; Seddon et 
al., 2003c; Kenealy et al., 2004; Iyengar et al., 2004; Jakobsdottir et al., 2005), and 
in a meta-analysis of AMD linkage studies (Fisher et al., 2005).  Initial fine-mapping 
of this region revealed two neighbouring genes, Pleckstrin Homology-domain 
containing family A member 1 (PLEKHA1) and a hypothetical gene (LOC387715) 
(now called Age-Related Maculopathy Susceptibility 2 (ARMS2)) in a region of high 
linkage disequilibrium (LD) (Rivera et al., 2005; Jakobsdottir et al., 2005; Conley et 
al., 2006).  These studies used relatively large sample sizes (Ncases 370-612, Ncontrols 
184-612) and found odd ratios of 5.7 to 8.2 attributable to the ARMS2 rs10490924 
(Ala69Ser) variant independently of CFH rs1061170 (Y402H).    
A second polymorphism was identified in the promoter region of the HtrA 
serine peptidase 1 (HTRA1) gene in a study of “wet” cases of AMD cases and 
controls of Chinese origin (Dewan et al., 2006).  The newly identified SNP, 
rs11200638, was associated with a 10-fold increase in AMD risk and was found to be 
in complete LD with the previously identified ARMS2 rs10490924 variant.  The 
association between SNP rs11200638 and AMD susceptibility was confirmed in a 
genome-wide association analysis of 581 cases of mostly wet AMD and 309 controls 
of Caucasian origin (Yang et al., 2006) which also showed that HTRA1, a member of 
a family of serine proteases, was expressed in the human retina and RPE as well as 
the drusen from the donor eyes of AMD patients (Yang et al., 2006).   
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More recently, analysis of 45 SNPs in the 200 kb region spanning the 
PLEKHA1, ARMS2 and HTRA1 genes, using 535 affected individuals and 288 
controls, revealed that a single coding variant, ARMS2 rs10490924 (Passociation < 10-30) 
can account for the association between other variants in the region and AMD, even 
more strongly than the SNP rs11200638 (Passociation < 10-19) (Kanda et al., 2007).  
Kanda and colleagues observed no promoter activity for SNP rs11200638 and no 
differences in HTRA1 mRNA expression between retinas of AMD controls and 
controls.  ARMS2 was shown to be expressed in the human retina and to localise to 
the mitochondrial outer membrane (Kanda et al., 2007).   
 
1.5.4 Other single gene associations with AMD 
 
Several studies have attempted to identify associations between AMD and genetic 
variants in candidate gene, some of which are involved in diseases showing 
phenotypic similarity to AMD. 
Amongst candidates examined in single gene studies of AMD, APOE variants 
show the clearest association with AMD (Swaroop et al., 2007).  Expression of the 
APOE protein by RPE cells has been observed (Anderson et al., 2001; Ishida et al., 
2004) and APOE has been shown to localise to the drusen of AMD donor eyes 
(Klaver et al., 1998a; Li et al., 2006a).  Furthermore, involvement of APOE in 
maintenance and repair of neuronal cell membranes of the peripheral and central 
nervous system implies a similar role in the repair of retinal damage.   
Several case-control and association studies have examined the involvement 
of APOE variants in AMD susceptibility and found a lower frequency of E4 carriers 
in unrelated AMD patients (E4freq ~ 0.07) compared with age- and sex-matched 
controls (E4freq ~ 0.15) in a relatively small number of AMD cases (N ~ 100) and 
controls (N ~ 200) (Souid et al., 1998; Klaver et al., 1998a).  Although this 
association has been replicated in other studies (Schmidt et al., 2002; Baird et al., 
2004), it seems to be in direct contrast to the proposed involvement of APOE in other 
complex disorders such as Alzheimer and coronary heart disease where E4 is the risk 
allele.   
The gene involved in the majority of cases of Stargardt disease, ABCA4, has 
also been tested for association with AMD, based on the phenotypic similarities 
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between Stargardt disease and AMD (Swaroop et al., 2007).  A study consisting of a 
relatively small number of individuals showed significant associations between 
missense polymorphisms in ABCA4 (D2177N and G1961E) and AMD (Allikmets et 
al., 1997 (N = 167 unrelated AMD cases only)).  The association was confirmed in a 
considerably larger cohort of 1,218 AMD cases and 1,258 controls, suggesting a 
dominant pattern of inheritance (Allikmets, 2000).  However, several studies (N > 
200 cases) have reported negative associations between variants in the ABCA4 gene 
and AMD susceptibility (Stone et al., 1998; Rivera et al., 2000; Schmidt et al., 
2003).        
Several additional reports have shown encouraging associations between 
AMD and the genes Cystatin C (amyloid angiopathy and cerebral hemorrhage) 
(CST3) (Zurdel et al., 2002), Toll-like Receptor 4 (TLR4) (Zareparsi et al., 2005b), 
Fibulin 5 (FBLN5) (Stone et al., 2004) and Vascular Endothelial Growth Factor 
(VEGF) (Haines et al., 2006).  However, these studies have not been replicated, 
possibly due to small number of samples analysed and hence low study power.  
 
1.5.5 Meta-analysis of established genetic associations with AMD 
 
A recent meta-analysis of the established associations (three or more published 
reports) between AMD and genetic variants was carried out in which variants in the 
CFH region (CFH rs1061170) and in the ARMS2 region (ARMS2 rs10490924) 
demonstrated the strongest replicable association with AMD (Swaroop et al., 2007).  
Between these two loci, ARMS2 rs10490924 was shown to confer the highest risk for 
AMD (OR = 2.62, P < 10-100) (Table 1.4).  Variants in the APOE (E2, E3 and E4), 
C2 (rs9332739 and rs547154) and CFB (rs4151667) genes also showed replicable 
but smaller associations with AMD across studies but significantly contribute to 
disease susceptibility (Table 1.4). 
 Association studies have provided valuable insights into the location of the 
genetic variants which influence AMD susceptibility.  The advances in genotype and 
re-sequencing technologies have allowed genetic association studies to examine large 






















































































































































































































































































































































































































































































































































































































































The development of animal models of AMD has been difficult due to the phenotypic 
and genetic heterogeneity of this disease in humans.  Furthermore, the contribution 
of the environmental risk factors of AMD has not been fully assessed.   
 Animal studies of AMD are limited in that only primates have a macula 
(Hope et al., 1992).  Transgenic pigs have some advantage because, like humans, 
they have a high cone to rod ratio and a slow disease process (Fauser et al., 2002).  
Rabbits have also been used but their retinal vasculature is significantly different 
from humans (Fauser et al., 2002).  High cost and time commitment are 
disadvantages of primate, pig and rabbit animal models (Edwards & Malek, 2007).  
Mice, despite the lack of macula, have a higher concentration of photoreceptors 
centrally compared with the periphery (Karan et al., 2005) and show a rapid 
progression of disease.   
 Several transgenic mouse models have been developed which exhibit some of 
the features of human AMD such as photoreceptor degeneration and drusen 
formation.  Examples include transgenic models of the autosomal dominant 
Stargardt-like macular dystrophy (expressing the mutated human ELOVL4 gene) 
(Karan et al., 2005), and Doyne honeycomb retinal dystrophy (expressing the 
mutated human EFEMP1 knock-in) (Fu et al., 2007).  Other transgenic models 
including the knock-out mouse models of the Monocyte Chemoattractant Protein 1 
(Ccl2) or the Ccl2 receptor, Chemokine CC Motif Receptor 2 (Ccr2) genes have 
been developed which show cardinal features of AMD such as accumulation of 
lipofuscin in and drusen beneath the RPE, photoreceptor atrophy and choroidal 
neovascularisation(CNV) (Ambati et al., 2003).  The Ccr2 and Ccl2 deficient mice 
show that impaired macrophage recruitment allows accumulation of complement 
C5a and IgG which induce VEGF production by RPE, possibly mediating 
development of CNV (Ambati et al., 2003).  Knock-out mouse models of other 
complement regulatory proteins have been developed which show the involvement 
of components of the immune response in AMD development.  Mice deficient in the 
complement regulatory protein, CD59 antigen (CD59a-/-), show increased deposition 
of the membrane attack complex (MAC) and develop CNV early in the disease 
process (Bora et al., 2007).  Mice deficient in complement factor H (Cfh-/-) show 
reduced visual acuity, increased sub-retinal deposits, thinning of the BrM and 
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disorganisation of the rod outer segments (Coffey et al., 2007).  Cfh-/- knock-out 
mice have shown that complement factor H is critically required for the long-term 
functional health of the retina.  An aged mouse model containing a knock-in of the 
human APOE*E4 gene, combined with a high-fat diet, shows key features of dry 
AMD, including diffuse and focal sub-RPE deposits, thickened BrM and hyper- 
pigmentation of the RPE (Malek et al., 2005).  This model combines three important 
AMD risk factors, including APOE*E4, age and a high-fat diet.  Mice deficient in the 
Superoxide Dismutase 1 (Sod1-/-) gene have features typical of human AMD 
(Imamura et al., 2006).  Older animals show drusen, thickened Bruch’s membrane 
and choroidal neovascularisation.  The number of drusen increases with age and the 
Sod1-/- RPE cells show oxidative damage and their β-catenin mediated cellular 





The principle aim of this project is to identify and quantitate biomarkers of disease 
using human plasma and to establish associations with genetic and environmental 
factors which influence those biomarkers (Figure 1.15).  This is based on the 
assumption that intermediate phenotypes of complex diseases have a simpler genetic 
architecture which results in added power in quantitative trait analysis compared with 
binary traits (Falchi et al., 2004).   
     
 
 









































































































































































































































































































































































































































































































































































Two groups of potential biomarkers of disease will be analysed, Aβ peptides 
and complement factor H (CFH) in plasma samples collected from the Vis 
population.   
Firstly, plasma Aβ40 and Aβ42 will be used as biomarkers for Alzheimer 
disease, since plasma Aβ concentration is believed to reflect a global measure of Aβ 
toxicity in other tissues, particularly the brain (Mayeux et al., 1999) where Aβ42 
deposition is the pathological hallmark of Alzheimer disease (Glenner & Wong, 
1984; Masters et al., 1985).  Concentrations of Aβ species in plasma will be 
measured for the first time in a general population, using optimised assays developed 
for use in EDTA anticoagulated plasma samples (Suzuki et al., 1994).  Associations 
between plasma Aβ and potential covariates will be assessed.  Plasma Aβ 
heritabilities will also be estimated using the pedigree information.  Finally, genome-
wide linkage and association analyses will be conducted to identify genomic loci 
which affect plasma Aβ concentrations in a general population. 
Secondly, plasma CFH will be used as a surrogate biomarker for age-related 
macular degeneration (AMD) since variants in the CFH gene have been shown to 
influence susceptibility to AMD (Klein et al., 2005; Edwards et al., 2005; Haines et 
al., 2005).  Association between potential covariates and plasma CFH will be 
assessed and the heritability of this trait will be estimated using the Vis pedigrees.  
Genome-wide linkage and association analyses will be conducted with the aim of 
identifying common genetic variants which affect plasma CFH concentration in a 
general population sample, which could influence susceptibility to AMD.  
Furthermore, genomic loci found to be associated with AMD, such as the 
CFHR3/CFHR1 deletion polymorphism (Hughes et al., 2006) will be genotyped in 
the Croatian DNA samples using a novel method.  Involvement of other CFH 
polymorphisms (Li et al., 2006) in AMD and in relation to plasma CFH 
concentration will be assessed in series of Scottish and Japanese AMD cases and 
controls after measuring plasma CFH concentrations in those samples.  Replication 
of the CFH association results will be carried out using DNA and plasma from a 
Dutch isolate population as part a European Union Framework collaboration 
(EUROSPAN) to identify disease susceptibility variants in isolated populations.   
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Finally, assessment of mass spectrometric techniques will be carried out with 
the aim of developing methods for identification and quantitation of new disease 
biomarkers.  The availability of large numbers of plasma samples provides a rich 
resource for the identification of novel biomarkers.  Firstly, depletion of highly 
abundant plasma proteins such as Albumin, shown to interfere with the detection of 
lower abundance proteins (Pieper et al., 2003), will be carried out.  Secondly, two 
approaches to protein analysis, “top-down” and “bottom-top”, will be examined in 
relation to protein quantitation in plasma (Chait, 2006).  If successful, large-scale 
protein quantitation of proteins and peptides in plasma will be used to identify novel 
biomarkers in population samples.  Protein concentrations can then be used to 











































In this chapter, details of experimental and analytical protocols, and the materials 
used are presented.  The description of methods has been divided into four main 
sections, molecular genetic techniques, biochemical methods, proteomic methods 
and statistical methods used in the analysis of results.  A complete list of the 
materials used is also given at the end.  
All experimental procedures involving the use of human blood and plasma 
were carried out at containment level 2, according to health and safety guidelines.  
All experiments involving PCR were undertaken in designated areas, using sterile 
techniques to avoid contamination.  All primers and probes were kept at stock 
concentrations of 100 μM at –20oC and were aliquoted according to need.     
2.2 Sample collection and description 
 
Prior to the start of this project, fasting blood samples had been collected from 1,042 
adult volunteers (age range between 18 and 93 years), randomly recruited from the 
two villages of Komiza (N=584) and Vis (N=458) situated on the Dalmatian island of 
Vis (Table 2.1).  All participants had given informed consent.  1,029 unselected 
individuals had complete data for more than 50 disease-related quantitative traits.  Of 
these, 8 were replicates since the same individuals had been sampled twice, giving a 
total population survey number of 1,021.  Plasma had been separated from each 
blood sample and DNA extracted by colleagues in Croatia.  Samples of citrate and 
EDTA (ethylenediaminetetraacetic acid) anticoagulated plasma, serum, and DNA 
from each individual were sent to MRC Human Genetics Unit in Edinburgh.  
Plasmas were stored at –80oC upon arrival.  DNA samples were diluted to a 
concentration of 10 ng/μl in TE (10 mM Tris HCl, 1 mM EDTA, pH 7), aliquoted 
into 96-well 0.8 ml storage plates (Abgene) and kept at 4oC. 
A Dutch population sample set, consisting of 500 DNA and EDTA 
anticoagulated plasma samples (Table 2.1) was used as a replication series for CFH 
analysis.  These samples were from the Rucphen (Erasmus Rucphen Family (ERF)) 
study and consisted of unrelated individuals from an isolated village community 
outside Rotterdam.   
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A series of unrelated Scottish cases of AMD and controls were used for the 
CFH analysis (Table 2.1).  The Scottish series comprised 382 case subjects with 
AMD (“dry” or “wet”) and 201 age- and sex-matched control subjects (Yates et al., 
2007).  Subjects were examined by an ophthalmologist, fundus photographs were 
taken, and data collected regarding medical history, lifestyle, and smoking history.  
A total of 337 case subjects from the Lothian region were recruited from ophthalmic 
clinics in Edinburgh and 45 case subjects from hospitals in Dundee and Inverness, 
between 2004 and 2006.  Age- and sex-matched control subjects were recruited from 
the same location and sources comprised 27 spouses and 174 subjects who had 
undergone cataract surgery.  DNA and EDTA anticoagulated plasma samples were 
stored in a similar way to the Croatian samples.  AMD grading was carried out by 
Dr. A. M. Armbrecht using the International Classification of Age-related 
Maculopathy and Macular Degeneration as follows (Bird et al., 1995); Grade 1: mild 
dry AMD in both eyes, grade 2: moderate dry AMD in one or both eyes, grade 3:  
severe dry AMD, with geographical atrophy, in one or both eyes, grade 4: severe wet 
AMD in one or both eyes.  AMD diagnosis was performed in ophthalmic clinics in 
Edinburgh, Dundee and Inverness, and classification into AMD subtypes, such as 
choroidal neovascularisation or geographic atrophy, was carried out.  This series was 
part of a larger association study of age-related macular degeneration (Yates et al., 
2007).  All individuals gave informed consent to the study.   
A series of 30 unrelated Japanese cases of AMD and 58 age- and sex-matched 
controls recruited by Dr. T. Iwata from the National Institute of Sensory Organs were 
also obtained for the population-specific analysis of CFH gene variants (Table 2.1).  
The grading system used for the clinical diagnosis and classification of AMD 
amongst cases was based on the Clinical Age-Related Maculopathy Staging 
(CARMS) as follows (Seddon et al., 2006b); grade 1: no drusen or < 10 small 
drusen, grade 2: approximately ≥ 10 small drusen, RPE hypo/hyperpigmentation, 
grade 3: approximately ≥ 15 intermediate drusen, grade 4: geographic atrophy, grade 
5: choroidal neovascularisation with RPE detachment.  All individuals gave informed 
consent to the study. 
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2.3 Molecular genetic techniques 
2.3.1 APOE genotyping 
 
APOE genotyping was carried out in the Vis population samples by polymerase 
chain reaction (PCR) amplification of DNA samples using a pair of oligonucleotide 
primers (Invitrogen) designed to amplify a 218 bp region spanning the two APOE 
variant sites112 (T > C) and 158 (C > T) (APOE forward primer: 5′-TCCAAGGA- 
GCTGCAGGCGGCGCA and APOE reverse primer: 5′-ACAGAATTCGCCCCGG- 
CCTGGTACACTGCCA) as shown in Figure 2.1.  The composition of the PCR 
using a 2x Thermo-Start® PCR Master Mix (ABgene) was as follows: 
 
- 1.25 units Thermo-Start® DNA Polymerase 
- 1x Thermo-Start® reaction buffer 
- 2.5 mM MgCl2 
- 0.2 mM each of dATP, dCTP, dGTP and dTTP 
 
Volume/Reaction (μl) Final Concentration
Thermo-Start PCR Master Mix (2X) 16.5 Stock diluted 1:2
Dimethyl Sulfoxide (2X) Sigma® 2.5 Stock diluted 1:2
Forward Primer (2 μM) 2.5 0.2 μM
Reverse Primer (2 μM) 2.5 0.2 μM
DNA template (10 μg/ml) 1.0 -  




PCR was carried out in 0.2 ml semi-skirted 96-well plates (Thermo-Fast® 96, 
AB gene) in a total volume of 25 μl per well.  2 μl of Orange-G® Loading Buffer was 
added to each PCR sample.  The final mix was loaded in a 2% agarose (Invitrogen) 
minigel and run at 100 V for approximately 45 minutes.  A 100 bp DNA size marker 
(Promega) was also run on each gel.  The bands were visualised using a UV 












































































T/C (amino acid 112) C/T (amino acid 158)
1 20 36 127 145 193 218
20bp 16bp 91bp 18bp 48bp 25bp
17bp 74bp 73bp
Figure 2.1 Illustration of the APOE genotyping.
DNA of each of the six possible APOE
 
genotypes, together with a full length 218bp 
amplified APOE
 
sequence containing the two variants digested with CfoI
 
captured on a 
4% MicroSieve
 
agarose gel, stained with ethidium
 
bromide is shown. Diagram and table 
below illustrate the APOE
 




cleaves the DNA if a Cytosine base is present at the site.  Black vertical arrows 
show other CfoI
 





APOE*E2 T (Cys) T (Cys)
APOE*E3 T (Cys) C (Arg)
APOE*E4 C (Arg) C (Arg)
APOE 112 T -> C (rs429358)
APOE 158 C -> T (rs7412)
Nucleotide                 
(Amino acid residue)
2.3.1.1 APOE genotyping by RFLP 
 
Genotyping was carried out by restriction fragment length polymorphism (RFLP) 
analysis.  This consisted of overnight digestion of the APOE PCR product at 37oC, 
using the restriction endonuclease enzyme CfoI (Roche), which is an isoschizomer of 
HhaI that cleaves either within residue 112 or 158 (Figure 2.1).  CfoI recognises the 
sequence GCG/C and generates fragments with 3′ cohesive termini.  Digestion was 
carried out in 15 μl reactions (Table 2.3).  Five microlitres of the digestion mix was 
added to 10 μl of PCR product in each well of a 0.2 ml semi-skirted Thermo-Fast® 
96 plate (ABgene).  Separation of digested fragments was carried out by agarose gel 
electrophoresis.  Four percent MicroSieve Low Melt agarose (Flowgen) gels were 
prepared in 0.5x TBE Buffer containing 0.002% of 10 mg/ml ethidium bromide 
(BDH®).  Electrophoretic separation was carried out for approximately 3 hours at 60 
volts.   
 
Volume/reaction (μl)
10x SuRE/Cut buffer L 1.50
Cfo I enzyme (10u/μl) 0.15
Gibco™ Water 3.35
PCR product 10.00  
Table 2.3 Composition of the CfoI digest for APOE genotyping 
 
Genotyping analysis was carried out based on the number and size of the 
bands observed on the gel (Figure 2.1).  The combination of bands expected for each 
genotype (Wenham et al., 1991) was obtained using the programme Restriction-
Mapper (http://www.restrictionmapper.org) (Table 2.4).  
 
APOE  Genotype Fragment sizes observed after RFLP analysis (bp)
E2/E4 91, 74, 73, 48, 25, 20, 18, 17, 16
E2/E3 91, 73, 48, 25, 20, 18, 16
E2/E2 91, 73, 20, 18, 16
E3/E4 91, 74, 48, 25, 20, 18, 16
E3/E3 91, 48, 25, 20, 18, 16
E4/E4 74, 48, 25, 20, 18, 17, 16  
    Table 2.4 Expected fragment sizes of amplified APOE after digestion with CfoI. 
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2.3.1.2 Sequencing of APOE*E2 carriers 
 
Due to the uncertainty associated with deducing the APOE*E2 genotypes by RFLP, 
putative carriers of the E2 allele (i.e. E2/E2, E2/E3 and E2/E4 genotypes) were 
sequenced in both directions using BigDye™ Terminator Cycle Sequencing version 
3 (Applied Biosystems®) (Table 2.5).  The aim was firstly to confirm the presence of 
the E2 allele in the APOE*E2 carriers, and secondly to differentiate between the 




Gibco™ H2O 6.0 -
BigDye 2.0 -
Primer 1.0 40 nM  
 Table 2.5 Composition of the BigDye sequencing reaction mix. 
 
Prior to sequencing reaction, 5 μl of each APOE PCR product was purified 
using 1 μl of 1 unit/μl Shrimp Alkaline Phosphatase (SAP, USB) and 0.5 μl of 10 
unit/μl exonuclease I (USB).  The phosphatase reaction required incubation with 
SAP for 15 minutes at 37oC followed by 15 minutes at 80oC in a thermal cycler (MJ 
Research).  The sequencing reaction was then carried out using 2 μl of the previously 
purified DNA template, in a 11 μl reaction volume (Table 2.5), by amplification 
using 25 cycles of 30 seconds at 96oC, 15 seconds at 50oC and 4 minutes at 60oC. 
 The sequencing reaction was followed by DNA precipitation, by 
adding 0.1 v/v NaOAc and 2.5 v/v of 95% ethanol (3M, pH 4.0).  This was followed 
by centrifugation (Multifuge 3) at 2000 g for 30 minutes at 20oC.  The pellet was 
washed once with 150 μl of 70% ethanol, dried and stored at –20oC.  After 
automated sequencing on an ABI PRISM® 3100 (HGU core facility), the generated 




2.3.1.3 Experimental controls 
 
Experimental controls were included throughout the genotyping reactions.  Negative 
controls included blank wells for PCR and digestion experiments.  Positive controls 
consisted of samples genotyped confidently as E3/E3 and E4/E4.  These were also 
included in the sequencing experiments. 
 
2.3.1.4 Genotyping replications  
 
A set of 95 random DNA samples from each of the two villages of Komiza and Vis 
was used to confirm the respective genotype of each individual by genotyping a 
second time.  Samples were selected based on their identification numbers using a 
random number generator with Microsoft Excel® software. 
 
2.3.2 Genotyping of STR markers 
 
Genome-wide linkage analysis was carried out using 810 short tandem repeat (STR) 
markers from the ABI Prism® Linkage Mapping Set HD5 (Applied Biosystems).  
Genotyping of markers in the Vis sample set was performed by Susan Campbell and 
Joanne Morgan using the Gene Mapper® Software version 3.7 (Applied Biosystems).  
Microsatellite markers were spaced, on average, 3-5 cM apart.  Genotyping errors 
were detected by Dr. C. Hayward using the software PedCheck which scans 
genotype data for inconsistencies in Mendelian inheritance.  Genotype data was then 
prepared for linkage analysis by Dr. C. Hayward. 
 
2.3.3 Genotyping of single nucleotide polymorphisms 
 
Three methods were employed for the genotyping of single nucleotide 
polymorphisms (SNPs).  Genotyping of 317,503 SNPs was carried out using the 
Human Hap300® Array (Illumina).  SNPs which had not been included in the 
Illumina platform were genotyped by a 5′ nuclease assay using TaqMan® probes 
(Applied Biosystems), or by direct sequencing. 
 
 67
2.3.3.1 Whole genome SNP genotyping  
 
317,503 SNPs were genotyped as part of the Human Hap300® (Illumina, San Diego, 
USA) genotyping platform in 986 Croatian individuals.  The array included all 
tagging SNPs from the HapMap Phase I SNPs, 8,000 non-synonymous SNPs and 
1,500 tagging SNPs within the human major histocompatibility complex (MHC).  
Genotypes were scored using the Bead Studio® software v.3 (Illumina).  A total of 
8,984 SNPs had less than 90% genotyping call rates and 379 had a minor allele 
frequency < 1% and were removed, leaving 308,140 SNPs for the follow-up 
genome-wide association analysis. 
 
2.3.3.2 SNP genotyping by TaqMan® 5′nuclease assay  
 
Five-prime nuclease assays using TaqMan® probes (Figure 2.2-A) were used to 
genotype SNPs in the CFH genomic region in four sample sets of Croatian, Dutch, 
Scottish and Japanese origin.  Assays were either custom, or pre-designed, involving 
a probe mix containing two minor groove binder (MGB) probes, each labelled with a 
different fluorescence reporter dye (FAM, VIC).  Custom-designed assays involved 
electronically providing around 750 bp of DNA containing the SNP of interest, to the 
supplier (Applied Biosystems) who designed and manufactured the primers and 
probes.    
A list of SNPs and the population series in which they were genotyped is 
provided below: 
 
• Croatian data set: rs1061170 (Y402H), rs1048663, rs412852 and rs1066420  
• Dutch data set: rs1061170 (Y402H), rs6677604, rs1329428, rs7517126, 
rs4086175, rs3766404, rs1048663, rs412852, rs1066420 and rs11582939 
 
• Scottish AMD data set: rs1061170 (Y402H), rs3766404, rs1048663, 
rs412852, rs1066420 and rs11582939 
 
• Japanese AMD data set: rs1061170 (Y402H), rs6677604, rs1329428, 




SNP genotyping in the Japanese DNA samples was carried out by Dr. T. 
Iwata in Japan due to Japanese regulations on export of DNA samples.  Genotyping 
of SNPs in the Dutch sample set was carried out by Susan Campbell.         
 Each reaction contained 0.25 μl of 20x TaqMan® probe mix, diluted 1 in 2 
using TE (10 mM Tris HCl, 1 mM EDTA, pH 7.0) from a 40x stock (Applied 
Biosystems), 2.5 μl of 2x TaqMan® Universal PCR Master Mix (ABI), and 2.25 μl 
of Gibco™ dH2O (Invitrogen).  Optical reaction plates (384-well, Applied 
Biosystems) were coated with 10 ng of DNA (10 ng/μl) and left to dry overnight.  
The reaction was carried out on a thermal cycler (MJ Research) and consisted of 40 
cycles of 10 minutes at 95oC, 15 seconds at 92oC and 1 minute at 60oC.     
After completion of the PCR, fluorescence was read using an ABI-HT7900 
SDS instrument (Applied Biosystems).  Results of the fluorescence-labelled allelic 
discrimination were consequently exported and analysed further using Microsoft 
Excel®.  The presence of FAM or VIC dye fluorescence alone indicated 
homozygosity for the FAM or VIC- specific allele.  An increase in both signals 
indicated heterozygosity.  
 
2.3.3.3 SNP genotyping by direct sequencing 
 
Genotyping of CFH rs2274700 was carried out by DNA sequencing.  This SNP was 
genotyped in the Croatian, Dutch and Scottish AMD series.  Genotyping was also 
carried out in the Japanese AMD series in Japan.  The reason for this method of SNP 
analysis was the presence of other polymorphisms in exon 10 of the CFH gene and 
the advantage of genotyping both SNPs. 
Forward (5′ TGTCTTTGGCAACTCTGAGC) and reverse (5′- 
CAGCCCCCACAAAAAGACTA) primers were designed to amplify a 436 bp 
region including exon 10 of the CFH gene, using the web resource Primer 3 (Rozen 
& Skaletsky, 2000).  PCR was carried out as shown in Table 2.4, using 1 μM (final 
concentration) of each primer at 60oC annealing temperature.  DNA purification and 
sequencing (ABI PRISM® 3100) was carried out by the MRC HGU core facility. The 
generated DNA sequences were analysed using the software Sequencher® v3.0 (Gene 
Code). 
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2.3.4 Genotyping of the CFHR3/CFHR1 deletion 
 
The deletion of the two CFH-related genes, CFHR3 and CFHR1, believed to be 
involved in protection from AMD (Hughes et al., 2006) was genotyped using a 
quantitative PCR (qPCR) assay which was developed in-house. 
 
2.3.4.1 Theory of quantitative polymerase chain reaction 
 
There is an exponential relationship between the concentration of DNA template 
material and concentration of PCR amplified product at any given cycle.  qPCR is a 
probe-based technique involving a reporter fluorescent and a quencher dye.  In the 
presence of the target sequence the probe anneals downstream of the forward primer 
and is cleaved by the 5′ exonuclease activity of Taq DNA polymerase during the 
extension phase.  At each cycle, cleavage of the probe results in the separation of 
reporter dye from quencher which is then detected (Figure 2.2-A).  The higher the 
starting copy number of the DNA template, the sooner a significant increase in 
fluorescence is detected above a baseline.  The parameter Ct is defined as the 
fractional cycle number at which the fluorescence passes the fixed threshold (Figure 
2.2-A).  The threshold is set so it crosses all amplification curves where the slopes of 
the curves are at their highest and curves are almost linear.   
 There is an inverse linear relationship between the Ct value and the log10 of 
the input DNA concentration.  The copy number calculation assumes a log phase 
amplification and a Ct value is usually taken to be about ten times the standard 
deviation of the baseline.  Quantitation of the sample is performed relative to a 
control, β-globin (HBB) gene amplification which is valid provided that both show 
similar slopes during the amplification process, indicating similar amplification 
efficiencies.  A two-fold difference in DNA copy number would result in one unit 




where Rc is the relative copy number of DNA and ΔCt is the difference in Ct of the 







igure 2.2 Diagrammatic presentation of the quantitative PCR methodology. 
 An example of the outcome showing a sample (black line) and a blank control (red line). 
2.3.4.2 Sequence analysis at the CFH locus 
 of genomic duplication were 
etion polymorphism was carried out in 
two stages.  Firstly, all individuals homozygous for the deletion were identified using 
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tretchS es of DNA which did not fall into regions
identified using the sequence alignment tool BLAST2 (Tatiana et al., 1999), as 
shown in Figure 2.3.  BLAST2 sequence analysis revealed a high degree of 
sequence homology between CFHR4 and CFHR3, shown in black, blue and green 
diagonal boxes (Figure 2.3).  Two regions of 3,764 bp and 828 bp were found to 
contain non-homologous sequence.  These two regions are marked by yellow and 
purple rectangles in Figure 2.3.  The software Primer Express® (Applied 
Biosystems) was used for designing optimal primers and probes in the 828 bp region.  
The betaglobin gene, HBB (11p15) was used as an endogenous control to provide 
relative quantitation of CFHR3 allele dosage. 
 Genotyping of the CFHR3/CFHR1 del
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a plex PCR.  Secondly, a high throughput real-time qPCR was developed and 
optimised for the genotyping of the deletion aimed at distinguishing between 
heterozygous carriers of the deletion and homozygous non-carriers.  The deletion 
was genotyped in the Croatian, Dutch and Scottish samples.  
 
2.3.4.3 Multiplex PCR of CFHR3/CFHR1 deletion 
 multi
Two pairs of primers were designed using the web resource Primer 3 (Rozen & 
 intron 3 
rams of DNA (10 ng/μl) was used as template in 13 μl reactions 
contain
 
Skaletsky, 2000).  One pair was designed to amplify a 219 bp product from
of the CFHR3 gene, located in the deleted region (forward primer, 5′ TGTTTTGCC- 
AACGGACCTAT; reverse primer, 5′ TTCTTGGTGCAAGATGACGA).  A second 
pair of primers was designed to amplify a 280 bp product from the HBB gene 
(11p15), for use as an endogenous control in the multiplex PCR (forward primer,  
5′ CAACTTCATCCACGTTCACC; reverse primer, 5′ GAAGAGCCAAGGACAG- 
GTAC).   
PCR amplification was carried out in 96-well semi-skirted plates (Abgene).  
Ten nanog
ing 7 μl of 2x Multiplex PCR Master Mix (Qiagen) and 1.25 μl of each of the 
four primers (10 μM concentration).  Reaction conditions for the multiplex PCR 
amplification were as described before using an annealing temperature of 62oC.  
After completion of PCR, 2 μl of Orange G® Loading Buffer was added to each 
sample.  Separation of PCR products was carried out by agarose gel electrophoresis.  
Agarose gels (3%) were prepared using Hi Pure® agarose (Biogene) in 0.5x TBE 
buffer containing 0.002% of 10 mg/ml ethidium bromide (BDH).  Electrophoretic 
separation was carried out for approximately 2 hours at 100 V.  A 100 bp DNA size 



















Result of sequence alignment of the genomic sequences of both CFHR4
 
and CFHR3
showing stretches of DNA homology.  The two candidate regions of
 
non-duplicated DNA 
used to design primers and probes are marked by yellow and purple lines.  Black, blue 
and green segments show varying levels of homology between the two sequences.   
Figure 2.4 Optimisation results of probe, primer and DNA template concentrations.
Amplification and standard plots for the FAM (A)
 






probe for the HBB
 
gene using ten-fold dilutions of sample DNA template.  All 
sample dilutions were carried out in triplicates.  The efficiency of each reaction was 
calculated as E.  Equations for each standard curve and the squared correlation 
































2.3.4.4 Quantitative PCR of CFHR3/CFHR1 deletion 
obes (Applied Biosystems) 
2.3.4.4.1 Designing the qPCR primers and probes 
 
Two sets of primers and minor groove binder (MGB) pr
were designed using the software, Primer Express® v.2.0 (Applied Biosystems).  
Each set consisted of a pair of primers and a 3′-fluorescent-tagged probe (Table 2.6).  
One pair of primers and a FAM™-labelled probe were designed inside intron 3 of 
CFHR3.  Another pair of primers and a VIC™-labelled probe was designed inside the 
HBB gene and used as an endogenous control. 
 







Table 2.6 Details of primer and MGB probes used in the quantitative PCR of 
CFHR3/CFHR1 deletion 
.3.4.5 Optimisation of primer and probe concentrations 
HBB genes were 
R was optimised using varying concentrations of primers and probes 
to suit




Optimal concentrations of primers and probes in both CFHR3 and 
determined by analysing their standard curves (Figure 2.4).  A duplex reaction was 
used in which beta globin and CFHR3 were simultaneously amplified in the same 
reaction tube.   
The qPC
 a multiplex set-up with minimum inter-experimental variation.  The 
optimisation procedure consisted of using 10-fold dilutions of a randomly selected 
DNA sample and detecting the accuracy with which quantitation would take place 
against a standard curve.  Optimal fluorescence was observed at 10 ng/ml of DNA 
template with the least amount of variation between sample replicates (Figure 2.4).  




E is the efficiency of the reaction o the slope of the standard curve.   
herefore the closer the slope of the standard curve is to –3.32 (E=100%) the higher 
Each qPCR was carried out in triplicate using 384-well optical reaction plates 
μl of DNA (10 ng/ml) used as 
.4 Biochemical techniques 
2.4.1 Commercial assay of amyloid-β in plasma 
ally carried out in 88 
stituted before use, in 
Standard Reconstitution Buffer.  A protease inhibitor cocktail containing 4-(2-
 
and slope refers t
T
the efficiency of the reaction.  The efficiency of amplification reactions at the 
selected template concentrations was above 99.5% for both CFHR3 and HBB. 
 
2.3.4.5.1 Experimental approach 
 
(Applied Biosystems).  5 μl reactions contained 1 
template, 2.5 μl of 2x TaqMan® Universal PCR Master Mix (Applied Biosystems), 
0.2 μl of each primer at 10 μM (Table 2.6), 0.2 μl of each probe at 1 μM (Table 
2.6), and 0.3 μl of Gibco™ dH2O (Invitrogen).  Care was taken to minimise 
experimental variation caused by pipetting errors and inconsistencies.  Reactions 
were carried out real-time, using the absolute quantitation (standard curve) setting on 
an ABI-HT7900 SDS instrument (Applied Biosystems).  Conditions used in the 
qPCR are as follows, 2 minutes at 50oC, 10 minutes at 95oC, and 40 cycles of 15 
seconds at 95oC and 1 minute at 60oC.  After completion of PCR, fluorescence was 
read using the software SDS (Applied Biosystems) and the resulting Ct values were 




Measurements of Aβ40 and Aβ42 concentrations were initi
DTA plasma samples from the island of Vis, using sandwich ELISA kits supplied E
by Biosource UK, following the manufacturer’s instructions.   
The Aβ40 and Aβ42 standards used in the experiment consisted of 
lyophilised synthetic peptide (Biosource UK) which was recon
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Amino
h was used to determine the concentration of Aβ40 or Aβ42 in each 
sample
 ‘sandwich’ ELISA, developed by Dr. N. Suzuki and optimised in the laboratory of 
Professor S. G. Younkin (Mayo Clinic, Jacksonville, USA) was used for in vitro 
β42 concentrations.  
 
Coating
ethyl) benzenesulfonyl fluoride (AEBSF) (Sigma) was used at a final 
concentration of 1mM.  Initially plasma samples (diluted 1:5) were tested in 
duplicate for assays of Aβ40 and Aβ42 peptides.  Colour development was achieved 
using 100 μl of Stabilised Chromogen (Biosource UK) per reaction well and 
reactions were terminated using a Stop Solution (Biosource UK) after 30 minutes.  
Photometric detection was carried out at 450 nm using the SkanIt plate reader 
(Thermo Electron) within 20 minutes of stopping the reactions.  Results were 
analysed using the SkanIt software version 2.1.84 (Thermo Electron) and Microsoft 
Excel®.     
Analysis consisted of subtracting the blank from the rest of the A450 optical 
density/absorbance readings followed by construction of a standard curve for each 
plate, whic
.  Inter and intra-experimental variation was also calculated using the 
coefficient of variation. 
 
2.4.2 Optimised assay of amyloid-β in plasma 
 
A
quantitative determination of human plasma Aβ40 and A
Analysis was carried out in triplicate using EDTA plasma samples collected from the 
isolated island of Vis.  Details of all buffer compositions are provided in section 2.6. 
The experimental procedure was carried as follows; centre wells of 96-well 
microtitre plates (Greiner Bio-one, US) were coated with 100 μl of 5 μg/ml 
monoclonal capture antibodies BAN50 (Aβ40) and BNT77 (Aβ42), diluted in
 Buffer.  Plates were incubated overnight at 4oC and blocked with 300 μl of 
blocking solution, Block Ace® (Serotec Ltd.) on the following day after discarding 
the unbound capture antibodies.  Incubation with the blocking agent was carried out 
overnight at 4oC.  All wells were then washed twice with 1x PBS buffer (pH 7.4).  
Fifty microlitres and 116.7 μl of Buffer EC were added to ‘standard’ and sample 
wells respectively, in order to prevent drying of the wells.  Synthetic Aβ40 and Aβ42 
standards at a stock concentration of 5000 fmol/ml were diluted using Buffer EC to a 
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starting concentration of 800 fmol/ml.  Four serial dilutions of 1 in 4 were prepared 
for plasma samples and a blank control (Buffer EC).  One hundred microlitres of 
each diluted standard was added to relevant wells in duplicate.  Plasma samples 
which had been thawed and mixed by inverting, were diluted 1 in 3 by adding 33.3 
μl of crude plasma to each well containing 116.7 μl Buffer EC in duplicate.  Four 
plasma samples were used as internal controls on each plate.  Plates were covered 
with SealPlate® (Applied Biosystems) and incubated overnight at 4oC.  After 
incubation, plates were washed twice using PBS.  One- hundred microlitres of 
horseradish peroxidase (HRP)-conjugated detection antibodies, BA27 (Aβ40) and 
BC05 (Aβ42), diluted 1 in 2000 using Buffer C was added to each centre well only.   
Plates were then incubated at room temperature for 4 hours before being washed 
twice with PBS and a third time using PBS-Tween® (Sigma).  Colour development 
was achieved by incubating samples and standards with 100 μl of the Developing 
Solution prepared by mixing equal portions of TMB (3,3′,5,5′-tetramethylbenzidine) 
peroxidase substrate (KPL, Inc., US) and peroxidase Solution B (KPL, Inc., US).  
Plates were incubated for 30 minutes (Aβ40) and 60 minutes (Aβ42) at room 
temperature.  Photometric detection was carried out at 450 nm using the Softmax® 
Pro plate reader (Molecular Devices) within 20 minutes of stopping the reactions 
with 100 μl of 1M phosphoric acid.  Results were analysed using the Softmax® Pro 
software (Molecular Devices) and Microsoft Excel®. 
 
2.4.3 Assay of complement factor H in plasma 
 
A ‘sandwich’ ELISA was developed and optimised to perform quantitation of human 
complement factor H (CFH) in plasma.  Measurements were carried out in EDTA 
ries described in Table plasma samples from Vis, Rucphen, Scotland and Japan (se
2.1).  Five plasma samples collected locally were used as internal controls 
throughout the experiments and for normalisation of measurements.  CFH 





2.4.3.1 Plasma extraction from blood 
ples were collected from local volunteers for use as internal controls in the 
using EDTA-coated tubes in 5-10 ml volumes.  Tubes 
om temperature for 30 minutes prior to 
Dilutions of OX23, a mouse monoclonal anti-CFH detection antibody (donated by 
, University of Oxford) and the HRP-conjugated goat anti-mouse 
ed for CFH assay as follows.  Fifty microlitres 
 added to each well and incubated at room temperature for 3 hours with 
absorbance was read at 450 nm using the SkanIt plate reader (Thermo Electron).  The 
 
Blood sam
CFH assay.  Blood was taken 
containing the extracted blood were left at ro
centrifugation at 2,500 g for 15 minutes.  Plasma was then collected and aliquoted 
into 20 μl fractions and stored at –80oC. 
 
2.4.3.2 CFH assay optimisation 
 
Dr. R. B. Sim
antibody (Biosource UK) were optimis
of 1 μg/ml of purified full-length human CFH (Dr. R. B. Sim), diluted in the Coating 
Buffer from a 1.5 mg/ml stock, was used to coat the wells of a 96-well microtitre 
plate (Greiner Bio-one) in duplicate.  CFH assay also included a blank control.  After 
incubation at room temperature for 2 hours, plates were washed 4 times using the 
Wash Buffer.  Unoccupied sites were blocked with 100 μl of 1% lyophilised bovine 
serum albumin (98% purity, Sigma) for 2 hours at room temperature with shaking 
(Grant-Bio).  This was followed by 4 washes, after which plates were stored at 4oC 
over night. 
 Serial dilutions of 1:1,000, 1:2,000 and 1:4,000, of the 340 μg/ml OX23 
detection antibody were made using the Sample Diluent.  Fifty microlitres of each 
dilution was
shaking.  Plates were washed 4 times using the Wash Buffer.  Fifty microlitres of 
HRP-conjugated antibody was serially diluted 1:1,000, 1:2,000, 1:4,000 and 1:8,000 
from the 580 μg/ml stock using the Sample Diluent.  These were then added to each 
well as determined previously by a checker-board titration.  Samples were incubated 
at room temperature for 30 minutes with shaking.  After 4 washes, colour 
development was achieved by adding 100 μl of stabilised TMB Chromogen 
(Biosource UK) and incubation for 1 hour at room temperature with shaking.  One 
hundred microlitres of the Stop Solution  was used to terminate the reaction and 
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titration curve obtained using the SkanIt software version 2.1.84 (Thermo Electron) 
was analysed using Microsoft Excel® and the best combination of the detection and 
secondary antibody dilutions were selected for further experiments. 
Optimal dilution of the 9.6 mg/ml sheep polyclonal anti-CFH capture 
antibody (Abcam) was established by coating the wells of a microtitre plate (Greiner 
Bio-One) with different dilutions of the capture antibody in the Coating Buffer.  Fifty 
microlitres of the diluted antibody was coated onto each well in duplicate.  After 
incubat
 for periods longer than 24 hours would have any 
trime
ion at room temperature for 2 hours, the plate was washed 4 times in the 
Wash Buffer  and unoccupied binding sites were blocked with the Blocking Solution  
as before.  The plate was washed 4 times and stored at 4oC overnight.  Serial 
dilutions of the CFH standard were prepared using the Sample Diluent  starting at a 
concentration of 300 ng/ml.  A blank control was also included.  Fifty microlitres of 
each standard was added to wells coated with the capture antibody and samples were 
incubated at room temperature for 2 hours using the plate shaker.  After 4 washes, 50 
μl of the detection antibody, at a concentration of 85 ng/ml, was added to each well 
and incubated at room temperature for 3 hours using the plate shaker.  Fifty 
microlitres of the HRP-conjugated (Biosource, UK) antibody, at a concentration of 
145 ng/ml, was added to each well after washing the plate 4 times.  Incubation was 
carried out for 30 minutes at room temperature, with shaking.  After washing the 
plate 4 times, colour development was achieved by adding 100 μl of TMB 
Chromogen (Biosource UK) and incubation for 1 hour at room temperature with 
shaking.  The reaction was stopped using 100 μl of Stop Solution  and photometric 
detection carried out as before. 
 Following the determination of optimal antibody concentrations, standard 
curves were constructed and inter- and intra- experimental variation was measured as 
described below.  Samples were also used to determine whether freeze-thawing or 
keeping plasma samples at 4oC
de ntal effect on detectable plasma CFH concentrations.  This was carried out 
using the same experimental procedure as described above, on plasma samples 
obtained from volunteers locally, in triplicate using varying dilutions of plasma i.e. 





Wells of a 96-well m μicrotitre plate (Greiner Bio-One) were coated with 50 l of 1.2 
g/ml sheep polyclonal anti-CFH antibody (Abcam) diluted in the Coating Buffer.  
After 2 hours of incubation at room temperature, plates were washed four times 
er.  One hundred microlitres of Blocking Solution  was used to 
μ
using the Wash Buff
block unoccupied binding sites.  Incubation was carried out at room temperature with 
shaking, for at least 2 hours.  Plates were stored at 4oC overnight after washing the 
wells four times using the Wash Buffer.  EDTA plasma samples were thawed, mixed 
by inverting, and centrifuged briefly prior to being diluted 1 in 5,000 using the 
Sample Diluent.  Five plasma samples, collected locally and used as internal 
controls, were pretreated as above.  Sample dilutions were carried out using a manual 
pipette and consisted of a 1 in 100 dilution (10 μl in 1,000 μl) followed by a 1 in 50 
dilution (20 μl in 1,000 μl).  Eppendorf® tubes (1.5 ml volume) (Eppendorf) were 
used for diluting samples.  Uniform dilution of samples was achieved by leaving the 
tubes on a rotor (Labinco) to mix for at least 10 minutes at room temperature after 
each dilution.  Doubling dilutions of the 1.5 mg/ml CFH standard were carried out 
from a starting concentration of 150 ng/ml which was diluted in the Sample Diluent.  
Fifty microlitres of each sample, standard and internal control samples were each 
added to the wells of the microtitre plate coated with the capture antibody.  After 
incubation for 2 hours at room temperature, with shaking, plates were washed four 
times using the Wash Buffer.  Fifty microlitres of the 85 ng/ml mouse monoclonal 
anti-CFH (OX23) detection antibody diluted in the Sample Diluent  from the 340 
μg/ml stock solution was added to each well and the plate was then incubated for 3 
hours at room temperature with shaking.  After four washes, 50 μl of the 145 ng/ml 
HRP-conjugated goat anti-mouse antibody (Biosource UK), diluted in Sample 
Diluent from the 580 μg/ml stock solution, was added to each well.  After 30 minutes 
of incubation at room temperature with shaking, plates were washed four times using 
the Wash Buffer.  Colour development was achieved after addition of 100 μl TMB 
Chromogen (Biosource UK) and incubation for 1 hour at room temperature on a 
shaker.  Enzymatic reactions were terminated using 100 μl of the Stop Solution  and 
the absorbance was read at 450 nm using the SkanIt plate reader (Thermo Electron).  
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Absorbance values obtained using the SkanIt software version 2.1.84 (Thermo 
Electron) were analysed using Microsoft Excel®.  The CFH standard curve was used 
to calculate sample CFH concentrations using their absorbance values.  Internal 
controls were used to normalise inter-experimental variation as described in Section 
2.5.3.  
 
2.4.4 Protein separation by electrophoresis  
 
Protein separation was carried out prior to in-gel staining and western blotting 
rocedures.  Two methods of one-dimensional polyacrylamide gel electrophoresis 
were employed.  These consisted of ‘home-made’ Laemmli gels and pre-cast 
of separation technique are 
e total protein content of each plasma sample was conducted using 
 spectrophotometer (Jenway) at 280 nm.  Quantitation was carried out using 0.1 
mg/ml and 1.0 mg/ml of bovine serum albumin (BSA, 98% purity, Sigma) as a 
 to deduce the total protein concentration: 
 





NuPAGE® Novex Bis-Tris (Invitrogen) gels.  Both type 
described below. 
 




standard.  The following formula was used
 
Concentration (mg/ml) = A280 x Dilution factor x 2.69 
 
A280 is the absorbance measured at 280 nm, 2.69 is approximately equal to 1/A280 of
1







2.4.4.2 Protein separation using Laemmli gels 
esis (PAGE) was carried using Hoefer® 
ng the glass parts with 70% ethanol, 10% 
 dodecyl sulphate (SDS) resolving gels were prepared (Table 2.7) and poured 
to approximately 1 cm below the position of the comb.  Gels were then overlaid with 
, at 1:1 ratio, to prevent the 
 
Denaturing polyacrylamide gel electrophor
SE 600 Vertical Slab units.  After cleani
sodium
approximately 1 ml of isobutanol saturated with dH2O
formation of air bubbles.  After gel setting, the isobutanol was discarded and the 
stacking gel (Table 2.7) was poured on top of the resolving gel and left to set.  
 
 
Resolving gel (10%) Stacking gel (4%)
H2O (Millipore) 7.04 ml 13.35 ml
Tris-HCl (Sigma) buffer 5.00 ml 2.40 ml
40% Acrylamide (BioRad) 4.86 ml 1.80 ml
2% Bis-acrylamide (BioRad) 2.68 ml 975 μl
20% SDS (Fisher Scientific) 0.20 ml 188 μl
10% Ammonium persulphate (Sigma) 0.20 ml 189 μl
Tetramethylethylenediamine (Invitrogen) 0.02 ml 37.5 μl
Tris-HCl buffer was used at 1.5 M pH 8.8 and 1.0 M pH 6.8 in the resolving and stacking 
gels respectively.  Volumes and concentrations are as recommended by Sambrook and 
Russell, 1989.  
   Table 2.7 Chemical composition of the Laemmli gels used in one-dimensional   
protein separation.    
  
Protein samples were incubated with 1x SDS Loading Buffer  for 10 minutes 
at 70oC.  Gels were run in 1x SDS Running Buffer  after loading the denatured 
samples and a broad range protein marker (BioRad). Electrophoresis was conducted 
2.4.4.3
tion, plasma 
amples were diluted 1 in 10 using distilled water (dH2O, Millipore), in order to 
reduce the complexity of plasma.  Samples were incubated with 10 μl of 4x 
itol (DTT) reducing 
at 50 mV overnight or until the dye front reached the bottom of the gel. 
 
 Protein separation using pre-cast gels 
 
One-dimensional pre-cast NuPAGE® Novex Bis-Tris (Invitrogen) gels were also 
used for protein separation.  Prior to denaturation and protein reduc
s
NuPAGE® sample buffer (Invitrogen), 5 μl of 50 mM dithiothre
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agent (Invitrogen) and dH2O (Millipore) to bring the volume up to 40 μl.  Samples 
were denatured at 70oC for 10 minutes and loaded on 4-12% NuPAGE® Novex Bis-
Tris gels (Invitrogen) immersed in 1x SDS Running Buffer.  The running buffer was 
prepared by adding 40 ml of 20x NuPAGE® 3-(N-morpholino) propane sulfonic acid 
(MOPS) SDS Running Buffer (Invitrogen) to 760 ml of dH2O (Millipore).  A 
“SeeBlue” Plus 2 prestained molecular weight marker (Invitrogen) was also loaded 
and electrophoresis was conducted at 200 volts for approximately 45 minutes.   
 
2.4.5 Semi-dry transfer of proteins to membranes 
 
Transfer of proteins separated using either of the transfer methods mentioned above 
was carried out using a semi-dry transfer device (BioRad).  Proteins were transferred 
 a Hybond™-C Extra nitrocellulose membrane (Amersham Biosciences) by firstly 
soaking in methanol (Fisher Scientific), then transferring to dH2O (Millipore) and 
lter paper, the same 
n 
eparately for individual experiments, in the Results chapters.  Membranes were 
blocked for 1 hour using an excess of phosphate buffered saline (PBS)-Tween®  
med milk (Premier International Foods), with gentle 
to
finally transferring into Transfer Buffer.  Six pieces of thick fi
size as the membrane, were also immersed in Transfer Buffer.  On the lower negative 
electrode of the transfer device, three pieces of filter paper, the membrane, the gel 
containing the separated proteins and finally another three pieces of filter paper were 
layered in order.  Air bubbles were removed using a plastic roller and transfer was 
conducted at or greater than 1.2 mA/cm2 at a maximum of 25 volts for 60 minutes. 
 
2.4.6 Western blotting 
 
The following is a general protocol used for the immunodetection of proteins after 
semi-dry transfer.  Details of antibodies and their concentrations are show
s
including 5% dried bovine skim
shaking at room temperature.  Incubation with the primary antibody, diluted in PBS-
Tween® containing 5% dried milk, was carried out in a sealed plastic bag with gentle 
shaking over night at 4oC.  After three 10 minute washes in PBS-Tween®  
membranes were incubated with the appropriate HRP-conjugated secondary 
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antibody, diluted in PBS-Tween® containing 5% dried milk.  After incubation on the 
rotor for 1 hour at room temperature, using a sealed bag, membranes were washed 
three times as before.   
 Detection of the secondary antibody was carried out by incubating the 
membranes with enhanced chemiluminescence (ECL) western blotting detection 
reagents (Amersham Biosciences), according to the manufacturer’s instructions.  
Excess detection reagents were drained off and the membrane placed in an X-ray 
film exposure cassette with a sheet of Kodak™ X-Omat AR imaging film placed on 
t prior to the IEC mass 
pectrometry experiments, as described later.  The silver staining was employed as a 
more sensitive method of visualising polypeptides after electrophoresis. 
s carried out 
 order to deduce the approximate position of the full length CFH protein band after 
gel electrophoresis.  SimplyBlue™ also provides the right level of sensitivity for 
a proteins. 
top of it.  Following sufficient time for exposure, a phosphorimager X-ray machine 
(Konica Minolta) was used for the development of the film. 
 
2.4.7 SDS-PAGE gel staining 
 
Two methods of blue and silver staining were used for the visualisation of proteins 
separated by SDS-PAGE.  The blue staining was carried ou
s
 
2.4.7.1 SimplyBlue™ staining 
 
SimplyBlue™ SafeStain (Invitrogen) was used for the staining of plasma proteins 
separated on NuPAGE® Novex Bis-Tris gels (Invitrogen).  Staining wa
in
differentiating between separated plasm
 After electrophoretic separation of plasma proteins, the SDS-PAGE gels were 
stained with 20 ml of SimplyBlue™ SafeStain (Invitrogen).  Incubation was carried 
out overnight on a shaking rotor, followed by destaining in MilliQ™ dH2O 





2.4.7.2 Silver staining 
 
Staining of polypeptides with a silver stain after gel electrophoresis is a process that 
lies on the differential reduction of silver ions that are bound to the side chains of 
ino acids (Switzer et al., 1979; Oakley et al., 1980; Merril et al., 1984).  Staining 
r nitrate is advantageous over ammoniacal silver solutions in that silver 
o prepare and do not generate potentially explosive by-
roducts.  Furthermore, the detection limit of this type of staining is as little as 0.1-










nitrate solutions are easier t
p
1.0 ng of protein.   
Silver staining was carried out to assess the purity of CFH standard used in 
the assay of complement factor H.  It was also used to confirm the depletion of high 
abundant proteins from plasma after using the multiple affinity removal system. 
SDS-PAGE gels containing the separated proteins were incubated in 5 gel 
volumes of the Fixing Solution  for 4 hours with gentle shaking.  Gels were then 
incubated twice in 
llowed by two incubations for 10 minutes in 10 gel volumes of dH2O 
(Millipore).  Staining was carried out for 30 minutes using 5 gel volumes of silver 
nitrate Staining Solution, diluted 200 times from a 20% stock, with gentle shak
ining Solution was removed by washing both sides of the gel for 20 seconds 
under a stream of dH2O (Millipore).  Five gel volumes of the Developing Solution  
were then added to each gel and development was carried out with gentle agitation at 
room temperature.  Finally the reaction was quenched by washing the gel in 1% 
acetic acid (Fisher Scientific) for 5 minutes, followed by three washes in dH2O 
(Millipore) for 10 minutes.  The stained gel was then dried and photographed. 
 
2.4.8 Proteomic and mass spectrometry methods 
 
Mass spectrometry techniques using immuno-depletion and magnetic bead 
separation and MALDI-TOF were developed and optimised in collaboration with Dr. 
A. Henzing and Dr. J. Creanor (University of Edinburgh).  Capillary electroph
a
of Edinburgh).  Ion echange chromatography experiments and 
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MS/MS procedures were conducted as a service by Mr. D. Lamont (University of 
Dundee). 
2.4.8.1 Immunodepletion of high abundance plasma proteins 
2.4.8.1.1 Background 
 
The multiple affinity removal system allows for the immunodepletion of unwanted, 
high abundance proteins from human plasma or CSF samples (Pieper et al., 2003).  It 
to six high 
abundance plasma proteins immobilised on sepharose beads (albumin, 
ha-1 antitrypsin, immunoglobulin A, transferrin and 
ough a 0.22 μm spin 
lter (Agilent Technologies) in a centrifuge at 2,795 g for 5 minutes.  In the 
 (Agilent Technologies) was slowly added to the filter 
sin using a syringe to remove any trapped air bubbles and equilibrate the Multiple 
consists of a multiple affinity column containing polyclonal antibodies 
immunoglobulin G, alp
haptoglobin).  The multiple affinity columns are widely used either alone or in 
combination with other treatment methods, including magnetic bead separation prior 
to protein analysis (e.g. MALDI-TOF, LC-MS and iTRAQ™). 
 
2.4.8.1.2 Protocol  
 
Ten microlitres of crude human plasma was diluted 20 times in 190 μl of “Buffer A” 
(Agilent Technologies).  The diluted solution was filtered thr
fi
meantime, 4 ml of “Buffer A”
re
Affinity Removal Spin Cartridge (Agilent Technologies).  Excess “Buffer A” was 
then removed from the top of the cartridge.  The first fraction, containing most of the 
low abundance proteins (F1), was obtained by centrifugation of 200 μl filtered 
plasma for 90 seconds at 100 g.  The remainder of the low abundance proteins bound 
to the filter were collected in the same tube by filtering 400 μl of Buffer A for 2.5 
minutes at 100 g.  The second fraction of the low abundance proteins (F2) was 
obtained by adding 400 μl of “Buffer A” to the top of the resin bed followed by 
centrifugation for 2.5 minutes at 100 g.  The fraction containing the more abundant 
plasma proteins bound to the cartridge was eluted by placing the spin column in a 
new 1.5 ml tube (Eppendorf) followed by addition of 2 ml of “Buffer B” (Agilent 
Technologies) using a syringe.  Finally, 4 ml of “Buffer A” was used to re-
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equilibrate the cartridge according to the manufacturer’s instructions.  F1, F2 and the 
eluted fraction were then stored at 4oC until further use. 
 
2.4.8.2 Hydrophobic interaction chromatography  
2.4.8.2.1 Background 
 
One of the most recent advances in the separation of specific peptides from a mixture 
f proteins and peptides has been the development of magnetic beads.  Peptides and 
uch as plasma, urine or 
cerebrospinal fluid and concentrated on magnetic micro-particles or beads.  Once the 
n eluted from the magnetic beads, they can be analysed by 
r Daltonics).  Beads were shaken gently at least 20 times prior to each 
use.  F1 and F2 fractions were merged after immunodepletion of high abundance 
 microlitres of MB-HIC Binding Solution (Bruker Daltonics) 
o
proteins are captured from complex biological material s
bound molecules have bee
MALDI-TOF MS without further purification.  This technique allows for the 
simultaneous detection of large numbers of plasma proteins ranging in size from 0.8 
to 15 kDa (Villanueva et al., 2004; Zhang et al., 2004b).  Six different surface 
properties including hydrophobic interaction chromatography (C3, C8 and C18), 
immobilised metal ion affinity chromatography, weak anion exchange 
chromatography and weak cation exchange chromatography, can often be used.  
Varying the functionality of the beads allows the enrichment of different peptides 




Three magnetic beads for hydrophobic interaction chromatography were used, which 
included magnetic bead high interaction chromatography (MB-HIC) C3, C8 and C18 
resins (Bruke
plasma proteins.  Ten
was added to 100 μl of the F1/F2 fractions in a thin 0.2 ml PCR tube (Agilent 
Technologies).  Five microlitres of the magnetic bead mixture was added to the 
mixture and mixed gently by pipetting five times.  The mixture was allowed to 
equilibrate at room temperature for 1 minute, before being placed into a magnetic 
bead separator (MBS) (Bruker Daltonics) for 20 seconds to achieve separation of the 
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beads from the sample.  The supernatant was collected with a pipette and stored for 
further analysis, while avoiding any contact between the beads and the pipette.  After 
transferring the tube from the MBS to an alternative device, 100 μl of MB-HIC 
Wash Solution (Bruker Daltonics) was added to the sample and the tubes were 
placed back into the MBS.  After 20 seconds the supernatant was disposed of gently 
and the beads were washed 3 times using the Wash Solution.  Elution of the protein 
and peptides bound to the beads was carried out by incubation with 10 μl of 50% 
acetonitrile solution (Sigma) for 1 minute at room temperature.  After separation 
using the MBS for 30 seconds, the supernatant containing the eluted peptides and 
proteins was removed and stored at 4oC for further use.  
 
2.4.8.3 Pretreatment with ZipTip™ 
 
Concentrating, desalting and purification of crude plasma samples was carried out 
using the ZipTip™ technology.  ZipTip™ is a 10 μl pipette tip with a bed of 
hromatography media fixed at its end.  ZipTip™ is capable of purifying and 
protein and peptides.  Two types of C18 
nd C4 ZipTip  tips were used, targeted at the low and the high molecular weight 
d using 50% acetonitrile in Milli-Q® dH2O.  Samples were 
eluted d
nd biomarker analysis.  
UF is in many ways better than alternative separation methods as it can be used to 
prepare larger proteins (>10 kDa) for electrophoresis and to simultaneously separate 
c
concentrating femtomoles to picomoles of 
™a
ranges respectively.   
Tips were first equilibrated using the wetting solution (50% acetonitrile in 
TFA in Milli-Q® dH2O) followed by washing in 0.1% TFA in Milli-Q® dH2O.  
Interaction between the diluted samples and the chromatography bed was carried out 
by pipetting up and down gently a few times.  Elution of the bound fraction of 
plasma was performe
irectly onto a MALDI plate for MS analysis.               
2.4.8.4 Ultrafiltration of plasma 
2.4.8.4.1 Background 
 
Ultrafiltration (UF) through membranes with specific molecular weight cut-offs can 
be used to prepare low-molecular-weight fractions for MS a
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smaller polypeptides (<10 kDa) for MS analysis (Chernokalskaya et al., 2004).  
 speed and protein recovery.  Peptides present in the 
ltrafiltrate are often analysed after being concentrated and desalted by solid phase 
n was 
nutes at 1,006 g.  Ten microlitres of the filtrate was acidified 
ith 5 μl of 1% trifluroacetic acid (TFA) pH 0.9 (Sigma).  Samples were desalted 
I-TOF MS 
oyager-DE™ STR (Applied Biosystems) in a linear mode.  The laser intensity was 
e depending on the window size of the 
roteins/peptides of interest i.e. lower laser intensity for smaller protein size.  The 
al., 2005).  An Agilent 3D capillary electrophoresis system (Agilent Technology) 
Other advantages include
u
extraction on hydrophobic interaction chromatography resins (e.g. C18 beads). 
2.4.8.4.2 Protocol 
 
This protocol was kindly provided by Elena Chernokalskaya (Millipore) for high 
throughput ultrafiltration of plasma peptides for MALDI TOF MS.  Three to five 
hundred microlitres of crude plasma was filtered using 10 kD molecular weight cut-
off filters (VivaScience).  Three to five hundred microlitres of control plasma 
samples diluted 1:1 in 10 mM Tris-HCl pH 7.5 was also filtered.  Centrifugatio
carried out for 30 mi
w
and concentrated using μC18 ZipTip™ pipette tips (Millipore) as before.  
 
2.4.8.5 MALDI-TOF MS analysis 
 
One microlitre of either the product of ultrafiltration or MB-HIC was co-eluted with 
1-2 μl of 5 mg/ml alpha-cyano-4-hydroxy cinnamic acid matrix, onto a MALDI 
target plate (Applied Biosystems).  Samples were left to dry in a fume hood.  Spectra 
of mass to charge ratio were obtained and recorded using a MALD
V
altered between 2,100-2,500 μJ/puls
p
results were analysed using the software Data Explorer version 4.0 (Applied 
Biosystems). 
2.4.8.6 Capillary electrophoresis coupled with MS 
 
The following protocol is a modified version of the capillary electrophoresis (CE) 
technique, which was used in conjunction with electrospray ionisation (ESI) coupled 
with tandem Fourier transform ion cyclotron resonance (FT-ICR) MS (Chalmers et 
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was used in the analysis.  Pretreatment of the 90 cm x 75 μm capillary (Agilent 
Technologies) was carried out once a day prior to the start of the experiment and 
™ inutes, 
llowed by 1 M NaOH (Sigma) for 15 minutes, dH2O (Millipore) for 15 minutes, 
also included in each run.  The capillary was washed after each run, using the 
sulting CE spectra consisted mainly of low levels of 
consisted of rinsing the capillary with MilliQ  dH2O (Millipore) for 5 m
fo
ammonia (BDH) for 25 minutes and dH2O for 15 minutes, using a pressure of 25 psi.   
 The experimental procedure consisted of electrophoretic separation of 
proteins at room temperature using the Running Buffer  at 30 kV for 80 minutes, 
using a flow rate of 500 nl/min.  After 10 minutes, 1 M ammonia (BDH) was 
injected for 7 seconds followed by injection of the protein sample diluted in the 
Running Buffer, at a positive pressure of 1 psi.  Two molar formic acid (Sigma) was 
finally injected into the capillary for 5 seconds.  Pressure was applied at 0.1 psi after 
40 minutes and raised by 0.1 psi every 2 minutes until reaching 0.5 psi.  Data 
acquisition was carried out at 280 nm when in the UV absorbance mode and the 
results were analysed using the Agilent ChemStation software (Agilent Technology). 
2.4.8.6.1 CE analysis of single protein sample 
 
Initially, three proteins consisting of ubiquitin (8.5 kg/mol, 90% purified, salt-free 
lyophilised powder from bovine erythrocytes, Sigma), myoglobin (16.7 kg/mol, 95-
100% salt-free, lyophilised powder from equine skeletal muscle, Sigma) and BSA 
(66.4 kg/mol, 99% lyophilised powder, Sigma) were used separately at two different 
concentrations of 10 μg/ml and 50 μg/ml.  Protein samples were diluted in the CE 
Running Buffer.  Negative controls, consisting of the Running Buffer alone, were 
protocol described before. 
Furthermore, some replicates of the negative control samples were found to 
contain the same peaks at approximately the same time points as those containing 
ubiquitin, myoglobin and BSA, and high levels of background noise.  The 
troubleshooting procedures, described in Section 2.4.8.6.2 were employed to 
eliminate the problem of high background noise and contaminating peaks detected in 
the CE spectra.  Following the troubleshooting procedure which consisted of filtering 
all buffers, avoiding air bubbles and dissolving the protein samples in the Running 





hile pipetting.           
 Low signal to noise ratio in CE can be the result of occluded optical slits in 
apillary interface or ageing Deuterium UV lamp.  In order to overcome the problem 
.5.1 
β.  The Genetic Power Calculator 
ttp://pngu.mgh.harvard.edu/~purcell/gpc) used for the estimation of power was 
based on the above formula (Purcell et al., 2003).   
ound noise and no peaks of ubiquitin, myoglobin or BSA were detected in the 
control samples.   
If CE was coupled with ESI-FT-ICR, MS detection was performed on a 12-T 
quadrupole system APEX-QE (Bruker Daltonics, Germany) equipped with a fourier 
transform mass spectrometer using an electrospray ionization interface (Agilent 
Technologies) and a CE probe.  The sheath liquid consisted of the CE Running 
Buffer and was delivered by a syringe pump with a flow rate of 150 μl/h.  The drying 
gas flow rate was 1.4 dm3/min (nitrogen 5.0 at a temperature of 150oC), a nebulising 
gas was not applied.  
.2 CE troubleshooting 
The possibility of contaminated buffers, interfering air bubbles and precipitated 
samples was investigated as follows.  All buffers were filtered though 0.2 μm filters 
(Millipore) in order to exclude precipitants and contaminants in buffers.  
Precipitation of protein samples was prevented by verifying that sample components 
were sufficiently soluble in the buffer.  Care was also taken to not introduce air 
bubbles into buffers w
c
of high background noise in CE spectra, the optical slit was regularly cleaned with 
methanol or water.  The Deuterium lamp was also replaced with a new lamp (Agilent 
Technologies) and calibrated. 
 
2.5 Statistical analyses  
2 Predictive power calculation 
 
The power of a study is the probability of successfully detecting an effect of a 
particular size and principally depends on effect size and sample size (Sham et al., 
2000).  If β is the probability of a false-negative or type II error, then power is 
calculated as 1 − 
(h
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Factors that contribute to effect size are typically unknown, therefore 
of effect, sample size (N) and required 
vel of statistical significance, α, defined as the false-positive, or type I error rate.  
variance components model was 
used fo
s associated with APOE genotypes 
ere assessed using a binary coding system, after converting each genotype class 
n the presence 
r absence of the particular genotype in that variable class.  The mean QT was then 
assumptions were made about the magnitude 
le
Levels of linkage disequilibrium (LD) between marker SNP and QTL of interest and 
allele frequencies were also assumed in order to estimate study power.  The number 
of unrelated individuals present in the Vis data set (N) was set at 500, α was set at 
0.01 and pairwise LD (r2) was assumed to be 0.80 between the marker and QTL of 
interest.  Power was then estimated for varying levels of effect size and allele 
frequencies, as shown in the Results chapter.  A 
r the estimation of power in a test of association based on differences in 
means, given the genotypes at the candidate locus (Sham et al., 2000).  The formulae 
used in the power estimation make use of the relationship between the average values 
of the test statistics and genetic parameters such as the proportion of variance 
accounted for by the QTL (between 0 and 1) and the degree of linkage 
disequilibrium between QTL and marker locus. 
 
2.5.2 Empirical analysis of power using plasma lipids 
 
The APOE allelic model was used to test for evidence of additivity or dominance 
associated with each of the APOE*E2, APOE*E3 and APOE*E4 alleles.  For an 
additive model, APOE genotypes were coded as 0, 1 or 2 based on the number of 
copies of the allele to be examined.  For the dominant model, APOE genotypes were 
coded as either 0 or 1 according to the presence or absence of the allele to be 
examined.  Changes in the mean plasma level
w
into a separate variable.  Genotypes were coded as 1 or 0 depending o
o
applied to the most common class (APOE*E3 homozygous genotype).   The effects 
of sex, age, BMI and smoking on plasma lipid concentrations were also tested in 
each set of analyses. The effect of each allele or genotype was measured in terms of 
the proportion of the QT variance explained by the covariate (R2) and the direction of 
the effect was shown by β, the regression coefficient of the linear correlation 
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between the trait and the genetic variant.  Negative values of β indicate a reduction in 
the mean trait value. 
 
2.5.3 Normalising inter-experimental variation in ELISA of CFH 
and Aβ 
 
Variation between repeated assays is a result of experimental technique, 
environmental conditions and performance characteristics of the assay method.  
Therefore, a set of appropriate control samples, assayed repeatedly over time, was 
used to correct for inter-assay variation observed in ELISA. 
 Normalisation of each of the replicated measurements was carried out as 
ollows: 
lised measurement = (x / y) x raw measurement 
Detection of outliers in assays of CFH and Aβ 
Quantitat ons was 
arried in triplicate.  Two methods of detecting large variation between 
CV (%) = (σ / μ) x 100 
 is the standard deviation of the mean (μ) of the three replicates from the same 





in which x is the mean of the means of the five internal triplicate control assays 
measured over the course of all assays (> 20) and y is the mean of the means of five 




ive determination of plasma CFH, Aβ40 and Aβ42 concentrati
c
measurements were employed.  First was the use of the coefficient of variation (CV), 




sample.  The standard threshold of significance for CV is 5%.  The CV percentage 
provides a reliable estimate of the variation observed between measurements of the 
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A second statistical technique for dealing with outliers is referred to as 
Grubb’s test (Taylor 1990; Iglewicz & Hoaglin 1993; Barnett & Lewis 1994; 
ggarwal et al., 2005), also called the extreme studentised deviate (ESD) method.  
Elimination of outliers resulte surements with lower CVs.   
The deviation of an outlier from a set of values is quantified using the 
in whic
deviati
lues of Z for a given number of samples.  The critical value of Z for N = 3 
was 1.15.  The two-tailed P-value was estimated for each measurement within a set 
of N = 3, by firstly calculating the stud  using the following formula: 
.5.5 Testing for normality 
 
The Kolmogorov-Smirnov goodness-of-fit test was used to check the normality of 
ple distributions using the statistical software SPSS v.12.  The test compares 
A





h Z is the difference between the outlier and the mean (μ) of all replicated 
measurements, including the outlier (x), divided by the standard deviation (σ).  A 5% 
threshold for significance was set, which meant that 5% of the values in a set of 
samples, assuming a Gaussian distribution, were more than 1.96 (Z) standard 






Using the student t distribution and N-2 degrees of freedom, the approximate two 
tailed P value was estimated after taking the number of samples into consideration.  






the set of values in the sample to a normally distributed set of values with the same 
mean and standard deviation.  A non-significant test result (P > 0.01) indicates that 
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the distribution of the sample is not significantly different from a normal distribution 
i.e. the sample distribution is normal. 
2.5.6 Quantile normalisation 
ariance components and regression analyses are sensitive to kurtosis and skewness 
o obtain the corresponding normal equivalent 
eviates (NED) or Z-scores for each observation (Figure 2.5).  When ties were 
ss all ties. 
s to estimate the coefficients 
he general linear model implemented in the software SPSS version 12.0 was used 
-characterised continuous covariates and 




in the trait distribution.  Failure to normalise such distributions would result in an 
increased probability of obtaining false positive results. 
 Quantile normalisation (Pilia et al., 2006; Sokal & Rohlf, 2000) was carried 
out by first ranking the observations and then matching the percentile of each 
observation to the corresponding percentile in a standard normal distribution.  The 
resulting percentiles were then used t
d
present, percentiles were averaged acro
 
2.5.7 Linear regression analyses 
 
General linear models were used in a number of analyse
of the linear regression, involving one or more independent variables that best predict 
the value of the dependent variable.  The following applications were all variations 
of the general linear model, and are explained in detail. 
 
2.5.7.1 Multiple regression 
 
T
to assess the significance of effects of well
/o





Figure 2.5 Transformation of cumulative percentages into normal equivalent 
deviates.
Cumulative percentiles from a standard normal distribution were transformed into a 
standard deviation scale, called normal equivalent deviates (NED).  Ranked 
percentiles of observed data measurements were replaced by a z-score (NED).  Note 
that there are no 0% or 100% points since the normal frequency distribution extends 
from negative to positive infinity.  Diagram copied from Sokal & Rohlf, 2000.
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where yi is the phenotype of the ith individual, μ is the mean value of the trait in the 
ample, cij is the value of the jth predictor for the individual i (e.g. age) and βj is an 
stimate of the magnitude of effect associated with the predictor.  β is the regression 
f the general linear model and represents the change in the quantitative 
ait associated with a unit change in the predictor, and therefore takes the same unit 
me variable.  This also holds true for assessing the effect associated with 
e model as marker genotypes are coded 0, 1 or 2 
ased on the number of copies of the minor allele. 
A t-statistic was used to determine whether values of β differed significantly 
from zero, the null hypothesis value of β,  
β
odel (R ) and to assess the 
goodness of fit of the model (F statistic).  The multi-locus model used in the 
univariate analysis of plasm
in the outcome explained by the model, 
relative to the amount of variation present in the first place: 
 
R2 = SSM / SST 











with βexpected, the expected value of β under the null hypothesis and SEβ, the standard 
error associated with β.   
 The linear regression methodology was used to estimate the proportion of the 
phenotypic variance explained by the components of the m 2
a CFH was derived using this methodology.  R2 is 
calculated based on the amount of variance 
 
SST represents the sum o
data and the mean value of the outcome.  SSM is the difference between the SST and 
the residual sum of squares (SSR) and symbolises the sum of differences between 
each of the observed data and the regression line.  
 The goodness of fit of the model is assessed by the least squares method 
which favours a model with minimal residual sum of squares.  The F-test is based on 
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the ratio of improvement due to the model, and the difference between the model and 
the observed data: 
F = MSM / MSR 
reedom.  In the case of MSM this 
2.5.7.2 Stepwise linear regression an
 
 ‘backward’ linear regression analysis was carried out to obtain the multimarker 
model best associated with levels of plasma CFH, using the software SPSS version 
tion of each was 
e.  Hence when both predictors are included in the model, R 
e substantially larger than when correlated predictors which account for the 
nearity between predictors 
 
Here, MSM represents the mean sums of square of the model and MSR shows the 
residual mean sums of squares.  In order to calculate the mean sums of squares, the 
sums of squares were divided by the degrees of f
was the number of variables in the model and for MSR it was the number of 
observations minus the number of parameters being estimated. 
 
alysis of markers 
A
12.0.  The analysis consisted of placing all predictors in the model and assessing the 
contribution of each one by calculating the significance value of the t-test for each 
predictor.  Each predictor was tested against a removal criterion (explained in Results 
Chapter 7) which would result in the predictor being kept or dropped.  The model 
was then re-estimated for the remaining predictors, and the contribu
assessed as before. 
 
2.5.7.2.1 Detecting collinearity among predictors 
 
An important assumption in any linear regression analysis is the absence of 
collinearity between subjects.  Collinearity exists when there is a strong correlation 
between two or more predictors in the regression model.   
 The statistics of collinearity estimates are very complex.  In short, collinearity 
affects the validity of regression analysis in three ways.  Firstly, it limits the size of 
the correlation coefficient R as uncorrelated predictors account for different (unique) 
variances in the outcom
will b
same variance are included in the model.  Secondly, colli
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makes it difficult to assess the individual importance of a predictor as highly 
correlated predictors account for similar variances in the outcome.  Thirdly, as 
collinearity between two or more predictors of a variable increases, so do the 
ce statistic below 0.1 were indicative of 
colline
2.5.7.3 Multi-locus association analysis 
 
Phasing of a given group  was carried out 
using the conditional haplotype association test, implemented in the software 
bitrarily.  An F-test was 
used to compare the models for H haplotypes with H-1 degrees of freedom.       
standard errors of the β coefficients, which in turn affects whether these coefficients 
are found to be statistically significant.   
Two estimates were used to represent collinearity between predictors, 




in which R2 represents the squared correlation between variables.  VIF indicates 
whether a predictor has a strong linear relationship with the other predictor(s).  VIF 
values greater than 10 were taken as indicative of redundant predictors (Myers, 
1990).  Similarly, values of the toleran
arity (Menard, 1995). 
 
 of SNPs and haplotype association analysis
package PLINK (Purcell et al., 2007).  A default ‘omnibus’ test was used to compare 
the null and alternate models.  The alternate model was based on the assumption that 
each haplotype had a unique effect and the null assumed that no haplotypes had any 
different effects.  Coefficients of regression were estimated for each phased 
haplotype with respect to a reference haplotype, chosen ar
2.5.7.4 The linear mixed model 
 
To take into account the non-independence of the outcome measures due to 
relatedness of the participants, a linear mixed model was used with a polygenic 
“background genetic” effect fitted as a random effect.  Random effects are those that 
vary in the population, have means of zero, are characterised by their variance and 
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affect the covariance of the data.  The mixed linear model is a modification of the 




This model adjusted the quantitative trait for a random additive polygenic effect, Gi 
and a residual effect, ei, with an additive genetic variance σ2A, and a residual variance 
σ2e, respectively.  Variance parameters and fixed effects (those with well-
haracterised effects, such as sex that do not vary across individuals) were estimated 
using the maximum likelihood method in SOLAR (freely available, Almasy & 
Blangero, 1998) or by the restricted maximum likelihood method in ASReml 
(commercial software under license, VSN International 2002)
2.5.7.5 Estimates of heritability 
N
h2 = σ2A / σ2P 
hich estimates the proportion of the total phenotypic variance (σ2 ) due to the 
n were carried out using a standard linear regression 
model of phenotype on allele dos et al., 1986) implemented in the 





arrow-sense heritabilities were used to estimate the proportion of the variance of 
the quantitative trait due to additive genetic factors, environmental factors and 
covariates using the software package SOLAR (Almasy & Blangero, 1998).  The 
linear mixed model used information on the covariance among relatives to estimate 
narrow-sense heritabilities (h2), 
 
w P
additive genetic variance (σ2A).   
 
2.5.7.6 Genome-wide association analysis 
 




stratification as a result of the clustering of the Croatian dataset into two sub-groups 
(roughly corresponding to the two villages) was accounted for, using a permutation 
pproach (Purcell et al., 2007).  Covariate effects were also accounted for prior to the 
 966 individuals was used in the 
 were members of 122 families.  
a
association analysis (described below).  Data from
st of genome-wide association, 58% of whomte
Seventeen individuals had been removed due to low genotyping rate (<90%) and 
three due to non-European ethnicity.   
The genome-wide rapid association using mixed model and regression 
(GRAMMAR) method was used to take into account the relatedness of the 
participants and covariate effects (Aulchenko et al., 2007).  First, the data was 
analysed by Dr. V. Vitart using the linear mixed model.  The residuals (y*) from this 
analysis were obtained by: 
 
 
The residuals adjusted for relatedness, covariate and fixed effects were then used as 






where ei is the vector of residuals (obtained above), μ is the mean quantitative trait, g 
 the vector of genotypes (additive or dominance model) at the marker under study, 
6.1 Correction for multiple testing 
Correction for multiple testing was carried out using the Bonferroni correction with 
e significance threshold of P < 1.6E-07, equivalent to a 5% genome-wide 
significance (α′).  The following formula was used to obtain a significance threshold 
after correction for 308,140 independent tests (A total of 317,503 SNPs were 
is






genotyped, of which 8,984 were removed due to low genotyping call rates ( < 90%) 
and 379 were removed due to low minor allele frequency ( <1%) leaving 308,140 
SNPs ): 
α′ = 1 – (1 ‐ α)1/308140 
nted in the software package SOLAR (Almasy & Blangero, 1998).   This 
method estimates the amount o ative trait due to a particular 
enetic locus (σq2), residual genetic factors (σg2) and individual-specific, random 
ear mixed model  
nd tests for significance approximately every 5 cM along the genome.  The 
kage by comparing the likelihood of the 
stricted model in which the variance due to the QTL (σ2q) is fixed to 0, to that of a 
model where σ2q is estimated.  The dif e two log10 likelihoods 
ssical LOD score of linkage analysis.    
 
in which α would be equivalent to a 0.05 level of significance and α′ is the threshold 
of significance after correction for multiple testing (α′ ≈ 1.7E-07). 
 
2.5.8 Genome-wide linkage analysis  
 
The pedigree-based variance component linkage methodology that maximises the use 
of all available phenotypic information was used in a genome-wide linkage analysis 
impleme
f variance in a quantit
g
environmental factors (σe2), based on the phenotypic covariance between arbitrary 
relative pairs. An additional random QTL effect is fitted in the lin
a
variance-covariance matrix takes the form: 
 
Ω = σ2q Π + 2σ2g Φ + σ2e I 
 
where Π is the matrix whose elements provide the predicted proportion of alleles (0, 
1 or 2) that each pair of individuals share IBD at a QTL linked to a genetic marker 
locus.  Φ is the kinship matrix describing polygenic factors and Ι is the identity 
matrix describing sporadic environmental factors.  IBD probabilities were calculated 
by Dr. V. Vitart from the STR genotype information  using the statistical software 
Loki (Heath, 1997).   
 The model tested for multipoint lin
re
ference between th
produced a LOD score equivalent to the cla
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2.5.9 Estimation of Hardy-Weinberg equilibrium 
 
Hardy-Weinberg equilibrium (HWE) describes a mathematical relationship between 
alleles and genotypic frequencies.  If p is the frequency of the allele A, then the terms 
p2, 2pq and q2 will estimate the frequencies of AA, Aa and aa respectively.  A 
number of assumptions are made for the test.  Firstly, that the population is large 
enough in size so that allele frequencies are not subject to change simply because of 
 
e 
 was used.  The test is 
onditional on the allele frequencies, p and q, and the hypothesis of Hardy-Weinberg 
the sampling which leads to random genetic drift.  Secondly that the allele 
frequencies have not changed from one generation to the next and finally that 
mutation, migration and natural selection are negligible. 
 A Fisher’s exact test of HWE (Wigginton et al., 2005), implemented in th
genome-wide association tool set PLINK (Purcell et al., 2007)
c
proportions is rejected if the frequency of heterozygous genotypes is too large or too 
small.  The conditional probabilities for the heterozygotes given the allele 




w n11, n12 and n22 are the observed frequencies of the three genotypes,and  the 
frequency of the n1 allele is calculated as n1 = 2n11 + n12.  The sample size is denoted 
by n.  P-values representing the probability of deviations from the Hardy-Weinberg 
equilibrium were calculated.  
 
2.5.10 Analysis of linkag
here, 
e disequilibrium 
The squared correlation, r2 was used as the measure of linkage disequilibrium (Crow 
& Kimura, 1970).  It has been shown that r2 can be related to population genetics 
parameters as it is inversely proportional to the effective population size (r2 ~ (1 + 
Nθ)-1, in which θ is the recombination fraction between the two loci) and directly 




2003).  Furthermore, r2 is not adjusted to loci having different allele frequencies and 
exhibits more reliable sampling properties since it is not biased upward in small 
sample sizes and for low allele frequencies (Shifman et al., 2003).  The r2 measure is 
a normalised estimate of D, the first measure of linkage disequilibrium introduced, 
hich is highly sensitive to differences in allele frequency (Robbins, 1918).   
05) was used to estimate 
airwise r  for biallelic markers,  
 
aplotype containing the two alleles, namely A1 and 
B1,  and p1q1 is the product of frequencies of A1 and B1.  The magnitude of D is 
proportional to (1 - θ)g, where bination fraction 
e loci and the number of generations since the mutational event 










where p and q represent the two alleles at a biallelic locus.  D estimates the 
difference between the observed frequency of co-occurrence of both alleles on the 




where h11 is the frequency of the h















2.5.11 Bioinformatic resources 
 
The following online databases were used in the bioinformatic analysis of results. 
• International HapMap Project (www.hapmap.org)  
Data Rel 21A/PhaseII, Jan 2007 based on the NCBI Build 35 assembly 
• The National Centre for Biotechnology Information 
(www.ncbi.nlm.nih.gov) 
• UCSC Genome Bioinformatics (www.genome.ucsc.edu) 
March 2006 assembly Human Genome Brwoser  
• Ensembl Genome Browser (www.ensembl.org) 
 








2.6 List of reagents   
T























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Analysis of biomarkers for complex human diseases
 
3.1 Introduction 
Large-scale associati m to identify genetic variants that 
omising tool 
r deciphering the genetic basis of complex diseases.  It is therefore important that 
e most appropriate sample size and a suitable genotyping platform are selected that 
est suit the population of interest.   
Power is defined as the probability that a direct or indirect test of association 
etween a genetic marker and the phenotype will be statistically significant given 
at such an association exists.  Power depends on a number of factors, including the 
agnitude of genetic effect, sample size, prior probability and the type I error rate, α.  
 association studies, assumptions are made about the effect size of the genetic 
ariant and the level of linkage disequilibrium (LD) between the marker and the 
ausative variant as well as their respective allele frequencies.     
In this chapter, the results of an empirical and predictive analysis of power, 
sing the association between APOE genotypes and concentrations of plasma total 
holesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and high-density 
poprotein (HDL) cholesterol are presented.  The aim was firstly to try and replicate 
e well-established relationship between APOE genotypes and levels of circulating 
C, TG, LDL and HDL and secondly, to estimate the power to detect variants of 
mall to large effect size, using a predictive approach in the Vis sample set. 
APOE protein variants have been shown to affect levels of triglyceride and 
ery low density lipoproteins (vLDL) in human plasma (Utermann et al., 1979).  
ariation in human APOE protein, as a result of three common polymorphisms, have 
een reported to influence plasma cholesterol and triglyceride, and to confer 
usceptibility to type III hyperlipoproteinemia (Schneider et al., 1981, Breslow et al., 
982, Rall et al., 1982).  The APOE isoforms interact differently with specific 
poprotein receptors, which can alter circulating levels of cholesterol (Dong et al., 
994).  Studies have associated APOE*E2 carriers with lower levels of plasma total 
nd LDL cholesterol than in APOE*E3 homozygous individuals (Schneider et al., 
981; Weisgraber et al., 1982; Utermann et al., 1985; Sing & Davignon, 1985).  The 
POE*E4 allele displays an opposite pattern, with higher levels of total and LDL 
plasma cholesterol (Utermann et al., 1985; Sing & Davignon, 1985). 
 
on studies, which ai




























3.2.1 APOE genotyping in Vis sample set 
 
Genomic DNA from 584 individuals from the village of Komiza, and 457 individuals 
from the village of Vis, on the Croatian island of Vis, were amplified using PCR.  
The APOE genotype of each sample was established after overnight digestion with 
CfoI and running on an agarose gel.   
 
n and sequencing 
experim
te et al., 
1997), 
The software PedCheck (http://watson.hgen.pitt.edu, University of 
Pittsburgh) was used to detect any genotyping incompatibilities based on the 
pedigree data already assembled.  Furthermore, APOE allelic and genotypic 
frequencies were determined in both villages of Komiza and Vis separately, using the 
software SPSS v12.0 (Table 3.1).  Frequencies were based on 555 individuals from 
Komiza (29 missing) and 437 from Vis (20 missing), either due to missing DNA 
samples or lack of genotypic data after repeated digestio
ents. 
 As Table 3.1 shows, APOE allele frequencies observed in our population 
sample from Croatia agree with previous findings in Mediterranean populations with 
a long established agricultural economy, having a high frequency of the APOE*E3 
allele and relatively low frequencies of the APOE*E4 and APOE*E2 alleles.  
Comparison of allele and genotypic frequencies in Vis with published data from 
unrelated individuals in the U.K. population (Corbo et al., 1995; Lucot
revealed a reduction in the APOE*E4 allele frequency from 14% in the U.K. 
to 8% in the village of Komiza.  The frequency of the homozygous APOE*E4 
genotype was also found to be reduced from 1.6% in the U.K. general population to 
0.5% in the village of Komiza.  An increase in the APOE*E2 homozygote frequency 
of 0.3% in the U.K. to 4% in Komiza was also observed.  Although the APOE*E2 
and APOE*E4 alleles are far less frequent than the APOE*E3 allele, and their 
homozygous genotypes are rare, the sample set was found to be consistent with 

































































































































































































































































































3.2.2 Empirical analysis of power using plasma lipids 
 association 
between APOE genotypes and plasma lipid concentrations in Vis.  The complete set 
f APOE data from the island of Vis was used to evaluate the relationship between 
n individual’s APOE status and normalised plasma concentrations of HDL, LDL, 
C, and TG in a univariate analysis, using the statistical software package SOLAR 
lmasy and Blangero, 1998).  
The narrow-sense heritability (h2) defined as the ratio of a trait’s additive 
ariance to its total variance, is a measure of the predictability of offspring trait 
alues based on parental trait values.       
In the present study, narrow-sense heritabilities were estimated using a 
olygenic model which uses information on the covariance among relatives to 
stimate the proportion of the trait variance that is due to additive genetic factors, 
nvironmental factors and covariates.  The relatedness of individuals was taken into 
ccount by assigning the related individuals a shared environmental grouping.  This 
onsisted of the mother’s ID in each pedigree.  APOE genotypes were used as 
ovariates in the univariate analysis of plasma lipids based on the APOE allelic and 
enotypic models.   
The normality of the plasma lipid distributions were checked prior to the 
nivariate analysis of APOE genotypes and plasma lipid concentrations, using the 
olmogorov-Smirnov test for normality.  Deviations from normality were checked 
sing the statistical software SPSS (v.12).  Distributions of plasma HDL, LDL, TC 
nd TG concentrations were all found to deviate significantly from normality (PHDL = 
.5E-34; PLDL = 1.1E-12; PTC = 1.9E-09; PTG = 1.0E-85).  This emphasised the need 
 transform the data to give normal distributions in order to reduce the probability of 
lse-positive results in future analyses.  Plasma HDL, LDL, TC and TG 
easurements were normalised successfully using square, square-root, natural log 
nd natural log transformations respectively (PKolmogorov-Smirnov < 0.01) using the 
oftware package SPSS v.12.   
Narrow-sense heritability of plasma HDL concentration was estimated in the 
is sample set using a square transformation and was found to be non-significant at 
.133 (± 0.10 SE, P = 0.203) using sex, age and BMI as significant covariates (Table 
 



























3.2).  The APOE*E2 allele was significantly associated with an increase in plasma 
DL (β = 0.22 ± 0.09; P = 0.026, P = 0.014) explaining 3.5% of the phenotypic 
DL were observed for 
APOE*E2
associated with a decrease in LDL 
levels 
ion of this chapter.         
ut 14.5% of the phenotypic variance. No significant 
associa
H add dom 
variance (R2 = 0.035).  No significant associations were detected between APOE*E3, 
APOE*E4 and plasma HDL in this sample set.   
Square-root transformed plasma LDL concentration showed a narrow-sense 
heritability of 0.17 (± 0.11 SE, P = 0.042) with sex and age as significant covariates 
(Table 3.2).  The most significant associations with L
 and APOE*E4 alleles using a dominant model (PAPOE2 = 2.2E-09, PAPOE4  
= 1.6E-05), explaining 11.2% and 10.1% of the trait variance respectively (Table 
3.2).  Furthermore, the APOE*E2 allele was 
(β = -0.530).  The effect associated with APOE*E4 was in the opposite 
direction (β = 0.364).   
Analysis of plasma LDL using the genotypic model showed highly 
significant effects associated with the E2/E3 (P = 1.7E-08, β = -0.538) genotypes and 
E3/E4 (P = 5.4E-07, β = 0.441) genotypes, in support of the dominant model fitted to 
the E2 and E4 alleles (Table 3.2).  However, no association was observed between 
E2 or E4 homozygous genotypes and plasma LDL.  This is discussed in the summary 
and conclusions sect
Measurement of natural logarithm-transformed plasma total cholesterol (TC) 
showed a non-significant narrow-sense heritability of 0.145 (± 0.08 SE, P = 0.093), 
using sex, age, age-by-sex interaction and BMI as covariates (Table 3.2).  Highly 
significant evidence for dominant effects on TC were associated with APOE*E2 (P = 
4.0E-08, β = -0.504) and APOE*E4 (P = 1.2E-05, β = 0.331) alleles.  The APOE*E2 
and APOE*E4 alleles were found to explain 15.1% and 14.2% of the TC trait 
variance respectively.  The effect associated with the APOE*E3 allele on plasma TC 
concentration did not differ significantly from zero.  In the genotypic model, a highly 
significant association was observed between the E2/E3 genotype and TC (P = 1.2E-
07, β = -0.528) and between E3/E4 genotype and TC (P = 2.0E-06, β = 0.403).  Each 
of the genotypes explained abo
tion was observed between APOE genotypes and the concentration of plasma 
triglyceride.   
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Table 3.2 Univariate analysis of APOE
 
genotypes and plasma lipids concentrations.
1,030 unselected samples, consisting of related and unrelated individuals, were used in the 
univariate analysis APOE
 
genotypes and levels of plasma HDL (high density lipoprotein), LDL 
(low density lipoprotein), TC (total cholesterol) and TG (triglyceride).  β
 
is the regression 
coefficient which represents the change in mean plasma concentration of each normalised trait 





shows the proportion of the phenotypic variance explained by each covariate.  
Narrow-sense heritabilities (h2) were estimated for each trait.  Statistically significant results 
are shown in bold.  n.a., not applicable.  All analyses were carried out using the software 
SOLAR (Almasy & Blangero, 1998).    
Trait            
(mean±SD)
h 2 (S.E.) 
(P -value)
APOE          
allele/genotype
P                  
(Genotypic model) β  (S.E.) R
2
(Tra ns fo rm a t io n) add. dom.
HDL 0.133 (0.10)
(3.9±1.03) (0.203)
(square) E2 0.026 0.014 0.220 (0.09) 0.035
E3 0.608 0.556 - 0.026
E4 0.165 0.172 - 0.026
E2/E2 0.989 - 0.026
E2/E3 0.054 - 0.035
E2/E4 0.132 - 0.031
E3/E3 n.a.* -
E3/E4 0.182 - 0.031
E4/E4 0.632 - 0.031
LDL 0.170 (0.11)
(7.1±1.04) (0.042)
(square root) E2 1.9E-08 2.2E-09 -0.530 (0.08) 0.112
E3 0.239 0.096 - 0.088
E4 7.8E-05 1.6E-05 0.364 (0.08) 0.101
E2/E2 0.346 - 0.089
E2/E3 1.7E-08 -0.538 (0.09) 0.112
E2/E4 0.157 - 0.089
E3/E3 n.a.* -
E3/E4 5.4E-07 0.441 (0.09) 0.107
E4/E4 0.675 - 0.089
TC 0.145 (0.08)
(9.2±1.09) (0.093)
(natural log) E2 1.1E-07 4.0E-08 -0.504 (0.09) 0.151
E3 0.373 0.207 - 0.129
E4 5.1E-05 1.2E-05 0.331 (0.08) 0.142
E2/E2 0.156 - 0.129
E2/E3 1.2E-07 -0.528 (0.09) 0.146
E2/E4 0.703 - 0.129
E3/E3 n.a.* -
E3/E4 2.0E-06 0.403 (0.09) 0.144
E4/E4 0.783 - 0.129
TG 0.270 (0.14)
(0.4±0.47) (0.027)
(natural log) E2 0.734 0.488 - 0.139
E3 0.220 0.455 - 0.137
E4 0.201 0.247 - 0.139
E2/E2 0.293 - 0.139
E2/E3 0.537 - 0.139
E2/E4 0.137 - 0.139
E3/E3 n.a.* -
E3/E4 0.571 - 0.139
E4/E4 0.370 - 0.139
P               
(Allelic model)
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The narrow-sense heritability of TG after natural logarithm-transformation 
 
smoking were all found to be significant covariates for changes in plasma TG 
oncentration and were included in the regression model. 
The effect of the APOE genotype on plasma lipid concentrations, which is an 
xample of a large effect genetic influence, was therefore supported in samples from 
Vis.  The results of the empirical analysis of power showed that there was sufficient 
ower available to detect genetic associations of effect size (R2) greater than 3% in 
e Vis data set (Table 3.2).  
.2.3 Predictive analysis of power 
 
he power to detect a quantitative trait locus (QTL) influencing a quantitative trait 
ated in a sample of 500 unrelated individuals.  
Analysis was carried out using the programme Genetic Power Calculator (Purcell et 
l., 2003).  Assuming a 1% threshold for a type I error rate, power was estimated for 
TL of varying effect size and frequency.  The proportion of the phenotypic 
2) was taken as representative of the effect size of 
that QTL.   
The results showed that there was insufficient power in 500 unrelated 
dividuals to detect a QTL with an effect size of 1% (Power = 0.15) (Figure 3.1).  
e number of unrelated individuals, the power to detect a QTL of 2%, 
3%, 4% and 5% effect size increased to 0.38, 0.60, 0.76 and 0.87, respectively with 
arker allele frequency of 0.05 - 0.07 (Figure 3.1).  Results showed an exponential 
crease in the available power (0.15 to 0.99) as the QTL effect size increased from 
ately 8% (Figure 3.1).  The power to detect QTL of large effect size 
(10% and 15%) was predicted to increase exponentially to 0.998 (R2 = 10%) and 1 













by genetic association was estim
a
Q








Figure 3.1 Predicted power for detecting polymorphisms of small to large effect 
size, influencing a quantitative trait by genetic association.
Predictive power for the detection of a genetic locus influencing a quantitative trait in 500 
unrelated individuals shows that there is sufficient power ( ≥
 
0.50) available in the Vis 
dataset to detect polymorphisms of ≥
 
3% effect size.  Power was estimated for markers of 
small, moderate and large effect size as measured by the proportion of phenotypic 
variance explained by the marker (R2). The marker and the causative variant are 
assumed to be in strong linkage disequilibrium ( > 0.80) and to have the same allele 
frequencies.  α
 
is the type I error rate.  Data was obtained using the Genetic Power 
Calculator®
 























Marker ID Marker          allele frequency R
2 Power (α = 0.01) Effect size
M1 0.05 0.01 0.152 1%
M2 0.05 0.02 0.377 2%
M3 0.05 0.03 0.596 3%
M4 0.05 0.04 0.764 4%
M5 0.07 0.05 0.870 5%
M6 0.10 0.08 0.987 8%
M7 0.17 0.10 0.998 10%
M8 0.20 0.12 0.999 12%
M9 0.20 0.15 1.000 15%
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3.2.4 ummary and discussion 
aluate power empirically by 
ttempting to replicate genetic effects associated with APOE locus variants on 
lasma lipid concentrations.  Power was also estimated for genetic variants of small 
 large effect using the variance components methodology implemented in the 
enetic Power Calculator® (Purcell et al., 2003).  
Firstly, the APOE genotypes of 1,021 individuals from Vis island were 
etermined, using PCR and RFLP analysis, in order to carry out a univariate analysis 
f the association between APOE genotypes and plasma concentrations of HDL, 
DL, TC and TG.  The regression model also included smoking, BMI, age and sex 
s covariates.  Lower plasma HDL concentrations have been reported in males and 
mokers compared with females and non-smokers (Bihari-Varga et al., 1981).  
moking has also been shown to be associated with elevated plasma LDL and TG 
oncentrations in disease-free individuals (Freeman et al., 1993).  Plasma 
oncentrations of TC and TG have been reported to increase with increasing age and 
MI in disease-free individuals (Mann et al., 1988).  Furthermore, male smokers 
ffected with coronary artery disease (CAD), for which plasma lipids are strong risk 
ctors, have been shown to have reduced concentrations of plasma HDL compared 
ith female non-smokers (Hill et al., 1991).  Increased concentrations of plasma TG 
ave been reported in females affected with CAD (Hill et al., 1991). 
The significant covariates described above were used to construct a polygenic 
odel in order to estimate narrow-sense heritabilities (h2) of plasma lipid 
oncentrations.  However, significant estimates of heritability were only observed for 
lasma LDL (h2 = 0.17, P = 0.042) and TG (h2 = 0.27, P = 0.027) (Table 3.2).  A low 
r zero additive variance places a constraint on the magnitude of additive effects of a 
TL, however a high additive variance does not necessarily indicate that any QTL 
llows a strictly additive model, since it is possible to have a high additive genetic 
ariance even when all loci follow a dominant model (Abney et al., 2001).  It is also 
ossible to have a trait that is strongly influenced by genetic variation that has a 
latively low additive variance (i.e. low h2), for example if selection has been acting 
on the trait (Fisher, 1958; Charlesworth & Hughes, 2000).  A high heritability 
S
 
In this chapter, the relationship between APOE genetic variants and concentrations of 




























estimate would however increase the power for detecting common susceptibility 
ariants with an additive effect.   
 found for plasma HDL (h2 = 0.51, 
P < 0.0
 compared with 
the urb
v
Published data have reported significant heritabilities for plasma lipid 
concentrations as summarised in Table 3.3.  Heritability estimates of plasma LDL 
(h2 = 0.17, P < 0.05) and TC (h2 = 0.28, P < 0.05) in a sample of 868 individuals 
from the isolated Rucphen (Dutch) population were found to be similar to those 
observed in the Vis population (Isaacs et al., 2007) (Table 3.3).  However, in the 
Rucphen population, significant heritabilities were
5) and TC (h2 = 0.19, P < 0.05) in contrast to the findings in the Vis data set 
(Table 3.3).  This could be due to the lack of power in the Vis data set (472 related 
individuals) compared with the Rucphen samples (868 related individuals) due to the 
lower number of related individuals from whom the heritability estimates are 
extracted.  Furthermore, distant relationships within the Vis pedigrees (despite the 
presence of a single large pedigree of 125 related individuals) could account for the 
reduced power.   
The large difference between the heritabilities observed for HDL in Vis and 
Rucphen samples could be the result of extreme isolation and increased inbreeding in 
Vis compared with the Rucphen community (Isaacs et al., 2007) since higher 
estimates of heritability in less inbred populations could be due to increased variation 
in the trait distribution.  Inbreeding can also result in diversity by creating a higher 
proportion of extremes in the population (Rudan & Campbell, 2004).  Indeed, lower 
variation in HDL distribution has been reported in the Vis population
an Croatian population (Polasek et al., 2006). 
Compared with Vis, significantly higher heritabilities have been reported for 
plasma lipids in 806 individuals from the founder population of Hutterites (Abney et 
al., 2001), in a sample of 160 pairs of unselected Dutch twins (Beekman et al., 2002) 
and in an urban population series of 85 Caucasian families ascertained through a 











HDL 0.22 n.s. n.s. 3.5 n.s. n.s.
LDL -0.53 n.s. 0.36 11.2 8.8 10.1
TC -0.50 n.s. 0.33 15.1 12.9 14.2





HDL -1.44 -0.03 0.90
LDL -13.06 0.01 6.68
TC -12.60 -0.29 7.99
TG 3.94 0.36 -3.86 1.0
Vis, Croatia
Ottawa, Canada (Sing & Davignon, 1985)
Effect of the APOE  allele
Effect of the APOE  allele (β) R2 (%)








Rucphen        
(n=868)
Dutch twins   
(n=320)
GET Study, USA       
(n=85 families)
HDL 0.13 0.63* 0.51* 0.75* 0.54*
LDL 0.17* 0.50* 0.17* 0.83* 0.34*
TC 0.15 - 0.19* 0.82* -
TG 0.27* 0.37* 0.28* 0.71* 0.41*
Table 3.4 Comparison of APOE
 
association with plasma lipid concentrations 
between Vis and published data.
APOE
 
allele frequencies and the allele-specific effects (β) on plasma lipid 
concentrations obtained from 1,030 unselected individuals from Vis compared with 
published data (Sing & Davignon, 1985) on the direction of the APOE
 
allele-specific 
effects on plasma LDL and TC concentrations. The proportion of the phenotypic 
variance explained by APOE
 
allelic variants (R2) was found to be higher in the Vis 
population compared with the randomly selected cohort of 122 unrelated individuals 
from Ottawa (Sing & Davignon, 1985). HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; TC, total cholesterol; TG, triglyceride. N.S., non-significant            
Table 3.3 Comparison between reported estimates of heritability of plasma lipid 
concentrations and estimates obtained in the Vis population. 
Narrow-sense heritability estimates of plasma lipid concentrations were
 
found to vary 
between the Vis population and published data on related individuals from the founder 
population of Hutterites (Abney et al., 2001), related individuals from the isolated Dutch 
(Rucphen) population (Isaacs et al., 2007), 160 pairs of unselected Dutch twins 




proband in the Genetic Epidemiology of
 
Hypertriglyceridemia Study (GET) (Edwards et 
al., 1999).  HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total 
cholesterol; TG, triglyceride. Asterisks denote statistically significant results (P < 0.05).            
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Inconsistencies in the estimated h2 between populations could also be the 
mple sets used in different studies (Table 3.3) as the 
umber of related individuals (the degree of relatedness in the data set) and the type 
may result in reduced power in estimating heritabilities (Hsu et al., 2005).  The effect 
h2 estimations 
 the Dutch twins (Beekman et al., 2002) compared with the general population 
amples (Table 3.3).  However, heritability based on sibling pairs (especially twins) 
may include non-additive genetic effects and shared environment which contribute to 
tal data provides additional heritability through the 
arent-offspring covariance which is an unbiased estimate of additive genetic 
variance (Hsu et al., 2005).  This may be the case in studies (Table 3.3) in which 
rved for some traits.  The lack of significant h2 estimates 
btained in the Vis population can also be explained by the possible action of natural 
election on these traits (Fisher, 1958; Charlesworth & Hughes, 2000) associated 
with different environmental exposures such as diet, smoking and exercise (Vuletić 
c & Mujkić, 2006) which influence plasma lipid concentrations.   
Analysis of plasma HDL showed suggestive association with the APOE*E2 
llele, under both dominant (P = 0.014) and additive (P = 0.026) models.  Weak 
association is probably due to the low frequency of the E2 allele in this population.  
APOE alleles, or any of the APOE 
enotypes, and plasma HDL concentration.  The lack of association between APOE 
nd plasma HDL has also been reported in the literature (Sing & Davignon, 1985) 
(Table 3.4) suggesting that despite a high reported heritability (Abney et al., 2001; 
et al., 2007; Beekman et al., 2002; Edwards et al., 1999) the variation in 
uman plasma HDL concentration is determined by genetic factors other than APOE.    
The results showed that reduced concentrations of plasma LDL (β = -0.530) 
ignificantly associated with the APOE*E2 allele (P = 2.2E-09), while 
raised plasma LDL concentrations (β = 0.364) are strongly associated with the E4 
llele (P = 1.6E-05).  Under the allelic model, evidence of dominance was also 
bserved for the E2 and E4 alleles.  APOE genotypes, notably the E2/E3 and E4/E4 
result of differences in sa
n
and depth of the pedigrees can affect the magnitude of h2.  More distant relationships 
of the degree of relatedness is demonstrated by the significantly higher 
in
s
greater phenotypic resemblance among sibling pairs than parent-offspring pairs (Hsu 
et al., 2005).  Inclusion of paren
p















C and the 
APOE 
and pl
pes, also showed significant associations with differences in plasma LDL 
concentrations (PE2/E3 = 1.7E-08, PE3/E4 = 5.4E-07).  The lack of significant 
association between the E2/E2 and E4/E4 genotypes and plasma LDL is probably 
due to the low frequencies of those genotypes in the Vis sample set (frequencyE2/E2 = 
0.011, frequencyE4/E4 = 0.007).  The APOE association with plasma LDL is 
consistent with other reported data showing that variation at the APOE locus explains 
8.3% of the total LDL variance (Sing & Davignon, 1985), compared with 11.2% for 
the APOE*E2 and 10.1% for the APOE*E4 alleles in Vis (Table 3.4).  The stronger 
associations reported in Vis could be due to the larger sample size of 1,031 
individuals from Vis compared with only 122 individuals from Ottawa (Sing & 
Davignon, 1985).  More accurate family structure and trait measurements can also 
result in better estimates of the proportion of phenotypic variance explained (Dawn 
& Barrett, 2005).   
Analysis of plasma TC showed highly significant evidence for a dominance 
effect associated with APOE*E2 (P = 4.0E-08, β = -0.504) and APOE*E4 (P = 1.2E-
05, β = 0.331) alleles, explaining 15.1% and 14.2% of the total TC variance 
respectively.  The effect on differences in plasma TC concentration associated with 
the APOE*E3 allele did not differ significantly from zero.  Analysis of T
genotypic model showed highly significant associations between the E2/E3 
genotype and TC (P = 1.2E-07, β = -0.528) and between the E3/E4 genotype and TC 
(P = 2.0E-06, β = 0.403), both explaining about 14.5% of the phenotypic variance.  
Despite the same direction of effect reported for the APOE*E2 and APOE*E4 alleles 
on plasma TC, the proportion of the phenotypic variance explained by those alleles 
in other studies has been considerably lower (R2 = 6.9%) (Sing & Davignon, 1985) 
(Table 3.4).  This could again be the result of larger sample size in Vis (N = 1,021) 
compared with the sample size used by Sing and Davignon (N = 122).          
Finally, no significant association was observed between APOE genotypes 
asma triglyceride concentration despite obtaining a significant heritability 
estimate for this trait in Vis (Table 3.2).  Variation at the APOE locus has been 
shown to explain 1% of the variance in plasma TG concentration in unrelated 
samples from Ottawa (Sing & Davignon, 1985) implying that variation in this trait in 
Vis may be explained by genetic factors other than APOE (Table 3.4).      
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A wider range of plasma TG and HDL concentrations and a smaller range of 
plasma LDL concentration was observed in the general Croatian population 
compared with the Vis population (Polasek et al., 2006).  Although reduced genetic 
and environmental diversity in isolated human populations are expected to reduce the 
variance in observed phenotypic values (Rudan, 1999a; Rudan et al., 1999b), it 
appears that specific population genetic processes in this isolate, such as inbreeding 
and population substructure could be acting to maintain the variation in these traits 
(Rudan & Campbell, 2004). 
In conclusion, the empirical analysis of power using the association between 
APOE genotypes and plasma lipid concentrations showed that there was sufficient 
power to replicate associations between APOE alleles and plasma LDL and TC 
concentrations with effect sizes ranging between 10-15%.  Significant (but weaker) 




03) showing that there is sufficient power to detect effect sizes low as 3.5%.  
Lack of power to detect an association of small effect size (1%), as reported for 
APOE and TG by Sing and Davignon (1985), was apparent in the Vis data set by the 
absence of association between APOE and TG.   
Predictive analysis of power showed that the power to detect a causal variant 
increases with the effect size of the marker of interest (assumed to be in high LD 
with the causal variant) and with the marker allele frequency.  The results of the 
predictive analysis of power, using the Genetic Power Calculator (Purcell et al., 
2003), showed that in a QTL association analysis, sufficient power (≥ 60%) would be 
available for detecting variants with effect size of approximately 3% using 500 
unrelated individuals (Figure 3.1).  However, a power of only 15% and 37% would 
be available to detect variants of effect size 1% and 2%, respectively.  The lack of 
power in detecting variants of small effect size (1-2%) is probably due to t
 of unrelated individuals in the Vis data set (N = 500) who contribute much of 
the power.  Furthermore, the power may be underestimated due to higher extents of 
LD which has been show to exist in the Vis isolate compared with urban populations 
(Vitart et al., 2005; Vitart et al., 2006).  
Klein (2007) estimated power for the Illumina Hap300 genotyping platform, 
as used in this study, and showed that it increases with increasing sample size and 
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magnit
300 array (light green bar in Figure 3.2).  The number 
of unre
confirming that adequate power is 
availab
ude of effect (Figure 3.2).  Therefore, for a sample size of 500 unrelated 
individuals in a case/control study, there would be sufficient power ( > 0.50) to 
detect variants with a genotype relative risk (GRR) greater than 2.5.  GRR of 2.5 
would be considered of moderate effect size when expressed in terms of the 
proportion of the phenotypic variance (R2) in QT association analyses.  In the same 
study, the number of unrelated individuals needed to obtain 80% power in detecting 
a polymorphism with a smaller effect size (GRR = 1.75) was estimated to be around 
2,000 using the Illumina Hap
lated individuals needed to detect a causative variant with a GRR of 1.75 and 
80% power, was found to be higher when using the Affymetrix 550K array (dark 
green bar Figure 3.2). 
These results reported by Klein were obtained from a CEPH population and 
emphasised that more power could be obtained by genotyping more individuals at 
fewer loci rather than fewer individuals at more SNPs.          
In conclusion, both predicted and empirical power analyses were carried out, 
the latter using known biomarkers of dyslipidaemia.  The effect of the APOE 
genotype on plasma lipid levels was replicated, 
le.  It is also predicted that there would be sufficient power in the Vis data set 















Figure 3.2 Analysis of power in a case-control genome-wide association study.
The graph shows the power estimated for varying genotype relative risks (GRR) for a test 
of genotypic association using the Illumina Hap300 array in a case-control cohort.  A.
 
For 
a sample size of 500 individuals, indicated by the dotted pink line, there would be 




The bar chart shows 
the total number of individuals needed to achieve 80% power to detect a causative QTL 
assuming a GRR of 1.75.  The light green bar represents the Illumina Hap300 array used 
in a CEPH population sample set.  Blue, red, dark green and dark
 
blue bars show the 
Affymetrix 250K Nsp, Affymetrix 250K Sty, Affymetrix 500K and Illumina 550K 

















BIOCHEMICAL AND LINKAGE 




























y tangles are the two main pathological features of the 
rains of patients with Alzheimer disease (Hardy & Selkoe, 2002).  Amyloid-β [1-
2] (Aβ42), tau and phosphorylated tau in cerebrospinal fluid (CSF) are established 
iomarkers for Alzheimer disease diagnosis (AD) (Kanai et al., 1998).  Aβ42 
ggregates more easily in the brain than the shorter amyloid-β [1-40] (Aβ40) due to 
e presence of two additional hydrophobic amino acids.  Aβ42 is believed to be the 
itial species deposited in the brain, making it the key molecule in AD pathology 
ardy & Selkoe, 2002).  Aβ is produced in the brain and cleared to the plasma via 
e CSF and the blood-brain barrier (Zlokovic et al., 2004).  The mouse Apoe protein 
as been shown to participate in the Aβ transport through the blood-brain barrier 
ell et al., 2007).   
It has been proposed that elevated concentrations of plasma Aβ42, the 
redominant form in senile plaques reflect a generalised increase in both neural and 
on-neural cells (Mayeux et al., 1999).  It is well established that all of the mutations 
at cause early-onset familial Alzheimer disease (FAD) result in an increase in the 
lasma Aβ42 concentration (Scheuner et al., 1996).  Furthermore, both plasma Aβ40 
nd Aβ42 concentrations are elevated in first-degree relatives of late-onset 
lzheimer disease (LOAD) families (Ertekin-Taner et al., 2008).  This study 
upports the notion that plasma Aβ concentrations show premorbid elevations in 
dividuals who are genetically predisposed to LOAD.  A prospective 
pidemiological study of 530 individuals (NAD cases = 165), in which the 
oncentrations of plasma Aβ40 and Aβ42 were measured over three years, showed 
at compared with those who never developed AD, patients with AD at baseline and 
ose who developed AD later had significantly higher plasma Aβ42 concentrations 
ayeux et al., 1999, 2003).  These studies showed that in patients with newly 
cquired AD, the plasma Aβ42 concentration declined significantly compared with 
e control individuals or those with prevalent AD.  The ratio of Aβ42 to Aβ40 
(Aβ42:Aβ40) in plasma has previously been shown to be a good indicator of the 
 
Brain amyloidosis, comprising extracellular deposits of amyloid-β (A
and taupathy characterised by intracellular accumulation of hyperphospho



























harmful levels of Aβ42 deposited in the brain (van Oijen et al., 2006; Graff-Radford 
t al., 2007).  These studies showed that the risk of dementia was increased in 
β β
been estimated to be around 41% and 56% respectively (Ertekin-Taner et al., 2001).  
93; Basun et al., 1995). 
e
individuals with high concentrations of plasma Aβ40 or low concentrations of 
plasma Aβ42 as a results of the deposition of Aβ42 in plaques prior to the onset of 
AD. 
Narrow-sense heritabilities of both plasma A 40 and A 42 have previously 
Linkage analyses, using plasma Aβ as an intermediate phenotype, in extended 
LOAD families have identified peaks with significant ( > 3.0) LOD scores on 
chromosome 10q (Ertekin-Taner et al., 2000; Ertekin-Taner et al., 2001).  APOE 
variants are, to date, the only common genetic susceptibility factors which have been 
reliably associated with late-onset Alzheimer disease in multiple studies (Saunders et 
al., 1993; Corder et al., 1993).  The APOE*E4 allele has been associated with an 
increased risk of LOAD by lowering the age of onset in a dosage-dependent manor 
(Strittmatter et al., 19
The analysis of plasma Aβ in this study is based on the hypothesis that Aβ40 
and Aβ42 peptides are produced and secreted by body cells (predominantly by the 
brain) as a result of genetic predisposition and environmental factors such as 
oxidative stress (Ross & Poirier, 2004).  The fractions of Aβ40 and Aβ42 which are 
released into the plasma (resulting in an increase in plasma Aβ concentrations) 
reflect the CSF concentration, which is in turn influenced by the severity of 
aggregation in the brain (Mayeux et al., 1999, 2003) and both increase with age.  
However, a reduction in the plasma concentration of Aβ42 about the time of onset of 
Alzheimer disease (shown by a reduction in the ratio of Aβ42:Aβ40) is thought to 
represent an increase in the rate of deposition of Aβ42 in the brain (Hardy & Selkoe, 
2002) based on the analysis of the Tg2576 mouse model of AD which over-produces 
Aβ42 (DeMattos et al., 2002).  In this chapter, the results of the assay of human 
Aβ40 and Aβ42 in plasma are presented.  The aim is to use plasma Aβ40 and Aβ42 
as biomarkers for Alzheimer disease to identify genetic and environmental factors 
which influence them in a general population sample.    
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Plasma Aβ40 and Aβ42 concentrations were firstly measured by ELISA.  
Covariate effects, including APOE genotype, associated with circulating 
concentrations of Aβ40, Aβ42 and Aβ42:Aβ40 ratios were also assessed.   
Furthermore, a genome-wide linkage analysis using 810 microsatellite markers was 
carried ou
 
t in order to identify QTL associated with differences in plasma Aβ40 and 
Aβ42 c
cting Aβ1-16) and BNT77 (detecting 
Aβ11-2
lues obtained for individual 
plasma samples (in duplicate) were highly variable.     
oncentrations in a general population sample from the Croatian island of Vis.   
A number of assays for the measurement of Aβ40 and Aβ42 are available 
commercially, however, their use in plasma has not been validated.  One such assay, 
available from Biosource®, was initially tried but failed to produce reliable results for 
reasons that are explained later.  Two “sandwich” ELISAs (Suzuki et al., 1994), 
developed in the laboratory of Professor S. G. Younkin (Mayo Clinic, Jacksonville, 
USA) and optimised for use with EDTA anticoagulated plasma, were employed to 
measure circulating concentrations of Aβ40 and Aβ42 in 999 fasting plasma samples 
collected from the island of Vis (Figure 4.1).  The assay involved two mouse 
monoclonal capture antibodies, BAN50 (dete
8), which were used to coat ELISA microplates (Suzuki et al., 1994).  Two 
mouse monoclonal antibodies, BA27 (detecting Aβ1-40) and BC05 (detecting Aβ35-
43) were then used as detection antibodies for the specific detection of Aβ40 and 
Aβ42 respectively (Suzuki et al., 1994) (Figure 4.1).   
 
4.2 Results  
4.2.1 Commercial assay of Aβ40 and Aβ42 in plasma 
 
Eighty-eight EDTA plasma samples from the village of Komiza on Vis island were 
used in the initial quantitation of the two Aβ species (Aβ40 and Aβ42) using a 
commercial sandwich ELISA kit (Biosource®).  In vitro quantitative determination 
was carried out in duplicate for each sample (diluted 1 in 5) and each 96-well plate 
also contained serial dilutions of the standard peptide of known concentration and a 
blank control.  Despite obtaining reliable standard curves (Figure 4.2), from which 





•BC05 → Aβ42 Capture Antibody














Figure 4.1 Diagrammatic representation of the “sandwich” ELISAs of plasma Aβ40 
and Aβ42.
Monoclonal capture antibodies, BAN50 and BNT77 were paired with monoclonal 
detection antibodies BA27 and BC05 in two independent assays to detect plasma Aβ40 
and Aβ42 concentrations by fluorometric
 
detection at 450 nm (A).  The BAN50 antibody 
recognises residues 1-16 and the BNT77 antibody recognises residues 11-28.  BA27 
(epitope: Aβ1-40) and BC05 (epitope: Aβ35-43) specifically detect Aβ40 and Aβ42 
peptides respectively, as shown on the amino acid sequence of the 43-residue Aβ
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Figure 4.2 Standard curves of the two commercial assays of Aβ40 and Aβ42 in 
plasma.





assays, including a blank control.  The equation of the best-
 
fitted line was obtained by linear regression (Microsoft Excel) and used to measure the 
exact concentration of the two Aβ
 
species in EDTA plasma samples.  The squared 
correlation coefficient (R2), for each line is also shown.
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 Binding of Aβ to carrier molecules results in the sequestration of the Aβ 
sma 
uo et al., 2000).  Therefore, pre-treatment of plasma samples using extremes of pH 
as suggested, which would be used to separate the bound fraction of Aβ from its 
arrier proteins.  Samples were pre-treated with different dilutions of acid (formic 
cid 95%) and alkali (5M NaOH) solutions for 30 minutes and then neutralised.  
ach neutralised sample was then run on a 15% polyacrylamide gel, which included 
ynthetic Aβ peptide as a positive control, and transferred to a PVDF membrane for 
robing with primary and secondary antibodies.  However, no clear results were 
btained, possibly because Aβ concentrations in plasma were below the threshold 
oncentrations required for antibody detection.  This confirmed the need for a more 
ensitive method of Aβ detection in human plasma.  
.2.2 Optimised assay of Aβ40 and Aβ42 in plasma 
his work was carried out as part of a collaboration with Professor S. G. Younkin.  A 
sandwich” ELISA was used, which had been specifically designed and optimised 
r measurement of Aβ40 and Aβ42 in EDTA anticoagulated plasma (Suzuki et al., 
994).  The problem of sequestration by carrier molecules in plasma was overcome 
y the antibodies having a higher affinity for Aβ peptides (Suzuki et al., 1994).      
TA plasma samples were used in the ELISA as both Aβ 
ptide spe
exclusion was set at three standard deviations (SD) above the mean CV of 11.7 (± 



















Quantitative determination of plasma Aβ40 and Aβ42 concentrations was 
carried out in triplicate using 999 plasma samples collected from the island of Vis.  
Previously unthawed ED
pe cies have been shown to be highly sensitive to freeze-thawing (S. G. 
Younkin, personal communication).  In a second round of quantitation, sample 
replicates with high coefficients of variation (CV > 20%) were retested and a new set 
of measurements was obtained which was combined with the previous 
measurements.  Outlier values within replicates were excluded using the Grubb’s test 
for outlier detection assuming a normal distribution between replicated values.  
However, samples in which the three replicates showed a normal distribution but still 
had a high CV were excluded.  For Aβ40 measurements, the CV threshold for 
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11.7, SD).  For Aβ42 measurements, the CV threshold was also set at three standard 
deviations above the mean CV of 24.1 (± 22.2, SD).  Therefore, 50 individuals from 
the Aβ40 and 51 individuals from the Aβ42 distributions were excluded based on the 
above criteria.  This preliminary investigation was carried out in order to minimise 
the probability of obtaining false positive results due to measurement error.   
The distributions of plasma Aβ40 and Aβ42 concentrations, after the exclusion of 
outlier samples, were analysed using the software SPSS v.12 (Figure 4.3).  The 
distribution of Aβ40 measurements showed a 22.5-fold variation in values, with a 
mean of 48 pg/ml (11.1 pM).  This increased to a 74-fold range in plasma Aβ42 
concentrations, with a mean of 22.5 pg/ml (5 pM).  Using the Kolmogorov-Smirnov 
statistic, both distributions were found to deviate significantly from normality (PAβ40 
= 7.6E-25, PAβ42 = 4.8E-75).  High kurtosis values also showed that the two 
istributions were leptokurtic (Figure 4.3).  This suggested the need to transform the 
 of false-positive 
sults in further analyses.  However, conventional normalisation procedures such as 
 
d
data to a normal distribution, in order to reduce the probability
re
natural log, square-root and cube-root transformation methods failed to transform the 
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N Minimum Maximum Mean S.D. Mean S.E.
Plasma Aβ40 
Concentration (pg/ml) 958 7.85 176.57 48.03 14.2884 11.7 0.16
Kurtosis
 
N Minimum Maximum Mean S.D. Mean S.E.
Plasma Aβ42 
Concentration (pg/ml) 947 3.13 231.71 22.54 13.3817 98.5 0.16
Kurtosis
Figure 4.3 Plasma Aβ
 









concentrations were measured in EDTA plasma samples 
using a “sandwich”
 
ELISA developed and optimised by the Younkin
 
laboratory (Suzuki et 
al., 1994).  Tables of descriptive statistics are also presented for the two species of Aβ
 




Therefore, a quantile transformation explained in Section 2.5.6  was applied 
 
ransformed measurements were then used to analyse the effects of possible 
covariates on plasma Aβ concentrations. 
4.2.3 sis of plasma Aβ covariates in Vis 
 
he association between possible covariates and concentrations of both 
plasma β40 and Aβ42 were assessed using a univariate analysis of variance 
implem nted in the software SPSS v.12.  Normalised distributions of Aβ40, Aβ42 
and Aβ β40 ratio were used in the analysis of the covariates sex, age, BMI, 
smoking and APOE alleles.   
 was hypothesised that the strong association of APOE with LOAD might 
be explained by the differential affinity of APOE protein variants for binding Aβ in 
plasma s shown in brain (Strittmatter et al., 1993; Mahley & Huang, 1999; Stratman 
et al., 2005).  However, binding of APOE to Aβ deposits, in which Aβ is at high 
concentration, may be quite different to plasma, where Aβ is at very low 
concentration.  No significant associations were detected between any of the APOE 
alleles and plasma Aβ40 (Table 4.1), Aβ42 (Table 4.2) or Aβ42:Aβ40 ratio (Table 
4.3).  APOE locus variation was therefore not a significant covariate for plasma Aβ 
peptide concentration. 
t covariate for plasma Aβ40 concentration, 
with older age resulting in increased plasma Aβ40 (β = 0.028, P = 1.3E-28) which 
explained 12.2% of the variation in the unadjusted trait variance (Table 4.1).  Age 
was also found to be a significant covariate for changes in the ratio of plasma 
Aβ42:A 40 concentrations, explaining 4.5% of the total trait variance (Table 4.3).  
Increase in age was found to be associated with a significant decrease in the 
normalised concentration of Aβ42:Aβ40 in plasma (β = 0.017, P = 7.5E-11) (Table 
4.3).  
moking was associated with an increase in plasma Aβ40 concentration 
(β=0.304, P=1.5E-04).  Smoking was found to explain 1.5% of the total unadjusted 
Aβ40 variance (Table 4.1).   













Tables 4.1-4.3 Analysis of covariate effects associated with concentrations
 
of 
Aβ40, Aβ42 and Aβ42:Aβ40 ratio in plasma.
A univariate analysis was used to detect significant associations between changes in 
plasma concentrations of Aβ40 (Table 4.1, 937 individuals), Aβ42 (Table 4.2, 928 
individuals) and Aβ42:Aβ40 ratio (Table 4.3, 890 individuals) and potential covariates 
sex, age, smoking, BMI and APOE
 
alleles.  Significant associations are highlighted in 




is the regression coefficient and 
shows the unit change in the transformed mean QT associated with
 
a unit change in the 
covariate.  R2
 
represents the proportion of the total unadjusted phenotypic variance 




Blangero, 1998) after taking the relatedness of individuals into account. 
Mean χ2 d.f. P β (S.E.) R2
Sex -0.70 0.08 1 0.781 - 0.000
Smoking -0.85 14.40 1 1.5E-04 0.304 (0.08) 0.015
Age -0.70 123.05 1 1.3E-28 0.028 (0.00) 0.122
BMI -0.70 3.57 1 0.058 - 0.002
APOE2 -0.70 0.27 1 0.604 - 0.000
APOE3 -0.70 0.49 1 0.481 - 0.000
APOE4 -0.70 0.17 1 0.675 - 0.000
Mean: -0.701 (±1.24, SD)
Mean χ2 d.f. P β (S.E.) R2
Sex -0.70 0.07 1 0.793 - 0.000
Smoking -0.81 6.04 1 0.014 0.020 (0.08) 0.006
Age -0.70 0.81 1 0.368 - 0.000
BMI -0.70 0.16 1 0.684 - 0.000
APOE2 -0.70 0.01 1 0.917 - 0.000
APOE3 -0.70 0.22 1 0.637 - 0.000
APOE4 -0.70 0.51 1 0.472 - 0.000
Mean: -0.701 (±1.24, SD)
Mean χ2 d.f. P β (S.E.) R2
Sex -0.70 0.16 1 0.670 - 0.000
Smoking -0.70 0.01 1 0.933 - 0.000
Age -0.70 42.38 1 7.5E-11 -0.017 (0.003) 0.045
BMI -0.70 1.79 1 0.181 - 0.000
APOE2 -0.70 0.01 1 0.928 - 0.000
APOE3 -0.70 0.18 1 0.668 - 0.000
APOE4 -0.70 0.43 1 0.513 - 0.000








Smoking was also a significant covariate for plasma Aβ42 concentration, explaining 
.6% of the total trait variance (Table 4.2).  Smoking was found to be associated 
ith a significant increase in the normalised Aβ42 concentration (β = 0.02, P = 
Plasma Aβ heritability in Vis 
Narrow-sense heritabilities (h2) were estimated for normalised Aβ40, Aβ42 and 
β42:Aβ40 concentrations using plasma measurements from 588 individuals in 126 
eneral population pedigrees, collected from the island of Vis. A linear regression 
odel implemented in the software package SOLAR (Almasy & Blangero, 1998) 
as used for the analysis. 
Estimates of narrow-sense heritability (h2) did not reach significance for any 
f the traits examined (h2Aβ40 = 0.028 ± 0.114, P = 0.401; h2Aβ42 = 0.168 ± 0.112, P = 
h2Aβ42:Aβ40 = 0.130 ± 0.104, P = 0.101).  These findings are discussed in the 
.2.5 A genome-wide linkage scan of plasma Aβ in the Vis 
population 
ultipoint genome-wide linkage scan of normalised plasma Aβ40 (N = 952), 
β42 (N = 942) and Aβ42:Aβ40 (N = 904) was carried out using 810 microsatellite 
arkers typed in DNA samples collected from the villages of Komiza and Vis on the 
 of Vis.  Markers were spaced at approximately 5 cM intervals.  Analysis was 
ponents methodology implemented in the software 
masy & Blangero, 1998).  The null hypothesis being tested was 
itive genetic variance due to a putative quantitative trait locus (QTL) 
odel therefore did not include a QTL effect, but modelled 
 The null hypothesis of no linkage was 
l polygenic model with that of a model 
ated the additive genetic variance at the putative QTL.  The significant 




















carried out using the variance com
package SOLAR (Al
that the add
equalled zero.  The null m
only the polygenic effects on the phenotype. 
tested by comparing the likelihood of the nul
that estim
covariates o
included in the m
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The results of the linkage scan for all 22 autosomal chromosomes are summarised in 
Figures 4.4-4.6.  No multipoint LOD (Z) scores indicative (Z ≥ 3) or suggestive (Z ≥ 
2) of linkage were observed in this analysis.  However, a number of loci reached 
LOD scores above an arbitrary threshold of 0.6 for the traits examined (Figures 4.4-
4.6).  These are summarised in Table 4.4.  For plasma Aβ40, no peaks of Z ≥ 1 were 
e 6q23 between markers D6D1656 and 
2S2211 and D2S391.  A linkage peak between markers 
D7S65
estive significance levels.  This 
therefore emphasised the need for genome-wide association analysis using a high 
 analysis 
β42:Aβ40 ratio are presented in the Chapter 5. 
 
detected.  The peak observed on chromosom
D6S281 (LOD = 0.92) was the highest linkage peak detected in the plasma Aβ40 
analysis.   
Two loci were detected with Z ≥ 1 on chromosomes 2 and 7 in the analysis of 
plasma Aβ42.  The highest linkage peak was observed on chromosome 2p25 (LOD = 
1.19) between markers D
7 and D7S640 was detected on chromosome 7q21 with a LOD score of 1.09. 
Using the ratio of Aβ42:Aβ40 in plasma, no linkage peaks were detected with 
Z ≥ 1.  All linkage peaks covered large genomic regions with many potential 
candidate genes and none reached even sugg
density of single nucleotide polymorphisms.  The results of the association
f plasma Aβ40, Aβ42 and Ao
 
4.2.6 Summary and discussion 
 
In this chapter, the results were presented of the biochemical assay and genetic 
linkage analysis of Aβ in a general population sample from the island of Vis.  The 
two amyloid-β species, Aβ40 and Aβ42, were used as biomarkers of Alzheimer 
disease.  Aβ is the main component of extracellular senile plaques in the brains of 
patients diagnosed with Alzheimer disease (Glenner & Wong, 1984; Masters et al., 
1985; Spires & Hyman, 2004).  The assembly of Aβ into amyloid fibrils and various 
toxic intermediates has been implicated as the main pathologic trigger of Alzheimer 




Figure 4.4 Results of plasma Aβ40 genome-wide linkage scan.
LOD scores obtained following a multipoint genome-wide linkage scan with 810 
microsatellite markers are presented for each autosomal chromosome. Markers were 
spaced at approx. 5cM intervals.  The analysis used a polygenic model containing 
smoking and age as  significant covariates for plasma Aβ40 levels.  The analysis was 
carried out using the software package SOLAR (Almasy & Blangero, 1998). 
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Figure 4.5 Results of plasma Aβ42 genome-wide linkage scan.
LOD scores obtained following a multipoint genome-wide linkage scan with 810 
microsatellite markers are presented for each autosomal chromosome. Markers were 
spaced at approx. 5cM intervals.  A polygenic model was used with smoking as a 
significant covariate for plasma Aβ42 levels.  The analysis was carried out using the 
software package SOLAR (Almasy & Blangero, 1998). 
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Figure 4.6 Results of genome-wide linkage scan for the ratio of Aβ42:A β40 in 
plasma.  
LOD scores were obtained following a multipoint genome-wide linkage scan with 810 
microsatellite markers and are presented for each autosomal chromosome. Markers 
were spaced at approx. 5cM intervals.  A polygenic model was used including age as a 
significant covariate.  The analysis was carried out using the software package SOLAR 



































































































































































































































































































































































































































































































































































































Although Aβ42 accounts for approximately 10% of secreted Aβ, Aβ42 is the 
itially deposited species, hence its plasma concentration may decrease early in the 
ementia process (Yamazaki et al., 1997).  Therefore, a high plasma concentration of 
β40, when combined with a low concentration of Aβ42 (i.e. a low ratio of 
β42:Aβ40) could indicate an increased risk of dementia as a result of Aβ42 
eposition in the brain (van Oijen et al., 2006; Graff-Radford et al., 2007). 
myloid-β assay 
lasma concentrations of Aβ40 and Aβ42 were used as surrogate biomarkers for 
lzheimer disease.  The concentrations of Aβ40 and Aβ42 were measured in 999 
lasma samples collected from the island of Vis.   
The validity of a commercial ELISA kit (Biosource®) for measurement of Aβ 
eptides in EDTA plasma was assessed as well as a “sandwich” ELISA developed 
nd optimised for use in human plasma (Suzuki et al., 1994) in collaboration with 
rofessor S. G. Younkin (Mayo Clinic, Jacksonville, USA).  The Younkin assay 
roved to be more sensitive for detection of Aβ species in EDTA plasma than the 
ommercial assay and inter and intra-experimental variation were low.  The 
istributions of plasma Aβ40 (mean = 48.03 pg/ml) and Aβ42 (mean = 22.54 pg/ml) 
howed a 22-fold and 74-fold range of values respectively (Figure 4.3).  The plasma 
oncentration of Aβ40 (mean 11.1 pM) was unexpectedly low compared with other 
tudies (e.g. 119.2 pM, Ertekin-Taner et al., 2008; 44.3 pM, van Oijen et al., 2006; 
0.7 pM, Mayeux et al., 2003) although there is considerable variation between 
tudies.  In addition the proportion of total Aβ due to Aβ40 is 69% in the present 
tudy, similar to Mayeux et al. (2003) (70%) but lower than van Oijen et al. (2006) 
2%) and Ertekin-Taner et al. (2008) (91%).  The plasma concentration of Aβ42 
ean 5 pM) is however similar to other studies (4 pM, van Oijen et al., 2006; 12 
M, Ertekin-Taner et al., 2008; 13 pM Mayeux et al., 2003).  Such differences could 
e due to age and other covariates.   
      
 





























Identification of covariates for plasma Aβ 
 
The analysis of covariate effects was carried out after removal of outlier 
measurements from the Aβ distributions.  Plasma Aβ40 and Aβ42 concentrations 
showed leptokurtic distributions, which were consequently normalised using a 
quantile transformation.   
Age and smoking were identified as significant covariates for plasma Aβ40, 
explaining 12.2% (P = 1.3E-28) and 1.5% (P = 1.5E-04) of the total trait variance, 
spectively (Table 4.1).  Smoking was found to be significantly associated with an 
β42 concentration, explaining 0.6% of the total trait variance (P 
 established history of smoking 
tobacco
 in the disease process when Aβ42 starts 
accumu g in the brain (Fukumoto et al., 2003; Mayeux et al., 2003).  A 
ignificant association between plasma Aβ40 concentration and age has been 
re
increase in plasma A
= 0.014) (Table 4.2).   
Published data have shown a reduced density of cortical plaques and elevated 
nicotinic receptor binding in individuals with an
 (Perry et al., 1996; Perry et al., 2000).  Nicotine, the primary alkaloid in 
tobacco, has been shown to partially prevent the neurotoxicity of Aβ (Zamani & 
Allen, 2001) possibly by disruption of Aβ fibrils leading to reduced peptide 
aggregation (Ono et al., 2002; Dickerson & Janda, 2003).  Furthermore, levels of 
soluble and insoluble Aβ40 and Aβ42 in frontal cortex and Aβ40 in temporal cortex 
and hippocampus have been shown to be significantly decreased in smoking 
compared to non-smoking individuals/patients with Alzheimer disease (Hellström-
Lindahl et al., 2004).  The association of cigarette smoking with increased levels of 
Aβ40 and Aβ42 in plasma may therefore, in agreement with published data, indicate 
release of Aβ species from the brain as a result of the disruption of amyloid fibrils. 
Finally, an increase in age was associated with a decrease in the ratio of 
Aβ42:Aβ40 in plasma (P = 7.5E-11), explaining 4.5% of the total trait variance 
(Table 4.3).  Age has long been known to be a major confounder in susceptibility to 
AD and is associated with an increased incidence and quantity of neurofibrillary 
tangles and senile plaques (Morimatsu et al., 1975; Younkin, 1998).  The 
concentrations of Aβ40 and Aβ42 in plasma have also been shown to increase 




reported in a population of non-demented individuals (Mayeux et al., 1999; Mehta et 
nset of symptoms of late-onset AD (Mayeux et al., 1999).  
The lac
as observed in this population.   
e 
hypoth
al., 2000).  An increase in the mean plasma Aβ40 in the general population of Vis is 
therefore consistent with the findings of Mayeux et al. and Mehta et al.  However, it 
has also been suggested that elevated plasma concentration of Aβ42 can be detected 
several years before the o
k of association between plasma Aβ42 and age in the Vis population is in 
contrast to this finding.  On the other hand, the association between older age and a 
decrease in the plasma Aβ42:Aβ40 ratio could be indicative of a reduction in plasma 
Aβ42 concentration.  This is unlikely however, since no direct association between 
plasma Aβ42 and age w
No significant associations were observed between concentrations of plasma 
Aβ40, Aβ42 and Aβ42:Aβ40 and either sex or BMI in the Vis data set.  However, 
elevated plasma Aβ42 concentrations have been reported in females with mild 
cognitive impairment (Assini et al., 2004).      
No significant associations were observed between the three APOE alleles 
and concentrations of Aβ species in plasma (Tables 4.1-4.3).  However, the 
APOE*E4 isoform has been shown to form a stable complex with Aβ peptide in 
vitro (Strittmatter et al., 1993).  In contrast, lipidated APOE*E3 has been found to 
bind Aβ peptide with a 20-fold higher affinity than lipidated E4 (Stratman et al., 
2005).  Also, studies have confirmed the presence of the APOE*E4 protein in brain 
lesions and the role of the human APOE in amyloid deposition in the AD mouse 
model by injecting APOE isoforms into the mouse plasma (Bales et al., 1999).  Th
esis that APOE protein variants regulate Aβ species in plasma and hence 
affect susceptibility to LOAD was therefore rejected.  However, Ertekin-Taner et al. 
(2008) found significantly reduced Aβ42 in APOE*E4 homozygotes compared with 
other genotypes, which was not evident for Aβ40.  However, the low allele 
frequency of the E4 allele in the present study will have reduced the power to detect 
this effect of APOE (E4 homozygotes represent 0.5-0.9% of the Vis population). 
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Heritability of plasma Aβ 
 
Narrow-sense heritability estimates for plasma Aβ40, Aβ42 and Aβ42:Aβ40 
concentrations did not reach significance in the Vis population samples.  This does 
not necessarily reflect the lack of a genetic component.  Low estimates of h2 could be 
due to lack of power as a result of small sample size or the presence of many distant 
relationships.  A low narrow-sense heritability could also be consistent with the 
presence of recessive alleles which have a strong effect in rare homozygotes on 
plasma Aβ concentrations.  Recessive loci of large effect would result in non-
significant estimates of narrow-sense heritability, which only accounts for additive 






heritabilities (Sham et al., 2000; Dawn & Barrett, 2005).  In addition, the small size 
of the pedigrees reduces the power of linkage analysis to detect typical QTL effects 
(Blangero, 2004).     
l genetic variance (additive, dominance and epistatic variance) would not be 
possible in the Vis sample set due to the small sibship size in the pedigrees.   
 
Genome-wide linkage analysis of plasm
nome-wide multipoint linkage analysis did not identify any significant linkage 
peaks using 810 microsatellite markers in over 900 individuals from the general 
population of Vis island.  Low power for linkage mapping of QTL contributing less 
than 3% of the variance, which comprise the majority of the QTL identified to date 
in complex traits, was found using the genetic power calculator (Purcell et al., 2003), 
partly due to the small sample size of most pedigrees.  None of the markers showed 
suggestive evidence of linkage with LOD score values ≥ 2.  The highest LOD score 
for plasma Aβ40 concentration was detected on 6q23 (Z = 0.92).  The highest LOD 
score in the Aβ42 linkage analysis was found on chromosome 2p25 (Z = 1.19) 
followed by 7q21 (Z = 1.09).  The highest LOD score for plasma Aβ42:Aβ40 ratio 
was observed on 17p13 (Z = 0.98).  Results of the linkage analysis have been 
discussed in the Discussion chapter.  In short, failure of linkage can be either due to 
the small effect size or low frequencies of the underlying additive genetic factors 
influencing plasma Aβ concentrations, consistent with the non-significant 
 146
In conclusion, the analyses of plasma Aβ covariates, plasma Aβ heritabilities 
and a genome-wide linkage scan of plasma Aβ were carried out in a general 
population sample.  The results showed that age and smoking were found to be 
significantly associated with concentrations of Aβ40 and Aβ42 in plasma.  The 
possibility of an interaction between APOE protein variants and Aβ species in 
plasma was excluded in a univariate analysis of association between APOE alleles 
and plasma Aβ concentration.  Since multipoint linkage analysis of plasma Aβ did 
not identify either suggestive or significant linkage peaks due to the low power of 
linkage to detect typical QTL effects, a high-resolution genome-wide association 
analysis was carried out to identify genomic loci of smaller effect associated with 





















































ons of Aβ40, Aβ42 and the ratio of Aβ42:Aβ40 in 966 plasma samples 
ollected from the Croatian island of Vis were used as intermediate phenotypes in a 
uantitative trait locus (QTL) association study.  Plasma Aβ measurements were 
arried out using a “sandwich” ELISA as described in the previous chapter.   
Mutations in three genes, APP, PSEN1 and PSEN2 account for about 70% 
ampion et al., 1999) of patients with autosomal dominant familial Alzheimer 
isease (FAD) (St George-Hyslop et al., 1987).  Although FAD accounts for less 
an 1% of all AD cases worldwide, the identification of rare mutations in these 
enes led to the pathophysiological hypothesis of the amyloid cascade (Figure 1.7).  
enetic variation is believed to play a significant role in the Alzheimer disease 
rocess, since heritability of AD has been estimated to be around 60% (Gatz et al., 
997).  In addition, APOE*E4 has been identified as a common genetic susceptibility 
ariant influencing late-onset Alzheimer disease (LOAD).  It has been suggested that 
ere are at least four other genes of large effect similar to APOE*E4 and many other 
enes of smaller effect in Alzheimer disease (Daw et al., 2000).   
Linkage to chromosome 10q22 has previously been detected in extended 
OAD pedigrees, containing affected individuals with high plasma Aβ42 and/or 
β40 concentrations (Ertekin-Taner et al., 2000).  The IDE gene, encoding insulin 
egrading enzyme which is known to degrade Aβ, has been shown to be associated 
ith increased risk of LOAD (odds ratio of 2.7), possibly by influencing plasma 
β42 concentration (P = 0.02) (Prince et al., 2003; Ertekin-Taner et al., 2004).  The 
LAU gene, which encodes a urokinase-type plasminogen activator, also resides in 
e 10q22 region.  Polymorphisms in PLAU have been shown to influence 
usceptibility to LOAD in a study involving three independent series, each of which 
howed significant association between PLAU and plasma Aβ42 with an odds ratio 
f 1.2 (P = 0.0006) (Ertekin-Taner et al., 2005).   
In this thesis, direct associations between plasma Aβ concentration and 
ic polymorphisms were assessed using a QT genome-wide association 
 
In this chapter, the results of a whole-genome association analysis of plasm





























approach.  Circulating Aβ concentrations were used as surrogate biomarkers for AD 
ith the aim of identifying genomic loci which influence the concentrations of these 
 
ethod, as described 
 904 individuals were used to 
identify
w
peptides in plasma, which could influence an individual’s susceptibility to LOAD.  
An understanding of the genetic influences on intermediate traits such as Aβ peptides 
may help to identify new pathways involved in Alzheimer disease process. 
5.2 Results 
5.2.1 Genome-wide association analysis of plasma Aβ in Vis
 
Genome-wide association analysis of QTL affecting concentrations of Aβ40, Aβ42 
and Aβ42:Aβ40 in plasma was carried out in 966 individuals from the island of Vis.  
The Illumina Human Hap300, based on the HapMap data Release 21A and 
consisting of 317,503 single nucleotide polymorphisms (SNP), was used in the 
association analyses.  The genome-wide association tool set PLINK version 0.99s 
(Purcell et al., 2007) was used to perform the pedigree-based QT association analysis 
(Aulchenko et al., 2007).     
 Outlier values within each of the Aβ40 and Aβ42 measurements were 
excluded as described before.  The distributions of Aβ40, Aβ42 and the ratio of 
Aβ42:Aβ40 were then normalised by a ranking transformation m
in Section 2.5.6.  The residuals were first obtained from a regression model of Aβ40, 
Aβ42 and Aβ42:Aβ40 concentrations after adjusting for the relatedness of 
individuals, covariates and fixed effects.  These residuals were then used as the 
dependent variable in a linear regression analysis for estimating the effect of each 
SNP on plasma Aβ peptides.  Finally, SNPs showing evidence of association to 
plasma Aβ were analysed using a full Measured Gentoype (MG) model to obtain 
fixed effect sizes and P-values (Section 2.5.7.4) (Aulchenko et al., 2007).     
 
5.2.1.1 QTL association analysis of plasma Aβ40 
 
The concentrations of Aβ40 measured in plasma from
 associated QTL in a genome-wide scan.  The results of the genome-wide 
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A total of 8,984 SNPs were removed due to low genotyping rate ( < 90%) and 
79 SNPs were removed due to low minor allele frequency ( < 1%) in the 
opulation, leaving 308,140 in the final analysis.   
ficance 
fter a Bonferroni correction for multiple testing (P ≤ 1.0E-07).  However, nine 
NPs reached suggestive significance (Passociation ≤ 1.6E-05) and one other showed 
otential association.  The criteria for a potential association were based on the 
resence of at least one SNP with P ≤ 1.0E-04 and/or at least three SNPs with P ≤ 
.0E-03 within a 200 kb region.   
Based on the above criteria, suggestive and potential associations with plasma 
β40 were observed on chromosomes 8p, 8q, 9p, 9q, 14q, 20p and Xp.  A summary 
f the SNPs at these loci is shown in Table 5.1.  Two of the most significant 
ssociations with plasma Aβ40 were observed in chromosomal region 9q33 with the 
strotactin 2 (ASTN2) SNPs rs2900131 (P = 2.1E-06) and rs7866525 (P = 3.2E-06), 
hich explained 2.4% and 2.3% of the total trait variance respectively using the full 
G model.  Both SNPs are relatively common in this population (MAFrs2900131 = 
.495, MAFrs7866525 = 0.493) and lie within intron 16 of the 989.8 kb ASTN2 gene.  
he effect sizes associated with the minor allele at both SNPs, represented by the β 
alues in Table 5.1 were protective, resulting in a significant reduction in plasma 
β40 concentration (βrs2900131 = -0.23 ± 0.05 (SE), βrs7866525 = -0.22 ± 0.05 (SE)).  
nalysis of the association peak at 9q33 revealed a cluster of associated SNPs which 
panned a region of about 500 kb within the 3′ end of the ASTN2 gene showing high 
vels of LD (Figure 5.2).  Both rs2900131 and rs7866525 were found to be in 
trong linkage disequilibrium (r2 > 0.80) with rs2295741 (SNP 28, Figure 5.3), 
hich was 50 bp upstream of ASTN2 exon 15 close to the exon-intron junction.   
ASTN2 is a transmembrane protein with several domains, including three 
pidermal growth factor (EGF)-like domains, a membrane attack complex/perforin 
ACPE) domain and one fibronectin type 3 (FN3) domain, which is mainly 
ncoded by the 5′ end of the gene.  Four isoforms of ASTN2 have been identified, 
ely A, B, C and D, which differ in their transcription start site.   
3
p










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.2 Analysis of the chromosomal region 9q33 showing suggestive evidence 
of association with plasma Aβ40.
The results of the genome-wide association with plasma Aβ40 concentration in the 
chromosomal region 9q33. The 2 Mb region spanning the SNP rs2900131 showing 
suggestive association with plasma Aβ40 is shown above. Analysis of linkage 
disequilibrium (r2) (below) shows several LD blocks in the 0.9 Mb region containing the 
cluster of suggestively associated SNPs, with decreasing shades of black representing 
reductions in the level of pairwise LD. The black arrow shows the approximate position of 






coding genes are also shown to scale (blue arrows show the direction of transcription).  
































Figure 5.3 Analysis of plasma Aβ40 association and linkage disequilibrium between 
SNPs at the 9q33 locus. 
The 9q33 locus spanning part of the ASTN2
 
gene (drawn below the association figure, to 
scale), shows suggestive association with plasma Aβ40 in the Vis population. Levels of 
pairwise linkage disequilibrium (LD) shown in terms of the squared correlation (r2 ) are also 
presented.  Decreasing shades of black represent reductions in the level of pairwise LD.  
Analysis of LD was carried out in 492 unrelated individuals from
 
Vis using Haploview. 
Vertical green bars mark exons 12-16 of the full length ASTN2.  The red bar marks the 
start position for the ASTN2
 
isoform D.  Direction of transcription is shown by the black 
arrow head.
ASTN2 16 15 14 13 12
155
Genomic location
The region of high LD containing the associated SNPs was found near the 
anscription start site of the ASTN2 isoform D (Figure 5.2).  Furthermore, the 
earest SNP to the ASTN2 isoform D start sites (vertical red line, Figure 5.3), 
ly 
Figure 5.3).   
wo markers on chromosome 9p21 (rs10968018 and rs3913107) also reached 
the suggestive significance threshold (Prs10968018 = 2.8E-06, Prs3913107 = 9.4E-06).  
Each SNP accounted for about 2.2% of the phenotypic variance and both were 
associated with a significant reduction in plasma Aβ40 concentrations, as shown by 
the value of β (Table 5.1).  The two SNPs lie within 4 kb of each other and about 80 
kb away from a hypothetical gene, C9orf72.     
n intronic SNP, rs12009327, within intron 39 of the Dystrophin (DMD) 
gene in chromosomal region Xp21 showed association with plasma Aβ40, reaching 
suggestive significance (P = 8.6E-06).  The nearest Illumina SNP to rs12009327 is 
rs120011023, which is located 10.9 kb downstream and showed weaker association 
(Passociation = 1.9E-04).  DMD rs12009327 is located about 4 kb downstream of exon 
39 in a region of “high regulatory potential” based on the scores computed from 
alignm an, chimpanzee, macaque, mouse, rat, dog, 
and cow (UCSC Human Genome Browser, March 2006 assembly).  Regulatory 
potential scores are obtained by comparing the frequencies of short alignment 
patterns between known regulatory elements and neutral DNA (King et al., 2005; 
Kolbe et al., 2004).   
ther markers showing suggestive association with plasma Aβ40 
concentration were found to be situated in intergenic regions (rs761865, rs1461554 
and rs1473522), often at a considerable distance from the nearest genes (rs7829617 
and rs10504478) as shown in Table 5.1.  Two of these SNPs, rs10504478 (showing 
potential association, P = 2.1E-05) and rs1473522 (showing suggestive association, P 
= 8.6E-06) were situated at the same locus in chromosomal region 8q13.  These two 
markers are about 300 kb apart and SNP rs10504478 was found to be located 
approximately 3 kb downstream of the Lactamase Beta 2 (LACTB2) gene. 
tr
n
rs803904, was found to be in strong LD (r2 > 0.60) with the two most strong
associated SNPs, rs2900131 and rs7866525 (
T
A




5.2.1.2 QTL association analysis of plasma Aβ42 
 
Plasma Aβ42 concentrations were measured in 999 individuals, as described 
previously.  Aβ42 has been reported to be the major constituent of neural plaques in 
the Alzheimer disease brain.  Normalised plasma Aβ42 measurements were used to 
carry o
h showed potential association with 
plasma
n peak in chromosomal region 2q32 consisted of two SNPs 
which r
   
 
ut a genome-wide QTL association analysis which aimed to detect associated 
genomic loci.   
Genome-wide association analysis using 308,140 SNPs  revealed three loci (4 
SNPs) which passed the threshold for suggestive significance (Passociation ≤ 1.0E-05).  
These loci were located in chromosomal regions 2q32, 5q14 and Xp11 (Figure 5.4).  
Three more loci (5 SNPs) were detected whic
 Aβ42 based on a SNP cluster with P ≤ 1.0E-04.  These associations were 
observed in chromosomal regions 9q33, 15q21 and 20q13.     
The most significant association was observed at rs2386421 (P = 5.7E-07) 
located in intron 3 of the EGF-like repeats and Discoidin I-like domains 3 (EDIL3) 
gene in chromosomal region 5q14 (Table 5.2).  This polymorphism accounted for 
2.8% of the phenotypic variance and the minor allele was found to be associated with 
a significant increase in Aβ42 concentration.  The 400 kb EDIL3 gene encodes an 
integrin-ligand protein with an EGF-like and discoidin I-like domain thought to be 
involved in vascular development.  However, rs2386421 was the only SNP detected 
at this locus, hence it requires replication.   
The associatio
eached the threshold for suggestive significance (rs1113932, P = 5.5E-06 and 
rs4267464, P = 8.7E-06).  The two SNPs are located in highly conserved regions 
predicted to have a strong “regulatory potential” (King et al., 2005; Kolbe et al., 
2004; UCSC Human Genome Browser, March 2006 assembly) in intron 2 of the 
Transmembrane protein with EGF-like and two Follistatin-like domains 2 (TMEFF2) 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Both associated SNPs in TMEFF2 explain 2% of the underlying phenotypic variance 
nd the minor alleles were associated with an increase in Aβ42 concentration in 
lasma (βrs1113932 = 0.36 ± 0.08 SE; βrs4267464 = 0.36 ± 0.08 SE) (Table 5.2).  Analysis 
ere located in a region of high LD at the 5′ end of 
TMEFF2 (Figure 5.5, SNPs 14-18).   
A SNP on chromosome Xp11, rs5917513 (P = 5.6E-06) also reached 
e-wide significance and the minor allele was found to be associated 
ificant increase in plasma Aβ42 concentration (β = 0.19 ± 0.04 SE) 
Table 5.2).  Rs5917513 is an intergenic SNP situated in a non-conserved region 150 
DYNLT3) gene, encoding a T-
plex associated testis-expressed protein, and the Synaptotagmin-Like 5 (SYTL5), 
in-like protein.                   
A peak of association consisting of rs2067885 (P = 2.2E-05) and rs12916154 
P = 1.7E-04) showed potential association at a locus within chromosomal band 
Table 5.2).  The most strongly associated SNP is located in intron 16 of the 
 member 4 (ATP8B4) gene in a region of high evolutionary 
e Multiz alignment of DNA sequences from 
ammalian, amphibian, bird, and fish species using a 
odel (Siepel et al., 2005; UCSC Human Genome 
bly).  This SNP explains 2.0% of the phenotypic 
ce and the minor allele results in a significant increase in Aβ42 plasma 
oncentration (β = 0.23 ± 0.05 SE) (Table 5.2).  The 15q21 locus has previously 
een reported to be associated with risk of LOAD, in a case/control association study 
i et al., 2008).  The LOAD study identified an intergenic SNP (rs10519262) 
etween ATP8B4 and SLC27A2, which is in strong LD with ATP8B4 SNP rs7176805 
 a distal promoter region.  However, SNP rs10519262 was not found to be in strong 
D with either of the above polymorphisms in our study or in the HapMap database. 
a
p
of LD at the 2q32 locus containing rs1113932, showed that this and two other SNPs, 




kb upstream of the Dynein, Light chain, Tctex-type 3 (
com
gene encoding a synaptotagm
(
15q21 (
ATPase Class I type 8B
conservation.  The latter is based on th
17 vertebrates, including m
phylogenetic hidden Markov m














Figure 5.5 Analysis of plasma Aβ42 association and linkage disequilibrium 
between SNPs at the 2q32 locus. 
Association of Aβ42 plasma at the 2q32 locus spanning the 5′
 
end of the TMEFF2
 
gene 
(drawn below the association figure, to scale). Levels of pairwise linkage disequilibrium 
(LD) shown in terms of the squared correlation (r2 ) are also presented, showing a region 
of strong LD at the association peak. Decreasing shades of black
 
represent reductions in 
the level of pairwise LD. Analysis of LD was carried out in 492 unrelated individuals from 
Vis using Haploview. Vertical bars mark exons 1-4 of TMEFF2. The direction of 




























 A peak on chromosome 20q13 also showed potential association with Aβ42 
lasma concentration (Figure 5.4).  Two markers, rs6122718 (P = 2.4E-05) and 
5-
risphosphate-dependent RAC Exchanger 1 (PREX1) gene were found to account 
r 2.0% of the phenotypic variance in the Vis population (Table 5.2).  The protein 
ncoded by this gene acts as a guanine nucleotide exchange factor for the RHO 
mily of small GTP-binding proteins.   
A group of SNPs at a 9q33 locus showed potential association with Aβ42 
oncentration in plasma (Figure 5.4).  Markers rs10513414 (P = 3.4E-05) and 
3739836 (P = 6.5E-05) were the most significantly associated SNPs, accounting 
r at least 1.8% of the phenotypic variance (Table 5.2).  SNP rs10513414 is located 
bout 6 kb downstream of the Ring Finger and CCCH-type Zinc Finger Domains 2 
 or MNAB) gene, encoding a membrane-associated DNA binding protein.  
NP rs3739836 is situated in intron 1 of the Zinc Finger and BTB Domain 
ontaining 26 (ZBTB26) gene, encoding a zinc-finger protein.  The associated SNPs 
over a region of about 425 kb, which contains many other genes, including another 
inc-finger protein coding gene (ZNF482), two olfactory receptors (OR5C1 and 
R1K1), a G Protein-coupled Receptor (GPR21), a RAB GTPase Activating Protein 
) and a Phosphoducin-Like gene (PDCL) gene. 
.2.1.3 QTL association analysis of the ratio of Aβ42:Aβ40 in plasma 
he plasma concentrations of Aβ42 and Aβ40 were measured in 999 samples from 
e island of Vis, as described previously.  The ratio between the circulating levels of 
β42 and Aβ40 was calculated after exclusion of outlier measurements as described 
 Section 2.5.4.  Plasma Aβ42:Aβ40 ratios have been shown to be a useful 
iomarker for identifying individuals at increased risk of cognitive impairment and 
OAD (Graff-Radford et al., 2007).  Low Aβ42:Aβ40 ratios have been suggested to 
dicate decrease in the concentration of Aβ42 peptide in plasma as a result of 






























increased deposition of A
al
 162
A genome-wide QTL association analysis of the Aβ42:Aβ40 ratio in plasma 
was carried out with the aim of identifying genomic loci that potentially influence 
Aβ42 deposition in the brain.  The 308,140 SNPs from the Illumina Hap300 array 
were used in the final analysis.   
The genome-wide association analysis of the Aβ42:Aβ40 ratio revealed 6 
SNPs which passed the threshold for suggestive significance (P ≤ 1.0E-05).  These 
are located in chromosomal regions 1q41, 1q44, 1p13, 2q22, 10q23 and 15q23.  Five 
other lo
6) potentially explaining 
the 
munoglobulin Superfamily member 2 (IGSF2) gene in a region of high 
eak showing suggestive association with plasma Aβ42:Aβ40 ratio was 
observed at a 2q22 locus.  This peak spanned about 375 kb of the 686.8 kb 
Thrombospondin, Type I, Domain-containing 7B (THSD7B) gene (Table 5.3).   
ci were detected which showed potential association in chromosomal regions 
1q44, 6q24, 8p23, 19q13 and 22q13 (Figure 5.6). 
The marker showing the highest association with plasma Aβ42:Aβ40 ratio 
was SNP, rs2886199, in intron 40 of the Usher Syndrome 2A (USH2A) gene in 
chromosomal region 1q41 (P = 1.1E-06).  SNP rs2886199 explained about 2.7% of 
the Aβ42:Aβ40 ratio variance and the minor allele was associated with a reduction in 
the ratio (β = -0.39 ± 0.08 SE) (Table 5.3).  USH2A rs2886199 lies near a region of 
high conservation and “regulatory potential” (UCSC Human Genome Browser, 
March 2006 assembly) about 20 kb from another associated SNP, rs11120605 (β = -
0.206, P = 1.1E-03) in the same intron.   
Another marker showing suggestive association on chromosome 1 was 
rs755854, located in chromosomal band 1p13 (P = 1.5E-0
2.7% of the phenotypic variance (Table 5.3).  This SNP is in intron 6 of 
Im
“regulatory potential” (King et al., 2005; Kolbe et al., 2004; UCSC Human Genome 
Browser, March 2006 assembly).  However no other potential SNPs within the same 
region satisfied the criteria for suggestive or potential associations.   
SNP rs13379548 in chromosomal region 15q23 passed the suggestive 
association threshold (P = 2.1E-06) and potentially explained 2.6% of the 
Aβ42:Aβ40 ratio variance (Table 5.3).  The minor allele of this SNP, which is 
located 120 kb upstream of a hypothetical gene, FLJ13710, was found to be 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The most significantly associated SNP at this locus was rs1349159 (P = 7.5E-06), in 
tron 11 of THSD7B, potentially explaining 2.3% of the phenotypic variance.  The 
05 SE).  The plasma Aβ42:Aβ40 ratio in 
addition to SNP rs1349159, was found to be associated with seven other SNPs within 
HSD7B gene and detailed analysis revealed high levels of pairwise LD between 
ese markers in the Vis data set (Figure 5.7).  These intronic SNPs covered a region 
f about 300 kb between exons 8 and 17 near the 3′ end of the THSD7B gene.   
An association peak was observed at 10q23 which reached suggestive levels 
f significance for rs3904537 (P = 1.0E-05), potentially accounting for 2.2% of the 
henotypic variance (Table 5.3).  This SNP is located in a “gene desert” defined as 
aving no known genes within a 1Mb distance on either side of the marker.   
Another suggestive association was found between plasma Aβ42:Aβ40 ratio 
P = 1.0E-05), located in chromosomal region 1q44.  This 
 with no known genes in its vicinity. 
A SNP in chromosomal region 8p23, rs1532583, showed potential genome-
ciation significance (P = 1.4E-05) and was found to be situated in intron 1 
 the CUB and Sushi Multiple Domains 1 (CSMD1) gene (Table 5.3).  This SNP 
 the phenotypic variance and the minor allele resulted 
e in the plasma Aβ42:Aβ40 ratio (β = -0.24 ± 0.06 SE).  Further analysis 
vealed another cluster of SNPs within the same 2.05 Mb 
ignificance levels of P ≤ 1.0E-04, located 1.1 Mb away from 
Figure 5.6).  Analysis of LD at this locus did not reveal any particular 
o association peaks.  Furthermore, no reports of predicted 
gulatory potential at these sites have been documented.   
A potential association peak in chromosomal region 6q24 identified two 
NPs (rs1038390 and rs4896663) associated with an increase in the Aβ42:Aβ40 
tio in plasma (Table 5.3).  The marker more significantly associated with the trait, 
1038390 (P = 1.6E-05), resides in intron 2 of the Fucosidase, Alpha-L- 2 (FUCA2) 
ene.  The other SNP, rs4896663 (Passociation=1.8E-04) was found to be located 3 kb 
pstream of the same gene.  FUCA2 encodes a plasma alpha-L-fucosidase precursor 
rotein.  However, the validity of this finding would need to be replicated as the  
in
rs1349159 minor allele was associated with a significant increase in the ratio of 
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Figure 5.7 Analysis of the suggestive association peak at 2q22 in relation to the 
Aβ42:Aβ40 ratio in plasma.   
Association of the Aβ42:Aβ40 ratio with a 2q22 locus spanning the 3′
 
end of the 
THSD7B
 
gene (drawn below the association figure, to scale). Levels of pairwise linkage 
disequilibrium (LD) terms of the squared correlation (r2 ) are also presented.  





1.0E-04 (labelled in the association figure) all showed strong 
pairwise LD (r2 > 0.50). The analysis was carried out in 492 unrelated individuals from 
Vis island, using Haploview. Vertical bars mark the last 14 exons of THSD7B (exons 7-
 








association peak consists only of the two SNPs mentioned above.  Similarly the SNP, 
5756540 (Passociation = 1.3.0E-05), together with rs4821599 at a 22q13 locus showed 
 SNP 
rs5756540 is located in the first intron of the C1q and Tumour Necrosis Factor-
related protein 6 (C1QTNF6) gene, encoding a secreted protein involved in the 
activation of the complement pathway and SNP rs4821599 is located approximately 
20 kb downstream of C1QTNF6 SNP rs5756540.  This region was not assessed 
further since it did not satisfy the criteria for potential or suggestive genome-wide 
association.     
inally a potential association was detected with SNPs in chromosomal 
region 19q13 which contains a cluster of 15 Kallikrein genes (KLK), encoding a 
family of serine proteases (Figure 5.6).  The highest associated marker, rs1654537 
(P = 2.4E-05) is located in intron 4 of the KLK6 gene and the minor allele is 
associated with a significant decrease in the Aβ42:Aβ40 ratio in plasma (β = -0.24 ± 
0.06 SE), potentially explaining 2.1% of the phenotypic variance (Table 5.3).  SNP 
rs1654537 is localised to a highly conserved region about 50 bp downstream of 
KLK6 exon 4, exon-intron junction.  This locus was not analysed further since no 
other SNPs showed suggestive or potential genome-wide association with plasma 
Aβ42:A 40 ratio. 
5.3 Summary and discussion   
 
In this chapter the results of a genome-wide association analysis of plasma Aβ40, 
Aβ42 and the Aβ42:Aβ40 ratio were described.  Association analyses were carried 
out using the Illumina Human Hap300 Array consisting of 317,503 SNPs, after 
adjusting for covariate effects and relatedness among subjects.  The aim was to 
identify riation correlated with changes in the concentrations of Aβ species 
in plasma, potentially influencing susceptibility to LOAD.  Further research into the 
mechanism of action of candidate associated loci that are replicated in 
additional/independent samples will help to identify new pathways involved in AD 
pathogenesis. 
 
   
rs





Genome-wide association analysis of plasma Aβ40 
 
Whole genome association analysis of plasma Aβ40 revealed a number of loci which 
reached the genome-wide threshold for suggestive significance (P ≤ 1.0E-05) after 
correcting for multiple testing using a stringent Bonferroni correction (Figure 5.1).  
However, none of the associated SNPs showed full genome-wide significance after 
correction for multiple testing, so replication of these results is required.  The 
putative loci modifying Aβ40 were identified in chromosomal regions 8p, 8q, 9p, 9q, 
14q, 20p and Xp (
Two of the most significant asso
Figure 5.1, Table 5.1).   
ciations were observed in the ASTN2 gene at 
ronal migration and is likely to play a role in the movement of 
neurons along glia fibres (Hatten & Mason, 1990; Zheng et al., 1996).  Furthermore, 
ve on granule cells from the neurological 
utant mouse model that suffers a failure of glial-guided neuronal migration 
ted markers was in the range of 2.0-2.4%.  The DMD gene is highly 
omplex, containing at least eight independent, tissue-specific promoters including a 
9q33.  ASTN2 rs2900131 (P = 2.1E-06) and rs7866525 (P = 3.2E-06) minor alleles 
resulted in a significant decrease in Aβ40 concentrations using an additive model 
(βrs2900131 = -0.23 ± 0.05 SE, βrs7866525 = -0.22 ± 0.05 SE).  Further analysis revealed a 
cluster of SNPs near the transcription start site of the ASTN2 alternative transcript D 
with P-values for association with plasma Aβ40 less than 1.0E-03.  ASTN2 encodes a 
transmembrane protein which is highly expressed in post-mitotic neuronal precursors 
in the cerebellum, hippocampus and cerebrum of the developing brain (Zheng et al., 
1996).  In vitro studies have shown that astrotactin acts as a ligand for neuron-glia 
binding during neu
astrotactin is shown to be missing or defecti
m
(Edmondson et al., 1988).  Therefore genetic variation in this gene may influence 
transcription of one or more isoforms during the development of the brain.    
Other genomic loci which were found to show suggestive association with 
changes in plasma Aβ40 concentrations were the DMD locus on chromosome Xp21 
and a number of other SNPs lying within gene deserts (Table 5.1).  Some of the 
SNPs, including DMD rs12009327, were found to be located in regions of high 
conservation and strong predicted regulatory potential, indicating a potential role in 




brain-specific promoter.  DMD mRNA is differentially spliced, producing a range of 
expressed in brain astrocytes (Nicchia et al., 2008).  The dystrophin protein is a 
large, rod-like cytoskeletal protein, which is found at the inner surface of muscle 
e peaks identified fo β
Genome-wide association analysis of plasma A 42
ntribute 
to Aβ4
2001).  The exact mechanism by which the function or expression of TMEFF2 is 
different transcripts which encode a large set of protein isoforms some of which are 
fibers.  Dystrophin is part of the dystrophin-glycoprotein complex (DGC), which 
bridges the inner cytoskeleton and the extracellular matrix and is mutated in 
Duchenne muscular dystrophy (Lindenbaum et al., 1979).   
In summary, while a number of new and interesting candidate genes were 
identified, there was no overlap with linkag r A 40.  All 




Testing for association of plasma Aβ42 concentration resulted in the identification of 
a number of loci which passed the threshold for suggestive significance.  Potential 
associations were observed with SNPs in chromosomal regions 2q32, 5q14, 9q33, 
15q21, 20q13 and Xp11 (Figure 5.4).  Some of these SNPs were within genes, 
including TMEFF2 (2q32), ATP8B4 (15q21) and PREX1 (20q13).  Two 
polymorphisms (rs1113932 and rs4267464) were identified in intron 2 of the 
TMEFF2 gene (Passociation ≤ 1.0E-05) which showed suggestive associations with 
plasma Aβ42 concentrations (Table 5.2).  TMEFF2 encodes a transmembrane 
protein, predominantly expressed in the brain that acts as a survival factor for 
hippocampal and mesencephalic neurons.  The TMEFF2 protein has been found in 
AD plaques (Siegel et al., 2006) and genetic variation within the gene may co
2 deposition.  Three SNPs in the peak of association located in intron 2 of the 
TMEFF2 gene were found to be highly correlated both with each other and with 
Aβ42 concentration through strong levels of pairwise LD (Figure 5.5).  The strength 
of association falls in intron 4 of the gene TMEFF2 where a region of 
“recombination hotspots” separates the associated SNPs (in a region of high LD) 
from the surrounding region (Figure 5.5).  The presence of a region with high LD 
separated by recombination from its surrounding regions will facilitate the 
identification of potentially functional polymorphisms using LD mapping (Goldstein, 
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affected by genetic variation in and around TMEFF2 requires further analysis.  The 
major objective at this stage is to replicate the association results in an independent 
population sample or in LOAD case-control samples.   
Potential associations were detected with plasma Aβ42 concentration in the 
ATP8B4 (rs2067885) and PREX1 (rs6122718 and rs6095239) genes (Table 5.2).  
Association studies have previously identified the 15q21 locus, containing the 
ATP8B4 gene, as a potential LOAD susceptibility locus (Li et al., 2008).  The 
ATP8B
ivated by 
hosphatidylinositol-3,4,5-trisphosphate and the beta-gamma subunits of 
volved in neurotrophin-
Aβ42 
4 SNP rs2067885 is located in a region of high sequence conservation in 
intron 2, which may indicate involvement of a region regulating gene expression.  
The PREX1 protein is found mainly in the cytoplasm and is act
p
heterotrimeric G proteins.  PREX1 has been shown to be in
derived signalling and neuronal migration during development in mice (Yoshizawa 
et al., 2005), similar to astrotactin 2.   
The Aβ42 association analysis found other potential associations with SNPs 
of low minor allele frequency in the Vis data set (Table 5.2).  However, the 
probability of obtaining false-positive results in association tests is increased for 
SNPs of low frequency, so these results in particular need to be replicated.  The 
proportion of the phenotypic variance accounted for by these potential 
associations ranged from 1.8% to 2.8% (Table 5.2).  
 
Genome-wide association analysis of plasma Aβ42:Aβ40 ratio 
 
Genome-wide association analysis of the ratio of Aβ42:Aβ40 in plasma revealed a 
number of loci showing suggestive associations, in chromosomal regions 1q41, 1q44, 
1p13, 2q22, 6q24, 8p23, 10q23, 15q23, 19q13 and 22q13 (Figure 5.6).  Lower ratios 
of Aβ42:Aβ40, accompanied by high Aβ40 concentration, have been associated with 
increased risk of AD (Graff-Radford et al., 2007).  This could indicate a higher 
proportion of Aβ42 being deposited in the brain early in the Alzheimer disease 
process due to the presence of a risk allele.   
Variants associated with reductions in the plasma Aβ42:Aβ40 ratio included 
the following: USH2A SNP rs2886199 is located in intron 40 of this gene which is 
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associated with mutations in Usher’s syndrome type 2 and autosomal recessive 
retinitis pigmentosa  (Eudy et al., 1998; Liu et al., 1999).  The USH2A protein is a 
basement membrane-associated protein which may be important in the development 
and ho
SD7B gene reached suggestive genome-wide 
signific
993).  Chondroitin sulphate 




meostasis of the inner ear and retina.  It contains laminin EGF motifs, a 
pentraxin domain, and many fibronectin type III motifs.   
CSMD1 SNP rs1532583 is located in intron 11 of the gene and potentially 
explains 2.2% of the phenotypic variance (Table 5.3).  CSMD1 is a regulator of the 
classical pathway of complement activation which is highly expressed in the central 
nervous system.  However, analysis of LD in the region did not reveal any associated 
functional or coding variants and the associated SNPs were not located in regions of 
high sequence conservation or regulatory potential.  The validity of all these findings 
needs to be replicated and examined further using a higher resolution genetic 
analysis of the region.   
A SNP in intron 11 of the TH
ance for association with the ratio of Aβ42:Aβ40 in plasma (Table 5.3).  
THSD7B encodes a thrombospondin type-1 domain-containing secreted protein with 
a catalytic domain which cleaves large aggregating chondroitin sulphate 
proteoglycans (aggrecan and versican).  Chondroitin sulphate proteoglycans have 
been found in senile plaques of human AD tissue and have been shown to inhibit 
glial growth in AD brains (Canning et al., 1
p
of the brain (Snow et al., 1995).  Detailed analysis of the locus con
THSD7B gene showed a cluster of associated SNPs all of which are intronic, 
spanning a region of about 300 kb, all in strong LD with each other (r2 > 0.60) 
(Figure 5.7).   
Another potentially interesting candidate for association with plasma 
Aβ42:Aβ40 ratio was identified as the KLK6 gene.  The marker showing the 
strongest association, rs1654537, was found to be located in a highly conserved 
region about 50 bp downstream of an exon-intron junction which could influence 
gene expression through splicing.  The KLK6 protein has been imm
ains and, in tissue culture, the enzyme has been found to generate 
amyloidogenic fragments from the amyloid precursor protein, suggesting potential 
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involvement in Alzheimer's disease (Little et al., 1997).  Furthermore, the brains of 
LOAD patients have been found to contain significantly lower concentrations of 
KLK6 than normal (Zarghooni et al., 2002) indicating a protective role for this serine 
protease.  The same pattern has been reported in LOAD CSF samples (Mitsui et al., 
2002).  Therefore genetic variants in KLK6 could influence its protease activity or 
express
PH1A (chromosome 1) components of γ-secretase after 
screeni
lysis therefore need to be validated by means of replication in other 
data se
ion level, resulting in higher levels of Aβ42 deposition in the brain and 
changes in the plasma Aβ42:Aβ40 ratio. 
 Variants in the amyloid precursor protein (APP) gene and the enzymes 
involved in APP processing at the cellular level have been shown to be associated 
with autosomal dominant familial AD (St George-Hyslop et al., 1987).  In the Vis 
data set, no association was observed between concentrations of Aβ species in 
plasma and the variants of APP (chromosome 21), PSEN1 (chromosome 14), PSEN2 
(chromosome 1) or A
ng for associations in the regions harbouring those genes.  However, as Table 
5.4 shows, the number of SNPs in the Illumina Hap300 array, which cover these 
genes is low (APP (290 kb), 40 SNPs; PSEN1 (83.5kb), 4 SNPs; PSEN2 (24.8 kb), 2 
SNPs; APH1A (3.5 kb), no SNPs).  Therefore, fine-mapping of the genomic regions 
encompassing the genes involved in direct processing and production of Aβ species 
may identify stronger associations.       
 In conclusion, genome-wide association analysis of plasma Aβ40, Aβ42 and 
the ratio of Aβ42:Aβ40 was carried out for the first time in a general population 
sample and revealed biologically interesting candidate loci potentially influencing 
susceptibility to AD.  A number of hits reached suggestive levels of significance 
without any signs of association in the neighbouring SNPs.  The results of this 
association ana
ts such as a second Croatian sample (N ~ 1,000) who have also recently been 
genome scanned using the Illumina Hap300 array or the LOAD cohorts of cases and 
controls available in the Younkin lab.  This has become possible as part of a 
collaboration with the Mayo Clinic (Jacksonville, USA) aimed at the identification of 
genomic loci affecting predisposition to AD.  With access to one of the world’s most 
extensive collections of LOAD patients and controls, the findings of the current 


















































































































































































































































































































































































   



























































































































The findings of the current genetic analysis of plasma Aβ identified common 
enetic variation of relatively small effect size.  It has been suggested that there are 
eimer disease (Daw et al., 2000).  As shown in Chapter 3, 
there is sufficient power in the Vis population data set to identify variants of small 
ffect by genetic association provided there is a strong LD relationship between the 
arker and the functional variant.  Since a number of potentially relevant 
olymorphisms identified here failed to reach the full genome-wide significance 
reshold, increasing the sample size may help to detect variants of small effect size 
ple (N ~ 1,000) 
 whom a Human Hap300 genome-wide scan will soon be completed and plasma 
β analysis is planned.   
g
at least four other genetic loci with variants of moderate to large effect size, similar 











































BIOCHEMICAL AND LINKAGE ANALYSES 



























6.1 Introduction  
 this chapter the results of biochemical analysis of human plasma CFH have been 
scribed and the effects of a number of covariates on CFH plasma levels assessed.  
he quantitative variation observed in plasma CFH concentration is believed to be 
n reported that 





the result of combined genetic and environmental factors.  It has bee
63% of the variation in plasma CFH concentration is genetically determ
general population of Spanish origin (h2 = 0.63 + 0.07; P < 0.0001) (Esparza-
ordillo et al., 2004).  Furthermore, in a whole genome QT linkage analysis, 
sparza-Gordillo and colleagues observed suggestive linkage to three genomic 
gions, 1q32, 2p21 and 15q22.  
Common variants of the CFH gene have been implicated in age-related 
acular degeneration with rs1061170 (Y402H) showing strong association with 
MD (Haines et al., 2005; Edwards et al., 2005; Klein et al., 2005; Zareparsi et al., 
005a).  This polymorphism is located in a region of CFH that definitely binds a 
eparin-like glycosaminoglycan (GAG) (Prosser et al., 2007) and possibly binds C-
active protein (CRP) (Pepys, 2008).  Strong evidence from crystal structure 
nalysis shows that GAG binding is altered by this amino acid substitution (Prosser 
t al., 2007).  Plasma CFH concentration was therefore investigated as a possible 
urrogate biomarker for age-related macular degeneration.   
The aim was to determine concentrations of CFH in the plasma of individuals 
om two isolate populations of Croatian and Dutch origin, and to assess the effect of 
ovariates, including CFH Y402H, on plasma CFH concentrations.  Plasma CFH 
easurements will also be used as the quantitative trait in a genome-wide linkage 
nalyses of markers associated with plasma CFH concentration in Vis.   
Measurements of plasma CFH were also carried out in a Scottish series of 
MD cases and controls to assess whether they significantly differed between the 
o groups hence assessing its potential as a biomarker for AMD.  A sensitive 
sandwich” ELISA was first developed (Figure 6.1) and optimised using purified 
ll-length human CFH as the standard.  A mouse monoclonal anti-human CFH 




























Figure 6.1 Diagrammatic presentation of “sandwich”
 
ELISA of CFH.
A sheep polyclonal antibody was used as the capture antibody to pull down as much of 
the antigen as possible. A mouse monoclonal antibody was used as
 
the detection 
antibody to provide improved specificity. Fluorometric
 











































Purity of the CFH standard was tested by silver staining a 10% SDS-polyacrylamide 
gel containing 18.75 μg of the 150 kDa purified full-length CFH (left) compared with a 67 
kDa 98% purified lyophilised BSA sample (right) which confirmed the presence of serum 
albumin in the CFH standard.  B.
 
Western blot analysis of 7.5 μg of purified CFH (left) 
and human plasma (right). CFH was detected using 13.6 ng of the monoclonal OX23 
primary antibody and 1.16 μg of HRP-conjugated goat anti-mouse secondary antibody.  
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RC Immunochemistry Unit, Oxford) was therefore tested using a highly 
ensitive silver stain (Figure 6.2-A) as described in Chapter 2.  The purified full-
ngth CFH was found to be of relatively high purity (estimated as about 90% from 
e silver stained gel).  The presence of BSA in the purified CFH standard, 
onfirmed by the silver stained BSA sample (Figure 6.2-A), is believed to enhance 
e stability of the protein.  The concentration of the full length CFH was measured 
reviously (Dr. R. B. Sim) and used as the concentration of the standard. 
The specificity of the mouse monoclonal anti-human CFH (OX23) antibody 
indly provided by Dr. R. B. Sim) for binding to plasma CFH was also examined in 
 western blot using the full-length human CFH protein standard as a positive control 
).  Detection of the full-length CFH protein by the OX23 antibody was 
onfirmed in a western blot analysis (Figure 6.2-B) using the purified human CFH 
tandard.  Western blot analysis of human plasma showed that the antibody 
cognised the full-length human CFH protein (150 kDa) but cross-reacted strongly 
ith serum albumin at high concentrations in the human plasma (Figure 6.2-B).  
his suggested that the antibody had been raised to a BSA-conjugated fragment of 
FH.  However, detection of albumin would depend on the polyclonal capture 
ntibody reacting with serum albumin.  The lack of detection of albumin by the 
olyclonal capture antibody was confirmed by the absence of signal from the “blank” 
ells in CFH ELISA plates, which were coated with the capture antibody and 
locked with BSA.   
.3 CFH assay optimisation 
ssay optimisation was carried out in order to determine the optimal conditions for a 
ber of factors including the concentration of the antibodies, the concentration of 
the CFH standard, the sample dilution factor and the incubation times. 
 
The purity of the external protein standard can cause variation in


























6.3.1 Optimisation of antibody and standard concentration
The optimal concentration
s 
 for the detection antibody to provide adequate assay 
l of CFH 
standar
on of incubation time with TMB chromogen  
atic reaction in which tetramethylbenzidine 
 the presence of hydrogen 
nt.  The effect 
of varying the time course of incubation with chromogen is shown in Figure 6.4.   
 
sensitivity was found to be 85 ng/ml, since the curve for optimising the concentration 
of this antibody measured a wide range of absorbances corresponding to 1 μg/ml of 
CFH standard at four different dilutions of the HRP-conjugated antibody (Figure 
6.3-A, light blue line).  The optimal concentration for the HRP-conjugated antibody 
was found to be 145 ng/ml, since the absorbance value was sufficiently high (A450nm 
= 2.5) at this dilution of antibody to provide adequate assay sensitivity (Figure 6.3-
A, vertical green line).  Figure 6.3-B shows the effect of two differing 
concentrations of the capture antibody on the level of absorbance detected.  Both 
concentrations showed optimal coverage in the range of 9.4-300 ng/m
d.  A concentration of 1.2 μg/ml of capture antibody was selected as optimal 
since it differed only negligibly from the 2.4 μg/ml concentration. 
 
 
6.3.2 Optimisation of sample dilutions 
Dilutions of plasma extracted from blood samples donated by local volunteers were 
used in duplicate to determine the optimal plasma dilution factor, as shown in Figure 
6.3-C.  The optimal sample dilution factor was found to be 1 in 5,000, assuming an 
approximate CFH concentration range of 100-600 μg/ml (Esparza-Gordillo et al., 
2004).  The aim was to ensure that plasma samples containing CFH in the range 100-
600 μg/ml would be diluted to within the range of purified CFH standard 
concentrations used to construct the standard curve. 
 
6.3.3 Optimisati
The final stage of the assay is an enzym
MB) chromogen is oxidized by horseradish peroxidase in(T
peroxide to yield a chinoid structure of intense blue colour.  The reaction is affected 
by a number of factors, such as temperature, time and pH.  The effect of temperature 
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Figure 6.3 Titration curves showing the stages of CFH assay optimisation.
A.
 
Coloured lines show the range of absorbance values covered by varying 
concentrations of the OX23 detection antibody. The optimal concentration of the 
OX23 detection antibody was found to be 85 ng/ml since this measured a wide range 
of absorbances corresponding to 1μg/ml of CFH at four different dilutions of the HRP-
conjugated antibody. The vertical green line shows the optimal concentration of HRP-
conjugated antibody resulting in sufficiently high absorbance level at 85 ng/ml of
OX23.  B.
 
Coloured lines represent two different concentrations of the capture 
antibody (red: 2.4 μg/ml and blue: 1.2 μg/ml) over a range of CFH standard 
concentrations. 1.2 μg/ml was selected as the optimal concentration of the capture 
antibody since it differed negligibly from the 2.4 μg/ml concentration.  C.
 
Effect of 
varying dilutions of five plasma samples (labelled P1-P5), ranging from 1 in 
3000 to 1 in 9000 dilutions, on detection of CFH concentration. Error bars represent 
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The optimal incubation time was found to be 60 minutes.  The pH was kept at 



























CFH Standard Concentration (ng/ml)
60 min
igure
sorbance measurements for ELISA of CFH were observed after 60 minutes.  
he figure shows that at the 60 minutes incubation time the reaction has not yet 
ateau phase indicating saturation of the peroxidase enzyme.   
Analysis of intra-experimental variation 
ive internal control plasma samples were used to assess intra-experimental variation 
etween samples.  Figure 6.5-A shows the variation observed between at least 8 
plicates of each sample.  Coefficients of variation (CV) were all below the 5% 
reshold, showing that there were no significant differences between sample 
plicates.  The small variation observed could be accounted for by pipetting errors. 
Analysis of inter-experimental variation 
ter-experimental variation was measured using the same internal controls.  
omparison of the mean of three replicates of each sample from three different 
assays showed minimal variation (Figure 6.5-B).   
 










































































Figure 6.5 Analysis of inter and intra-experimental variation of CFH ELISA assay.
A.
 
Intra-experimental variation within replicates of five plasma sample are shown (P1-P5). 
Each point represents the mean of at least 8 replicates. Variation was measured in terms of 
coefficient of variation (CV) shown below each point.  B.
 
Inter-experimental variation based 
on the mean of three replicates from three different assays are shown. Each point 
represents the mean of three measurements from three independent
 
assays. The CVs are 


































Table 6.1 Assay variation observed between different time-points.
No statistically significant differences were observed between initial measurements (day 0) 
and after a second episode of thawing (P > 0.05).  The table also demonstrates the stability 
of CFH measurements for samples which have been kept at 4oC for 2 and 4 days post-
 
thawing and refrozen. CV: coefficient of variation, SD: standard
 
deviation, P-value is 
calculated for the two-tailed t-test of the differences between day 0 and the second thaw.
Figure 6.6 Analysis of variation after periods of sample freeze-thawing
Graph showing plasma CFH levels measured in triplicate for five samples at four time-
points: day 0 (first thaw), day 2, day 4 and after a second thaw.  Error bars represent 











0 2 4 After second thaw MEAN SD CV (%) P
P1 506.36 532.66 487.85 422.47 487.34 46.99 9.64 0.099
P2 471.37 514.39 484.78 506.06 494.15 19.65 3.98 0.188
P3 682.52 650.54 603.26 602.38 634.68 39.03 6.15 0.176
P4 379.06 369.56 384.70 395.59 382.23 10.88 2.85 0.505
P5 546.08 589.59 536.88 548.34 555.22 23.44 4.22 0.878
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The slight increase in CV in samples P3 and P5 was believed to be due to pipetting 
rrors and experimental variation between assays, for example the use of different 
le freeze- 
thawing  
epeated freeze-thawing can have an adverse effect on levels of detectable proteins 
s it can damage the native structure of the polypeptide.  Five crude EDTA plasma 
amples were thawed from –80oC slowly on ice and stored at 4oC for four days.  
hereafter, they were re-frozen at –80oC overnight and re-thawed on the following 
ay.  Plasma CFH levels were measured at each time point (Figure 6.6).  Analysis of 
e results showed no statistically significant differences (P > 0.05) between CFH 
easurements following a second thaw (Table 6.1).  The high concentration of CFH 
 human plasma most likely accounted for the stability of the protein on repeated 
eeze-thawing.    
These results were of considerable significance for the following reasons.  
irstly, they demonstrated that reliable CFH concentration readings could be 
btained from samples which have been frozen twice.  Plasma samples collected 
om the island of Vis and used for CFH measurements had been thawed once for the 
nalysis of plasma cortisol.  Therefore, the assay was capable of providing reliable 
nd accurate plasma CFH concentrations.  Secondly, the small variation observed in 
lasma CFH between days 0 and 4 showed that samples can be stored at 4oC for up 
 4 days after thawing and used in multiple experiments.  
.3.7 Analysis of pipetting techniques in CFH assay 
 order to select the optimal pipetting method for the CFH ELISA, three different 
ipetting techniques were assessed and their contribution to the variation observed 
etween sample measurements was evaluated.  These included multi-channel, digital 
nd manual single pipettes.  Pipettes had previously been calibrated by weighing of 
ultiple pipettes using water samples.   
e
batches of reagents. 





























Analysis of the mean variation observed between CFH concentrations in 
eight plasma samples indicated that single pipette measurements differed 
significantly from measurements made with multi-channel pipettes.  The mean 
variation was also lower using single manual pipettes than when using digital 
d 
hen using the single manual pipette (CV = 5.7%) compared with the other two 
pipettes (Figure 6.7).  The results indicated that the least variation was observe
w
methods.  This was therefore used as the pipetting method for the CFH ELISA. 
 



























iagram showing the coefficients of variation for different pipetting methods.  The mean  
  
 Figure 6.7 Effect of different pipetting techniques on assay variation 
 
 D
 coefficient of variation is presented for each technique.  Values are calculated from 
 duplicates and are based on eight sample measurements.  The single manual pipette,  
 showing the least variation (CV=5.7%), was used as the pipetting method for the ELISA  










samp using five internal 
 
 
lmasy & Blangero, 1998) which takes the relatedness of individuals into account 
ate analysis are 
be 
H) 
d on the additive 
ffect of the CFH rs1061170 minor allele C.  Differences in mean effect of the minor 
llele on CFH concentration were estimated from β, the regression coefficient, in 
nits of μg/ml.   
 
lasma CFH measurements 
 
Plasma CFH concentrations were measured in 1,004 samples from the island of Vis 
(Figure 6.8-A), 490 samples from an isolated Dutch (Rucphen) population (Figure 
6.8-B), 549 samples from a Scottish AMD series (Figure 6.8-C) and 88 samples 
from a Japanese AMD series (Figure 6.8-D) using the optimised assay, as described 
in Section 2.4.3.3.  All measurements were carried out in triplicate and the mea
le replicates were then normalised for inter-assay variation 
controls.  Details of the series analysed are presented in Table 2.1. 
6.4.1 Analysis of plasma CFH in the island of Vis 
 
The distribution of plasma CFH concentrations in samples collected from the isolated 
island of Vis showed a three-fold range of values, with a mean of 400.2 μg/ml.  The 
distribution fitted a normal distribution with a kurtosis factor of 0.49 ± 0.15. 
Kurtosis has been defined as a measure of departure from normality (DeCarlo, 1997) 
and values below 0.80 refer to a normal distribution.  The normality of the 
distribution reduces the probability of obtaining false positive results in future 
analyses. 
 
6.4.1.1 Analysis of covariates 
 
The association between covariates and plasma CFH concentration was assessed in a 
univariate analysis using a general linear model, with the statistical software SOLAR 
(A
by constructing a relationship matrix.  The results of the covari
summarised in Table 6.2.  SNP rs1061170 (CFH Y402H) has been shown to 
strongly associated with AMD.  The association between rs1061170 (CFH Y402
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Figure 6.8 Plasma CFH measurements in four study populations.
The distribution of unadjusted plasma CFH measurements in samples from the Croatian 
island of Vis (A), the isolated Dutch (Rucphen) population (B), a cohort of urban Scottish 
AMD cases and non-AMD controls (C)
 
and a cohort of Japanese AMD cases and controls
(D). Population-specific descriptive statistics are presented below each graph. Kurtosis 
values smaller than 0.8 (Figures A and B) represent a normal distribution.  Data were 
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Table 6.2 Plasma CFH covariate analysis in Vis.
Results of the association analysis between plasma CFH and a number of covariates 
including age, sex, body mass index (BMI), CFH
 
Y402H (rs1061170) (additive model of 
the minor allele) and interaction between sex and age. The analysis was carried out using 
1,004 individuals from the island of Vis. P-values are presented for each covariate effect.  
β
 
is the regression coefficient which indicates the change in the
 
mean plasma CFH 
concentration (±
 
standard error, SE). R2
 
is the proportion of the unadjusted phenotypic 
variance explained. Analysis was carried out using a linear regression model implemented 
in the software package SOLAR (Almasy & Blangero, 1998)
SNP MAF HWD p -value
rs1061170 0.39 0.50
Genotypic Frequency (%)
TT (36.3), TC (49.1), CC (14.9)
Table 6.3 Descriptive statistics for rs1061170 (CFH
 
Y402H) in the Vis population.
rs1061170 allele and genotypic frequencies were measured in 472 unrelated individuals 
from the island of Vis.  Deviation from Hardy Weinberg equilibrium was also assessed.
MAF: minor allele frequency, HWD P-value were calculated for deviation from Hardy 
Weinberg equilibrium. Analysis was carried out using the software package PLINK (Purcell 
et al., 2007)
Covariate χ2 d.f. P β ± SE (μg/ml) R2
Age 1.69 1 0.193 n.a. 0.000
Sex 9.44 1 0.002 -11.2 ± 3.68 0.008
Age by Sex 8.60 1 0.003 0.9 ± 0.95 0.061
BMI 50.67 1 1.1E-12 3.3 ± 0.44 0.087
Smoking 0.22 1 0.642 n.a. 0.000
CFH  Y402H 45.89 1 1.2E-11 -18.9 ± 2.78 0.048
Dependent variable: CFH (Mean 406 μg/ml ± 55.9 SD)
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The rs1061170 SNP was incorporated as a potential covariate into a SOLAR 
olygenic regression model that used plasma CFH concentration as the quantitative 
ait and included other potential covariates including sex, age, age-by-sex, smoking 
 family structure and covariates to 
stimate the heritability of the trait and the proportion of trait variance explained by 
e covariates.   
402  
variant resulted in a decrease of 18.9 μg/ml (± 2.78, SE) in the mean plasma CFH 
oncentration (P = 1.2E-11) (Table 6.2).  Sex, age-by-sex interaction and BMI also 
ith plasma CFH concentrations. 
Male sex was associated with a decrease of 11.2 μg/ml (± 3.68, SE) in the 
ean plasma CFH concentration (P = 0.002).  Age was not a significant covariate 
P = 0.193) (Table 6.2).  A significant association was 
a CFH and BMI.  Each unit increase in BMI was found 
μg/ml  (± 0.44, SE) increase in mean plasma CFH (P = 
Table 6.2).  A significant interaction was observed between age and sex, 
 males being associated with a 0.90 μg/ml (± 
ean plasma CFH concentration (P = 0.003).  Smoking 
id not show any significant association with changes in plasma CFH (P = 0.642). 
Plasma CFH concentration also showed a significant narrow-sense 
eritability, estimated in the Vis population as 0.46 ± 0.13 (P = 0.00058).  The 
roportion of the phenotypic variance accounted for by significant covariates was 
stimated to be 0.204.   This confirmed the presence of other genetic and/or 
nvironmental factors which influence plasma CFH. 
.4.2 Plasma CFH distribution in the isolated Rucphen (Dutch) 
community 
FH measurements were carried out in 490 plasma samples of unrelated individuals 
om an isolated Dutch population, using the CFH ELISA described previously.  
formation on the age and sex of the individuals screened were reported in Table 
.1, which was used for the analysis of covariates.     
p
tr
and BMI.  The polygenic model incorporates the
e
th
Addition of one copy of the minor allele, T (His ) of the CFH Y402H
c
showed significant association w
m
when analysed on its own (
also observed between plasm
to be associated with a 3.3 
1.1E-12) (
with each one year increase in age of















Measurements of plasma CFH were normalised using internal controls as 
described before.  The measured plasma CFH showed a two-fold range of 
concentration (Figure 6.8-B).  The mean plasma CFH concentration in the Rucphen 
population was 509.7 μg/ml (± 56.3, SD).  CFH measurements in this population 
also showed a normal distribution with a kurtosis value of 0.11 ± 0.22. 
6.4.2.1
 
e, sex, age-by-sex 
interac
o 
cottish AMD cases (mean age = 
5.6 years, 62.8% females) and 198 age and sex-matched controls (mean age = 73.1 
l. 
 Analysis of covariates 
Tests for association between covariates and plasma CFH concentration were carried 
out in the Dutch Rucphen samples by univariate analysis using a general linear 
model implemented in the statistical software SPSS v12.  Ag
tion and SNP rs1061170 (CFH Y402H) genotypes (Table 6.4) were tested as 
possible covariates in the analysis.   
 Both rs1061170 and age had significant effects on plasma CFH concentration 
in the Rucphen population (Figure 6.9).  Mean plasma CFH decreased by 13 μg/ml 
for each copy of SNP rs1061170 minor allele using an additive model (P = 4.8E-04).  
Age was also found to be a significant covariate since plasma CFH concentration 
increased with age (β = 0.57 μg/ml per one year increase in age, P = 2.9E-03).  Sex 
was not found to be a significant covariate for plasma CFH concentration in this 
population.  The proportion of the phenotypic variance explained by the tw
significant covariates, age and SNP rs1061170, was estimated at 0.039.  
   
6.4.3 Analysis of plasma CFH in the Scottish AMD series 
 
Plasma CFH measurements were carried out in 351 S
7
years, 62.2% females) (Table 2.1, Chapter 2). 
 
6.4.3.1 Analysis of plasma CFH covariates in the Scottish AMD cases 
 
The distribution of plasma CFH in cases of AMD was found to be leptokurtic and 
showed a 4.2-fold range of values (Figure 6.8-C).  The mean unadjusted plasma 






























Figure 6.9 Plasma CFH covariate analysis in the isolate Dutch population.
Diagram showing significant changes in mean plasma CFH associated with 
significant covariates in a linear regression analysis.  The y-axis shows changes in 
the mean plasma CFH associated with age and SNP rs1061170 (CFH
 
Y402H).  Error 
bars are standard error of the mean.  P-values are shown for each covariate effect.   
SNP MAF HWD P -value
rs1061170 0.32 0.28
Genotypic Frequency (%)
TT (47.0), TC (41.6), CC (11.4) 




Y402H) allele and genotypic frequencies measured in 500 
unrelated individuals from the isolated Dutch Rucphen population.  Deviation from 
Hardy Weinberg equilibrium was also assessed.




Available covariates including age, sex, age-by-sex, smoking and CFH rs1061170 
402H) were tested for association with plasma CFH concentration using the 
he potential 
be statistically significant. 
.4.3.2 Analysis of plasma CFH covariates in the Scottish AMD control 
sample  
he control population had a platykurtic distribution with a 1.8-fold range (Figure 
.8-C).  The mean unadjusted plasma CFH concentration in the Scottish control 
eries was 428.3 μg/ml.   
Association tests were carried out for potential covariates including sex, age, 
ge-by-sex, smoking and SNP rs1061170 (CFH Y402H) using the general linear 
odel implemented in the statistical software package SPSS v.12.  The results 
dicated that age was the only significant covariate for plasma CFH with a reduction 
f 18.2 μg/ml in the mean CFH concentration associated with each year of life (P = 
.031)  (Figure 6.10).  No significant associations were observed with other 
ovariates in the model. 
Comparison of plasma CFH concentrations between Scottish 
AMD cases and controls 
lasma CFH concentrations were compared between 351 cases of AMD and 198 
isease-free controls using the statistical software package SPSS v.12.     
Mean unadjusted plasma CFH in the AMD cases was 412.6 μg/ml, 15.7 
g/ml lower than the Scottish control population (Figure 6.8-A and Figure 6.11).  
n independent-samples two-tailed t-test was used to compare the AMD cases and 
ontrols and the results showed that there were significant differences in plasma CFH 
oncentration between AMD cases and controls after adjusting for age (Ptwo-tailed = 
.003) (Figure 6.11).  The proportion of the variance in plasma CFH concentration 
xplained by disease status, represented as R2, was found to be 0.016.  A binary 
gistic regression analysis of plasma CFH concentration divided into quartiles, 
howed an AMD odds ratio of 2.1 (95% C.I. 1.3 - 3.4, P = 0.003) associated with the 
west quartile (0 - 25%) compared with the highest quartile (75% - 100%). 
(Y
general linear model implemented in the software SPSS v.12.  None of t

















































































Figure 6.10 Analysis of plasma CFH covariates in an urban Scottish 
population.
Diagram showing the association between plasma CFH concentration
 
and a number 
of covariates in 187 control individuals of Scottish origin.  Age was found to be the 
only significant covariate which was associated with a decrease in mean plasma 
CFH as shown on the y-axis.  Error bars are standard errors of the mean. 
Figure 6.11 Analysis of plasma CFH concentrations between Scottish AMD 
cases and controls.
Diagrammatic presentation of the plasma CFH differences between cases and
controls in the Scottish AMD cohort (top).  Table shows the disease status used as
a covariate for plasma CFH levels in a general linear model. Error bars represent
95% confidence interval of the mean.  d.f.: degrees of freedom. F: F test statistic with 
the P-value for the test.  R2
 
shows the proportion of the variance in plasma CFH 
concentration explained by the covariates.
Covariates
Type III Sum     
of Squares d.f. F p R
2
Sex 0.126 1 0.081 0.775 0.000
Age 1.157 1 0.750 0.387 0.001
Disease status 13.870 1 8.989 0.003 0.016
193
6.4.4 Analysis of plasma CFH in a Japanese AMD series 
ars, 16.7% female) and 58 age-matched controls (mean age of 76.6 years, 60.3% 
male) of Japanese origin.  Mean plasma CFH was found to be 326.8 μg/ml (± 
Age, sex, age-by-sex and CFH rs1061170 (Y402H) were used as covariates 
 a general linear model to assess their effects on changes in the mean plasma CFH 
oncentration in AMD cases and controls separately, using the statistical software 
PSS v.12.  Both case and control distributions were checked for normality, using 
e Kolmogorov-Smirnov test and both were consistent with a normal distribution (P 
 0.01).  None of the potential covariates were found to be associated with plasma 
FH in the Japanese cases or controls (P > 0.05).   
The minor allele frequency of the CFH rs1061170 (Y402H) variant was 
3.3% and 4.3% in the AMD cases and controls, respectively.  The difference was 
und to be significant (P = 0.037).   
n independent-sample two-tailed t-test was then used to compare the means of 
lasma CFH concentrations in AMD cases and controls, using the software SPSS 
.12.  The assumption of homogeneity of variances of the two groups was tested 
sing Levene’s test which did not reject the hypothesis that the variances are equal in 
ases and controls (F = 0.136, P = 0.713) (Table 6.5).  The t-statistic was then 
alculated for the combined groups, as the ratio of the difference between sample 
eans divided by the standard error of the difference.  The results showed no 
ignificant difference between the means of plasma CFH between Japanese AMD 
ases and controls (Ptwo-tailed = 0.469) (Table 6.5).   
.4.5 Comparison of plasma CFH in general populations of Vis, 
Rucphen, Scotland and Japan 
lasma CFH concentrations were compared between samples of Croatian (N = 
,004), Dutch (N = 490), Scottish (disease-free controls) (N = 198) and Japanese 
MD-free controls) (N = 58) general populations.  Comparisons were carried out 
fter adjusting for the effect of the significant covariates identified earlier.   
 
Quantitation of plasma CFH was carried out in 30 AMD cases (mean age of 77.3 
ye
fe





































































































































































































































































































































































































The unadjusted mean CFH concentration in the Vis population was 109.5 
g/ml lower than the mean value obtained in the Rucphen (Dutch) population (P = 
CFH 
1061170, the difference in the mean CFH concentrations between the Vis and 
Rucphen populations was no longer significant (P = 1.00). 
he unadjusted mean CFH concentration in the Scottish control population 
was 81.4 μg/ml lower than the mean plasma CFH in the Rucphen (Dutch) population 
(P = 3.4E-57).  After adjusting for covariates age and CFH rs1061170, this 
difference was also found to be non-significant (P = 1.00). 
he unadjusted mean CFH concentration in the Scottish control population 
was 28.1 μg/ml higher than the unadjusted mean in the Vis population (P = 7.9E-11).  
However, after adjusting for covariate effects associated with age, sex and CFH 
rs1061170, this difference was also found to be non-significant after adjustments (P 
= 1.00)
inally, the difference in the mean plasma CFH concentration between the 
general population of Vis and the Japanese control population was found to be non-
significant (P = 1.00).  The difference in the mean plasma CFH between the Scottish 
and the Japanese control populations was also found to be non-significant after 
adjusting for the effects associated with age and CFH rs1061170 (P = 1.00). 
 
6.5 Genome-wide linkage analysis of plasma CFH 
 
Genom -wide analysis of linkage was carried out using the variance components 
methodology implemented in the software SOLAR (Almasy & Blangero, 1998).  The 
genome-wide linkage scan consisted of 810 STR markers genotyped in 1,042 
individuals from the island of Vis.  The series consisted of randomly selected 
individuals, 58% of whom were members of 122 pedigrees.  A full description of the 
samples was presented in Table 2.1.  Microsatellite markers were spaced 
approximately 5 cM apart.  A full description of the linkage scan and the underlying 
principles were described in Section 2.5.8. 
he null hypothesis being tested was that the additive genetic variance due to 
a putative quantitative trait locus (QTL) equalled zero and so only the polygenic 
μ











on of human complement factor H in plasma.  The possibility of the 
polyclo
Inter and intra-experimental variation was assessed and the coefficients of 
variation were all found to be below 5%.  Analysis of assay results and variation 
lasma CFH to 
ld be explained by reduced genetic and 
environ
(due to pedigree relationship) on the phenotype were modelled.  The 
hypothesis of no linkage was tested by comparing the likelihood of the null 
polygenic model, including the significant covariates of sex, age-by-sex interaction, 
BMI and SNP rs1061170 (CFH Y402H), with that of a model that estimated the 
additive genetic variance at the putative QTL.   
The results of the linkage scan for all 22 autosomal chromosomes are 
summarised in Figure 6.12.  The highest LOD score detected was 1.16 on 
chromosome 10.  No multipoint LOD scores indicative (Z ≥ 3) or suggestive (Z ≥ 2) 
of linkage were observed in this analysis. 
6.6 Summary and discussion  
 
A high throughput “sandwich” ELISA was developed and optimised for the 
quantitati
nal capture antibody detecting the CFH-related proteins in plasma (as a result 
of competition with full length CFH) cannot be excluded despite the western blot 
analysis of the detection antibody showing high specificity to the full length CFH.  
Determining the proportion of the quantitated protein which is accounted for by the 
related proteins will therefore require further investigation.  
after one or two sample freeze-thawing demonstrated the ability of p
withstand freeze-thawing and the stability of the protein at 4oC for up to four days. 
 
Analysis of plasma CFH in the Vis population  
  
Plasma CFH measurements were carried out in four populations.  The concentrations 
detected in 1,004 individuals from the Croatian isolate of Vis showed a three-fold 
range in values (218 - 654 μg/ml).  The range of values differed slightly from what 
has previously been reported in an urban Spanish population (100 - 600 μg/ml) 
(Esparza-Gordillo et al., 2004).  This cou
mental variation in this isolate population as a result of geographical isolation 
(Rudan, 1999a; Polasek et al., 2006).      
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Figure 6.12 Results of plasma CFH linkage analysis in the Vis population.
LOD scores were obtained using a genome-wide linkage analysis of 810 microsatellite 
markers in 1,042 members of the Vis population. Markers were spaced at 
approximately 5 cM intervals. The model for linkage was based on a polygenic model 
consisting of BMI, SNP rs1061170, sex and age-by-sex interaction which were found to 
be significant covariates for plasma CFH. Analysis was carried out using the software 
package SOLAR (Almasy& Blangero, 1998).
198
The demographic history of the island of Vis dates back to approximately 
,000 years BC.  Since then the Vis population has gone through major admixture 
nd bottleneck events; the former occurred due to immigration from the Croatian 
reduction in 
th century, hence lowering the genetic heterogeneity (Vitart 
., 2006). Variation in plasma CFH measurements between the Vis population 
 be explained by assay differences, 
and the efficiency of the capture and 
he purity of the standard was assessed by silver staining and 
tested using a western blot (Figure 6.2). 
Test of association between plasma CFH concentration and a number of 
using a general linear regression model in SPSS v.12.  The 
 Y402H (rs1061170) risk allele (His402) which has been shown to increase 
et al., 2005; Edwards et al., 2005; Klein et al., 2005, 
et al., 2005a) was associated with significantly lower plasma CFH 
P = 1.2E-11, Table 6.2).  This amino 
 levels of circulating CFH by disrupting the stability, 
e protein from its main site of production in the liver. 
BMI was associated with a small increase in mean plasma CFH (3.3 μg/ml ± 
P = 1.1E-12) and explained 8.7% of the 
Table 6.2).  Raised BMI (≥ 30) has been shown to 
ated with increased risk of AMD, independently of CFH variant Y402H, 
et al., 2006a).  Since low rather than high 
ntrations are expected to increase the risk of AMD, this 
 difficult to explain unless there is some confounding factor, 
 that influences plasma CFH.  However, age alone was not associated 
a CFH.  The concentration of CFH in plasma has been shown to increase 
parza-Gordillo et al., 2004).  One explanation for the lack of association 
a CFH and age in the Vis population is that the effect of age on 
a CFH is accounted for by BMI.  This was tested and confirmed by removing 
rom the univariate analysis of plasma CFH which resulted in statistically 
t association between age and plasma CFH concentration (P < 0.001).  Sex 
1
a
mainland (17th century) and the latter as a result of emigration (44 - 88% 
population size) in the 20
et al
and other published populations can also
including the purity of the CFH standard 
detection antibodies.  T
the specificity of the antibody was 
covariates were assessed 
CFH
susceptibility to AMD (Haines 
Zareparsi 
concentrations in the Vis general population (
acid substitution could affect
solubility or secretion of th
 
0.44, SE) which was highly significant (
unadjusted phenotypic variance (
be associ












le in the 
stimula
This 
age-by-sex interaction were found to be significantly correlated with plasma 
CFH concentrations in the Vis population (Psex = 0.002, Page*sex = 0.003).    Age and 
sex have been shown to significantly correlate with incidence of macular 
degeneration and the disease is more common amongst older women (Maltzman et 
al., 1979).  According to Evans (2001) age and genetic susceptibility are the two 
most important risk factors in AMD (Evans, 2001).   
Smoking was not significantly correlated with changes in plasma CFH 
concentration in the Vis population (P > 0.05) (Table 6.2).  However, smoking has 
been shown to be associated with increased risk of AMD in older individuals 
(Seddon et al., 2006a).  Furthermore, smoking has a well-established ro
tion of pro-inflammatory responses and is associated with increased levels of 
inflammatory markers (Bakhru & Erlinger, 2005).   
The heritability of plasma CFH concentration in the Croatian isolate 
population of Vis was estimated to be 0.46.  However, this heritability estimate is 
limited to additive gene effects and excludes non-additive factors such as dominance 
and epistasis, which makes this a conservative estimate of overall heritability.  Sex, 
age-by-sex interaction, BMI and the AMD susceptibility SNP rs1061170 (Y402H) 
together explained 20.4% of the plasma CFH variance in this population.  
confirms the presence of other genetic or environmental factors which influence 
plasma CFH and hence potentially affect susceptibility to AMD. 
 
Analysis of plasma CFH in the Rucphen (Dutch) population 
 
Plasma CFH concentration was measured in 490 unrelated individuals from the 
Rucphen (Dutch) community used as a replication series.  The results showed a two-
fold range of concentration and a mean of 509.7μg/ml (Figure 6.8-B).   
 Covariate analysis included age, sex, an age-by-sex interaction and the CFH 
rs1061170 (Y402H).  Age was found to be a significant covariate for plasma CFH 
concentration in this population (P = 2.9E-03) and an increase in age resulted in 
increased plasma CFH concentration (β = 0.57 μg/ml per year).  BMI data were not 
available for these samples.  Similar to the results of the Vis population, the CFH 
Y402H (rs1061170) risk allele (His402) was associated with significantly lower 
plasma CFH concentrations in the Rucphen population (P = 4.8E-04) (Figure 6.9). 
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Analysis of plasma CFH in the Scottish AMD series  
 
Analysis of plasma CFH was carried out in 351 unrelated Scottish cases of AMD and 
198 age- and sex-matched AMD-free controls. 
 A number of covariates including age, sex, age-by-sex interaction, smoking 
and CFH rs1061170 (Y402H) were analysed for potential associations with plasma 
CFH concentrations.  In the Scottish cases of AMD, none of the potential covariates 
were fo
cottish control population could 
be explained by ascertainm
uartile (75% - 100%).  AMD disease status was found to significantly explain 1.6% 
ion of plasma 
 cases and 
und to be significantly associated with plasma CFH.  In the Scottish control 
population, age was the only significant covariate for plasma CFH, associated with a 
reduction of 18.2 μg/ml in the unadjusted mean CFH concentration per year increase 
in age (P = 0.031) (Figure 6.10).  BMI data were not available for the Scottish AMD 
case-control samples.  Lack of association between plasma CFH concentrations and 
sex, smoking and CFH rs1061170 (Y402H) in the S
ent bias as the study sample had already been selected 
based on the absence of disease. 
 Comparison of plasma CFH concentrations between Scottish AMD cases and 
controls showed that CFH concentrations were significantly higher in the control 
population compared with cases of AMD (P = 0.003) after adjusting for age (Figure 
6.11).  Furthermore, binary logistic regression analysis of plasma CFH concentration 
divided into quartiles, showed an AMD odds ratio of 2.1 (95% C.I. 1.3 - 3.4, P = 
0.003) associated with the lowest quartile (0 - 25%) compared with the highest 
q
of the variation in plasma CFH concentration (P = 0.003).  Identificat
CFH concentration as a risk factor for AMD is a novel finding.  Circulating CFH 
concentration appears to be one of many factors which influence susceptibility to 
age-related macular degeneration.  Whether the difference between
controls is a cause or effect requires further investigation however, low plasma CFH 
is plausibly associated with increased activation of the alternative complement 






Analysis of plasma CFH in the Japanese AMD series  
nd to be 326.8 μg/ml in the cases of 
morphisms other than rs1061170 (Y402H) which 
1170, this difference was found to be 
on-significant (P = 1.00).  The mean age was found to be significantly different 
etween the Vis (56.1 ± 0.49, SE) and the Rucphen (59.2 ± 0.62, SE) populations.  
urthermore, the minor allele frequency of CFH rs1061170 (Y402H) was found to 
 significantly different between the Vis (MAF = 0.39) and the Rucphen (MAF = 
 
Plasma CFH measurements were carried out in 30 cases of AMD and 58 age-
matched controls.  Mean plasma CFH was fou
AMD and 337.6 μg/ml in the controls (Figure 6.8-D).   
Plasma CFH concentrations did not differ significantly between AMD cases 
and controls in the Japanese population (P = 0.469) (Table 6.5).  The small number 
of samples entails a lack of power to detect an association between predictors and 
plasma CFH concentration and to find significant differences between AMD cases 
and controls in this population.   
  It is interesting that despite a small sample size, the allele frequency 
differences for CFH SNP rs1061170 were significant between the Japanese cases and 
controls despite the lack of association between this SNP and AMD reported 
previously (Uka et al., 2006; Gotoh et al., 2006; Okamoto et al., 2006).  There may 
be a reduced frequency of poly
affect AMD by influencing plasma CFH concentrations in the Japanese population.   
 
Comparison of the results between the Croatian, Dutch, Scottish and 
Japanese populations 
 
Reduced genetic heterogeneity as a result of isolation (Rudan et al., 1987; 
Forenbaher et al., 1999), genetic drift, founder effects (Smoljanović et al., 2006; 
Rudan et al., 2006; Jeran & Havas, 2007) or selection at the CFH locus due to 
previous history of infections (Hageman et al., 2006) may have resulted in the higher 
frequency of protective alleles (associated with higher plasma CFH concentration) in 
the isolate populations of Vis and Rucphen.  The unadjusted mean CFH 
concentration in the isolated Dutch Rucphen population was approximately 100 
μg/ml higher than that obtained in the Croatian samples which was found to be 
statistically significant (P = 1.9E-178).  However, after adjusting for the covariate 






0.32) populations using a Fisher’s exact test (P = 1.5E-03).  This implies that the 
a CFH 
in both populations.   
riates, the difference in plasma CFH concentrations 
betwee
Statistically significant differences in the unadjusted mean plasma CFH 
 the Dutch population (P = 1.1E-74) and the Scottish 
differences observed between plasma CFH measurements in the two populations are 
due to differences in age distributions and the minor allele frequency of the CFH 
rs1061170 variant which was found to be significantly associated with plasm
 The mean plasma CFH concentration in the Scottish control population was 
28.1 μg/ml and 81.4 μg/ml lower than the values obtained in the Vis (P = 7.9E-11) 
and Rucphen (P = 3.4E-57) populations.  However when age, sex and CFH 
rs1061170 were included as cova
n the two populations was no longer significant (P = 1.00).  While no 
statistically significant differences were observed in the minor allele frequency of the 
CFH rs1061170 (Y402H) polymorphism between the Vis population (MAF = 0.39) 
and the Scottish urban population (MAF = 0.34) (P > 0.05), age distributions were 
found to significantly differ between the two populations (P = 3.5E-29).  Therefore, 
this could have resulted in differences in plasma CFH distributions. 
concentrations were observed between the Japanese control series and the Vis 
population (P = 3.1E-13),
AMD-free control population (P = 7.9E-23).   
 
Genome-wide linkage analysis of plasma CFH in Vis 
   
It has been suggested that the probability of obtaining a QTL through linkage 
depends on the heritability of the trait attributable to that QTL (Almasy & Blangero, 
1998).  Based on this hypothesis, a genome-wide linkage screen of plasma CFH 
using 810 microsatellite markers was performed in 1,042 individuals from Vis in 
order to identify genomic loci which regulate plasma CFH concentration.  No LOD 
scores indicative (LOD ≥ 3) or suggestive (LOD ≥ 2) of linkage were observed in the 
linkage analysis (Figure 6.12).  The power to detect a QTL by linkage depends on 
the proportion of variation accounted for by the QTL, the number of families and the 
family size and structure (Atwood & Heard-Costa, 2003).  The small average QTL 
effect size underlying the variation in plasma CFH is probably the main reason for 
the lack of significant evidence of linkage.  Predictive analysis of power to detect 
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QTL by variance components methodologies has been assessed based on the family 
structure in the Vis data set and the results have shown that sufficient power is only 
available for the detection of QTL of at least 30% effect size (Dr. V. Vitart, personal 
communication).   
In conclusion, analysis of plasma CFH concentration using a novel CFH 
encing this trait.  
Multip
ng association mapping.  Therefore, a 
igh-resolution genome-wide association analysis was carried out to identify 
ELISA identified significant associations between the CFH SNP rs1061170 (Y402H) 
and plasma CFH in the Vis and Rucphen data sets (Table 6.2 & Figure 6.9) 
suggesting that there may also be other variants within the CFH locus which 
influence plasma CFH concentration.  The SNP rs1061170 could be affecting the 
concentration of CFH in plasma by altering the stability of the protein or its secretion 
from the liver.  A second novel finding is the identification of plasma CFH as a risk 
factor for AMD since significant differences in plasma CFH concentrations were 
observed between Scottish AMD cases and controls (Figure 6.11).  Furthermore, a 
narrow-sense heritability of 0.46 was estimated for plasma CFH in the Vis 
population suggestive of underlying additive genetic variants influ
oint linkage analysis of plasma CFH did not identify suggestive or significant 
linkage peaks, due to low power in linkage (Figure 6.12).  However, as the 
predictive analysis of power showed sufficient power is available in the Vis data to 
detect variants of effect size as low as 3% usi
h











































 this chapter, the genetic analysis of the CFH locus and results of a genome-wide 
e as a 
 Edwards et al., 2005; 
lein et al., 2005) a number of studies identified other genetic susceptibility factors 
 the region.  Haplotypes consisting of multiple SNPs excluding the CFH Y402H 
ariant were shown to have a stronger association with disease susceptibility than 
402H-containing haplotypes (Li et al., 2006).  Furthermore, a common haplotype 
arrying a deletion of approximately 86 kb containing the CFHR3 and CFHR1 genes 
as found to be associated with decreased risk of AMD, acting independently of 
402H (Hughes et al., 2006).            
Figure 7.1 Diagrammatic representation of the CFH locus. 
Diagram showing the CFH locus on chromosome 1q32 spanning approximately 357 kb 
of DNA.  Five CFH-related genes are also shown (CFHR1-5).  Blue, green and pink blocks 
below the black line represent three areas of genomic duplication with more than 96%   
sequence homology.  Red arrows show the direction of transcription and exons are shown   
as black vertical lines (Figure adapted from Hughes et al., 2006).     
Following the identification of plasma CFH as a biomarker for AMD, and the 
ssociation between the CFH SNP rs1061170 (Y402H) with plasma CFH, a genome-
ide association analysis using 317,503 SNPs (Illumina HumanHap300 Array®) was 
arried out with the aim of identifying polymorphisms which affect plasma CFH 
oncentration, hence influence susceptibility to AMD.  Polymorphisms identified in 
revious published work to influence susceptibility to AMD and not included in the 
lumina Hap300 array were genotyped by TaqMan® assays.  The results of 
 
In
association analysis are presented.  Following identification of the CFH gen





























genotyping the CFHR3/CFHR1 deletion were also included in the association 
nalysis.       
fect against AMD through its association with 
ther variants directly increasing plasma CFH concentration.   
 
 threshold cycle (Ct) values observed for amplification of the CFHR3 (FAM 
uorescence) and HBB (VIC fluorescence) genes (Figure 7.2).  The observed Ct 
retically, a unit difference 
nce 
 
 the DNA template.  Therefore, a Ct difference of zero to 0.4 was taken as a 




7.2.1 Genotyping of the CFHR3/CFHR1 deletion 
 
A common deletion polymorphism of CFHR3/CFHR1 (Figure 7.1) has been found 
to significantly protect against AMD independently of the CFH Y402H variant 
(Hughes et al., 2006).  The deletion is present on a protective haplotype which is 
present in 7.8% of AMD chromosomes and 20% of chromosomes of control 
individuals.  The working hypothesis in the present study was that the deletion 
polymorphism confers a protective ef
o
 A high throughput real-time quantitative PCR (qPCR) was developed to 
genotype the CFHR3/CFHR1 deletion polymorphism as described in Methods.  
7.2.1.1 Results of CFHR3/CFHR1 deletion genotyping 
Genotyping of the CFHR3/CFHR1 deletion was carried by calculating the difference 
in
fl
value is proportional to the number of target genes.  Theo
in Ct would indicate a loss or gain of one copy number of the template.  A differe
in Ct value of exactly one unit between CFHR3 and HBB was rarely obtained.  This
is believed to be the result of varying efficiencies of primers and probes in annealing 
to
h
heterozygous genotype.  Homozygous deleted genotypes resulted in no amplification 
of the CFHR3 template.  The genotypes of individuals homozygous for the
CFHR3/CFHR1 deletion were confirmed in a duplex PCR in which the absence of a 
219 bp amplicon of CFHR3 in the presence of a 280 bp amplicon of HBB 
represented a homozygous deleted genotype (Figure 7.3).  Heterozygous non-deleted 
or homozygous non-deleted genotypes were shown by the presence of the 219 bp 







































Figure 7.2 Genotyping of the CFHR3/CFHR1
 
deletion by quantitative real-time PCR.
Examples of a homozygous non-deleted (A)
 
and a heterozygous (B)
 
genotype are 
shown.  Amplification plots captured in real-time are shown on the top.  Extracted Ct
 
values used to deduce each genotype are presented at the bottom (blue: FAM-labelled 
CFHR3
 
probe, red: VIC-labelled HBB
 
probe) .  The Ct
 
value is where the vertical dotted 
line crosses the x-axis.  Each reaction was carried out in triplicate.    
Figure 7.3 Screening for individuals  
homozygous for the CFHR3/CFHR1
 
deletion.
A sample that is homozygous for the 
deletion with a single band at HBB
 
(D/D)and a sample with ambiguous 





(N/N or N/D).  Each well 
contains 10 μl of PCR product run on a 2% 
agarose mini-gel.  A 100 bp DNA marker is 
shown on the left.  D/D, homozygous for 
deletion; N/N, homozygous non-deleted; 
N/D, heterozygous for deletion.    
219bp
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 Genotyping of the CFHR3/CFHR1 deletion was carried out in triplicate using 
NA from individuals from the Croatian island of Vis, from the Dutch Rucphen 
olate and from the Scottish general population series of AMD cases and controls 
or 
the software package PLINK (Purcell et al., 
ncies were consistent with Hardy- 
einberg equilibrium using a threshold of PHWD < 1.0E-04.  The frequency of the 
FHR3/CFHR1 deleted allele did not differ significantly between the Scottish non-
MD controls (MAF = 0.206) and the Croatian isolate population (MAF = 0.197) (P 
 0.592) (Table 7.1).  The minor allele frequency was significantly higher in the 
utch Rucphen isolate (MAF = 0.295) compared with Vis (P = 1.1E-06).  The 
FHR3/CFHR1 deletion minor allele frequency observed in Scottish cases of AMD 
AF = 0.132) was 36% lower than in the Scottish controls (P = 1.4E-03) (Table 
.1).  The frequency of the deleted allele in the AMD cases was 58% lower than that 
bserved in Croatian sample set (P = 7.2E-04) (Table 7.1).   
QTL Association analysis of CFH in Vis 
enome-wide association analysis of plasma CFH was carried out using the genome-
ide association tool set PLINK (Purcell et al., 2007).  Test of association was 
erformed using 317,509 polymorphisms consisting of 317,503 SNPs from the 
lumina Hap300 array and 6 bi-allelic markers genotyped independently, as 
escribed before.  The aim was to identify quantitative trait loci which affect plasma 
FH concentration and to examine their influence on susceptibility to AMD.     
.2.2.1 CFH SNP genotyping  
ix polymorphisms, including the CFHR3/CFHR1 deletion were genotyped using 
ither the TaqMan® allelic discrimination assay discussed above or by direct 
equencing (Table 7.2).  The aim was to assess the association between plasma CFH 
oncentration and SNPs reported by Li and colleagues (2006) to influence 
usceptibility to AMD. 
D
is
(Table 7.1).  Genotypes of 472 individuals in pedigrees from Vis were checked f
Mendelian inheritance errors using 




























Croatian                                
(N=932)
Dutch                     
(N=866)
Scottish        
AMD Cases           
(N=726)
Scottish            
AMD Controls 
(N=384)
D/D 3.9 5.8 2.5 4.7
N/D 33.3 47.6 21.5 31.8
N/N 62.8 46.6 76.0 63.5









   
   














SNP ID Minor Allele MAF P  (HWD) N
rs2274700 T 0.421 0.777 948
rs1048663 A 0.155 0.861 956
rs412852 C 0.418 1.000 954
rs1066420 G 0.145 1.6E-04 958
Table 7.1 Genotype and allele frequencies for the deletion of the CFHR3/CFHR1
 
in 
four population sample sets.
Summary of the genotype and allele frequencies of the CFHR3/CFHR1
 
deletion using 
unrelated individuals from the Croatian and Dutch isolates, and a cohort of Scottish AMD 
cases and disease-free controls.  N
 
shows the number of chromosomes for which the 
genotyping was carried out. 
Table 7.2 Details of additional (non-Illumina) CFH
 
SNPs genotyped in the Vis 
(Croatian) sample set.
Summary of allele frequencies observed for the CFH
 
SNPs.  These SNPs represent the 
high risk haplotype described by Li and colleagues (Li et al., 2006; Table 2), except for 
the SNP rs1066420 which has replaced rs128054 in the database (NCBI Build 35 
assembly) and was therefore used in the present study.  P-values detected for deviations 
from Hardy Weinberg equilibrium are shown.  MAF, minor allele frequency; HWD, Hardy-
 
Weinberg disequilibrium; N, number of chromosomes.
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A haplotype was identified by Li and colleagues (2006) to affect 
usceptibility to AMD independently of CFH Y402H.  This haplotype consisted of 
nger genome-wide association with AMD than CFH 
Y402H (Li et al., 2006).  Following the publication of the report by Li et al., the SNP 
1280514 was replaced by rs1066420 in the database (NCBI Build 35 assembly).  
aimed to identify the effect on plasma CFH concentration associated with 
FH rs2274700 and the 5-SNP haplotype.  SNPs rs2274700, rs1048663, rs412852 
nd rs1066420 were genotyped as described before (Table 7.2).  SNP rs11582939 
as included in the Illumina Hap300 array.  All genotypes were checked for 
endelian inheritance errors and none were found.  Deviations from Hardy-
einberg equilibrium were also excluded.  CFH rs1066420 was the only SNP which 
howed significant deviation from HWE (PHWD = 1.6E-04).  Direct sequencing of 
amples with ambiguous genotypes was used to exclude the possibility of genotyping 
rrors, and this marker was consequently removed from further analysis.  The only 
ifference in CFH SNP allele frequencies observed between those genotyped in Vis 
nd those reported in HapMap was rs2274700, which had a MAF of 0.42 compared 
ith 0.50 in HapMap. 
.2.2.2 Genome-wide QTL association analysis of CFH 
e-wide association analysis of 317,508 markers was carried out using 966 
 the island of Vis, 58% of whom were members of 122 families 
Figure 7.4).  Twenty-five individuals with missing phenotypes were removed, 
8,984 SNPs were excluded because of low 
and 379 SNPs were removed due to minor allele 
e genome-wide significance threshold 
10 (P) = 6.8 after correction for 308,144 tests using the Bonferroni 
 
 
   
s
five SNPs, rs2274700, rs1048663, rs412852, rs1280514 and rs11582939.  Of these, 
CFH rs2274700 showed stro
rs



















leaving 941 in the final analysis.  
genotyping call rates (<90%) 
frequencies <1% leaving 308,144 SNPs.  Th
was set at –log
correction.        
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Figure 7.4 Results of the genome-wide quantitative trait locus association analysis of 
plasma CFH in the Vis population.
Log10
 
transformed significance values for plasma CFH test of association are presented for 
each chromosome, using the software Haploview.  An association test of 308,144 markers 
was carried out in 941 individuals.  Significant and suggestive thresholds of significance 
(after correction for multiple testing) are represented by red (-log10
 




(P)= 5.0) lines, respectively.    
Table 7.3 Summary table of SNPs showing evidence of genome-wide association with 
plasma CFH.  
Details of SNPs in chromosomal regions showing evidence of significant genome-wide 
associations (P ≤
 







1.0E-04) with plasma CFH concentration.  Analysis was carried 
out in 941 individuals (related and unrelated).  MAF: minor allele frequency, HWD: Hardy 
Weinberg disequilibrium.  SNP positions are based on the NCBI Build 35 assembly.      
SNP Minor 
allele







rs6677604 A 0.209 1q31 193418575 5.19E-56 0.674 CFH  intron 11
rs2026429 C 0.051 1q31 193811328 2.67E-10 0.304 ASPM  Intron 13
rs6003 G 0.049 1q31 193762678 7.95E-10 0.286 F13B  His115Arg
rs1983298 G 0.088 2q35 219981339 3.39E-06 0.306 PTPRN  intron 3
rs358248 T 0.371 4p15 22459983 1.19E-05 0.037 GBA3  intron 4
rs7529369 T 0.077 1q31 192940547 1.39E-05 1.000 KCNT2  intron 2
rs6555300 A 0.486 5p15 4587213 3.59E-05 0.439 Gene desert
rs950493 G 0.166 1p36 6879070 4.18E-05 0.816 CAMTA1  intron 3






Highly significant associations were observed between plasma CFH 
concentration and twelve polymorphisms within the Regulator of Complement 
 
enome-wide significance (P ≤ 1.6E-07) after a Bonferroni correction for multiple 
nd three were located in the ASPM, F13B and KCNT2 genes, 
only the last of which is outside the RCA cluster (Table 7.3).  The polymorphisms 
cated in the CFH or CFH-related genes showed considerably greater genome-wide 
ignificance compared with those in the ASPM, F13B or KCNT2 genes and were 
erefore thought to be better candidates for plasma CFH associations.  All genotypes 
ere consistent with HWE and had genotype call rates above 97%, which excluded 
e possibility of false-positive associations due to genotyping errors.          
Five SNPs in or around the CFH gene showed suggestive genome-wide 
ignificance (P ≤ 1.0E-05) with plasma CFH (Figure 7.5).  Similarly, five SNPs 
howing suggestive genome-wide associations with plasma CFH were found in 
hromosomal regions 2q35 (PTPRN), 4p15 (GBA3), 5p15 (intergenic region), 1p36 
) and 11p15 (intergenic region) (Table 7.3).  
The most significant association with plasma CFH was obtained with SNP 
6677604 which is located in intron 11 of the CFH gene (P = 5.2E-56) (Figure 7.4 
nd Table 7.3).  Another SNP, rs2026429, which is located in intron 13 of the 
bnormal Spindle-like Microcephaly-associated (ASPM) gene also showed a 
enome-wide significant association with plasma CFH (P = 2.7E-10) (Table 7.3).  
his SNP has a relatively low minor allele frequency (MAF) of 0.051 and may 
erefore be more likely to be a false-positive.  However, the region of 1q31 shows 
nusually strong linkage disequilibrium (Figure 7.5).  SNP rs6003, a coding variant 
f the F13B gene which encodes the coagulation Factor XIII B protein, was also 
und to be significantly associated with changes in plasma CFH concentration (P = 
.9E-10).  Rs6003 is a non-synonymous coding SNP in F13B which is associated 
ith a H115R substitution in the protein although it is less common in this sample set 
ith a minor allele frequency of 0.049 (Table 7.3) and could therefore be a false-
ositive.  SNP rs7529369 which lies upstream of CFH was also a significant hit from 
e genome-wide association analysis (P = 1.4E-08) (Table 7.3).   
Activation (RCA) cluster in chromosomal region 1q31, each with P-values meeting
g
testing (Figure 7.4 and Figure 7.5).  Nine of these were located at or near the CFH 




































Figure 7.5 High resolution view of the Regulator of Complement Activation (RCA) 
cluster on 1q31 and SNPs associated with plasma CFH concentration in Vis.
Transformed
 
p-values for the test of association in 472 unrelated individuals are shown. 
Thresholds for significant (P≤1.6E-07) and suggestive (P≤1.0E-05)
 
genome-wide 
association are marked with red and blue lines respectively. The
 
genomic context including 
the CFH
 
gene cluster is also shown. Blue arrows represent direction of transcription.  
Figure 7.6 Differences in plasma CFH 
concentration associated with rs6677604 
genotypes.
Box plots showing differences in plasma CFH 
concentrations between the three genotype groups 
of CFH
 
SNP rs6677604. The minor allele A is 
shown to be associated with an increase in 
concentration under an additive model. The bars 
represent the range from the smallest to the largest 
non-outlier measurement. Empty circles show the 
5% extremes of the distribution. N
 
shows the 













































rs10801555 rs412852 (Li et al., 2006)
rs1066420 (Li et al., 2006)rs1048662 (Li et al., 2006)rs11582939 (Li et al., 2006)
N=285 N=149 N=17
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This SNP is located in intron 2 of the gene encoding a Potassium Channel protein of 
e subfamily T number 2 (KCNT2), which is expressed mainly in the human brain.  
tase 
eceptor type N (PTPRN) gene also showed suggestive genome-wide significance 
which 
k associations but included several SNPs forming a peak with at least 
two SNPs showing P-values below 1.0E-04.  SNP rs358248 is an intronic SNP in the 
Beta-Glucosidase Acid 3 (GBA3) gene with a minor allele frequency of 0.37 (P = 
1.2E-05) (Table 7.3).  GBA3 encodes a cytosolic beta-Glucosidase enzyme which is 
predom antly expressed in the liver.  SNP rs950493 is also an intronic SNP in the 
Calmodulin binding Transcription Activator 1 (CAMTA1) gene (P = 4.2E-05) (Table 
7.3).  The protein product acts as a transcription factor that interfaces with the 
calcium tem of the cell to alter gene expression patterns and has been 
implicated in human episodic memory function (Huentelman et al., 2007).  The 
remaining two SNPs, rs6555300 (P = 3.6E-05) and rs1487204 (P = 5.3E-05), both 
lie outside any known genes.  SNP rs6555300 is located in a gene desert and 
rs187204 is 139 kb from the nearest gene (Table 7.3).   
leven SNPs showing genome-wide significant associations with plasma 
CFH (P ≤ 1.6E-07) spanned a region of about 300 kb containing the CFH gene 
cluster including four of the CFH-related genes (CFHR1-5) (Figure 7.5 and Table 
7.4).  The strongest association was with SNP rs6677604 which is located in intron 
11 of CFH and explains about 28.3% of the phenotypic variance after adjusting for 
fixed effects and covariates (P = 1.4E-36) (Table 7.4).  The rs6677604 A (minor) 
allele was associated with a 59.4 μg/ml increase in mean plasma CFH level under an 
additive model.  Less common polymorphisms identified in F13B and ASPM genes 
were also associated with large changes in mean plasma CFH concentration reaching 
enome-wide significance due to their low allele frequencies (Table 7.4).  
ifferences in plasma CFH concentration associated with genotypes of the CFH SNP 
6677604 are presented in box-plots in Figure 7.6.  The diagram shows a 
rogressive increase in plasma CFH concentration associated with each copy of 
6677604 allele A, with the highest levels being associated with the AA genotype.   
 
th
SNP rs1983298 which lies in the third intron of the Protein Tyrosine Phospha
R































































































































































































































































































































































































































































   




























   








   
   
   
   
   




























































































































































































































































































































































































































































































































































































































































Three of the remaining eight genome-wide significant associations occurred outside 
7.9E-19) and rs4086175 (P = 
4.5E-18) which are upstream of the CFHR4 and CFHR2 genes, respectively (Table 
.4).  CFH rs2274700 was found to be the only coding variant showing significant 
enome-wide association (P = 2.8E-12), explaining about 14% of the phenotypic 
ariance and encoding an Ala473Ala synonymous substitution within CFH exon 10 
).  Five other SNPs, including the SNP rs1061170 (CFH Y402H) reached 
uggestive genome-wide significance for association (P ≤ 1.0E-05) (Figure 7.5 and 
).   
.2.2.3 Analysis of linkage disequilibrium across the CFH locus 
arkers spanning the CFH and CFH-related genes were 
 assess the extent of pairwise linkage disequilibrium (LD) in the region.  The 
is was carried out using the software Haploview® (Barrett et al., 2005) in 492 
 the Vis sample set (Figure 7.7).  LD was measured in 
s of r2 so that the relationship between markers was not affected by differences 
Section 2.5.10.  Five haplotype blocks were 
LD and SNP haplotypes with a frequency 
wn in Figure 7.7.  Pairwise LD between SNP rs6677604 and 
orphisms reported in the literature to affect susceptibility to AMD including 
CFHR3/CFHR1 deletion (Hughes et al., 2006), SNP rs1061170 (CFH Y402H) 
et al., 2005; Edwards et al., 2005; Klein et al., 2005, Zareparsi et al., 2005a) 
CFH rs2274700 (Li et al., 2006) was specifically assessed.  The CFHR3/CFHR1 
 in strong LD with CFH rs6677604 (r2 = 0.84) and occurred 
e haplotype block.  The most common haplotype harbouring the rs6677604 
inor (A) allele and the CFHR3/CFHR1 deleted allele was found to have a 
This haplotype also contained the CFH 
402) allele, previously shown to have a protective effect on AMD.  
D was found to be relatively weak (r2 < 0.35) between rs6677604 and 
 
the CFH gene (Figure 7.5).  These included the deletion of the CFHR3/CFHR1 














in allele frequencies, as explained in 
constructed, based on a solid spine of 





deletion was found to be
in the sam
m
frequency of 0.12 in the Vis sample.  
rs1061170 T (Tyr
Pairwise L




CFHR3 CFHR1 CFHR4 CFHR2 CFHR5
Block 2 Block 3 Block 4 Block 5
Figure 7.7 Analysis of linkage disequilibrium across the CFH
 
locus based on the 
analysis of 492 unrelated individuals from Vis island. 
Pairwise LD is shown in terms of the squared correlation coefficient (r2) between 28 markers 
spanning CFH
 
and CFH-related genes. Five haplotype blocks were constructed based on a
 
solid spine of LD and the tagging markers for each haplotype are
 
marked with grey vertical 
arrow heads. Inter-block LD is also presented. The frequency of each haplotype is shown 
next to it in grey.  CFH
 
genomic regions and the position of markers are shown at the top.  
Markers showing significant genome-wide association are marked with red asterisks.  Black 
squares represent high LD (r2>0.70) with fading colours showing reduction in LD. The level of
 
pairwise LD is shown inside each square. Alleles of the CFHR3/CFHR1
 
deletion are encoded 
as C, deleted and A, non-deleted. Analysis was carried out using the software Haploview.
* ** * ***
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Figure 7.7 also shows the seven markers showing genome-wide significant 
ssociations with plasma CFH concentration (marked by red asterisks), represented 
rkers 
occurred in haplotype block 2.  A further haplotype analysis was carried out firstly to 
assess whether the variance observed in plasma CFH was better explained by CFH 
rs6677604 alone, or by a haplotype containing this SNP.  Secondly, a haplotype 
analysis was carried out to assess whether the effect of rs6677604 on plasma CFH 
was independent from that of other variants found in the genome-wide association 
analysis to be significantly associated with plasma CFH. 
 
7.2.2.4 Identification of a multi-marker model for plasma CFH 
concentration 
 
Multi-m sis of plasma CFH was carried out, firstly using the “backward” 
stepwise linear regression methodology implemented in the statistical software SPSS 
v.12.  Analysis of “backward” regression was based on the probability of P > 0.05 of 
the model’s F-ratio as a removal criterion of a component.  The F-ratio is calculated 
by dividing the average improvement in prediction by the model (MSM) by the 
average difference between the model and the observed data (MSR).  All SNPs as 
well as e fixed effect sex and covariates age and BMI were initially included in the 
model and the contribution of each predictor was assessed based on the significance 
value o or that predictor.  The significance value was checked against the 
removal criterion for F (P > 0.05) and if a predictor (SNP or covariate) was not 
making a statistically significant contribution to how well the model predicted the 
outcom  variable it was removed and the model was re-estimated for the remaining 
predictors.  The contribution of the remaining model components was then re-
assessed.   
n important assumption in linear regression analysis is the normality of the 
distribution.  Plasma CFH distribution was checked for normality using the 
Kolmogorov-Smirnov test.  The test statistic with the null hypothesis of a non-
normal distribution was found to be non-significant at the 1% level (P = 0.01).  
94 unrelated individuals from the island of Vis were included in the analysis 
and 22 were removed due to low genotyping call rates (< 90%).  Twenty-seven bi-
a










luded in this model.  The 
arker data was then checked for collinearity, which exists when there is a strong 
el (Section 
timate collinearity between predictors, 




markers, spanning the CFH and CFH-related genes, were included in the 
multi-marker analysis as covariates in a model assuming an additive effect of the 
minor allele (1 d.f.).  Age and BMI were included as covariates.  Sex was analysed as 
a fixed effect.   
Twenty models with different combinations of predictors were assessed.  The 
best model which explained the highest proportion of the phenotypic variance, 
consisted of six SNPs, age and BMI (Table 7.5).  Age and BMI were found to 
significantly correlate with plasma CFH concentration in this model (P < 0.05).  The 
most strongly associated SNP, rs6677604, was also inc
m
correlation between two or more predictors in the regression mod
2.5.7.2.1).  Two parameters were used to es
the variance inflation factor (VIF) and tolerance (1/VIF).  VIF indicates whether a 
predictor has a strong linear relationship with the other predictor(s).  VIF values 
greater than 10 are taken as indicative of redundant predictors (Myers, 1990).  
Similarly, values of the tolerance statistic below 0.1 are indicative of collinearity 
(Menard, 1995).  Markers rs3766404 and rs7517126 were found to contain redundant 
information (VIF > 10).  This was also evident from the high level of pairwise LD 
between these two SNPs (r2 = 0.84) (Figure 7.7).  However, removal of SNP 
rs3766404 resulted in a reduction of the VIF below 10 indicating that the effect 
associated with SNP rs3766404 was now fully explained by SNP rs7517126.  
Furthermore, the effect of SNP rs3766404 would be accounted for by the high 
pairwise LD between rs3766404 and rs7517126 (r2 = 0.85) and to a lesser extent 
between rs3766404 and rs6677604 (r2 = 0.58).   
A univariate analysis of variance approach was used to validate the above 
model and to evaluate the 
is was carried out as part of the general linear model (GLM) methodology 
implemented in the software SPSS v.12.  Five SNPs, rs1292487, rs6677604, 
rs7517126, rs10801575 and rs6667243, were used in a test of between-subject 
effects, under an additive model (1 d.f.), including age and BMI as signif
tes (Table 7.6).   
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Table 7.5 Results of the linear regression test for collinearity
 
of markers used in 
the analysis of plasma CFH.
27 markers spanning CFH
 
and the CFH-related genes together with age, sex and BMI 
were used in a “backward” linear regression analysis. The table shows the model which 
explained the highest proportion of the plasma CFH phenotypic variance. A test of 
collinearity was also carried out to detect SNPs which carried redundant information. 
CFH rs3766404 was removed from further analysis due to its high variance inflation 
factor (VIF >10). β
 
shows the changes in mean plasma CFH concentration under an 
additive model of the minor allele for each SNP. t-statistics and their significance values 
(P) are also shown. VIF (variance inflation factor) and tolerance are explained in the text.  
Regression analysis was carried out using the statistical software SPSS v.12.0.
Table 7.6 Results of the univariate analysis of plasma CFH using
 
a multi-marker 
model obtained by ‘backward’ regression analysis.
Non-redundant, significant markers from the ‘backward’ linear regression analysis were 
tested in a multi-marker analysis of plasma CFH concentration in the Croatian sample 
set. R2
 
represents the proportion of the phenotypic variance explained by each 
component. R2model
 
is a measure of how much of the variability in the trait distribution is 
accounted for by the model. For adjusted R2model
 
see text. F-statistics and their 
significance value (P) are also shown. Regression analysis was carried out using the 
statistical software SPSS v.12.0.
β (μg/ml) S.E. t-test P Tolerance VIF
Age 0.54 0.19 2.87 4.4E-03 0.956 1.05
BMI 2.96 0.63 4.68 4.2E-06 0.957 1.05
rs1292487 17.02 7.30 2.33 2.0E-02 0.341 2.93
rs3766404 -41.88 19.80 -2.12 3.5E-02 0.082 12.24
rs6677604 61.96 9.54 6.49 3.2E-10 0.253 3.95
rs7517126 58.40 17.79 3.28 1.1E-03 0.097 10.30
rs10801575 -27.40 8.02 -3.42 7.2E-04 0.230 4.35
rs6667243 14.77 7.07 2.09 3.7E-02 0.273 3.67
Collinearity Statistics
Type III Sum 
of Squares d.f. Mean Square F P R
2
rs1292487 6159.4 1 6159.4 2.51 1.1E-01 0.006
rs6677604 170912.8 1 170912.8 69.73 9.6E-16 0.140
rs10801575 14109.5 1 14109.5 5.76 1.7E-02 0.013
Age 27548.7 1 27548.7 11.24 8.7E-04 0.026
BMI 71042.7 1 71042.7 28.99 1.2E-07 0.064
R2model = 0.380 (Adjusted R2model = 0.369)
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All SNPs in the 5-marker model excluding rs6667243 (P > 0.05) and rs7517126 (P > 
.05) were found to be significantly associated with plasma CFH concentration.  The 
est model therefore consisted of the SNP rs1292487, located 1.6 kb upstream of 
CFHR4, and the covariates age and BMI.      
The proportion of phenotypic variance explained by the full model 
ponents was estimated at 38% (R2model=0.38) (Table 7.6).  The adjusted R2 
erived from the population from which the 
ample was taken.  Therefore, the difference of 1.1% between the R2model and the 
djusted R2model shows that if the model were derived from the population rather than 
 sample it would account for approximately 1.1% less variance in the outcome.  
his means that the model was a good predictor of the correlation between model 
omponents and the trait distribution at the population level.  When the three SNPs 
ere included in the model, without the covariates, the adjusted R2 value was 
stimated to be 29.2% which did not significantly differ from the effect of the single 
NP (R2rs6677604 = 28.3% (Table 7.4)).  The marker data was checked for all 
ignificant 2-way interactions using the same methodology and none were detected.  
he three remaining SNPs in the best model, rs1292487, rs6677604 and rs10801575, 
ere then used in a conditional haplotype analysis of plasma CFH concentration with 
ge and BMI as covariates, which is described below.  
.2.2.5 Haplotype-based association analysis of CFH 
he 3-SNP model identified by ‘backward’ regression was used in a haplotype 
ssociation analysis using the conditional haplotype-based testing tool, implemented 
e software package PLINK (Purcell et al., 2007).  The underlying theory of 
aplotype analysis in PLINK has been described in the Section 2.5.7.3. 
Six common haplotypes (minor haplotype frequency (MHF) ≥ 0.01), out of a 
ossible total of 8, were identified in 410 unrelated individuals from Vis (Fmodel = 




CFH; SNP rs6677604, in intron 11of the CFH gene and SNP rs10801575 located 4.4 
kb upstream of 
com
accounts for the model complexity and shows that 36.9% of the trait variance would 



































































































































































































































































































































































































































































   
   






   
   
   









   
   
   


































































































































Age and BMI were included as covariates in the analysis.  Sixty-two individuals 
s identified using SNPs rs1292487, rs6677604 
and rs10801575 were associated with an increase in mean plasma CFH concentration 
TAT = 55.51 μg/ml, P = 1.1E-26; βTAC = 16.24 μg/ml, P = 2.9E-04) (Table 7.7).  
our out of the six haplotypes were associated with reductions in mean plasma CFH 
n (Table 7.7).  However, only TGT (β = -65.58 μg/ml, P = 1.5E-03) and 
β=-58.11 μg/ml, P=2.1E-09) resulted in a significantly decreased plasma CFH.      
The effect of each common haplotype on plasma CFH concentration, 
CFH Y402H and CFHR3/CFHR1 deletion polymorphisms, was 
ing the conditional haplotype association test implemented in the 
et al., 2007).  Conditional association 
a CFH and the TAT haplotype, given the rs1061170 (CFH Y402H) 
t, showed that the effect associated with the haplotype was independent of 
P = 2.3E-23) (Table 7.7).  In other words, the reduced associated with 
plotype was still highly significant in the absence of the rs1061170 (CFH 
ct.  The decrease observed in the significance value can be explained by 
 freedom of the model. 
The most common haplotype, TGC (MHF = 0.481) was associated with a 
μg/ml in plasma CFH concentration and was also found to have an 
P = 2.3E-03) from that of CFH rs1061170 (Y402H) (Table 7.7).   
A test of association between the TAT haplotype and plasma CFH, 
onditional on the CFHR3/CFHR1 deletion polymorphism resulted in a sharp fall in 
e P-value (P = 5.3E-03), however the haplotype effect on plasma CFH remained 
absence of the deletion polymorphism 
) despite a high level of pairwise LD between the two polymorphisms (r2 
 0.84) (Figure 7.7).  In contrast, the effect associated with the TGC haplotype was 
nditioned on the deletion polymorphism, indicating that the 
aplotype effect is not independent (P = 0.088) (Table 7.7).  Some of the decrease in 
-value could however be the result of reduction in the number of degrees of 
reedom in the test.  The TGT haplotype however, remained significant when 
orphism (P = 0.038).  
were removed due to low genotyping call rate (< 90%).   
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7.2.3 QTL analysis of plasma CFH in the Dutch sample set 
 
Plasma CFH concentrations were m




easured in 500 unrelated individuals from a 
Dutch isolated (Rucphen) population, and used as a replication series to validate the 
genotyped as described in the next ection.  Information on age and sex of the 
individual samples was also obtained, as shown in Table 2.1. 
 
7.2.3.1 Genotyping of markers 
 
A total of eight markers were selected to be genotyped in the Dutch samples.  These 
included the most significant SNP associations from the genome-wide association 
analysis, the CFHR3/CFHR1 deletion polymorphism and rs1061170 (CFH Y402H).  
Attempts to design a genotyping assay for rs4086175 were unsuccessful and this 
SNP was consequently excluded from the analysis.  CFH SNP rs2274700 was 
genotyped by direct sequencing. 
 
7.2.3.2 Single marker association analysis of plasma CFH 
 
marker association with plasma CFH was carried out using the linear 
regression methodology implemented in the genome-wide association software 
package PLINK v.0.99s.  The results confirmed the findings of the Vis population 
 set since CFH SNP rs6677604 was the most significantly associated marker 
(P = 4.9E-25) (Figure 7.8).  CFH rs1061170 was also found to be significantly 
associated with differences in plasma CFH concentration in this sample set (P = 
1.8E-04) (Table 7.8). 
 The effect of individual markers associated with plasma CFH concentration 
in the Dutch sample set was assessed in a univariate analysis of variance.  Age was 
used as a significant covariate for plasma CFH in all analyses (Table 7.8).  CFH 
SNP rs6677604 was found to explain 21.8% of the phenotypic variance (P = 4.9E-
25).  Allele frequencies of the markers were generally similar between the two 
population samples except for the CFHR3/CFHR1 deletion polymorphism (MAFVis = 
0.197 compared with MAFRucphen = 0.295) (Table 7.8). 
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Figure 7.8 Plasma CFH association test and linkage disequilibrium analysis in the 
Dutch (Rucphen) isolate.  
Results of the association analysis of plasma CFH concentration in 453 unrelated Dutch 
individuals. The significance threshold after correction for multiple testing using the 
Bonferroni correction, is marked by the red line. Two markers rs2274700 and rs7517126 
were excluded from the analysis due to low genotyping call rates
 
(< 90%). Pairwise 
linkage disequilibrium (LD) between each of the seven markers is
 
shown in terms of the 












Marker ID Minor Allele MAF R2 p N
rs6677604 A 0.211 0.218 4.90E-25 896
CFHR3/CFHR1 
deletion D 0.295 0.132 1.26E-14 866
rs3766404 C 0.167 0.113 5.01E-13 898
rs1329428 T 0.453 0.091 2.75E-10 860
rs7517126 G 0.132 0.101 1.05E-09 722
rs2274700 T 0.434 0.086 6.07E-06 470
rs1061170 C 0.322 0.032 1.78E-04 898
Table 7.8 Single marker associations with plasma CFH concentration in the Dutch 
(Rucphen) isolate.  
Results of single marker univariate regression analysis in unrelated Dutch individuals.  All 
analyses included age as a significant covariate for plasma CFH levels.  Minor allele 
frequencies (MAF) are shown for each marker.  R2
 
represents the proportion of 
phenotypic variance explained by each marker and the significance value (P) for the 
association.  N
 
is the number of chromosomes of unrelated individuals analysed.
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The SNP rs6677604 was found to explain a slightly smaller proportion of the 
ariance in plasma CFH in the Rucphen population (R2 = 21.8%) compared with Vis 
2 = 28.3%) despite having the same minor allele frequency in both populations 
AF = 0.21).   
er levels of pairwise LD than in the Vis sample set.  CFH SNPs 
rs2274700 and rs1329428 (r2 = 0.65), and rs6677604 and CFHR3/CFHR1 deletion 
2 = 0.60), were the only pairs of markers with detectable LD.   
.2.4 Analysis of CFH association with AMD 
ssociation analysis was carried out in 382 cases of age-related macular 
egeneration (AMD) and 201 sex and age-matched disease-free controls.  The 
verage age of individuals in the series was 75.6 years (± 9.5 SD) in cases and 73.1 
ears (± 8.0 SD) in controls (Table 2.1).  All individuals were unrelated and of 
cottish ethnicity.  The criteria used for assessing disease status and AMD grading 
ere described in Section 2.2.   
Twenty-five SNPs, including those from other genes previously found to 
fluence susceptibility to AMD had previously been genotyped in all samples.  
even new markers including six SNPs and the CFHR3/CFHR1 deletion 
olymorphism were added to the genotype data.  Details of allele frequencies and the 
sults of the case-control association analyses are summarised in Table 7.9.  Using a 
isher’s exact test of association, the association showing the highest significance 
as observed with the rs1061170 (CFH Y402H) variant (OR = 2.23, CI: 1.73 - 2.90, 
 = 7.1E-10) which explained 6.8% of the AMD disease variance estimated by the 
orrelation coefficient of the logistic regression η2 (Table 7.9, Figure 7.9).  Five 
arkers including CFH rs3766404 (OR = 0.49, CI: 0.33 - 0.73, P = 3.9E-04; η2 = 
P = 3.3E-05; η2 = 0.034), rs6677604 
P = 4.6E-04; η2 = 0.022), CFHR3/CFHR1 deletion (OR 
P = 1.4E-03; η2 = 0.017) and rs7517126 (OR = 0.51, CI: 0.34 
0.76, P = 1.3E-03; η2 = 0.023) were all found to exhibit significantly protective 

























0.025), rs2274700 (OR = 0.55, CI: 0.42 - 0.73, 
(OR = 0.53, CI: 0.38 - 0.75, 
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Figure 7.9 Test of association in unrelated cases of AMD and controls.
Plot of log10
 
-transformed P-values for Fisher’s exact test of single-marker association 
using 382 unrelated cases of AMD and 201 disease-free controls are shown. The 
significance threshold after Bonferroni correction for multiple testing is marked with a red 
line. Linkage disequilibrium (LD) between markers used in the analysis is shown below, 
and on the association plot, as pairwise squared correlations (r2). SNP 9 (rs1066420) is 






































Analysis of linkage disequilibrium in the Scottish samples showed that 
ssociated SNPs fell into three groups of LD (r2 > 0.70) (Figure 7.9).  The first group 
52 (SNP # 7), 
both significantly increasing the risk of AMD with ORs of 2.23 (95% CI 1.7 - 2.9) 
and 2.04 (95% CI 1.6 - 2.6), respectively.  The second group consisted of CFH 
rs1329428 (SNP # 6) and rs2274700 (SNP # 4) both showing a protective effect 
against AMD.  CFH rs1329428 (P = 7.6E-09) was found to be more significantly 
associated with AMD than rs2274700 (P = 3.3E-05).  The third LD group consisted 
of a number of markers with lower but still significant effects on disease 
predisposition.  These included CFH rs3766404 (SNP # 1), rs6677604 (SNP # 5), 
CFHR3/CFHR1 deletion (SNP # 10) and rs7517126 (SNP # 11).  Interestingly, 
markers in the third group all showed highly significant associations with plasma 
CFH concentration, resulting in a large increase in the mean plasma CFH 
concentration (Figure 7.10).  Figure 7.10 shows that the change in the direction of 
effect on AMD susceptibility correlates strongly with the change in the direction of 
effect on plasma CFH concentration.  Three SNPs, rs1048663 (# 3), rs11582939 (# 
8) and rs1066420 (# 9) which formed components of the 5-SNP haplotype of Li et al. 
(2006), were found to be effectively neutral in their effects on AMD and plasma 
CFH concentration (Figure 7.10).  The results suggest that plasma CFH 
concentration and CFH rs1061170 are acting as combinational factors influencing 
susceptibility to AMD.  Furthermore, plasma CFH concentration was found to 
explain % of the AMD disease variance (P = 1.7E-03) (Table 7.10).  CFH 
rs1329428 (# 6) in intron 15 was the only SNP which was found to show a highly 
ith both AMD and plasma CFH concentration (Figure 7.10). 
Logistic regression analysis of AMD susceptibility factors in the Scottish 
ed using the binary logistic regression methodology implemented 
PSS v.12 and odds ratios (OR) were calculated 
efficient of the logistic regression (β).  The results confirmed CFH SNP 
ARMS2 SNP rs10490924 on chromosome 10q26 as the 
tibility loci for AMD (Figure 7.11).    
a





in the statistical software package S
using the co



















































Figure 7.10 The relationship between AMD odds ratios and the effects on plasma 
CFH concentration associated with single variants.
Diagram shows the sharp change in the direction of effect on AMD
 
susceptibility (odds 
ratios) correlating with the direction of effect on plasma CFH concentration (shown by β, 
the numbers in parentheses). The results suggest that plasma CFH concentration and 
CFH
 
rs1061170 (Y402H) could be influencing AMD susceptibility in a combinational 
manner. Numbers correspond to rs3766404 (1), rs1061170 (2), rs1048663 (3), 
rs2274700 (4), rs6677604 (5), rs1329428 (6), rs412852 (7), rs11582939 (8), rs1066420 
(9), CFHR3/CFHR1
 
deletion (10), rs7517126 (11), rs4086175 (12).   
Table 7.10 Association between plasma CFH and AMD in the Scottish cohort.
Plasma CFH concentration is shown to significantly explain 1.8% of the AMD disease 
variance in 352 unrelated cases of AMD and 198 controls (P
 
= 1.7E-03). The result was 
obtained using a t-test in a linear regression analysis. β
 
is the regression coefficient of the 
binary trait and its standard error (SE), η
 
is the proportion of the binary trait variance 
explained by the covariate (plasma CFH). Analysis was carried out using the software 
SPSS v.12.
Parameter β S.E. t P η
Plasma CFH 
concentration 0.0011 0.0004 3.15 1.7E-03 0.018





































































































































































































































































































































































































































































































































The odds ratios (OR) for CFH Y402H CC and CT genotypes, relative to the 
T genotype, were found to be 6.5 (95% CI 3.5 - 11.9, P = 1.5E-09) and 4.1 (95% CI 
.3 - 7.3, P = 1.8E-06), respectively.  Similarly an OR of 7.9 (95% CI 3.5 - 17.9, P = 
 
omozygotes.  Age and smoking were found to be associated with increased risk of 
MD with ORs of 1.8 (95% CI 1.2 - 2.7, P = 0.002) and 1.4 (95% CI 0.9 - 2.0, P = 
.075), respectively (Figure 7.11).  Results of the logistic regression analysis of the 
ffects of CFH polymorphisms rs1329428, rs2274700 and rs6677604, and the 
FHR3/CFHR1 deletion polymorphism were consistent with the findings of Fisher’s 
xact test of association performed earlier (Figure 7.11).  Tests of interaction 
etween CFH SNPs rs1061170 (Y402H), rs2274700, rs6677604 and the 
FHR3/CFHR1 deletion polymorphism were indicative of an independent effect 
ssociated with the rs1061170 (CFH Y402H) SNP (ORY402H*rs2274700 = 6.1, 95% CI 
.3 - 11.2, P = 7.9E-09; ORY402H*rs6677604 = 6.2, 95% CI 3.3 - 11.4, P = 4.9E-09; 
RY402H*deletion = 6.3, 95% CI 3.4 - 11.8, P = 7.8E-09) (Figure 7.11). 
Analysis of the association between plasma CFH and AMD showed that the 
west quartile of plasma CFH concentration (0 - 25%), relative to the highest 
uartile (75 - 100%), was associated with an increased risk of AMD with an OR of 
.1 (95% CI 1.3 - 3.4, P = 0.003) (Figure 7.11).  Tests of interaction between plasma 
FH quartile and rs6677604, rs2274700 and rs6677604*rs2274700 resulted in ORs 
f 2.2 (95% CI 1.3 - 3.6, P = 0.003), 2.2 (95% CI 1.3 - 3.9, P = 0.005) and 2.5 (95% 
I 1.4 - 4.4, P = 0.002).  These results suggest that the effects associated with CFH 
6677604 and rs2274700 on AMD susceptibility can both be explained by their 
ffects on plasma CFH concentration.  Test of interaction between CFH quartiles and 
FH Y402H showed an OR of 4.3 (95% CI 1.8 - 10.0, P = 0.001) compared with 
FH quartiles alone (OR = 2.1, 95% CI 1.3 - 3.4) or CFH Y402H alone (OR = 6.5, 
5% CI 3.5 - 11.9) (Figure 7.11).  The results suggest an antagonistic model for the 
ffects associated with CFH SNP rs1061170 and low plasma CFH concentration 
ince an interaction between the two resulted in a lower odds ratio than the one 
bserved for rs1061170 alone.  High CFH concentration (75 - 100% quartile) 
ombined with the CFH 1061170 (Y402H) low-risk genotype (TT) resulted in a 
decreased risk of AMD compared with either alone.  Finally, low concentrations of 
T
2





























as observed at 
the hap
 CFH (0 - 25% quartile) combined with the CFH 1061170 (Y402H) low-risk 
genotype (TT) resulted in an intermediate risk of AMD. 
7.2.4.1 Analysis of haplotype association with AMD 
 
Analysis of interactions between CFH and flanking SNPs associated with AMD 
susceptibility was carried out in 382 Scottish cases of AMD and 201 age, sex and 
ethnicity-matched disease-free controls.  Firstly, disease association between 5-SNP 
haplotypes (rs1048663, rs2274700, rs412852, rs11582939 and rs1066420) reported 
by Li et al. (2006) to be more strongly associated with AMD than CFH rs1061170 
(Y402H) alone was partially replicated in the Scottish series.  The fifth SNP in the 
haplotype, rs1066420, used by Li et al. was excluded from the current analysis due to 
deviation from Hardy- Weinberg equilibrium (PHWD < 0.0001).  Haplotype 
association with AMD was carried out using the haplotype association tool set in 
PLINK (Purcell et al., 2007), which identified one risk and two protective haplotypes 
(Table 7.11).  The risk (GCCC, OR = 1.47 P = 6.8E-08) haplotype w
lotype frequency of 0.516 and the two protective haplotypes, GTTC (OR = 
0.654 P = 3.5E-06) and GCTC (OR = 0.205, P = 1.8E-03), were observed at minor 
haplotype frequencies (MHFs) of 0.294 and 0.016, respectively (Table 7.11).     
 Secondly, conditional haplotype association was used to assess the 
relationships between AMD susceptibility loci and haplotypes, particular CFH SNPs 
such as rs1061170 (Y402H), rs6677604 and the CFHR3/CFHR1 deletion 
polymorphism.  A test of AMD association using the 4-SNP haplotypes showed that 
the effects associated with the GCCC and GTTC haplotypes were not significant 
when conditioned on the CFH Y402H variant (PGCCC = 0.951, PGTTC = 0.200) (Table 
7.11).  In other words, the effects of the two haplotypes were fully explained by CFH 
rs1061170 (Y402H).  The effect associated with the less common protective 
haplotype, GCTC (MHF = 0.016) was suggestive of being independent from the 
CFH rs1061170 (Y402H) variant (P = 0.004).  The effect on AMD susceptibility 
associated with each of the 4-SNP haplotypes was still significant when conditioned 
on the CFHR3/CFHR1 deletion polymorphism (PGCCC = 1.5E-05) and CFH 
rs6677604 (PGCCC = 1.7E-05) indicating that they are not explained by this deletion 






























































































































































































































































































































































































































































































































































7.2.5 AMD association analysis in the Japanese series 
CFH and AMD were conducted in a small Japanese 
l series in order to assess whether the polymorphisms affecting plasma 
Japanese population, alone explaining the lack of power to detect significant 
 in the Japanese population.  DNA samples of 
0 unrelated AMD cases (mean age of 77.3 years, 16.7% female) and 58 unrelated 
ge-matched controls (mean age of 76.6 years, 60.3% female) of Japanese origin 
ere genotyped for association between CFH or ARMS2 and AMD.  Genotyping was 
arried out by Dr. T. Iwata at the National Institute of Sensory Organs, in Tokyo due 
 Japanese restrictions on the export of DNA samples.  The AMD grading criteria 
sed for disease diagnosis were described in Section 2.2. 
Analysis of SNP frequencies in these unrelated Japanese samples showed that 
e minor allele frequencies of SNPs rs1061170 (CFH Y402H) (minor allele 
equency (MAF) = 0.043), rs412852 (MAF = 0.052), rs3766404 (MAF = 0.086) and 
6677604 (MAF = 0.043) were significantly reduced compared to those observed in 
e Scottish samples (Table 7.12).  In contrast, higher MAFs were observed for 
10490924 (MAF = 0.336), rs1048663 (MAF = 0.414) and rs11582939 (MAF = 
.422) (Table 7.12).  A test of association with AMD was carried out using 10 SNPs 
panning the CFH gene or the ARMS2 SNP rs10490924 located on chromosome 
0q26.  Two of the SNPs, rs7517126 and rs4086175, were removed due to low 
inor allele frequencies (MAF < 0.01).  SNP rs1066420 was found to deviate 
ignificantly from Hardy-Weinberg equilibrium (P < 0.001) and was hence removed.  
he allelic model was found to be the most suitable model for the test of association 
fter comparing the significance of the allelic, dominant, recessive and genotypic 
odels, using the software package PLINK v1.0 (Purcell et al., 2007).   





Tests of association between 
case-contro
CFH in Croatian and Dutch samples were present at a different frequency in the 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
238
SNPs rs1061170 (CFH Y402H) and rs10490924 (ARMS2) were found to be 
e only significantly associated markers in the Japanese series, using a Fisher’s 
). 
The results of the AMD association analysis in the Japanese series showed that 
FH SNP rs1061170 C allele increased the risk of AMD with an OR of 3.41 (95% 
I 1.06 - 10.95, P = 0.037).  Similarly, rs10490924 (ARMS2) T allele was shown to 
crease the risk with an OR of 2.82 (95% CI 1.19 - 4.27, P = 0.015).  The –log10 of 
e significance threshold for the test of association was set at 2.20 (P = 0.006) after 
onferroni correction for eight tests.  None of the eight markers passed the threshold 
f significance because of the small sample size.  However, the same risk and 
rotective odds ratios as those found in the Scottish AMD series were also observed 
 the Japanese series.  SNPs rs1061170 (CFH Y402H) (OR = 3.41, 95% CI 1.06 - 
0.95, P = 0.037), rs412852 (CFH) (OR = 2.82, 95% CI 0.93 - 8.56, P = 0.077) and 
10490924 (ARMS2) (OR = 2.26, 95% CI 1.19 - 4.27, P = 0.015) were found to 
onfer risk.  In contrast, SNPs rs1329428 (CFH) (OR = 0.69, 95% CI 0.37 - 1.29, P 
 0.268), rs3766404 (CFH) (OR = 0.56, 95% CI 0.15 - 2.11, P = 0.547) and 
6677604 (CFH) (OR = 0.38, 95% CI 0.04 - 3.29, P = 0.665) were found to have 
rotective effects against AMD.  The results are therefore similar to those in 
aucasian samples although the small sample size reduced the power to detect 
ignificant associations with the same SNPs.   
.3 Summary and discussion  
 this chapter, the results of a whole-genome association analysis of plasma CFH 
ere presented.  Tests of association were carried out using 317,503 biallelic 
arkers as part of the Illumina Hap300 array, in 941 individuals from the island of 
is, 58% of whom were members of 122 families.  Polymorphisms not included in 
e Illumina Hap300 array, which have been reported in the literature to influence 
usceptibility to AMD, were genotyped separately.  The polymorphic deletion of the 
FHR3/CFHR1 genes, reported previously to have a protective effect against AMD 
ughes et al., 2006) was genotyped in order to assess the effect of the deletion 
olymorphism on plasma CFH and its correlation with polymorphisms in the CFH 
th































 the major AMD risk haplotypes (Li et al., 2006).   
(P = 4.5E-18) (Table 7.4).  Five other 
NPs, including the SNP rs1061170 (CFH Y402H) reached suggestive association 
Genotyping was carried out using a real-time quantitative PCR assay which 
first had to be developed and optimised (Table 7.1).  TaqMan® SNP genotyping 
assays and direct sequencing were used for genotyping of the CFH rs2274700 and 
four other SNPs, reported to form
A SNP quality control measure (The Wellcome Trust Case Control 
Consortium, 2007; Samani et al., 2007), was included by careful checking of 
genotype call rates of all the associated markers using the software Beadstudio 
(Applied Biosystems), which showed that call rates were all greater than 95%.  
 
Results of genome-wide association analysis of plasma CFH 
     
A CFH intronic SNP, rs6677604, was identified as showing the most significant 
association with plasma CFH concentration in the genome-wide association analysis 
where it explained 28.3% of the total trait variance (P = 5.19E-56) (Figure 7.5).  
Five other CFH SNPs (rs3766404, rs4086175, rs1329428, rs2274700 and 
rs10801555) showed significant associations with plasma CFH (P ≤ 1.6E-07).  CFH 
rs2274700, identified by Li et al. (2006) to strongly affect AMD susceptibility was 
the only coding variant showing significant genome-wide association (P = 2.8E-12), 
explaining about 14% of the adjusted phenotypic variance and encoding an 
Ala473Ala substitution in exon 10 (Table 7.4).  The other significant associations 
occurred outside the CFH gene (Figure 7.5).  These included the polymorphic 
deletion of the CFHR3/CFHR1 genes (P = 3.2E-27) and two intergenic SNPs 
rs7517126 (P = 7.9E-19) and rs4086175 
S
with plasma CFH (P ≤ 1.0E-05) (Figure 7.5 and Table 7.4).  
Analysis of the public sequence of the CFH locus harbouring the associated 
markers identified regions with predicted roles in regulation of gene expression as 
estimated by the regulatory potential (RP) score (Figure 7.12).  The RP scores were 
obtained by Dr. P. Gautier (MRC HGU, Bioinformatics Department) from the UCSC 
Genome Browser (March 2006 assembly) and were estimated based on the 
alignments of human, chimpanzee, macaque, mouse, rat, dog and cow genomic 
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Sequences of DNA with potential regulatory roles in gene expression (regulatory potential 
(RP)) were identified after analysis of the region showing genome-wide genetic 
association (blue line) with plasma CFH concentration. Regions of regulatory potential 
(green line) were detected within 0.5 kb of the association SNPs
 
rs3766404 (150 bp), 
rs2274700 (100 bp) and rs6677604 (51 bp) as shown in the 60 kb magnified region 
below. A region of 170 bp with high RP was detected 100 bp downstream of the CFH
 
rs1061170 (Y402H) variant. The RP scores were obtained from UCSC
 
(March 2006 
assembly) based on the alignments of human, chimpanzee, macaque, mouse, rat, dog 
and cow sequences. The RP scores were calculated after comparing the frequencies of 
short alignment patterns between known regulatory elements and neutral DNA. The 
















The RP scores were calculated after comparing the frequencies of short alignment 
atterns between known regulatory elements and neutral DNA (Kolbe et al., 2004; 
ing et al., 2005). 
ngly 
ssociated CFH SNPs, rs3766404, rs2274700 and rs6677604 (Figure 7.5) spanning a 
gion of approximately 90 kb (Figure 7.12).  Regions of high RP score in the 
icinity of the highest associated SNPs rs6677604, rs2274700 and rs3766404 implied 
 possible role in regulation of gene expression associated with these regions (King 
t al., 2005).  No correlations between LD break-down and the reduction in 
ignificance of association were observed after comparing the LD patterns in the 
lasma CFH associated locus (Figure 7.7) with the association peaks with potential 
gulatory roles (Figure 7.12).  Such a correlation, as a result of recombination, 
ould help in narrowing down the region containing a potential regulatory 
olymorphism.  However, the genomic region surrounding the highest associated 
NP, rs6677604, is currently being analysed further for a functional role in CFH 
xpression. 
Several other markers were also found to be associated with changes in 
lasma CFH levels (P ≤ 1.0E-05), including a coding variant, F13B H115R (P = 
.9E-10) and four intronic SNPs in the genes, ASPM (1q31), KCNT2 (1q31), PTPRN 
q35), GBA3 (4p15) and CAMTA1 (1p36) (Table 7.3).  However, these associations 
re likely to occur as a result of the extended LD across the RCA region, possibly 
sulting from past selection (Voight et al., 2006).   
Significantly associated SNPs found in the genome-wide association analysis 
f plasma CFH in the Vis population were replicated in an unselected sample of 500 
nrelated Dutch individuals from the Rucphen isolate.  CFH rs6677604 was again 
und to be the most significantly associated polymorphism (P = 4.9E-25) explaining 
1.8% of the total variance in plasma CFH concentration (Figure 7.8, Table 7.8).  
evels of pairwise LD were generally lower in the Dutch sample set, compared with 
e Vis (Figure 7.8) and Scottish data sets (Figure 7.9).  The Rucphen community is 
 recent genetic isolate in the southwest Netherlands for which a comprehensive 
enealogical database exists (Sayed-Tabatabaei et al., 2005).  This population was 
unded in the middle of the 18th century by approximately 150 individuals and was 
p
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isolated until the last few decades when rapid growth and minimal immigration took 
place (Isaacs et al., 2007).  Since population admixture seems to have been kept to a 
minimum due to low immigration rates, selection at the CFH locus in the Vis and 
Scottis
 by a haplotype which accounted for more of the trait variance than the 
single 
-SNP haplotype alone explained 
29.2% 
h populations could account for higher levels of pairwise LD in the CFH 
genomic region in these populations (Bamshad & Wooding, 2003).  The possibility 
of selection at the CFH locus is analysed further in the final Discussion chapter.    
Analysis of pairwise LD between the SNPs associated with plasma CFH 
concentration, spanning the CFH and the CFH-related genes, showed that the most 
strongly associated SNP, rs6677604, was in strong pairwise LD with the 
CFHR3/CFHR1 deletion polymorphism (r2 = 0.84) (Figure 7.7).  CFH rs2274700 
(Ala473Ala, exon 10), which has previously been reported to increase susceptibility 
to AMD, was found to be in high LD with CFH rs1329428 intron 15 (r2 = 0.96).  
CFH SNP rs1061170 (Y402H) (exon 9) showed only borderline genome-wide 
significance with plasma CFH concentration (Figure 7.7).   
 In order to determine if the effect associated with CFH SNP rs6677604 could 
be explained
marker, a multi-marker model was obtained using the ‘backward’ regression 
analysis of 27 markers spanning the CFH and CFH-related genes.  A 3-SNP 
haplotype was obtained, consisting of rs1292487 (located 1.6 kb upstream of CFH), 
rs6677604 (located in CFH intron 11) and rs10801575 (located 4.4 kb upstream of 
CFHR4) which together with covariates age and BMI explained 36.9% of the trait 
variance (Table 7.5 and Table 7.6).  However, the 3
of the plasma CFH variance compared with 28.3% with rs6677604 alone. 
Using a haplotype specific test of association, four 3-SNP haplotypes 
significantly associated with changes in plasma CFH concentration were identified 
(Table 7.7).  A common haplotype (MHF = 0.177) containing TAT at sites 
rs1292487, rs6677604 and rs10801575, resulted in an increase of 55.51 μg/ml in the 
mean plasma CFH concentration (P = 1.1E-26) (Table 7.7).  This can be compared 
with the corresponding figure of 59.4 μg/ml for rs6677604 alone (Table 7.4).  Two 
other haplotypes, TGT (MHF = 0.105) and TGC (MHF = 0.481) were associated 
with a decrease of 65.6 μg/ml (P = 1.5E-03) and 58.1 μg/ml (P = 2.1E-09) in plasma 
CFH concentrations, respectively (Table 7.7).   
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In order to assess whether the effect associated with the above haplotypes on 
plasma CFH concentration was independent of the CFH rs1061170 (Y402H) SNP 
and the CFHR3/CFHR1 deletion polymorphism, a conditional haplotype analysis 
was carried out.  This showed that the effect associated with the TAT haplotype, 
conditional on rs1061170 (Y402H) was still highly significant (P = 2.3E-23) (Table 
7.7).  The most common haplotype, TGC (MHF = 0.481), associated with a decrease 
of 58.1
 TGC haplotype was not 
Relati
 0.57, CI: 0.41 - 0.81, P = 1.4E-03) 
 μg/ml in plasma CFH concentration was also found to have an independent 
effect (P = 2.3E-03) from that of CFH rs1061170 (Y402H) (Table 7.7).  A test of 
association between the TAT haplotype and plasma CFH, conditional on the 
CFHR3/CFHR1 deletion polymorphism resulted in a reduced but still highly 
significant P-value (P = 5.3E-03) indicating that the haplotype explained more of the 
variation in plasma CFH than the deletion polymorphism (Table 7.7), despite a high 
level of pairwise LD between the SNP rs6677604 and the deletion polymorphism 
(Figure 7.7).  The effect on plasma CFH associated with the
independent of the deletion, since it was no longer significant (P = 0.088) when 
conditioned on the deletion (Table 7.7).   
In summary, the TAT haplotype containing the rs6677604 minor allele and 
associated with increased plasma CFH explained more of the variation in plasma 
CFH concentration than the CFHR3/CFHR1 deletion polymorphism (P = 5.3E-03).  
Whether the larger proportion of phenotypic variance explained by the haplotype 
containing CFH rs6677604 is the result of a functional regulatory sequence in the 
region of rs6677604 can only be determined experimentally. 
 
onship between plasma CFH association and AMD   
 
Genetic analysis of 382 Scottish AMD cases and 201 controls, using Fisher’s exact 
test of association, was consistent with the CFH rs1061170 (Y402H) variant being 
the strongest AMD susceptibility locus, with an odds ratio of 2.23 (CI: 1.73 - 2.90, P 
= 7.1E-10) (Table 7.9).  This variant explained 6.8% of the AMD disease variance in 
the Scottish series (η2 = 0.068).  Other polymorphisms, including CFH SNPs 
rs3766404 (OR = 0.49, CI: 0.33 - 0.73, P = 3.9E-04), rs2274700 (OR = 0.55, CI: 
0.42 - 0.73, P = 3.3E-05) and rs6677604 (OR = 0.53, CI: 0.38 - 0.75, P = 4.6E-04), 
CFHR3/CFHR1 deletion polymorphisms (OR =
 244
and rs7
een shown to influence susceptibility to 
AMD i
s conducted using two 
dependent series of unrelated American individuals of European descent (Hageman 
 between CFH 
517126 (OR = 0.51, CI: 0.34 - 0.76, P = 1.3E-03) were found to have 
significantly protective effects against AMD (Table 7.9, Figure 7.9).  The 
proportion of the disease variance explained by CFH SNPs rs6677604, rs2274700 
and the CFHR3/CFHR1 deletion polymorphism, individually, was 2.2%, 3.4% and 
1.7% respectively (Table 7.9). 
Table 7.13 summarises the major published work on the genetic association 
between the CFH locus and AMD.  Despite six studies which identified the CFH 
rs1061170 (Y402H) variant in exon 9 as the highest genetic susceptibility locus for 
AMD, with odds ratios ranging between 3.3 - 5.5 (P < 1.0E-04) (Haines et al., 2005; 
Edwards et al., 2005; Zareparsi et al., 2005a; Hageman et al., 2006) three other 
studies pointed to CFH SNP rs2274700 in exon 10 as the most significant single 
SNP conferring genetic susceptibility to AMD (Li et al., 2006 (P < 1.0E-30); Hughes 
et al., 2006 (P < 1.0E-08); Francis et al., 2007 (P < 1.0E-03)).  Furthermore, 
haplotypes containing the CFH SNP 2274700 (Li et al., 2006; Hughes et al., 2006) 
or the CFHR3/CFHR1 deletion polymorphism and CFH SNPs rs6677604 and 
rs2274700 (Hughes et al., 2006) have b
ndependently of the CFH rs1061170 (Y402H) (Table 7.13).   
The findings of the present study were consistent with the CFH rs1061170 
(Y402H) (OR = 2.23, P = 7.1E-10) as showing a substantially stronger association 
with AMD than the CFH rs2274700 polymorphism (OR = 0.55, P = 3.3E-05) (Table 
7.9, Table 7.13).  One study in which CFH SNP rs1061170 was found to be more 
significantly associated with AMD than SNP rs2274700 wa
in
et al., 2005) (Table 7.13).  The lower significance of association
rs2274700 and AMD in the above American and Scottish series could be explained 
by different selective forces acting in these populations, but the Irish and the North 
American populations of Hughes et al. (2006) and Li et al. (2006) have essentially 
identical population histories, so this seems unlikely.  Selection at the CFH locus has 
been implicated as a major cause of diversity in the CFH genomic region (Hageman 


































   


















   








   
   





















   







   
   





















   








   
   

































   
   















   
   















   

















   






   
   
   
   

































































































   






   
   
   
   













































   






   
   
   
   












































   
   







   
   
   






































   






   
   
   
   

















































   






   
   
   
   






































   
   
































   






   
   
   
   






































   
   
























   







   
   
   













































































   







   
   
   

















































   
   
   























   







   
   
   

























































































































































































































































































































































Secondly, the high association of the CFH rs2274700 in the US population 
ported by Li et al. (2006) may be the result of population substructure leading to 
purious associations (Wellcome Trust Case Control Consortium, 2007).  This 
 as being more strongly associated with risk of AMD than CFH 
rs1061170 (Table 7.13). 
Markers associated with AMD after Bonferroni correction for multiple testing 
ere representative of three LD groups (r2 > 0.50) in the Scottish AMD series 
).  These LD groups contain SNPs rs1061170 (Y402H) and rs412852 
D group 1), which showed borderline association with plasma CFH 
oncentrations, rs1329428 and rs2274700 (LD group 2), and rs3766404, rs6677604 
nd CFHR3/CFHR1 deletion polymorphism (LD group 3), which showed highly 
ignificant associations with plasma CFH concentrations (Figure 7.9).  It was 
erefore hypothesised that the polymorphisms in LD groups 2 and 3 affect AMD 
usceptibility independently of the CFH rs1061170 (Y402H) by significantly altering 
lasma CFH concentrations.     
To test the above hypothesis, conditional haplotype analyses were carried out, 
sting for non-independence of marker associations to disease depending on their 
resence in different LD groups.  The effect of a 5-SNP haplotype, containing 
1048663, rs2274700, rs412852, rs1066420 and rs11582939 reported by Li et al. 
006) on the AMD association in the Scottish case-control sample, conditional on 
ther SNPs such as rs1061170 (CFH Y402H), rs6677604 or the CFHR3/CFHR1 
eletion polymorphism was analysed.  The results showed that the effects associated 
ith the GCCC and GTTC haplotypes were not significant when conditioned on the 
FH Y402H variant, consistent with non-independence (PGCCC = 0.951, PGTTC = 
.200) (Table 7.11).  The effect associated with the less common haplotype, GCTC 
HF = 0.016), was consistent with partial independence from the CFH Y402H 
ariant (P = 0.004).  A previous study has also shown that the effect of the GCCC 
aplotype is no longer significant when conditioned on CFH rs1061170 (Y402H) 
haplotype | CFH Y402H = 0.938) (Li et al., 2006).  However, in the same study, the 
TTC haplotype is shown to confer susceptibility independently of the CFH Y402H, 
 finding which is inconsistent with the present study.  Furthermore, Li et al. showed 
re
s




























eletion of CFHR3/CFHR1 genes (PGCCC = 1.5E-05) and the 
CFH 
and Dutch populations were present at different 
frequen
 effect associated with the protective haplotype, GCTC, was non-significant 
when conditioned on the CFH Y402H variant (Phaplotype | CFH Y402H = 0.396) 
which was again inconsistent with this study.   
The results of the conditional haplotype analysis in the Scottish AMD series 
also showed that the effects of the 4-SNP haplotypes were significant when 
conditioned on both the d
SNP rs6677604 (PGCCC = 2.8E-02) (Table 7.11) and were therefore 
independent of these polymorphisms.   
In summary, the results suggest that CFH rs2274700, rs6677604 and the 
CFHR3/CFHR1 deletion polymorphism are strongly associated with plasma CFH 
concentrations as a result of high pairwise linkage disequilibrium, and collectively 
influence AMD susceptibility (P < 0.05) independently of the SNP rs1061170 (CFH 
Y402H).     
Genetic analysis of AMD was carried out in a Japanese series aiming to 
assess whether the polymorphisms affecting differences in plasma CFH 
concentration in the Croatian 
cies in the Japanese population, perhaps explaining the lack of power in 
detecting significant associations between CFH and AMD in the Japanese 
population.  The analysis was carried out using a Fisher’s exact test of association in 
a small series of 30 unrelated cases of AMD and 58 unrelated age-matched controls.  
The analysis also included the ARMS2 rs10490924 polymorphism on 10q26, 
previously found to affect susceptibility to wet AMD in the Japanese population 
(Yoshida et al., 2007; Kondo et al., 2007).  CFH rs1061170 (Y402H) was found to 
confer the largest risk of AMD (OR = 3.41, 95% CI 1.06 - 10.95, P = 0.037) 
followed by the ARMS2 SNP rs10490924 (OR = 2.26, 95% CI 1.19 - 4.27, P = 
0.015) (Table 7.12).  Other CFH markers did not show significant associations with 
AMD, probably due to the small number of samples analysed and lack of power. 
The allele frequency of the CFH Y402H variant has been found to show 
ethnic variation, with lower frequencies in Chinese and Japanese populations, 
compared to the Caucasians (Chen et al., 2006; Uka et al., 2006; Lau et al., 2006; 
Okamoto et al., 2006).  AMD association studies of the 1q31 and 10q26 loci have 
revealed conflicting results.  Most studies have failed to detect significant association 
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between CFH Y402H and wet AMD in the Chinese (Chen et al., 2006) or Japanese 
(Uka et al., 2006; Gotoh et al., 2006; Okamoto et al., 2006) populations.  Absence of 
a CFH association has also been reported for dry AMD in the Japanese population 
(Fuse e
7) populations.          




t al., 2006).  However, a significant association between wet AMD and CFH 
Y402H has been published for the Chinese population (Lau et al., 2006).  On the 
other hand, variants in the 10q26 locus have been shown to significantly confer 
susceptibility to wet AMD in both Chinese (Dewan et al., 2006) and Japanese 
(Yoshida et al., 2007; Kondo et al., 200
Considering the large proportion of the AMD cases in the present study had 
presented with the ‘wet’ form of the disease (23 out of 30 cases, Table 2.1), the 
results are consistent with significant associations between CFH Y402H and ARMS2 
rs10490924 variants and ‘wet’ AMD.  Comparison of the allele frequencies between 
the control 
on in the minor allele frequencies of the CFH SNPs rs1061170 (Y402H), 
rs6677604, rs412852 and ARMS2 rs10490924 in the Japanese population compared 
with its Scottish counterpart (Table 7.14).  Despite the reduction in the minor allele 
frequency of the ARMS2 SNP rs10490924 in the Scottish population compared with 
the Japanese, this SNP showed the strongest association with AMD in the Scottish 
population (OR = 2.6, P = 9.0E-11) (Table 7.9).  Despite a significant reduction in 
the frequency of the CFH Y402H risk allele C in the Japanese population, this 
variant showed the strongest association with AMD in this population (OR = 3.4, P = 
0.037).  The minor allele frequencies of three SNPs from the 5-SNP haplotype 
identified by Li et al. (2006) increased in the Japanese control population compared 
with the Scottish sample (Table 7.14).  The findings of the present study are 
consistent with a significant association between CFH rs1061170 (Y402H) and ‘wet’ 
AMD in the Japanese population.  The lack of a sufficiently large sample size was 
the limiting factor in detecting significant associations in the available Japan
eries.   
In conclusion, genome-wide association analysis of plasma CFH resulted in 
significant associations with several polymorphisms close to and within the CFH 
gene.  The strongest association was with an intronic SNP within CFH, which 
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The association was also replicated in a Dutch sample set (Figure 7.8).  The 3-SNP 
TAT haplotype identified by ‘backward’ regression was associated with a 55.5 μg/ml 
crease in plasma CFH concentration (Table 7.7) compared with a 59.4 μg/ml 
crease associated with the single SNP rs6677604 (Table 7.4) showing that the 
nalysis showed that the effect of this (TAT) haplotype 
on CFH concentration was independent of the CFH Y402H variant, and of the 
/CFHR1 deletion polymorphism (Table 7.7), previously shown to affect 
et al., 2006).   
Genetic analysis of 382 Scottish AMD cases and 201 disease-free controls 
CFH SNP rs1061170 (Y402H) being the strongest AMD 
ned 6.8% of the disease variance (Table 7.9).  
a CFH concentration was found to explain up to 1.8% of the 
Table 7.10) with an odds ratio of 2.1 (95% C.I. 
P = 0.003) (Figure 7.11).  The results indicate that SNPs, which are 
a CFH concentration collectively influence AMD 
P < 0.05) independently of the CFH rs1061170 (Y402H) 
orphism.   
Although the 3-SNP haplotype did not significantly narrow down the 
not account for a significantly larger effect on plasma 
P (rs6677604), it is still plausible that the combination of the 
them, affect plasma CFH by regulating gene 
potential of the sequence within the CFH 
any non-coding regions with potential roles in regulating gene 
In the final Discussion (Chapter 9) a model is proposed for AMD 
study, which aims to dissect the complex 
e, in particular in the context of plasma CFH. 
in
in
haplotype did not explain more of the effect on plasma CFH than the single SNP 
alone.  Conditional haplotype a
CFHR3
AMD susceptibility (Hughes 
was consistent with 
susceptibility locus, which explai
Variation in plasm
variation in susceptibility to AMD (
1.3 - 3.4, 
strongly associated with plasm
susceptibility (
polym
association region, and it did 
CFH than the single SN
three SNPs, or variants associated with 
expression.  Analysis of the regulatory 
locus also identified m
expression.   
susceptibility based on the findings of this 





















































reatly a termediate 
henotypes for human diseases.  The goal is the large-scale quantitation and 
creening of proteins which indicate differences in gene expression or protein 
rnover in the general population, using proteins of known relevance to human 
isease.   
A number of techniques have been employed for the analysis of simple 
ixtures of proteins and peptides.  These include photometric, radiometric, 
munological and electrophoretic techniques.  However, large-scale detection and 
nalysis of proteins has only become possible due to the advent of mass 
pectrometric techniques.  Mass spectrometry (MS) methods are commonly based on 
ample ionisation and fragmentation followed by detection.  The main features of 
ome of the classical techniques, such as MALDI-TOF, capillary electrophoresis and 
PLC are their abilities to confidently detect and characterise protein samples, based 
n digestion, ionisation or fragmentation products.  More sophisticated methodology 
uch as liquid chromatography coupled with tandem MS/MS facilities, and Fourier 
ansform ion cyclotron resonance (FT-ICR) have provided significantly higher 
solution for determining protein masses with sub-femtomole sensitivity.  The 
bility of some of these techniques, in particular capillary electrophoresis coupled 
ith FT-ICR MS/MS, in relative-quantitation of proteins in samples such as urine 
as been assessed and is promising (Weissinger et al., 2004).  The most widely 
ccepted procedure for the relative quantitation of proteins in human tissue is 
RAQ™ coupled with MS/MS.  (Ross et al., 2004; DeSouza et al., 2005).  Relative 
uantitaion using iTRAQ™ is performed via tandem mass spectrometry (MS/MS) 
fter labelling with four possible tags placed on primary amines.  Quantitation is 
erformed via the differences in abundances of four product ions with mass/charge 
tios of 114, 115, 116 and 117 Da, that are each cleaved from one of the four 
ossible tags.           
Despite the large amount of information relating to disease in human plasma, 
uantitative analysis of the plasma proteome has faced great challenges.  One of the 
major problems which needs to be overcome prior to any type of large-scale analysis 
 
Development of techniques capable of large-scale protein quantitation would 





























of plasma is its complexity.  Plasma contains low abundance proteins, which are 
ainly products of tissue leakage at pg/ml levels, in the presence of several highly 
esis was also used as a method of fractionation prior 
to ionis
I plate (Figure 8.1).  The spectrum of crude human plasma was 
m
abundant proteins.  Furthermore, the high abundance proteins often mask the lower 
abundance ones, making their detection more difficult.     
 The aim of this chapter is to assess the ability of the various mass 
spectrometry techniques to detect and quantitate plasma proteins.  Both methods of 
ionisation, namely MALDI-TOF MS and electrospray ionisation (ESI) FT-ICR, were 
assessed.  Capillary electrophor
ation and MS analysis.  Finally, measurement of plasma CFH concentrations 
by ELISA were used to assess the ability of ion exchange chromatography, coupled 
with nano-scale liquid chromatography (nLC) joined with tandem MS (MS/MS) to 
determine relative quantities of CFH protein in different plasma samples.         
Several ‘upstream’ methodologies were assessed in their efficiency and 
ability to overcome the problem of complexity and “interference” by high abundance 
proteins in plasma.  Interference refers to saturation effects as highly abundant 
proteins suppress the detection of the low abundance protein fragments.  Methods to 
overcome the problem of interference included immunodepletion of high abundance 
proteins, chromatography, ultrafiltration and hydrophobic interaction 
chromatography to selectively collect proteins and peptides of low abundance.  
8.2 Results 
8.2.1 Immunodepletion of high abundance plasma proteins 
 
Immunodepletion was carried out using a multiple affinity removal spin column 
(cartridge) as described in Section 2.4.8.1.  The column is designed to remove greater 
than 98-99% of six interfering high-abundance proteins, including albumin, IgG, 
IgA, transferrin, haptoglobin and α1-antitrypsin from the human plasma.  Ten 
microlitres of crude plasma was used as the starting material and each sample was 
co-eluted twice, together with 1-2 μl of α-cyano-4-hydroxycinnamic acid (α-cyano) 
matrix onto a MALD
obtained by MALDI-TOF MS capturing the mass range of 3.5 kDa to 100 kDa.  The 
spectrum was mainly dominated by singly and doubly charged ions of serum 






































































































































































































































































































































































































































































































































































After immunodepletion of the most abundant proteins in plasma, using the 
epletion column, the absence of albumin, in both its ionic forms, was confirmed.  
 smaller mass 
However, as the mass spectra of immunodepleted plasma obtained by 
Figure 8.1-A), immunodepletion alone does not result in 
any proteins, especially in the mass range 30 kDa to 100 kDa which is 
ass range for protein ionisation using MALDI-TOF 
The ability of the multiple affinity column in eliminating the most abundant 
a proteins was also assessed by silver staining SDS polyacrylamide gels 
Figure 8.1).  The silver stain, with detection limits of 0.1-1.0 ng of protein 
ed the absence of the high abundance proteins, after separation by SDS-
eir molecular weight.  Comparison of the flow-through to the 
a showed the absence or significant reduction in the intensity of 
acroglobulin, transferrin, serum albumin, alpha-1 antitrypsin and 
e flow-through fraction contained the 
aining 10% of plasma proteome consisting of the low abundance fraction.  The 
e bands at higher intensity in the eluted column fraction 
strated the efficiency of the depletion system. 
After assessing the efficiency of the multiple affinity column in depleting the 
a, a number of techniques were employed to further 
ise detection and to assess the quantitative aspect of mass spectrometry.   
.2.2 MALDI-TOF mass spectrometry 
a using MALDI-TOF MS, the mass range was divided into 
all mass range (1 kDa < m/z <5 kDa), the medium mass range (5 
/z < 100 kDa) and the large mass range (100 kDa < m/z < 200 kDa).  This 
erential ionisation capacity of MALDI, with the medium mass 
onisation.  The aim was to assess the use 
a CFH and Aβ levels measured previously by ELISA as internal calibrators 
in the medium and small mass ranges, respectively.  If successful, the relative 
d
This improved the resolution for detecting other proteins present in the
range of 5 to 25 kDa.   
MALDI-TOF MS show (
detection of m
believed to be the favourable m
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2,937 and 3,473.  No peaks in the 
gion of 4.3 to 4.5 kDa were detected, indicating that the low concentrations of 
nce of other peaks could be deduced based on the intensities of the observed 
CFH and Aβ peaks.  Each MALDI-TOF MS experiment also included three negative 
controls which consisted of the spotted matrix alone.      
 Since immunod
ALDI-TOF MS, different techniques were optimised and applied to the three 
assigned mass ranges, and the results were as follows. 
8.2.2.1 MALDI-TOF MS of the small mass range 
 
Crude 
tips, according to the manufacturer’s instructions (Millipore).  After fractionation by 
chromatography resins embedded in the ZipTip™μ-C18 tips, the sample was co-eluted 
with α-cyano-4-hydroxycinnamic acid (α-cyano) matrix onto the MALDI plate and 
subject to mass spectrometric detection, as described in Methods.  Each plasma 
sample was analysed independently three times on the same plate.   
 This fractionation procedure resulted in improved spectra with higher signal 
to noise ratio (Figure 8.2).  Mass spectra from plasma treated in this way revealed a 
larger number of peaks compared with spectra from crude or immunodepleted 
samples.  The highest peak was detected at m/z 2,753.4 and was present in sample 
replicates.  However, neither the intensity nor the area under the peak, were found to 
be reproducible between sample replicates.  Furthermore, due to the limita
MALDI-TOF with regard to protein identification, the identity of this peak could
only be postulated based on its m/z ratio.  The peak was believed to be a fragment of 
human immunoglobulin in plasma, using the Mascot protein search engine.  
reproducible peaks were detected at m/z 1,896, 
re
amyloid-β species at the pg/ml level were preventing them from being detected by 
this technique.   
 Ultrafiltration of plasma using 10 kDa molecular cut-off filters (Millipore), 
which prevented passage of molecules larger than 10 kDa, followed by acidifying 
samples with 1% TFA prior to desalting and concentrating with μC18 ZipTip™ 
pipette tips, resulted in an even larger number of peaks in the small protein size 
window (Figure 8.3).   
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Mass spectra of the treated human plasma showing an improvement in the mass 
spectrometry signal associated with ZipTip™
 
treatment compared with immunodepletion.  
Mass spectra were obtained for the small mass range of 1 kDa to 5 kDa using MALDI-
 
TOF MS.  A.
 
The spectrum of crude human plasma shows high levels of background 
noise.  B.
 
Immunodepletion of high abundance proteins results in a better resolution.  C.
 
The highest signal to noise ratio is observed for the diluted, concentrated and ZipTip™
 
purified samples.  Spectra were obtained using the MALDI-TOF MS Voyager-DE™
 
STR 
(Applied Biosystems) in a linear mode.
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Figure 8.3 MALDI-TOF MS spectrum of human plasma after ultrafiltration using 
10K MW cut-off columns.  
Mass spectrum of human plasma after ultrafiltration followed by ZipTip™
 
treatment of 
crude plasma using 10K MW cut-off columns showing improvements in the number of 
detectable peaks and the intensity of the m/z signal compared with spectra of 
immunodepleted human plasma.  Mass spectra were obtained for the
 
small mass 
range of 1.3 kDa to 5 kDa using MALDI-TOF MS.  Ultrafiltration of 2 ml of crude 
plasma was followed by diluting, acidifying and concentrating with ZipTip™. Spectra 
were obtained using the MALDI-TOF MS Voyager-DE™
 
STR (Applied Biosystems) in 
a linear mode.
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As before, samples were spotted onto a MALDI plate in triplicate, using 1-2 μl of α-
yano matrix.  This technique produced more promising results, with a larger number 
es 
f the same sample. The high level of variation between replicates could be the result 
f the number steps involved in the purification of plasma samples introducing high 
vels of inter-experimental variation. 
The ability of MALDI-TOF MS to quantitate proteins and peptides in the 
mall mass range was assessed by spiking plasma samples with known 
oncentrations of synthetic human Aβ42 (Sigma).  With human Aβ42 plasma 
oncentrations ranging from 10 pg/ml to 200 pg/ml, lack of detection of a peak at 4.5 
Da had previously indicated the inability of MALDI to detect Aβ42 at physiological 
vels.  Firstly, single polypeptide analysis was carried out using Aβ42 at 
oncentrations of 200 pg/ml, 500 pg/ml, 1000pg/ml, and 1000 ng/ml diluted in 
PLC dH2O.  After treatment with C18 ZipTip™, 1 μl of purified peptide was co-
luted with 1 μl of α-cyano matrix and spotted on a MALDI plate for MALDI-TOF 
S analysis.  The low sensitivity and resolution of this techniques resulted in the 
ck of detection of the Aβ42 at concentrations of 200 pg/ml, 500 pg/ml and 1000 
g/ml (Figure 8.4).  Detection of the peptide at 1000 ng/ml, considerably higher than 
s normal physiological or even disease-related concentrations, was achieved 
uccessfully and with high confidence (signal intensity, 4.2E+04).  Figure 8.4-D also 
howed that in the presence of the peptide at 1000 ng/ml, peaks which had dominated 
e spectrum at lower concentrations of Aβ42 (Figure 8.4 A-C), became part of the 
ackground noise.  This was frequently observed in MALDI-TOF analysis and was 
inating effect of proteins of high concentration relative 
e mass range. 
In order to assess the reproducibility of Aβ42 peptide detection, peptides 
 HPLC dH2O at concentrations of 200 ng/ml, 500 ng/ml and 1000 ng/ml 
and analysed by MS.  Each sample was 
the presence of negative controls consisting 
atrix alone.  The results showed high levels of variation between replicates.  
ore, no direct relationship between the starting concentration of Aβ42 
peptide and the peak height was observed (Figure 8.5).   
c
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Aβ42 peptide at a concentration of 200 ng/ml did not result in improved resolution 
ata not shown).  Increasing the concentration to 500 ng/ml resulted in a slight 
e 8.5).  
 further increase in the concentration of the eluted peptide to 1000 ng/ml resulted in 
 major improvement in the signal at m/z of 4,513 (3.0E+04).  Figure 8.5 also 
howed a feature of MALDI-TOF which is detrimental to quantitative detection of 
rotein peaks.  This is that the intensities of other peaks in the region, for example 
e peak at m/z of 2,752 (Figure 8.5-A) and those at m/z of 931, 1,046 and 1,296 
) were greatly influenced by the presence or absence of the Aβ42 
eptide peak (m/z of 4,513).   
MALDI-TOF MS of the medium mass range 
he medium size mass range consisted of proteins of m/z between 5 kDa and 100 
Da.  This is believed to be the optimum mass range for the MALDI-TOF technique.      
Although no internal calibrators had previously been quantitated in plasma 
r this mass range, the product of the alternatively spliced form of CFH, factor H-
ke 1 (FHL1) protein resided in this window.  With a mass of approximately 50 kDa, 
uantitative assessment of this protein in plasma would be of great interest, 
specially in relation to the full length CFH protein, with a size of 150 kDa. 
  Ten microlitres of crude plasma was used as starting material.  This was 
iluted and subject to immunodepletion as described (Section 2.4.8.1) in three 
dependent but parallel experimental replicates.  Following the depletion of high 
bundance proteins, the flow-through containing the low abundance proteins was 
ubjected to hydrophobic interaction chromatography using C18 magnetic beads, as 
escribed in Section 2.4.8.2. 
The results showed a significant improvement in the number of peaks 
etected and in their intensities (Figure 8.6).  Comparison of the resulting spectra 
ith the mass spectrum of human crude plasma showed a significant reduction in the 
tensity of the serum albumin peak.  Furthermore, the level of background noise 
articularly in the lower m/z range was greatly reduced after treatment with C18 
agnetic beads.   
(d
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Figure 8.5 Assessment of the MALDI-TOF technique in quantitative 
determination of differences in Aβ42 concentrations after ZipTip™
 
treatment.
MALDI-TOF MS analysis of plasma samples spiked with detectable concentrations of 
the human Aβ42 peptide showed large variation between replicates (data not shown) 
and no correlation between different Aβ42 concentrations and peak intensities.  
Synthetic Aβ42 peptides of 500 ng /ml (A)
 
and 1000 ng/ml (B)
 
concentration were 
desalted and concentrated by treatment with ZipTip™.  Resulting spectra were 
analysed by co-elution with alpha-cyano matrix and spotting onto a MALDI plate 
followed by detection on MALDI-TOF MS Voyager-DE™
 
STR (Applied Biosystems) in 




Figure 8.6 MALDI-TOF MS results of the human plasma medium size mass range after 
immunodepletion and hydrophobic interaction chromatography.    
Mass spectrum of the human plasma in the medium size range after
 
immunodepletion and 
hydrophobic interaction chromatography showing an increase in the signal:noise ratio and 
the number of detectable peaks after treatment.  Mass spectra were obtained for the 
medium size mass range (4.9-100 kDa).  A.
 
Treatment of human plasma by 
immunodepletion and magnetic bead separation using C18 magnetic beads resulted in 
reduced background noise and larger number of detectable peaks. B.
 
The mass spectrum 
of crude human plasma, of the medium mass range, is shown for comparison.  The 
significance value, on the right axis, shows the level of confidence with which signal 
intensities were detected which also showed an improvement compared with the pre-
 





Biosystems) in a linear mode.






































































A number of peaks were also observed at m/z regions of 6, 8, 13, 17 and 28 kDa.  
nother feature of the improvement in signal detection was the significance at which 
nce value reached 
.4E+04 for the highest peak observed at m/z of 6,635.  The significance of a mass 
eak is a function of the number of ionised species detected from a precursor protein 
t each m/z signal.   
.2.2.3 MALDI-TOF MS of the large mass range 
he large mass range proved to be the most challenging due to the difficulty in 
olecules of large mass to ionisation (Geno & MacFarlane, 1989).  On the 
ther hand, proteins belonging to the small mass range, despite ionisation being 
asier, tended to disappear in the time of flight (TOF) chamber and were not 
Several methods were assessed in the analysis of the large mass range, 
agnetic bead separation as well as C4 ZipTip™ 
atography specially designed to aid detection of proteins of large mass.  
dilution, acidifying and ZipTip™ treatment of plasma 
ples did not significantly differ from those using immunodepleted plasma 
Figure 8.7).  Analysis of the large mass range using crude plasma was not possible 
large, high abundance proteins which 
to ionisation attempts with the large 
a.  The spectrum of immunodepleted plasma 
ks at m/z of 131,970, 143,090 and 161,764 with a high level 
ons of m/z of approximately 132,804 and 
 spectrum but were almost lost in 
the peak at m/z of approximately 134,079 
atically from 50% to 100% (Figure 8.7, left y-axis) despite low 
Figure 8.7-A; 812, Figure 8.7-B), which accounted for the low 
ber of ionised protein species being detected from the sample. 
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Figure 8.7 MALDI-TOF MS results of the large mass range after 
immunodepletion and ZipTip™
 
treatment of crude human plasma.
Mass spectra of the human plasma after immunodepletion and ZipTip treatment 
showing the difficulty associated with analysing the large mass range (100-200 kDa) 
due to the disrupted signal and high background noise believed to be caused by 
interference from large and high abundance proteins. A.
 
Immunodepleted human 
plasma showing a high degree of complexity and lack of sufficient ionisation, as 
estimated by the low significance value on the right axis (see text).  B.
 
The spectrum 
of diluted, acidified and concentrated human plasma, using C4 ZipTip™
 
treatment 
specifically targeted at the larger fraction of plasma, not showing sufficient 
improvement in signal strength or confidence.  Spectra were obtained using the 
MALDI-TOF MS Voyager-DE™
 
STR (Applied Biosystems) in a linear mode.
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8.2.3 Capillary electrophoresis    
 
t
itially used as a surrogate for a peptide in order to optimise CE techniques for 
ample concentration and injection time.  The tryptophan molecule absorbs UV light 
t 280 nm and can therefore be detected by CE.  The aim was to use optimised CE 
onditions for quantitative measurements of protein concentrations in complex 
ixtures including plasma.  Thereafter, the CE fractionation phase could be coupled 
 a 12T FT-ICR instrument for ionisation followed by fragmentation and detection 
y MS.  
.2.3.1 Optimisation of peptide concentration 
hree concentrations (10 μM, 100 μM and 1,000 μM) of the amino acid tryptophan, 
iluted in the CE Running Buffer, were used in the initial analysis.  The injection 
uration time was set at 12 seconds.  Negative controls, consisting of the running 
uffer alone, were included in each run.   
Results of the CE fractionation of plasma were found to be highly consistent 
) and peak areas were significantly correlated with peptide concentration.  
ach sample was treated and analysed using three replicates in parallel.  Mean peak 
reas for each sample, observed at 100 μM and 1,000 μM concentrations of 
yptophan, were found to be 23.6 absorbance over time (A/t) (± 0.2 SD) and 250.6 
/t (± 2.7 SD), respectively (Figure 8.8).  The mean peak area observed for the 10 
M concentration of tryptophan was too low and classified as background noise.  
owever, manual inspection of the graph showed the presence of a small peak at 5.8 
inutes (Figure 8.8).  Low levels of inter-sample variation were observed (CV < 
.05).  Amino acid peaks were also consistently detected at 5.9 minutes (± 0.2 SD) in 
ach experiment which was used as a measure of the reproducibility of CE. 
   
 
Capillary electrophoresis (CE) techniques were used primarily for the quantitative
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Figure 8.8 Results of capillary electrophoresis of varying concentrations of 
tryptophan.
UV detection of tryptophan at three different concentrations using CE showed that peak 
areas were highly correlated with sample concentration.  UV absorbance was detected at 
280 nm for 10 μM (A), 100 μM (B)
 
and 1000 μM (C )
 
concentrations of DL-tryptophan, 
diluted in HPLC water.  The peak of DL-tryptophan was consistently detected at 5.9 
minutes (±0.2, SD).  An injection time of 12 seconds was used and each graph is the 
result of three replicates (CV < 0.05).  Negative controls, consisting of the running buffer 
only, were used in each experiment.  Live acquisition was carried out using the Agilent 










































Figure 8.9 Capillary electrophoresis results of varying the length of injection time 
on the observed tryptophan peak area.  
UV detection of 1mM DL-tryptophan at three different sample injection times showed a 
direct and consistent relationship between the injection time and tryptophan peak area.  
DL-tryptophan was diluted in HPLC water and used to assess the effect of different 
injection times of 6 seconds (A), 12 seconds (B)
 
and 18 seconds (C )
 
on the tryptophan 
peak areas.  Each analysis was carried out in triplicate and included a negative control, 
containing the running buffer only.  The tryptophan peak was consistently detected at 5.7 







For further discussion see text.
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8.2.3.2 Optimisation of injection times 
M concentration of DL-tryptophan resulted in the least amount of variation 
esolution (Figure 8.8).  This concentration of 
yptophan was therefore used to optimise the duration of injection time by 
omparing the results at 6, 12 and 18 seconds.   
The results showed a direct and consistent relationship between the injection 
me and the peak area observed for 1 mM of tryptophan (Figure 8.9).  Mean peak 
 128.0 absorbance over time (A/t) (± 1.1 SD) at 6 seconds length of 
± 1.7 SD) at 12 seconds and 368.8 A/t (± 2.4 SD) at 18 
o absorption peaks were observed in the negative control sample which 
 all three injection times, peaks of 
 at the mean time of 5.7 A/t (± 0.1 SD) 
inutes indicating good reproducibility.  Low levels of inter-sample variation were 
Tryptophan was used as a surrogate peptide for UV detection by CE which 
simple molecules based on their UV 
ple concentration and injection times 
ising as they showed a direct and consistent relationship between the two 
eters of sample concentration and injection time, and the peak area observed.  
ised CE conditions could therefore be applied to single protein samples in 
in handling protein samples.  
.2.3.3 CE analysis of single protein samples  
ollowing the optimisation of amino acid (tryptophan) concentration and injection 
mes, analytes containing a single protein were analysed using the protocol 
escribed above.  Initially, three proteins consisting of ubiquitin, myoglobin and 
SA were used individually for CE, at two different concentrations (10 μg/ml and 50 
g/ml).   
The results of the assessment of CE for quantitation of single protein samples 
f known concentration showed a high level of variation between replicates (CV > 
.05).  In the case of 10 μg/ml ubiquitin, no peaks were observed due to the high 
 
The 1 m






injection to 254.9 A/t (
seconds.  N
consisted of the running buffer alone.  At
tryptophan were observed consistently
m
observed between replicates (CV < 0.05). 
 
showed a potential for quantitation of 















level of background noise in all three replicates.  Myoglobin (10 μg/ml) showed a 
r pattern was seen for myoglobin (50 
g/ml)
 procedures, described in Methods Section 
ating peaks observed 
in the negative control samples resulted in loss of UV detection.  Although the 
abilities of CE involving 
8.2.3.4
high level of inter-experimental variation (CV = 26.1%).  BSA (10 μg/ml) also 
showed a high level of variation between replicates (CV = 24.6%).  In the case of 50 
μg/ml ubiquitin, even higher levels of inter-experimental variation were observed 
between measurements (CV = 76.1%).  A simila
μ  and BSA (50 μg/ml) samples with observed CVs of 78.6% and 82.0%, 
respectively.  Protein peaks were detected at the same time points for all three 
proteins, despite their molecular weight differences.  The same peaks were also 
detected in the negative control samples containing the running buffer alone 
suggesting contamination.  At the 10 μg/ml concentration, peaks of myoglobin and 
BSA were detected at 50.8 minutes (1.49, SD) and 53.4 minutes (0.42, SD), 
respectively.  At the 50 μg/ml concentration, peaks of ubiquitin, myoglobin and BSA 
were observed at 41.1 minutes (4.34, SD), 41.5 minutes (0.56, SD) and 42.6 minutes 
(0.68, SD), respectively.  Troubleshooting
2.4.8.6.2, were employed to eliminate the problem of high background noise 
(possibly the result of air bubbles in the solutions) and contaminating peaks detected 
in the CE spectra, which may have been the result of contaminated buffers or un-
dissolved proteins.    
The findings of the single protein analysis by CE showed high levels of 
variation between replicates and a lack of consistency between observed peaks.  The 
trouble shooting procedures aimed at eliminating the contamin
preliminary experiments assessing the quantitative 
tryptophan were promising, UV detection of samples of single proteins was 
unsuccessful.  The detection and analysis of proteins by CE coupled with FT-ICR 
MS was then assessed, despite the problem with detection of protein samples by UV, 
as discussed below.         
 
 CE coupled with FT-ICR MS 
 
CE was coupled with FT-ICR mass spectrometry for the detection and quantitation 
of single protein samples containing ubiquitin (8.5 kDa), myoglobin (16.7 kDa) and 
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BSA (66.4 kDa) using the protocol described in Section 2.4.8.6.  Negative controls 
containing the CE Running Buffer alone were used in each experiment.  MS 
detection was performed on a 12T quadrupole system APEX-QE (Bruker Daltonics, 
Germany) equipped with a Fourier transform mass spectrometer.   
 Sample fractionation by CE followed by detection with FT-ICR mass 
spectrometry was carried out several times with single protein samples containing 
ubiquitin, myoglobin and BSA.  No protein peaks were detected from the analysis, 
and mass spectra mainly consisted of peaks of buffer components of small m/z.  The 
detection ability of the quadrupole instrument was tested by directly injecting 1 
mg/ml of myoglobin diluted in HPLC H2O into the electrospray chamber.  Peaks of 
protonated myoglobin ions were detected, representing the 16.9 kDa ionised protein.  
However, attempts to detect protein samples of known concentration, using CE FT-
ICR MS were unsuccessful.  
8.2.4 Ion exchange chromatography 
 
Three Croatian plasma samples were selected from the higher and lower ends of the 
CFH distribution as measured by ELISA.  Samples were immunodepleted then 
separated by 4-12% pre-cast NuPAGE® gel electrophoresis.  Gel bands 
corresp
er molecular weight fraction was unsuccessful due to lack 
f detection of peptides corresponding to the factor H-like 1 (FHL1) protein.  Peptide 
lecular weight fraction using the protein 
 with the highest ion scores were then 
onding to the 150 kDa full length CFH (Figure 8.10, red box) and the 55 kDa 
factor H-like protein (Figure 8.10, yellow box) were excised, trypsin-digested and 
analysed by ion exchange chromatography (IEC) followed by nLC-MS/MS.  IEC 
and nano LC MS/MS experiments were conducted by Mr. Douglas Lamont at the 
University of Dundee.  The aim was to assess the correlation between plasma CFH 
concentrations measured by ELISA and IEC coupled with nLC-MS/MS.  This also 
provided the opportunity to analyse plasma levels of the 55 kDa factor H like protein 
in relation to the 150 kDa full length CFH.   
 Analysis of the low
o
ions were identified from the larger mo
earch engine Mascot.  Five peptide speciess
















Figure 8.10 Plasma protein staining prior to ion exchange chromatography.
Results of the protein staining of plasma samples selected for ion exchange 














gels and stained using SimplyBlue™
 
SafeStain. Gel regions containing the 150 
kDa full length CFH protein (red box) and the 55 kDa factor H-like1 protein (yellow box) 
were excised and analysed. Sample identification numbers are shown above each well.
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The corresponding ion peaks were identified on the mass spectra based on the 
tention time of the ions.  Peak areas corresponding to CFH peptide ions were 
igh CFH 
ples IDs 945, 241 and 2) and low CFH (samples IDs 379, 184 and 213) 
n (Figure 8.11).  In four out of the five peptide ions detected, peak areas 
ably between the six samples and did not correlate 
icantly with plasma CFH concentrations (R2 < 0.05, P > 0.10) using a linear 
Figure 8.12 A-D).  One of the five selected peptide 
 with findings of the CFH ELISA (R2 = 
P < 0.01) (Figure 8.12-E).  The overall squared correlation was also 
lated for the combined set of data but no significant correlation was observed 
C and ELISA measurements of plasma CFH (R2 = 0.05, P > 0.10). 
The results of the IEC experiments coupled with nLC-MS/MS showed the 
s of reliably and reproducibly determining plasma CFH concentrations when 
pared with measurements of ELISA which was successful in only one out of five 
ents. 
.3 Summary and discussion  
he results of assessing proteomic techniques such as MALDI-TOF MS, CE FT-ICR 
S and IEC nLC-MS/MS, in protein identification and quantitation were presented 
 this chapter.  The aims were to correlate measurements of plasma proteins 
erformed by ELISA with the MS results, and to assess the potential of MS-related 
chniques in biomarker discovery and quantitation.   
Initially, immunodepletion of high abundance plasma proteins, albumin, IgG, 
A, transferrin, haptoglobin and α1-antitrypsin, using a multiple affinity column, 
as tested using MALDI-TOF MS, which proved successful in improving the MS 
ignal (Figure 8.1).  Immunodepletion by multiple affinity removal columns is an 
ffective method of removal of highly abundant proteins simultaneously, with 
inimal carryover and low non-specific binding (Bjorhall et al., 2005).   
  
re
normalised to plasma CFH levels, and compared between samples of h
(sam
concentratio
were found to vary consider
signif
regression analysis of variance (






















































































































































































Figure 8.11 Comparison of CFH concentrations measured by ELISA and IEC.
Significantly correlated measurements of plasma CFH were observed in some peptide 
fractions as compared by ion exchange chromatography. Peak areas
 
from six 
immunodepleted plasma samples were measured for CFH peptide ions
 
produced by ion 
exchange chromatography (IEC) and detected by nLC-MS/MS.  Estimated measurements 
were compared to CFH concentrations determined by ELISA.  Five independent peptide 
ions were analysed as shown in A-E.  Peak areas were normalised to CFH concentration 
(μg/ml) in each sample. 
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Figure 8.12 Test of correlation between ELISA and IEC measurements of plasma 
CFH.
Squared correlation coefficients (R2) and their significance (P) were obtained using linear 
regression analyses, comparing the measurements of plasma CFH obtained by ELISA 
and IEC. Results showed that one out of five peptide ions correlated significantly with 
plasma CFH measurements of ELISA in all six plasma samples (E). Analysis was carried 
out using IEC normalised peak areas obtained for the five independent peptide ions (A-E) 
shown in Figure 8.11, using the software SPSS v.12.        
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Although depletion of highly abundant proteins in plasma significantly increases the 
number of proteins identified, studies have shown that both the degree of sample 
omplexity and the depletion method result in a non-selective loss of other proteins 
  
An example relevant to the present study is the claim that greater than 95% of Aβ40 
and Aβ an plasma reside within a sequestered pool of high abundance 
proteins such as albumin and transthyretin (Kuo et al., 1999; 2000).  A possible 
approach to address this problem is to disrupt the binding of the low molecular 
weight proteins to large carrier proteins by using denaturing conditions such as 
addition of acetonitrile to the plasma sample (Huang et al., 2005).  
 sis of plasma was performed in three protein mass 
ranges of small (1 kDa < m/z < 5 kDa), medium (5 kDa < m/z < 100 kDa) and large 
(100 kDa < m/z < 200 kDa) size.  Firstly, analysis of the small mass range, after 
treatment of crude plasma with ZipTip resulted in a significantly improved signal 
compared with immunodepletion, and a number of reproducible MS peaks were 
detected at m/z of 1,896, 2,937 and 3,437 (Figure 8.2).  Ultrafiltration of plasma, 
using 10 kDa molecular cut-off filters, followed by treatment by ZipTip resulted in 
even higher signal:noise ratio, probably due to the larger volume of starting plasma 
sample (Figure 8.3).  However, spiking the samples of human plasma with known 
concentrations of purified synthetic Aβ42 showed the lack of sensitivity associated 
with MALDI-TOF MS in detecting samples containing less than 500 ng/ml, which is 
considerably higher than the physiological concentrations of Aβ42 in the human 
plasma Figure 8.4).  Furthermore, the 500 ng/ml and 1,000 ng/ml concentrations of 
spiked Aβ42 at m/z of 4.5 were poorly correlated with each other, and high levels of 
er-sample variation (CV > 20%) were observed between replicates (Figure 8.5).   
Secondly, analysis of the medium mass range of plasma proteins, after 
munodepletion and separation by hydrophobic interaction chromatography using 
agnetic beads, resulted in higher signal:noise ratio and improved signal intensities 
ntensity of 4.4E0+04 for the highest peak at m/z of 6635) (Figure 8.6).  The aim 
as to detect the 55 kDa factor H-like protein in plasma, however this was 
nsuccessful and attempts at improving the spectra for mass range of 40 kDa and 100 
Da, by altering ionisation intensities and trying other techniques such as desalting 
c













and concentrating samples, did not result in improved sensitivity.  Magnetic bead 
separation techniques have been shown to greatly improve plasma peptide detection 
by MALDI-TOF MS (Villanueva et al., 2004).  Studies have reported peptide marker 
profiles detected using magnetic bead separation followed by MALDI-TOF MS in 
plasma samples of individuals affected by cancer compared with controls 
(Villanueva et al., 2006; van der Werff et al., 2008).  However, such studies have 
been restricted to pattern recognition between disease and control samples and have 
not involved quantitative assessments of protein profiles.  
 Thirdly, analysis of the large mass range after immunodepletion resulted in a 
number of detectable peaks at m/z of 131, 143 and 167 kDa, but only in the presence 
of high levels of background noise.  Immunodepletion followed by C4 ZipTip 
treatment resulted in slightly improved spectra, with two regions of approximately 
134 and 147 kDa becoming visible, despite the low intensity of peaks (Figure 8.7-
B). 
 Despite its widely accepted use in identification and characterisation of large 
molecules (Karas & Hillenkamp, 1988; Henzel et al., 1993, 2003), the results of the 
MALDI-TOF mass spectrometry in the present study were highly variable between 
replicates.  The high level of variation can be due to experimental limitations such as 
heterogeneous distribution of sample molecules on the MALDI spot.  This results in 
large variation between samples at different locations on the spot, which would 
create a different number of ionised molecules.  This is further complicated since the 
crystallisation with the matrix does not occur uniformly on each spot.  Considering 
the above caveats and the number of “upstream” experimental procedures carried out 
prior to mass spectrometry, it is not unexpected that high levels of inter-experimental 
variation was observed in MALDI-TOF MS.  In order to reduce the inter-
experimental variation, the instrument should be calibrated using test samples of 
known size and concentration or use of internal standards.   
Capillary electrophoresis (CE) was used as a method of fractionation of 
proteins in the sample prior to MS detection and quantitation.  Initially, UV detection 
and quantitation of single peptide samples was assessed, using an optimised protocol 
(Weissenger et al., 2004).  Firstly, optimisation of peptide concentration, using 100 
μM and 1000 μM of the amino acid tryptophan, resulted in peak areas of 23.6 A/t (± 
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0.2 SD) and 250.6 A/t (± 2.7 SD), respectively (Figure 8.8).  Peak areas were found 
to be highly correlated with sample concentrations and between replicates (CV < 
5%).  These results were promising and they showed that the specificity of CE was 
enough to detect 10-fold differences in concentration of a single amino acid.   
Secondly, optimisation of injection duration times, using 1 mM tryptophan, 
resulted in mean peak areas which showed a strong correlation with length of 
injection time for the single amino acid tryptophan (Figure 8.9).  Furthermore, peaks 
of tryptophan were observed consistently at the mean time of 5.7 minutes (± 0.1 SD), 
surements (CV > 5%).  Furthermore, observed peaks were believed to be the 
of three single protein 
sample
indicating good reproducibility of results.  
Tryptophan was used in the CE optimisation procedures since it is a simple 
amino acid which readily absorbs UV light.  Optimised concentration and injection 
times were then applied to three single protein samples, ubiquitin, myoglobin and 
BSA.  However, the results showed high levels of variation between replicated 
mea
result of contamination, since all detectable peaks occurred at the same time-point, 
despite differences in molecular weights of the proteins.  However, the problem was 
not solved by the troubleshooting procedures described before.   
Some studies have succeeded in differentially identifying more than a 
thousand polypeptide species in samples of diseased and control individuals using 
CE coupled with mass spectrometry in plasma and urine (Kaiser et al., 2004; Sassi et 
al., 2005).  Notably, a study involving the comparison of polypeptide patterns 
between urine samples obtained from healthy and sick individuals affected by a 
number of kidney diseases identified isoforms of albumin which significantly 
differed in “levels” between cases and controls using CE coupled with FT-ICR MS 
(Weissinger et al., 2004).  In the present study, mass spectrometric detection of 
protein samples after fractionation with CE was assessed after coupling the CE 
instrument to an FT-ICR mass spectrometer.  Analysis 
s consisting of ubiquitin, myoglobin and BSA using CE coupled with FT-ICR 
followed by mass spectrometry resulted in detection of no sample peaks.  Repeated 
attempts at detecting protein samples by FT-ICR MS resulted only in detection of 
low molecular weight buffer components and so were unsuccessful. 
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 Following the assessment of the two “top-down” mass spectrometry 
approaches which involved the analysis of intact proteins, a “bottom-up” approach 
was used involving fractionation by ion exchange chromatography (IEC) followed 
by trypsin digestion and nLC-MS/MS analysis.  Experimental procedures were 
carried
ike proteins, resulted in detection of full-
length 
e peptides obtained 
from th
by the failure to 
detect the short Factor H-like 1 protein in a mixture containing proteins of 
 out using plasma samples selected from the higher and lower ends of the 
distribution of CFH concentration.  Six samples were immunodepleted, separated on 
4-12% pre-cast polyacrylamide gels and stained (Figure 8.10).  Analysis of two 
molecular weight fractions, excised from the stained gels, containing the 150 kDa 
full length CFH and the 55 kDa factor H-l
CFH but failed to detect the shorter factor H-like 1 protein due to its lower 
abundance (believed to be about 10 times lower than full length CFH, ranging 
between 10-50 μg/ml).  Five peptide ions of high intensity were selected from the 
higher molecular weight fraction (Figure 8.11 A-E) in which the intensity of the 
peak representing the full length protein was measured.  In one of the five selected 
peptide ions, the concentration of the ion exchange chromatography peaks were 
found to correlate significantly with those of the CFH ELISA (R2 = 0.954, P < 0.01) 
(Figure 8.12-E).  The overall squared correlation of all the fiv
e six plasma samples and compared between IEC and ELISA, did not differ 
significantly from zero (R2 = 0.05, P > 0.10).  However, these results were more 
promising as far as the quantitation of plasma proteins is concerned, compared with 
the “top-down” approaches discussed before.  The results of the IEC experiments 
coupled with nLC-MS/MS showed that in one out of five experiments, plasma CFH 
measurements were highly correlated with measurements obtained by ELISA.   
The results of the mass spectrometry experiments highlighted several 
shortfalls of the proteomics techniques in relation to protein identification and 
quantitation.  Firstly, the most common issues are abundance and interference.  The 
results of the present study showed that interference, not only from the most common 
plasma proteins such as albumin and immunoglobulins, but from any protein species, 
which are often orders of magnitude more abundant than the protein of interest, can 
limit the detection by MS.  Data obtained using IEC nLC-MS/MS, which is a highly 
sensitive method of protein detection, confirmed the above result 
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approximately 150 kDa and 50 kDa after separation by electrophoresis.  Indeed, most 
“biomarkers of disease” which have been identified through protein profile 
differences seem to be of relatively high abundance in bodily fluids.  Examples 
include albumin fragments as biomarkers for renal disease found by CE-FT-ICR MS 
in urine (Weissinger et al., 2004); α-2 macroglobulin and transthyretin which are 
differentially expressed in plasma samples of AD and normal individuals, found by 
2D electrophoresis coupled with tandem mass spectrometry (Zhang et al., 2004a); 
and the C3 and C4 components of the complement pathway of the immune system 
and C1 inhibitors, which differed between plasma of healthy individuals and those 
with type 2 diabetes (Zhang et al., 2004a).  The findings of such studies require 
confirmation in large series by ELISA (Allard et al., 2004) or by genetic studies of 
the candidate biomarkers.  Furthermore, proteins of the immune system found 
differentially expressed between disease and healthy samples need further 
verification as to whether they are merely a non-specific result of inflammation.   
Secondly, high levels of variation observed between replicate samples in the 
analysis of proteins by MALDI-TOF MS and CE could be the result of cumulative 
variation at different stages of sample pre-treatment.  Furthermore, factors such as 
sample freeze-thaw cycles, clotting time and storage temperatures have been shown 
to affect variability between experiments and across different study groups (de Noo 
et al., 2005; Baumann et al., 2005).   
Thirdly, instrumental limitations could explain the high level of variation 
observed between replicates in MALDI-TOF MS and lack of detection of proteins by 
CE FT-ICR MS.  For example, the lack of consistent detection of protein species 
larger than 100 kDa and smaller than 10 kDa, due to the failure to ionise or move 
efficiently through the time-of-flight chamber, was a major limitation of the MALDI-
TOF MS technique.  Failed attempts at protein detection by CE coupled with FT-ICR 
MS were also due to technical problems associated with the instruments involved 
that could not be explained.   
In conclusion, despite the lack of success in optimising MALDI-TOF MS and 
CE FT-ICR MS techniques for protein detection and quantitation, the findings of the 
IEC coupled with nLC-MS/MS in relation to quantitation of the full length plasma 
CFH were promising.  This was achieved by using plasma CFH measurements 
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obtained by ELISA as internal controls to which IEC results were normalised.  
Whether this technique would be successful in identification and quantitation of 
novel biomarkers in human plasma requires further research. 
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rs of common 
nd ge environmental 
ariation associated with plasma biomarker concentrations.  The aims of the project 
ere drawn from the following hypotheses.  Firstly, based on the genetic architecture 
f complex traits, intermediate phenotypes have stronger genetic determinants than 
e downstream phenotype they mediate (Falchi et al., 2004).  Secondly, genetically 
implified isolated populations, with a more uniform distribution of environmental 
sks and reduced genetic heterogeneity provide optimal conditions for mapping 
omplex disorders (Wright et al., 1999).   
Two groups of protein biomarkers were analysed.  First, plasma complement 
ctor H (CFH) was selected as a potential biomarker for age-related macular 
egeneration (AMD), since common coding and non-coding variants in the CFH 
ene have been reported to show strong association with this disorder (Klein et al., 
005; Haines et al., 2005; Edwards et al., 2005; Zareparsi et al., 2005a).  Secondly, 
o isoforms of amyloid-β (Aβ40 and Aβ42) were selected as biomarkers for 
lzheimer disease (AD), since Aβ deposits in the brain are major constituents of the 
myloid plaques characteristic of this disorder (Glenner & Wong, 1984; Masters et 
l., 1985).  A third approach was to use mass spectrometric techniques to identify 
ew biomarkers for disease by analysis of plasma protein samples from an isolate 
opulation.     
xperimental overview 
ompletion of the human genome sequencing and the advent of high throughput 
enotyping technologies have allowed large-scale genetic analysis of polymorphisms 
hich influence susceptibility to common and complex human disorders.   
Physiological and anthropometric measurements and samples of human 
lasma and genomic DNA were collected from a population sample of 1,021 
dividuals from the isolated Croatian island of Vis after an initial epidemiological 
urvey of the island (Rudan et al., 1999b).  Extensive genealogical data were also 
btained from the island which later allowed construction of pedigrees within the 
opulation sample.   
s of this study were to analyse known and potential biomarke


































ts of moderate to large effect, such as the CFH Y402H polymorphism 
redisposing to age-related macular degeneration (Klein et al., 2005).  The 
ciations with bipolar disorder, coronary artery disease, 
ariants of modest effect size (Dawn & Barrett, 2005).  In the 
analysis of known (Aβ40 and Aβ42) and potential (CFH) biomarkers of disease 
using enzyme-linked immunosorbent assays.  Attempts were also made to identify 
and quantitate new biomarkers in human plasma, using techniques such as MALDI-
TOF mass spectrometry, capillary electrophoresis and ion exchange chromatography.  
Secondly, genome-wide linkage and association analyses were conducted after an 
initial assessment of power, in order to identify novel quantitative trait loci (QTL) 
which influence plasma concentrations of CFH, Aβ40 and Aβ42.     
 
Linkage versus association analysis
d association analyses are two of the most powerful genome-wide 
approaches for the identification of variants underlying complex traits, in which 
locus heterogeneity, epistasis, low penetrance and pleiotropy create special 
challenges (Lander & Schork, 1994).  Linkage studies in humans have been 
successful in mapping susceptibility variants of moderate to large effect, such as 
APOE*E4 as a strong and common predisposition locus in Alzheimer disease 
(Pericak-Vance et al., 1991; Corder et al., 1993).  Similarly, the MHC genes, HLA-
DR and HLA-DQ, have been identified as relatively strong susceptibility loci for type 
1 diabetes (Todd et al., 1987).  Genome-wide association studies are more recent 
phenomena but have already achieved great success in identifying replicable 
common varian
p
identification of novel asso
Crohn’s disease, rheumatoid arthritis, type 1 and type 2 diabetes using large case-
control studies (2,000 cases and 3,000 controls) was also a major success (Wellcome 
Trust Case Control Consortium, 2007).   
In the present study, genome-wide quantitative trait linkage analysis of 
plasma Aβ and CFH was unsuccessful in detecting loci with either suggestive (LOD 
> 2) or significant (LOD > 3) linkage as defined previously (Lander & Kruglyak, 
1995).  The lack of success of the linkage analysis can be due either to the small size 
of the study population (especially the size of the pedigrees) or to the lack of power 
of linkage to detect v
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case of
 large effect size 
xplaining 28% of the trait variance) the lack of power in linkage can be explained 
imulations, Sham and colleagues (2000) 
In this 
 plasma Aβ40 and Aβ42, the failure of linkage and the success of association 
could be explained by the lack of significant narrow-sense heritabilities (h2) observed 
for those traits.  The power in genome-wide analyses has been shown to be directly 
related to the QTL heritability in the case of association but to the square of the QTL 
heritability in the case of linkage (Sham et al., 2000).  Therefore, with decreasing 
QTL heritability, association will become progressively more powerful than linkage.  
However, in the case of plasma CFH, where a relatively high heritability of 46% was 
observed and the underlying QTL was found by association to be of
(e
by the small size of the pedigrees.  Using s
estimated that approximately 20,000 sib-pairs would be required to detect a QTL of 
10% effect size (i.e. explaining 10% of the QT variance) using linkage with 80% 
power.  The number of required sib-pairs decreases to approximately 1,000 for 
detection of statistically significant associations, assuming that the degree of linkage 
disequilibrium between the causal QTL and the marker is strong (r2 > 0.50).                  
 One way of assuring maximum power is achieved in linkage is to use 
simulations as part of the study design, which takes the particular features of the 
study, including family structure, marker map, allele frequencies and patterns of 
missing data into account, according to the null hypothesis of no linkage across the 
whole genome (Dawn & Barrett, 2005).  This method has been applied to genome-
wide linkage studies of plasma HDL (Arya et al., 2002), myocardial infarction 
(Broeckel et al., 2002), hypertension (Caulfield et al., 2003) and schizophrenia 
(Williams et al., 2003) in which the correct significance level has been determined 
for the specific study.    
  
Quality control prior to the association analyses 
 
study, markers with more than 5% missing genotypes were excluded as part of 
the quality control procedure before the association analyses.  In general SNPs are of 
questionable quality if their genotypes failed in many individuals or if the calling 
algorithm was not able to assign a genotype for many subjects.  Thresholds of 3% 
(Wellcome Trust Case Control Consortium, 2007) and 2% (Samani et al., 2007) have 
been used previously in the literature.  This criterion should be set separately for 
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different study groups as the DNA quality and the genotyping platforms may differ 
between studies.   
Similarly, individuals with more than 10% missing genotypes (i.e. > 90% call 
rate) were excluded in this study as part of a subject-wide quality control measure.  
Higher thresholds of subject-wide genotype call rate may be preferred.  However, 
subjects should initially be excluded based on a less stringent threshold of 10% 
missing call rate.  Genotype call rates can consequently be checked for each of the 
trait-associated markers and “re-called” based on a higher threshold.  Ambiguous 
genotypes can then be excluded.  This method will reduce the probability of 
reporting false-positive and -negative associations.  The heterozygosity across all 
SNPs can also be a good quality indicator, such that high heterozygosity (mean ± 3 
SD) may indicate DNA sample cross-contamination (Ziegler et al., 2008). 
In an assessment of population substructure in the Vis sample set using the 
Illumina Hap300 genotype data, after exclusion of outliers, subjects were classified 
into two clusters corresponding approximately to the two villages of Komiza and Vis 
based on excess allele sharing.  Adjustment for population stratification within the 
two clusters defined by allele sharing was performed using a permutation approach 
implemented in the whole-genome data analysis tool set PLINK (Purcell et al., 
2007).  Population substructure can generate spurious genotype-phenotype 
associations as the result of genetic markers with allele proportions which differ 
between the subgroup and the general population (Balding, 2006).  The statistical 
method of genomic control, which uses markers throughout the genome to adjust for 
any inflation in test statistics due to substructure, has been used to overcome spurious 
associations induced by population substructure in case-control studies (Devlin & 
oeder, 1999).   
approximately independent tests (Miller, 1981).  However, the Bonferroni correction 
R
 
Quality control post-association analyses 
 
In order to control for multiple testing in single SNP association analyses, the 
significance level, α (≤ 5%), was set so that all the tests together generate no more 
than the probability of a false positive, α.  The most conservative application of this 
theory is the Bonferroni correction, α′ ≈ α / n, assuming a number n of 
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is conservative in that it does not take account of tightly linked or associated loci.  
Alternatively, permutation procedures and false discovery rate (FDR) estimation 
have be
rior to the 
analysi
-of-fit test, which has approximately a χ2 null distribution but can 
e unreliable when there are low genotype counts.  CFH Y402H was the only 
E in the Vis dataset.  This was 
en employed to correct for multiple testing.  Permutation procedures involve 
retaining the genotype data (i.e. the observed LD structure) but randomising 
phenotype labels over individuals (Balding, 2006).  Analysing many such datasets 
can approximate the false positive rate.  However, the disadvantage of this method is 
that it is computationally demanding.  The other approach is to monitor the FDR, 
which is the proportion of false positive test results among all positives (Storey & 
Tibshirani, 2003).  In other words, the distribution of P-values is estimated as a 
mixture of outcomes under the null (uniform distribution of P-values) and alternative 
hypotheses (P-value distribution skewed towards zero).  The disadvantage of this 
method is that an expectation of the number of false positives is required p
s.    
 In the association analysis of plasma CFH, the conservative Bonferroni 
correction of multiple testing was used since a large number of markers showing 
highly significant genome-wide association (P ≤ 1.6E-07) were detected at the CFH 
locus.  In the association analysis of plasma Aβ, no markers passed the threshold of 
significance after Bonferroni correction for multiple testing.  In this analysis, less 
stringent thresholds of genome-wide significance were therefore set in return for 
greater power.  Consequently, associations worthy of further investigation were 
retained for replication or further analysis.   
All single-marker associations were checked for deviations from Hardy-
Weinberg equilibrium using a Fisher’s exact test (Guo & Thompson, 1992; 
Wigginton et al., 2005).  Testing for HWE deviations can also be carried out using a 
Pearson goodness
b
Illumina SNP which showed deviation from HW
investigated and found to be due to genotyping errors.  Consequently genotyping of 
this SNP was carried out using TaqMan and the genotype data were replaced.  
Deviation from HWE can be the result of faulty SNP genotyping.  Deviations from 
HWE can also be due to inbreeding, population stratification or selection (Balding, 
2006).  Deviations can also arise in the presence of a common deletion 
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polymorphism, because of a mutant PCR primer site or because of a tendency to 
miscall heterozygotes as homozygotes.  The SNP rs1066420 was found to 
significantly deviate from HWE in both Vis and Scottish AMD data sets and was 
consequently removed from the analysis.  However, this SNP is believed to be 
located within the polymorphic deletion of CFHR3/CFHR1, resulting in deviation 
from HWE.  One way of detecting false genotype data is to check for Mendelian 
errors of inheritance.  This was carried out for all markers prior to the genome-wide 
association analysis and polymorphisms showing errors in patterns of inheritance 
were excluded.     
Deviations from HWE have so far been mainly tested as a measure of data 
quality control.  However, since deviations from HWE can be due to deletion 
polymorphisms (Conrad et al., 2006) or segmental duplications (Bailey & Eichler, 
2006), test of HWE was used as a quality control check after the association analysis 
t the correlation between concentrations 
of Aβ i
in order to prevent exclusion of markers with potentially interesting trait associations 
as previously recommended (Zou & Donner, 2006).              
  
Analysis of plasma amyloid-β 
 
Quantitative determination of Aβ40 and Aβ42 in CSF, brain tissue and cell lines by 
ELISA have been reported in the literature (Gravina et al., 1995; Kuo et al., 1998; 
Lewczuk et al., 2004; Bibl et al., 2004; Duering et al., 2005).  However, there have 
been conflicting results in the literature abou
n CSF and plasma (Mehta et al., 2001; Fukumoto et al., 2003).  The problem 
arises when trying to determine concentrations of Aβ in plasma where they are about 
50-fold lower than those observed in CSF or brain.  Furthermore, large quantities of 
Aβ have been shown to be sequestered by plasma proteins, in particular serum 
albumin, potentially preventing them from being detected by immunoassays (Kuo et 
al., 1999).  This interaction is thought to be the result of the high reactivity of Aβ due 
to its amphipathic and amphoteric structure.  The C-terminal region of Aβ is 
composed of 12-14 hydrophobic amino acids derived from the APP transmembrane 
domain.  Conversely, the N-terminal 28 amino acids are mainly hydrophilic, with the 
exception of a stretch of five non-polar side chains localised at residues 17-21.  The 
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N-terminal of Aβ is also highly charged at physiological pH, carrying six negative 
and six positive charges, which are believed to aid its binding to carrier molecules.  
Albumin, the most abundant component of human brain homogenates, not only acts 
as a carrier protein but also interferes with the processing of Aβ-containing peptides 
in vivo by masking Aβ epitopes from proteases, inhibitors and matrix proteins 
(Matsumoto et al., 1997).  Another study showed that large proteins in plasma, such 
as α-2 macroglobulin and transthyretin, sequestered Aβ peptides in vitro (Kuo et al., 
2000).  These authors found that greater than 95% of Aβ40 and Aβ42 in plasma 
resides within a sequestered pool bound to proteins such as albumin.  The 
develop
itivity in the A  assay 
mercial assay (Suzuki et al., 1994).  However, development 
β in plasma would also be more 




by direct protein-protein interaction, Aβ peptide metabolism, or both.  Lipid-free 
ment of robust assays, which overcome the problem of interference and 
sequestration by high abundance plasma proteins, would be beneficial in reliable 
quantitation of plasma Aβ concentrations.  The antibodies used in the current study 
for the measurements of Aβ in EDTA plasma had a higher affinity for Aβ species 
than serum albumin and hence resulted in improved sens β
compared with the com
of techniques to release the bound fraction of A
a
 
APOE genotypes are not associated with plasma Aβ 
 
APOE has been consistently shown to influence genetic predisposition to Alzheimer 
disease (Corder et al., 1994; Rubinsztein & Easton, 1999).  We hypothesised that 
APOE isoforms may regulate concentrations of circulating A  species in plasma and 
thus influence susceptibility to AD.  This hypothesis was tested genetically, in 
univariate analyses of APOE allele dosage and plasma A  concentration, which 
showed no significant association between plasma Aβ and APOE.  Despite the lack 
of genetic evidence for direct interaction between APOE isoforms and Aβ in plasma, 
the interaction may be localised to the brain or at the brain-blood barrier where 
APOE has been shown to be highly localised.  The APOE protein is produced in 
abundance in the brain and induced at high concentrations in peripheral nerve injury. 
It is plausible that the APOE isoforms differentially affect amyloid plaque formation 
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APOE*E4 has been shown to form a stable complex with Aβ peptide in vitro 
(Stratman et al., 2005).  In contrast, lipidated APOE*E3 has been found to bind Aβ 
peptide with a 20-fold higher affinity than lipidated APOE*E4, which may prevent 
the accumulation of the neurotoxic Aβ species (Stratman et al., 2005; Mahley & 
Huang, 1999).  It has also been suggested that the extra-cellular accumulation of Aβ 
is due in part to a direct physico-chemical interaction with cholesterol in neuronal 
plasma membranes (Wood et al., 2002).  In vitro interaction between APOE isoforms 
and Aβ40 has been shown in hamster kidney cells (Aleshkov et al., 1997) and 
APOE2 knock-in mice have been reported to be protected against AD (Mann et al., 
2004), indicating possible involvement of APOE in the binding and clearance of Aβ 
in a tissue-specific manner. 
  
Genetic analysis of plasma Aβ 
 
Both species of plasma Aβ (Aβ40 and Aβ42) have been used to map genomic loci 
involved in Alzheimer disease, using series of late-onset AD cases and controls 
(Ertekin-Taner et al., 2000; Ertekin-Taner et al., 2005).  Two genes, IDE (Ertekin-
Taner et al., 2000; Prince et al., 2003; Ertekin-Taner et al., 2004) and PLAU 
rtekin-Taner et al., 2005), on chromosome 10q were identified in independent (E
cohorts, using linkage and association approaches.  However, in these studies 
families had been ascertained through AD probands presenting with high 
concentrations of plasma Aβ, in particular Aβ42.  To date no genome-wide 
association studies of plasma Aβ, in samples of unselected individuals have been 
reported.  In this study, genomic loci with potential relevance to Alzheimer disease 
were identified in a general population sample using a genome-wide association 
analysis approach.  None of the associated SNPs were significant after correction for 
multiple testing, so that replication is required.  However, some of the loci showing 
suggestive association with plasma Aβ have roles in neuronal migration and 
inflammatory response with high reported expression levels in the brain and 
therefore are good candidates for influencing plasma Aβ concentrations.     
There are numerous reports of positive associations in late-onset AD which 
have failed in replication studies (Prince et al., 2001).  Lack of success in replication 
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is dependent upon the size of the effect of a particular polymorphism and the size of 
the population studied.  The replication of the Aβ results in an independent data set 
has become feasible since the Croatian field work has now been extended to include 
the neighbouring isolated island of Korcula (Sujoldzić et al., 1989; Waddle et al., 
1998; Rudan et al., 1999b; Klarić et al., 2001) where a further 1,000 individuals have 
been sampled and are currently undergoing a genome-wide association scan.  Also, 
collaboration within the European Special Populations Research Network 
(EUROSPAN) consortium of isolate populations in Sweden, Netherlands, Croatia, 
Scotland and Italy (led by Professor H. Campbell, University of Edinburgh) will 
allow for replication and comparison of results in different isolate and urban 
populations.   
Putative associations detected in the current study could initially be replicated 
r validated in large series of Alzheimer disease 
ases and controls available at the Mayo Clinic in Florida.  Polymorphisms with 
l., 1998), 
heparin
in the Korcula sample set and furthe
c
confirmed roles in influencing plasma CFH concentrations can be analysed further 
by assessing the biochemical pathways in which they are involved.  Functional 
studies of potential regulatory loci can be carried out in vitro using luciferase reporter 
assays (Kanda et al., 2007) and in vivo using transgenic animal models or by 
injection of reporter constructs into zebrafish embryos (Patton & Zon, 2005; Kleinjan 
et al., 2008).  Assessment of protein interactions using techniques such as yeast-two-
hybrid can also reveal interaction partners for the associated proteins.      
 
Analysis of CFH in the context of AMD 
 
The full length human CFH is a multidomain, multifunctional plasma glycoprotein 
which acts as a cofactor for the factor I-mediated degradation of C3b and accelerates 
the decay of C3 convertase, down-regulating the alternative complement pathway 
(Whaley & Ruddy, 1976).  CFH is a member of a group of structurally and 
immunologically related plasma proteins which consist of individually folding 
protein domains called short consensus repeats (SCRs) (Zipfel & Skerka, 1994).  The 
CFH protein also binds cellular receptors such as CD18 (DiScipio et a
 (Meri & Pangburn, 1990), the acute phase protein C-reactive protein (CRP), 
although there is now some doubt about this (Jarva et al., 1999) and the surface of 
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certain pathogenic microorganisms such as S. pyogenes, N. gonorrhoeae and B. 
afzelii (Lindahl et al., 2000).     
 Plasma CFH deficiency resulting from CFH truncating mutations have been 
linked to rare, severe kidney defects in membranoproliferative glomerulonephritis 
type II (MPGN II) (Levy et al., 1986; lopezlarrea et al., 1987) and atypical 
haemolytic uraemic syndrome (aHUS) (Warwicker et al., 1998; Richards et al., 
2001; Caprioli et al., 2003).  Genetic variants in the CFH genomic region have also 
shown strong associations with age-related macular degeneration (AMD) (Haines et 
al., 2005; Edwards et al., 2005; Klein et al., 2005, Zareparsi et al., 2005a; Hughes et 
al., 2006; Li et al., 2006).   
 This study aimed to identify genetic and environmental factors which 
influen
ite the fact 
at genome-wide association analysis of plasma CFH revealed genetic 
sma CFH concentration.  The lack of 
ce plasma CFH concentration and hence affect predisposition to AMD and 
perhaps other CFH-associated disorders such as MPGN II or aHUS.  Plasma CFH 
concentration was measured using an optimised ELISA and covariate analyses 
showed that it is significantly influenced by sex, age-by-sex interaction and BMI.  
Narrow-sense heritability of plasma CFH was also estimated to be 0.46, accounting 
for the additive genetic effect of variants throughout the genome.  The heritability of 
plasma CFH has previously been reported to be 0.63 in an urban Spanish population 
(Esparza-Gordillo et al., 2004).   
Genome-wide linkage analysis of plasma CFH in the Vis series failed to 
identify regions of suggestive (Z > 2) or significant (Z > 3) linkage desp
th
polymorphisms of large effect influencing pla
power in linkage compared with association in the Vis samples could be the result of 
low power to detect QTL with low QTL-specific heritabilities.  Analysis of power to 
detect QTL using the variance components methodology, given the pedigree 
structure in Vis, has shown that for a fixed trait heritability of 0.40, there would only 
be sufficient power ( > 0.50, α = 0.05) to detect a QTL-specific heritability of 0.30 
(Dr. V. Vitart, personal communication).  This indicates that there is insufficient 
power in the Vis sample set to detect QTL with heritabilities smaller than 0.30, 
probably due to the family structure and the dependency of linkage on the QTL-
specific heritability.  However, the predictive analysis of power, showed that there is 
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sufficient power to detect variants of effect size as low as 3% using association in 
500 unrelated individuals from Vis assuming that the marker and the QTL are in 
 been strongly implicated in predisposition to AMD 
FH SNPs rs6677604 (CFH intron 11), rs1292487 
(1.6 kb
strong linkage disequilibrium.     
The SNP most strongly associated with plasma CFH, rs6677604, is a non-
coding polymorphism in CFH intron 11 which was found to explain 28.3% of the 
covariate adjusted phenotypic variance in the Vis population and 21.8% in the Dutch.  
Furthermore, the CFHR3/CFHR1 deletion polymorphism was found to be in strong 
linkage disequilibrium with CFH rs6677604 (Hughes et al., 2006; Hageman et al., 
2006).  The results of the genome-wide association analysis showed that the CFH 
Y402H variant which has
(Haines et al., 2005; Edwards et al., 2005; Klein et al., 2005, Zareparsi et al., 2005a) 
also influences plasma CFH concentration although the effect is weak compared with 
CFH rs6677604.   
The genomic region showing association with plasma CFH covered a region 
of approximately 300 kb from CFH to CFHR2, which consisted of many 
polymorphisms falling into several LD groups.  In order to identify a multi-marker 
combination of the SNPs which might explain more of the variation in plasma CFH 
than SNP rs6677604, a ‘backward’ regression analysis was carried out.  This resulted 
in a 3-SNP model, containing C
 upstream of CFH ) and rs10801575 (4.4 kb upstream of CFHR4), with age 
and BMI as covariates.  The 3-SNP haplotype which covered a region of 
approximately 230 kb was associated with an increase of 55.5 μg/ml in plasma CFH 
concentration compared with 59.4 μg/ml associated with the SNP rs6677604 alone 
(P > 0.05).  Analysis of complex traits in the context of haplotypes can be 
advantageous because protein products of the candidate genes occur in polypeptide 
chains whose folding and other properties may depend on particular combinations of 
amino acids (Clark, 2004).  Furthermore, in any given population, factors such as 
mutation, drift, selection, migration and recombination result in genetic variation that 
has a strong segment-wise haplotype structure to it (Clark, 2004).     
 The 3-SNP model was not shown to have a larger effect on plasma CFH than 
the single SNP, rs6677604, but it could help to understand the mechanism by which 
SNP rs6677604 may be influencing plasma CFH concentration.  For example, 
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including the SNPs rs6677604 and rs1292487 in the 3-SNP haplotype fitted with the 
DNA looping model during transcription (Figure 9.1) and the interaction between 
intronic enhancer elements with the RNA polymerase machinery located in the 
promot
ependent of both rs101160 (CFH Y402H) and the deletion 
polymo
 (Y402H) using 
er region of genes during transcription (Matthews, 1992; Nussinoc, 1992; 
Ogata et al., 2003).   
The role of the CFH-related proteins in regulation of complement is 
unknown.  However, SNP rs10801575 and the 3′ end of the CFH gene are in close 
proximity on chromosomes containing the CFHR3/CFHR1 deletion in which case 
the linkage disequilibrium between the SNP rs10801575 and polymorphisms in CFH 
could explain the effect associated with this SNP.    
Haplotype analysis conditional on the CFH rs1061170 (Y402H) or the 
CFHR3/CFHR1 deletion polymorphism showed that the effect associated with the 
haplotype was ind
rphism.   
In a case-control analysis of plasma CFH concentrations in the Scottish AMD 
series significant differences were observed between cases of AMD compared with 
disease-free controls in plasma CFH, which was found to explain 1.8% of the AMD 
variance.  This has potentially important implications for treatment of AMD since 
delivery of additional CFH using therapy to the RPE might contribute to disease 
prevention in high-risk individuals. 
Case-control analysis of AMD susceptibility loci showed that the SNPs 
identified to be strongly associated with plasma CFH concentration influenced AMD 
susceptibility independently of the CFH Y402H polymorphism.  The strongest 
genetic risk factor for AMD in the Scottish series was CFH SNP rs1061170 
(Y402H).  In contrast, the effect of the risk haplotype containing CFH rs2274700 (Li 
et al., 2006) was non-significant when conditioned on the CFH Y402H 
polymorphism implying non-independence.  Furthermore, the CFH SNPs rs2274700 
and rs6677604 together with the CFHR3/CFHR1 deletion polymorphism were found 
to collectively affect AMD susceptibility independently of rs1061170
conditional haplotype analyses, consistent with their effects on plasma CFH 
concentration.   
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Figure 9.1 A simplified diagrammatic presentation of a eukaryotic gene during 
transcription.
Diagram shows the DNA looping mechanism during transcription by the RNA 
polymerase complex. The diagram demonstrates the interaction between intronic 
regulatory (enhancer) elements and transcription factor subunits
 
which are bound 
directly to the RNA polymerase itself or the transcription pre-initiation complex located 
at the transcription start site.  Image reproduced from http://pps00.cryst.bbk.ac.uk/
 



















Based on these results, a model is proposed for AMD susceptibility which 
incorporates CFH rs1061170 (Y402H), ARMS2 rs10490924 and plasma CFH 
 model 
for AMD shows the CFH SNP rs1061170 (Y402H) and ARMS2 SNP rs10490924 as 
the strongest genetic susceptibility loci for AMD explaining 6.8% and 6.4% of the 
disease variance respectively.  The rs1061170 polymorphism which occurs in CFH 
module SCR7, binds a heparin-like glycosaminoglycan (GAG) (Prosser et al., 2007) 
and strong evidence from crystal structure analysis shows that GAG binding is 
altered by this amino acid substitution (Prosser et al., 2007).  This supports the case 
for a causal link between the polymorphism and a mechanism for AMD involving 
insufficient complement regulation in the ageing choroid.  The proposed model for 
AMD shown in Figure 9.2 shows that CFH SNPs rs6677604, rs2274700 and the 
CFHR3/CFHR1 deletion polymorphism significantly affect AMD susceptibility by 
influencing the plasma CFH concentration, accounting for 1.8% of the AMD disease 
variance.  This effect is found to be independent of the CFH rs1061170 (Y402H) 
which also shows a weaker association with changes in plasma CFH concentration 
but is postulated to have a strong effect on disease via functional effects on GAG 
binding (Prosser et al., 2007).  The combination of these effects in rs1061170 may 
explain its large effect on disease susceptibility.    
entification of the CFH Y402H polymorphism as the strongest associated 
genetic risk factor for AMD contradicts some published work, which identified the 
CFH SNP rs2274700 (Ala473Ala) as the single strongest genetic susceptibility factor 
for AMD (Li et al., 2006; Hughes et al., 2006).  Differences observed in the relative 
strength of association for rs1061170 and rs2274700 with AMD in different 
populations could be due to genetic differences between geographic sub-groups of 
individuals, irrespective of their disease status (population stratification) (WTCCC, 
2007).  The WTCCC authors reported allele frequency differences between samples 
of individuals from 12 geographical regions across Great Britain which have resulted 
in false-positive association findings in 16 genomic regions. 
 
 

























































































































































































































































































































































































































































































































































Although the 1q31 chromosomal region was not among the regions showing 
eographic differences in the UK population, the possibility of sample heterogeneity 
 
e presence of genetically stratified sub-groups cannot be excluded.  
A haplotype which contains the CFH Y402H risk allele has been shown to be 
e most divergent (compared with haplotypes containing the CFHR3/CFHR1 
eletion polymorphism) and least related to the sequence found in the chimpanzee, 
erhaps reflecting recent selection pressure acting on this allele (Hageman et al., 
006).  The CFH H402 variant has been shown to be less tightly sequestered than the 
FH Y402 variant by the M6 protein of S. pyogenes and might confer an evolutionary 
dvantage in that respect (Yu et al., 2007).  Furthermore, there is now evidence that 
e RCA cluster containing the CFH and CFH-related genes has been under strong 
election pressure, based on information from common SNPs (MAF > 0.05) 
vailable in the HapMap database (Voight et al., 2006).   
Reports have shown that the CFHR3/CFHR1 deletion polymorphism is 
cluded in an extended protective haplotype which contains CFH SNPs rs6677604 
nd rs2274700 (Hughes et al., 2006; Hageman et al., 2007).  This association is 
onfirmed in this study and the protective effect associated with the haplotype 
ontaining the CFH rs6677604 SNP is shown to be independent of CFH rs1061170 
402H) and more significant than CFH rs2274700 (Ala473Ala) or the 
FHR3/CFHR1 deletion.  A hypothesis that explains this result is that the regulatory 
olymorphisms in the non-coding sequence of CFH which affect CFH expression, 
re influencing plasma CFH concentration and hence affecting predisposition to 
MD.  Furthermore, the reported associations between AMD and the CFH SNP 
2274700 (Li et al., 2006) and CFHR3/CFHR1 deletion polymorphism (Hughes et 
l., 2006; Hageman et al., 2007) can be explained by a regulatory effect such as an 
nhancer sequence either close to rs6677604 or within the 3-SNP haplotype 
entified in this study.  However, the 3-SNP haplotype only narrowed the associated 
gion to 355 kb, in which sequence analysis identified many areas of “regulatory 
otential”, based on the alignments of human, chimpanzee, macaque, mouse, rat, dog 
nd cow genomic sequences (Kolbe et al., 2004; King et al., 2005).  Therefore, as a 
tarting point a 5 kb region spanning the highest associated peak, rs6677604, has 
g
in the U.S. population in relation to the association between CFH rs2274700 and




























been selected for further analysis.  This region was shown to contain several 
stretches of DNA showing “regulatory potential” which are highly conserved in 
mammals and fish and would therefore make a plausible candidate enhancer region 
for regulation of gene expression in CFH.   
Two approaches are being tested to assess whether a construct containing the 
5 kb region would drive expression of a luciferase reporter gene containing a basal 
promoter.  Firstly, cellular-based luciferase assays involving liver (HepG2) and RPE 
(ARPE-19) cell lines will be used to assess whether the construct can drive 
expression of the luciferase reporter higher than the basal promoter construct (Kanda 
et al., 2007).  Secondly, in vivo analysis of the same region using a different plasmic 
construct is possible by using the zebrafish embryo as a model (Kleinjan et al., 
2008).  This method involves injection of a construct containing the 5 kb region and 
a GFP/YFP reporter, into zebrafish oocytes and measuring the expression of the 
reporter compared with the background noise.  Despite being separated by about 100 
million years, there is a high level of conservation in the CFH genomic region 
between human and fish (Kemper et al., 1998, 2000).  Expression of the putative 
regulatory region in zebrafish embryos is expected to be largely concentrated in the 
liver as the main site of CFH expression and secretion. 
 
Mass spectrometry and biomarker analysis 
 
A number of mass spectrometry techniques were assessed for their ability to identify 
and/or quantitate variation in human protein concentrations in plasma samples from 
the general population of Vis.  Two main approaches of “top-down” (including 
MALDI-TOF MS and CE FT-ICR MS) and “bottom-up” (IEC nLC-MS/MS) were 
employed (Chait, 2006).   
 The two top-down approaches were largely unsuccessful in reliably 
identifying proteins in complex mixtures.  Quantitation was also not possible due 
either to variability or lack of signal.  Ion exchange chromatography of the digested 
plasma proteins, after separation by electrophoresis resulted in more promising 
results.  The lack of success in mass spectrometric techniques in protein quantitation 
is mainly due to the complexity of the fractions remaining even after 
immunodepletion or fractionation procedures.  If the complexity of the eluate 
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reaching the MS instrument is high, low concentrated proteins or peptides remain 
undetected even if the sensitivity limit of the instrument has not yet been reached.  
This suppression effect results from the competition of too many analyte molecules 
for protons during the ionisation process (Frohlich & Arnold, 2006).   
 
ral polymorphisms including 
FH SNP rs1061170 (Y402H) with highly significant effects on plasma CFH.   
iomarkers for Alzheimer disease 
f the association findings in independent samples.   
Mass spectrometry techniques such as iTRAQ, involving labelling of 
digested proteins have been suggested to be the only method of reliably assessing 
protein concentrations (relative to an internal standard) in complex mixtures (Ross et 
al., 2004; DeSouza et al., 2005).  However, currently the major disadvantage of 
using labelling techniques is the cost of the reagents involved.  The lack of expertise 
in the analysis of results using complex pattern recognition software is a second area 




Three approaches for biomarker discovery and quantitation were employed in this 
study.  Firstly, plasma CFH was chosen as a surrogate biomarker for age-related 
macular degeneration since genetic variation in the CFH gene has been shown to 
affect susceptibility to AMD.  This study resulted in the identification of plasma 
CFH as a biomarker for AMD and the discovery of seve
C
 Secondly, plasma Aβ species were used as b
in order to identify novel loci which influence susceptibility to AD.  Measurements 
of plasma Aβ in general population samples resulted in the identification of several 
potentially relevant genomic loci influencing plasma Aβ concentrations.  The effects 
associated with the putative loci in the context of Alzheimer disease will need to be 
assessed after replication o
 Thirdly, proteomic approaches were employed to discover new biomarkers 
for disease in plasma samples collected from Vis and to assess their importance by 
analysing the protein profiles and quantitating their concentrations.  The label-free 
techniques, MALDI-TOF and CE FT-ICR mass spectrometry were largely 
unsuccessful due to interference from high abundance proteins and instrument 
limitations.  More promising results were obtained from another label-free technique, 
ion exchange chromatography coupled with tandem mass spectrometry.  Assessment 
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of the iTRAQ method for protein quantitation was not possible due to shortage of 
time and the high cost of the reagents. 
 Finally this study demonstrated the advantage of using biomarkers of disease 
to identify genetic and environmental risk factors.  This approach should be applied 
al approaches are required, such as 
se-control association studies.  The strong associations between APOE and 
isease despite the lack of significant association of APOE with Aβ 
to other newly identified genetic risk factors of AMD such as plasma complement 
component 3 (C3) (Yates et al., 2007), complement factor B (CFB) and complement 
component 2 (C2) (Gold et al., 2006) since it is highly likely that genetic variants 
affecting plasma concentrations of these proteins influence the disease.  It should 
also be noted that although biomarkers can explain a significant proportion of a 
complex disease, the major disease susceptibility loci may be acting through some 
other unknown mechanism in which case addition
ca
Alzheimer d
clearly illustrates this point.   
By using biomarkers of disease, which have a simplified genetic architecture, 
this study identified a major CFH regulatory locus affecting age-related macular 
degeneration, as well as several loci with potential roles in influencing susceptibility 
to Alzheimer disease.  These findings will help to unravel part of the complex 
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